

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
19 September 2002 (19.09.2002)

PCT

(10) International Publication Number  
**WO 02/072754 A2**

(51) International Patent Classification<sup>7</sup>: C12N  
(21) International Application Number: PCT/US02/06713  
(22) International Filing Date: 1 March 2002 (01.03.2002)  
(25) Filing Language: English  
(26) Publication Language: English  
(30) Priority Data:  
60/274,434 8 March 2001 (08.03.2001) US

(71) Applicant (*for all designated States except US*): **THE GOVERNMENT OF THE UNITED STATES OF AMERICA**, as represented by **THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES** [US/US]; National Institutes of Health, Office of Technology Transfer, Suite 325, 6011 Executive Boulevard, Rockville, MD 20852-3804 (US).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **MOSS, Bernard** [US/US]; 10301 Dickens Avenue, Bethesda, MD 20814 (US). **WYATT, Linda** [US/US]; 11201 Huntover Drive, Rockville, MD 20852 (US). **EARL, Patricia** [US/US]; 3520 Woodbine Street, Chevy Chase, MD 20815 (US).

(74) Agent: **ALTMAN, Daniel, E.**; Knobbe, Martens, Olson And Bear, LLP, 16th floor, 620 Newport Center Drive, Newport Beach, CA 92660 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AT (utility model), AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, CZ (utility model), DE, DE (utility model), DK, DK (utility model), DM, DZ, EC, EE, EE (utility model), ES, FI, FI (utility model), GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK (utility model), SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Declaration under Rule 4.17:**

— *of inventorship (Rule 4.17(iv)) for US only*

**Published:**

— *without international search report and to be republished upon receipt of that report*

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: MVA EXPRESSING MODIFIED HIV ENVELOPE, GAG, AND POL GENES

(57) Abstract: The invention provides modified virus Ankara (MVA), a replication-deficient strain of vaccinia virus, expressing human immunodeficiency virus (HIV) *env*, *gag*, and *pol* genes.

WO 02/072754 A2

BEST AVAILABLE COPY

## MVA EXPRESSING MODIFIED HIV ENVELOPE, GAG, AND POL GENES

### Field of the Invention

The invention provides modified vaccinia Ankara (MVA), a replication-deficient strain of vaccinia virus, expressing human immunodeficiency virus (HIV) *env*, *gag*, and *pol* genes.

### Background of the Invention

Cellular immunity plays an important role in the control of immunodeficiency virus infections (P.J. Goulder *et al.* 1999 *AIDS* 13:S121). Recently, a DNA vaccine designed to enhance cellular immunity by cytokine augmentation successfully contained a highly virulent immunodeficiency virus challenge (D.H. Barouch *et al.* 2000 *Science* 290:486). Another promising approach to raising cellular immunity is DNA priming followed by recombinant poxvirus boosters (H.L. Robinson *et al.* 2000 *AIDS Rev* 2:105). This heterologous prime/boost regimen induces 10- to 100-fold higher frequencies of T cells than priming and boosting with DNA or recombinant poxvirus vaccines alone. Previously, investigators showed that boosting a DNA-primed response with a poxvirus was superior to boosting with DNA or protein for the control of a non-pathogenic immunodeficiency virus (H.L. Robinson *et al.* 1999 *Nat Med* 5:526). There is a need for the control of a pathogenic immunodeficiency virus.

### Summary of the Invention

Here we report that DNA priming followed by a recombinant modified vaccinia Ankara (rMVA) booster has controlled a highly pathogenic immunodeficiency virus challenge in a rhesus macaque model. Both the DNA and rMVA components of the vaccine expressed multiple immunodeficiency virus proteins. Two DNA inoculations at 0 and 8 weeks and a single rMVA booster at 24 weeks effectively controlled an intrarectal challenge administered seven months after the booster. These findings are envisioned as indicating that a relatively simple multiprotein DNA/MVA vaccine can help to control the acquired immune deficiency syndrome (AIDS) epidemic. We also report that inoculations of rMVA induce good immune responses even without DNA priming.

### Brief Description of the Drawings

**Figure I.** Phylogenetic relationships of HIV-1 and HIV-2 based on identity of *pol* gene sequences. SIV<sub>cpz</sub> and SIV<sub>smm</sub> are subhuman primate lentiviruses recovered from a chimpanzee and sooty mangabey monkey, respectively.

**Figure II.** Phylogenetic relationships of HIV-1 groups M, N and O with four different SIV<sub>cpz</sub> isolates based on full-length *pol* gene sequences. The bar indicates a genetic distance of 0.1 (10% nucleotide divergence) and the *asterisk* positions group N HIV-1 isolates based on *env* sequences.

**Figure III.** Tropic and biologic properties of HIV-1 isolates.

**Figure IV.** HIV-encoded proteins. The location of the HIV genes, the sizes of primary translation products (in some cases polyproteins), and the processed mature viral proteins are indicated.

**Figure V.** Schematic representation of a mature HIV-1 virion.

**Figure VI.** Linear representation of the HIV-1 Env glycoprotein. The *arrow* indicates the site of gp160 cleavage to gp120 and gp41. In gp120, *cross-hatched* areas represent variable domains (V<sub>1</sub> to V<sub>5</sub>) and *open boxes* depict conserved sequences (C<sub>1</sub> to C<sub>5</sub>). In the gp41 ectodomain, several domains are indicated: the N-terminal fusion peptide, and the two ectodomain helices (N- and C-helix). The membrane-spanning domain is represented by a *black box*. In the gp41 cytoplasmic domain, the Tyr-X-X-Leu (YXXL) endocytosis motif (SEQ ID NO: 9) and two predicted helical domains (helix-1 and -2) are shown. Amino acid numbers are indicated.

**Figure 1.** Temporal frequencies of Gag-specific T cells. (A) Gag-specific CD8 T cell responses raised by DNA priming and rMVA booster immunizations. The schematic presents mean Gag-CM9-tetramer data generated in the high-dose i.d. DNA-immunized animals. (B) Gag-specific IFN- $\gamma$  ELISPOTs in A\*01 (open bars) and non-A\*01 (filled bars) macaques at various times before challenge and at two weeks after challenge. Three pools of 10 to 13 Gag peptides (22-mers overlapping by 12) were used for the analyses. The numbers above data bars represent the arithmetic mean  $\pm$  SD for the ELISPOTs within each group. The numbers at the top of the graphs designate individual animals. \*, data not available; #, <20 ELISPOTs per  $1 \times 10^6$  peripheral blood mononuclear cells (PBMC). Temporal data for Gag-CM9-Mamu-A\*01 tetramer-specific T cells can be found in Figure 6.

**Figure 2.** Temporal viral loads, CD4 counts, and survival after challenge of vaccinated and control animals. (A) Geometric mean viral loads and (B) geometric mean CD4 counts. (C) Survival curve for vaccinated and control animals. The dotted line represents all 24 vaccinated animals. (D) Viral loads and (E) CD4 counts for individual animals in the vaccine and control groups. The key to animal numbers is presented in (E). Assays for the first 12 weeks after challenge had a detection level of 1000 copies of RNA per milliliter of plasma. Animals with loads below 1000 were scored with a load of 500. For weeks 16 and 20, the detection level was 300 copies of RNA per milliliter. Animals with levels of virus below 300 were scored at 300.

**Figure 3.** Postchallenge T cell responses in vaccine and control groups. (A) Temporal tetramer<sup>+</sup> cells (dashed line) and viral loads (solid line). (B) Intracellular cytokine assays for IFN- $\gamma$  production in response to stimulation with the Gag-CM9 peptide at two weeks after challenge. This *ex vivo* assay allows evaluation of the functional status of the peak postchallenge tetramer<sup>+</sup> cells displayed in Figure 1A. (C) Proliferation assay at 12 weeks after challenge. Gag-Pol-Env (open bars) and Gag-Pol (hatched bars) produced by transient transfections were used for stimulation. Supernatants from mock-transfected cultures served as control antigen. Stimulation indices are the growth of cultures in the presence of viral antigens divided by the growth of cultures in the presence of mock antigen.

**Figure 4.** Lymph node histomorphology at 12 weeks after challenge. (A) Typical lymph node from a vaccinated macaque showing evidence of follicular hyperplasia characterized by the presence of numerous secondary follicles with expanded germinal centers and discrete dark and light zones. (B) Typical lymph node from an infected control animal showing follicular depletion and paracortical lymphocellular atrophy. (C) A representative lymph node from an age-matched, uninfected macaque displaying nonreactive germinal centers. (D) The percentage of the total lymph node area occupied by germinal centers was measured to give a non-specific indicator of follicular hyperplasia. Data for uninfected controls are for four age-matched rhesus macaques.

**Figure 5.** Temporal antibody responses. Micrograms of total Gag (A) or Env (B) antibody were determined with ELISAs. The titers of neutralizing antibody for SHIV-89.6 (C) and SHIV-89.6P (D) were determined with MT-2 cell killing and neutral red staining (D.C. Montefiori *et al.* 1988 *J Clin Microbiol* 26:231). Titers are the reciprocal of the



serum dilution giving 50% neutralization of the indicated viruses grown in human PBMC. Symbols for animals are the same as in Figure 2.

**Figure 6.** Gag-CM9-Mamu-A\*01 tetramer-specific T cells in *Mamu-A\*01* vaccinated and control macaques at various times before challenge and at two weeks after challenge. The number at the upper right corner of each plot represents the frequency of tetramer-specific CD8 T cells as a % of total CD8 T cells. The numbers above each column of FACS data designate individual animals.

**Figure A.** Map and sequence of plasmid transfer vector pLW-48.

**Figure B.** Sequences of plasmid transfer vector pLW-48, Psy II promoter (which controls ADA envelope expression), ADA envelope truncated, PmH5 promoter (which controls HXB2 gag pol expression), and HXB2 gag pol (with safety mutations,  $\Delta$  integrase).

**Figure C.** Plasmid transfer vector pLW-48 and making MVA recombinant virus MVA/HIV 48.

**Figure D.** A clade B gag pol.

**Figure E.** Sequence of new Psyn II promoter.

#### Detailed Description of the Preferred Embodiment

##### Recombinant MVA Virus

Vaccinia virus, a member of the genus Orthopoxvirus in the family of Poxviridae, was used as live vaccine to immunize against the human smallpox disease. Successful worldwide vaccination with vaccinia virus culminated in the eradication of variola virus, the causative agent of the smallpox (The global eradication of smallpox. Final report of the global commission for the certification of smallpox eradication. History of Public Health, No. 4, Geneva: World Health Organization, 1980). Since that WHO declaration, vaccination has been universally discontinued except for people at high risk of poxvirus infections (e.g. laboratory workers).

More recently, vaccinia viruses have also been used to engineer viral vectors for recombinant gene expression and for the potential use as recombinant live vaccines (Mackett, M. *et al.* 1982 *PNAS USA* 79:7415-7419; Smith, G.L. *et al.* 1984 *Biotech Genet Engin Rev* 2:383-407). This entails DNA sequences (genes) which code for foreign antigens being introduced, with the aid of DNA recombination techniques, into the genome of the vaccinia viruses. If the gene is integrated at a site in the viral DNA which is non-

essential for the life cycle of the virus, it is possible for the newly produced recombinant vaccinia virus to be infectious, that is to say able to infect foreign cells and thus to express the integrated DNA sequence (EP Patent Applications No. 83,286 and No. 110,385). The recombinant vaccinia viruses prepared in this way can be used, on the one hand, as live vaccines for the prophylaxis of infectious diseases, on the other hand, for the preparation of heterologous proteins in eukaryotic cells.

For vector applications health risks would be lessened by the use of a highly attenuated vaccinia virus strain. Several such strains of vaccinia virus were especially developed to avoid undesired side effects of smallpox vaccination. Thus, the modified vaccinia Ankara (MVA) has been generated by long-term serial passages of the Ankara strain of vaccinia virus (CVA) on chicken embryo fibroblasts (for review see Mayr, A. *et al.* 1975 *Infection* 3:6-14; Swiss Patent No. 568,392). The MVA virus is publicly available from American Type Culture Collection as ATCC No. VR-1508. MVA is distinguished by its great attenuation, that is to say by diminished virulence and ability to replicate in primate cells while maintaining good immunogenicity. The MVA virus has been analyzed to determine alterations in the genome relative to the parental CVA strain. Six major deletions of genomic DNA (deletion I, II, III, IV, V, and VI) totaling 31,000 base pairs have been identified (Meyer, H. *et al.* 1991 *J Gen Virol* 72:1031-1038). The resulting MVA virus became severely host cell restricted to avian cells.

Furthermore, MVA is characterized by its extreme attenuation. When tested in a variety of animal models, MVA was proven to be avirulent even in immunosuppressed animals. More importantly, the excellent properties of the MVA strain have been demonstrated in extensive clinical trials (Mayr A. *et al.* 1978 *Zentralbl Bakteriol [B]* 167:375-390; Stickl *et al.* 1974 *Dtsch Med Wschr* 99:2386-2392). During these studies in over 120,000 humans, including high-risk patients, no side effects were associated with the use of MVA vaccine.

MVA replication in human cells was found to be blocked late in infection preventing the assembly to mature infectious virions. Nevertheless, MVA was able to express viral and recombinant genes at high levels even in non-permissive cells and was proposed to serve as an efficient and exceptionally safe gene expression vector (Sutter, G. and Moss, B. 1992 *PNAS USA* 89:10847-10851). Additionally, novel vaccinia vector vaccines were established on the basis of MVA having foreign DNA sequences inserted at

the site of deletion III within the MVA genome (Sutter, G. *et al.* 1994 *Vaccine* 12:1032-1040).

The recombinant MVA vaccinia viruses can be prepared as set out hereinafter. A DNA-construct which contains a DNA-sequence which codes for a foreign polypeptide flanked by MVA DNA sequences adjacent to a naturally occurring deletion, e.g. deletion III, or other non-essential sites, within the MVA genome, is introduced into cells infected with MVA, to allow homologous recombination. Once the DNA-construct has been introduced into the eukaryotic cell and the foreign DNA has recombined with the viral DNA, it is possible to isolate the desired recombinant vaccinia virus in a manner known per se, preferably with the aid of a marker. The DNA-construct to be inserted can be linear or circular. A plasmid or polymerase chain reaction product is preferred. The DNA-construct contains sequences flanking the left and the right side of a naturally occurring deletion, e.g. deletion III, within the MVA genome. The foreign DNA sequence is inserted between the sequences flanking the naturally occurring deletion. For the expression of a DNA sequence or gene, it is necessary for regulatory sequences, which are required for the transcription of the gene, to be present on the DNA. Such regulatory sequences (called promoters) are known to those skilled in the art, and include for example those of the vaccinia 11 kDa gene as are described in EP-A-198,328, and those of the 7.5 kDa gene (EP-A-110,385). The DNA-construct can be introduced into the MVA infected cells by transfection, for example by means of calcium phosphate precipitation (Graham *et al.* 1973 *Virol* 52:456-467; Wigler *et al.* 1979 *Cell* 16:777-785), by means of electroporation (Neumann *et al.* 1982 *EMBO J* 1:841-845), by microinjection (Graessmann *et al.* 1983 *Meth Enzymol* 101:482-492), by means of liposomes (Straubinger *et al.* 1983 *Meth Enzymol* 101:512-527), by means of spheroplasts (Schaffner 1980 *PNAS USA* 77:2163-2167) or by other methods known to those skilled in the art.

#### HIVs and Their Replication

The etiological agent of acquired immune deficiency syndrome (AIDS) is recognized to be a retrovirus exhibiting characteristics typical of the lentivirus genus, referred to as human immunodeficiency virus (HIV). The phylogenetic relationships of the human lentiviruses are shown in Figure I. HIV-2 is more closely related to  $\text{SIV}_{\text{smm}}$ , a virus isolated from sooty mangabey monkeys in the wild, than to HIV-1. It is currently believed

that HIV-2 represents a zoonotic transmission of SIV<sub>smm</sub> to man. A series of lentiviral isolates from captive chimpanzees, designated SIV<sub>cpz</sub>, are close genetic relatives of HIV-1.

The earliest phylogenetic analyses of HIV-1 isolates focused on samples from Europe/North America and Africa; discrete clusters of viruses were identified from these two areas of the world. Distinct genetic subtypes or clades of HIV-1 were subsequently defined and classified into three groups: M (major); O (outlier); and N (non-M or O) (Fig. II). The M group of HIV-1, which includes over 95% of the global virus isolates, consists of at least eight discrete clades (A, B, C, D, F, G, H, and J), based on the sequence of complete viral genomes. Members of HIV-1 group O have been recovered from individuals living in Cameroon, Gabon, and Equatorial Guinea; their genomes share less than 50% identity in nucleotide sequence with group M viruses. The more recently discovered group N HIV-1 strains have been identified in infected Cameroonians, fail to react serologically in standard whole-virus enzyme-linked immunosorbent assay (ELISA), yet are readily detectable by conventional Western blot analysis.

Most current knowledge about HIV-1 genetic variation comes from studies of group M viruses of diverse geographic origin. Data collected during the past decade indicate that the HIV-1 population present within an infected individual can vary from 6% to 10% in nucleotide sequence. HIV-1 isolates within a clade may exhibit nucleotide distances of 15% in *gag* and up to 30% in *gp120* coding sequences. Interclade genetic variation may range between 30% and 40% depending on the gene analyzed.

All of the HIV-1 group M subtypes can be found in Africa. Clade A viruses are genetically the most divergent and were the most common HIV-1 subtype in Africa early in the epidemic. With the rapid spread of HIV-1 to southern Africa during the mid to late 1990s, clade C viruses have become the dominant subtype and now account for 48% of HIV-1 infections worldwide. Clade B viruses, the most intensively studied HIV-1 subtype, remain the most prevalent isolates in Europe and North America.

High rates of genetic recombination are a hallmark of retroviruses. It was initially believed that simultaneous infections by genetically diverse virus strains were not likely to be established in individuals at risk for HIV-1. By 1995, however, it became apparent that a significant fraction of the HIV-1 group M global diversity included interclade viral recombinants. It is now appreciated that HIV-1 recombinants will be found in geographic areas such as Africa, South America, and Southeast Asia, where multiple HIV-1 subtypes

coexist and may account for more than 10% of circulating HIV-1 strains. Molecularly, the genomes of these recombinant viruses resemble patchwork mosaics, with juxtaposed diverse HIV-1 subtype segments, reflecting the multiple crossover events contributing to their generation. Most HIV-1 recombinants have arisen in Africa and a majority contain segments originally derived from clade A viruses. In Thailand, for example, the composition of the predominant circulating strain consists of a clade A *gag* plus *pol* gene segment and a clade E *env* gene. Because the clade E *env* gene in Thai HIV-1 strains is closely related to the clade E *env* present in virus isolates from the Central African Republic, it is believed that the original recombination event occurred in Africa, with the subsequent introduction of a descendent virus into Thailand. Interestingly, no full-length HIV-1 subtype E isolate (i.e., with subtype E *gag*, *pol*, and *env* genes) has been reported to date.

The discovery that  $\alpha$  and  $\beta$  chemokine receptors function as coreceptors for virus fusion and entry into susceptible CD4<sup>+</sup> cells has led to a revised classification scheme for HIV-1 (Fig. III). Isolates can now be grouped on the basis of chemokine receptor utilization in fusion assays in which HIV-1 gp120 and CD4<sup>+</sup> coreceptor proteins are expressed in separate cells. As indicated in Figure III, HIV-1 isolates using the CXCR4 receptor (now designated X4 viruses) are usually T cell line (TCL)-tropic syncytium inducing (SI) strains, whereas those exclusively utilizing the CCR5 receptor (R5 viruses) are predominantly macrophage (M)-tropic and non-syncytium inducing (NSI). The dual-tropic R5/X4 strains, which may comprise the majority of patient isolates and exhibit a continuum of tropic phenotypes, are frequently SI.

As is the case for all replication-competent retroviruses, the three primary HIV-1 translation products, all encoding structural proteins, are initially synthesized as polyprotein precursors, which are subsequently processed by viral or cellular proteases into mature particle-associated proteins (Fig. IV). The 55-kd Gag precursor Pr55<sup>Gag</sup> is cleaved into the matrix (MA), capsid (CA), nucleocapsid (NC), and p6 proteins. Autocatalysis of the 160-kd Gag-Pol polyprotein, Pr160<sup>Gag-Pol</sup>, gives rise to the protease (PR), the heterodimeric reverse transcriptase (RT), and the integrase (IN) proteins, whereas proteolytic digestion by a cellular enzyme(s) converts the glycosylated 160-kd Env precursor gp160 to the gp120 surface (SU) and gp41 transmembrane (TM) cleavage products. The remaining six HIV-1-



encoded proteins (Vif, Vpr, Tat, Rev, Vpu, and Nef) are the primary translation products of spliced mRNAs.

### Gag

The Gag proteins of HIV, like those of other retroviruses, are necessary and sufficient for the formation of noninfectious, virus-like particles. Retroviral Gag proteins are generally synthesized as polyprotein precursors; the HIV-1 Gag precursor has been named, based on its apparent molecular mass, Pr55<sup>Gag</sup>. As noted previously, the mRNA for Pr55<sup>Gag</sup> is the unspliced 9.2-kb transcript (Fig. IV) that requires Rev for its expression in the cytoplasm. When the *pol* ORF is present, the viral protease (PR) cleaves Pr55<sup>Gag</sup> during or shortly after budding from the cell to generate the mature Gag proteins p17 (MA), p24 (CA), p7 (NC), and p6 (see Fig. IV). In the virion, MA is localized immediately inside the lipid bilayer of the viral envelope, CA forms the outer portion of the cone-shaped core structure in the center of the particle, and NC is present in the core in a ribonucleoprotein complex with the viral RNA genome (Fig. V).

The HIV Pr55<sup>Gag</sup> precursor oligomerizes following its translation and is targeted to the plasma membrane, where particles of sufficient size and density to be visible by EM are assembled. Formation of virus-like particles by Pr55<sup>Gag</sup> is a self-assembly process, with critical Gag-Gag interactions taking place between multiple domains along the Gag precursor. The assembly of virus-like particles does not require the participation of genomic RNA (although the presence of nucleic acid appears to be essential), *pol*-encoded enzymes, or Env glycoproteins, but the production of infectious virions requires the encapsidation of the viral RNA genome and the incorporation of the Env glycoproteins and the Gag-Pol polyprotein precursor Pr160<sup>Gag-Pol</sup>.

### Pol

Downstream of *gag* lies the most highly conserved region of the HIV genome, the *pol* gene, which encodes three enzymes: PR, RT, and IN (see Fig. IV). RT and IN are required, respectively, for reverse transcription of the viral RNA genome to a double-stranded DNA copy, and for the integration of the viral DNA into the host cell chromosome. PR plays a critical role late in the life cycle by mediating the production of mature, infectious virions. The *pol* gene products are derived by enzymatic cleavage of a 160-kd Gag-Pol fusion protein, referred to as Pr160<sup>Gag-Pol</sup>. This fusion protein is produced by ribosomal frameshifting during translation of Pr55<sup>Gag</sup> (see Fig. IV). The frame-shifting

mechanism for Gag-Pol expression, also utilized by many other retroviruses, ensures that the *pol*-derived proteins are expressed at a low level, approximately 5% to 10% that of Gag. Like Pr55<sup>Gag</sup>, the N-terminus of Pr160<sup>Gag-Pol</sup> is myristylated and targeted to the plasma membrane.

### Protease

Early pulse-chase studies performed with avian retroviruses clearly indicated that retroviral Gag proteins are initially synthesized as polyprotein precursors that are cleaved to generate smaller products. Subsequent studies demonstrated that the processing function is provided by a viral rather than a cellular enzyme, and that proteolytic digestion of the Gag and Gag-Pol precursors is essential for virus infectivity. Sequence analysis of retroviral PRs indicated that they are related to cellular "aspartic" proteases such as pepsin and renin. Like these cellular enzymes, retroviral PRs use two apposed Asp residues at the active site to coordinate a water molecule that catalyzes the hydrolysis of a peptide bond in the target protein. Unlike the cellular aspartic proteases, which function as pseudodimers (using two folds within the same molecule to generate the active site), retroviral PRs function as true dimers. X-ray crystallographic data from HIV-1 PR indicate that the two monomers are held together in part by a four-stranded antiparallel  $\beta$ -sheet derived from both N- and C-terminal ends of each monomer. The substrate-binding site is located within a cleft formed between the two monomers. Like their cellular homologs, the HIV PR dimer contains flexible "flaps" that overhang the binding site and may stabilize the substrate within the cleft; the active-site Asp residues lie in the center of the dimer. Interestingly, although some limited amino acid homology is observed surrounding active-site residues, the primary sequences of retroviral PRs are highly divergent, yet their structures are remarkably similar.

### Reverse Transcriptase

By definition, retroviruses possess the ability to convert their single-stranded RNA genomes into double-stranded DNA during the early stages of the infection process. The enzyme that catalyzes this reaction is RT, in conjunction with its associated RNaseH activity. Retroviral RTs have three enzymatic activities: (a) RNA-directed DNA polymerization (for minus-strand DNA synthesis), (b) RNaseH activity (for the degradation of the tRNA primer and genomic RNA present in DNA-RNA hybrid intermediates), and (c) DNA-directed DNA polymerization (for second- or plus-strand DNA synthesis).

The mature HIV-1 RT holoenzyme is a heterodimer of 66 and 51 kd subunits. The 51-kd subunit (p51) is derived from the 66-kd (p66) subunit by proteolytic removal of the C-terminal 15-kd RNaseH domain of p66 by PR (see Fig. IV). The crystal structure of HIV-1 RT reveals a highly asymmetric folding in which the orientations of the p66 and p51 subunits differ substantially. The p66 subunit can be visualized as a right hand, with the polymerase active site within the palm, and a deep template-binding cleft formed by the palm, fingers, and thumb subdomains. The polymerase domain is linked to RNaseH by the connection subdomain. The active site, located in the palm, contains three critical Asp residues (110, 185, and 186) in close proximity, and two coordinated  $Mg^{2+}$  ions. Mutation of these Asp residues abolishes RT polymerizing activity. The orientation of the three active-site Asp residues is similar to that observed in other DNA polymerases (e.g., the Klenow fragment of *E. coli* DNA polI). The p51 subunit appears to be rigid and does not form a polymerizing cleft; Asp 110, 185, and 186 of this subunit are buried within the molecule. Approximately 18 base pairs of the primer-template duplex lie in the nucleic acid binding cleft, stretching from the polymerase active site to the RNaseH domain.

In the RT-primer-template-dNTP structure, the presence of a dideoxynucleotide at the 3' end of the primer allows visualization of the catalytic complex trapped just prior to attack on the incoming dNTP. Comparison with previously obtained structures suggests a model whereby the fingers close in to trap the template and dNTP prior to nucleophilic attack of the 3'-OH of the primer on the incoming dNTP. After the addition of the incoming dNTP to the growing chain, it has been proposed that the fingers adopt a more open configuration, thereby releasing the pyrophosphate and enabling RT to bind the next dNTP. The structure of the HIV-1 RNaseH has also been determined by x-ray crystallography; this domain displays a global folding similar to that of *E. coli* RNaseH.

#### Integrase

A distinguishing feature of retrovirus replication is the insertion of a DNA copy of the viral genome into the host cell chromosome following reverse transcription. The integrated viral DNA (the provirus) serves as the template for the synthesis of viral RNAs and is maintained as part of the host cell genome for the lifetime of the infected cell. Retroviral mutants deficient in the ability to integrate generally fail to establish a productive infection.

The integration of viral DNA is catalyzed by integrase, a 32-kd protein generated by PR-mediated cleavage of the C-terminal portion of the HIV-1 Gag-Pol polyprotein (see Fig. IV).

Retroviral IN proteins are composed of three structurally and functionally distinct domains: an N-terminal, zinc-finger-containing domain, a core domain, and a relatively nonconserved C-terminal domain. Because of its low solubility, it has not yet been possible to crystallize the entire 288-amino-acid HIV-1 IN protein. However, the structure of all three domains has been solved independently by x-ray crystallography or NMR methods. The crystal structure of the core domain of the avian sarcoma virus IN has also been determined. The N-terminal domain (residues 1 to 55), whose structure was solved by NMR spectroscopy, is composed of four helices with a zinc coordinated by amino acids His-12, His-16, Cys-40, and Cys-43. The structure of the N-terminal domain is reminiscent of helical DNA binding proteins that contain a so-called helix-turn-helix motif; however, in the HIV-1 structure this motif contributes to dimer formation. Initially, poor solubility hampered efforts to solve the structure of the core domain. However, attempts at crystallography were successful when it was observed that a Phe-to-Lys change at IN residue 185 greatly increased solubility without disrupting *in vitro* catalytic activity. Each monomer of the HIV-1 IN core domain (IN residues 50 to 212) is composed of a five-stranded  $\beta$ -sheet flanked by helices; this structure bears striking resemblance to other polynucleotidyl transferases including RNaseH and the bacteriophage MuA transposase. Three highly conserved residues are found in analogous positions in other polynucleotidyl transferases; in HIV-1 IN these are Asp-64, Asp-116 and Glu-152, the so-called D,D-35-E motif. Mutations at these positions block HIV IN function both *in vivo* and *in vitro*. The close proximity of these three amino acids in the crystal structure of both avian sarcoma virus and HIV-1 core domains supports the hypothesis that these residues play a central role in catalysis of the polynucleotidyl transfer reaction that is at the heart of the integration process. The C-terminal domain, whose structure has been solved by NMR methods, adopts a five-stranded  $\beta$ -barrel folding topology reminiscent of a Src homology 3 (SH3) domain. Recently, the x-ray structures of SIV and Rous sarcoma virus IN protein fragments encompassing both the core and C-terminal domains have been solved.

## Env

The HIV Env glycoproteins play a major role in the virus life cycle. They contain the determinants that interact with the CD4 receptor and coreceptor, and they catalyze the fusion reaction between the lipid bilayer of the viral envelope and the host cell plasma membrane. In addition, the HIV Env glycoproteins contain epitopes that elicit immune responses that are important from both diagnostic and vaccine development perspectives.

The HIV Env glycoprotein is synthesized from the singly spliced 4.3-kb Vpu/Env bicistronic mRNA (see Fig. IV); translation occurs on ribosomes associated with the rough endoplasmic reticulum (ER). The 160-kd polyprotein precursor (gp160) is an integral membrane protein that is anchored to cell membranes by a hydrophobic stop-transfer signal in the domain destined to be the mature TM Env glycoprotein, gp41 (Fig. VI). The gp160 is cotranslationally glycosylated, forms disulfide bonds, and undergoes oligomerization in the ER. The predominant oligomeric form appears to be a trimer, although dimers and tetramers are also observed. The gp160 is transported to the Golgi, where, like other retroviral envelope precursor proteins, it is proteolytically cleaved by cellular enzymes to the mature SU glycoprotein gp120 and TM glycoprotein gp41 (see Fig. VI). The cellular enzyme responsible for cleavage of retroviral Env precursors following a highly conserved Lys/Arg-X-Lys/Arg-Arg motif is furin or a furin-like protease, although other enzymes may also catalyze gp160 processing. Cleavage of gp160 is required for Env-induced fusion activity and virus infectivity. Subsequent to gp160 cleavage, gp120 and gp41 form a noncovalent association that is critical for transport of the Env complex from the Golgi to the cell surface. The gp120-gp41 interaction is fairly weak, and a substantial amount of gp120 is shed from the surface of Env-expressing cells.

The HIV Env glycoprotein complex, in particular the SU (gp120) domain, is very heavily glycosylated; approximately half the molecular mass of gp160 is composed of oligosaccharide side chains. During transport of Env from its site of synthesis in the ER to the plasma membrane, many of the side chains are modified by the addition of complex sugars. The numerous oligosaccharide side chains form what could be imagined as a sugar cloud obscuring much of gp120 from host immune recognition. As shown in Figure VI, gp120 contains interspersed conserved ( $C_1$  to  $C_5$ ) and variable ( $V_1$  to  $V_5$ ) domains. The Cys residues present in the gp120s of different isolates are highly conserved and form disulfide bonds that link the first four variable regions in large loops.



A primary function of viral Env glycoproteins is to promote a membrane fusion reaction between the lipid bilayers of the viral envelope and host cell membranes. This membrane fusion event enables the viral core to gain entry into the host cell cytoplasm. A number of regions in both gp120 and gp41 have been implicated, directly or indirectly, in Env-mediated membrane fusion. Studies of the HA<sub>2</sub> hemagglutinin protein of the orthomyxoviruses and the F protein of the paramyxoviruses indicated that a highly hydrophobic domain at the N-terminus of these proteins, referred to as the fusion peptide, plays a critical role in membrane fusion. Mutational analyses demonstrated that an analogous domain was located at the N-terminus of the HIV-1, HIV-2, and SIV TM glycoproteins (see Fig. VI). Nonhydrophobic substitutions within this region of gp41 greatly reduced or blocked syncytium formation and resulted in the production of noninfectious progeny virions.

C-terminal to the gp41 fusion peptide are two amphipathic helical domains (see Fig. VI) which play a central role in membrane fusion. Mutations in the N-terminal helix (referred to as the N-helix), which contains a Leu zipper-like heptad repeat motif, impair infectivity and membrane fusion activity, and peptides derived from these sequences exhibit potent antiviral activity in culture. The structure of the ectodomain of HIV-1 and SIV gp41, the two helical motifs in particular, has been the focus of structural analyses in recent years. Structures were determined by x-ray crystallography or NMR spectroscopy either for fusion proteins containing the helical domains, a mixture of peptides derived from the N- and C-helices, or in the case of the SIV structure, the intact gp41 ectodomain sequence from residue 27 to 149. These studies obtained fundamentally similar trimeric structures, in which the two helical domains pack in an antiparallel fashion to generate a six-helix bundle. The N-helices form a coiled-coil in the center of the bundle, with the C-helices packing into hydrophobic grooves on the outside.

In the steps leading to membrane fusion CD4 binding induces conformation changes in Env that facilitate coreceptor binding. Following the formation of a ternary gp120/CD4/coreceptor complex, gp41 adopts a hypothetical conformation that allows the fusion peptide to insert into the target lipid bilayer. The formation of the gp41 six-helix bundle (which involves antiparallel interactions between the gp41 N- and C-helices) brings the viral and cellular membranes together and membrane fusion takes place.

Use of Recombinant MVA Virus To Boost CD+8 Cell Immune Response

The present invention relates to generation of a CD8<sup>+</sup> T cell immune response against an antigen and also eliciting an antibody response. More particularly, the present invention relates to "prime and boost" immunization regimes in which the immune response induced by administration of a priming composition is boosted by administration of a boosting composition. The present invention is based on inventors' experimental demonstration that effective boosting can be achieved using modified vaccinia Ankara (MVA) vectors, following priming with any of a variety of different types of priming compositions including recombinant MVA itself.

A major protective component of the immune response against a number of pathogens is mediated by T lymphocytes of the CD8<sup>+</sup> type, also known as cytotoxic T lymphocytes (CTL). An important function of CD8<sup>+</sup> cells is secretion of gamma interferon (IFN $\gamma$ ), and this provides a measure of CD8<sup>+</sup> T cell immune response. A second component of the immune response is antibody directed to the proteins of the pathogen.

The present invention employs MVA which, as the experiments described below show, has been found to be an effective means for providing a boost to a CD8<sup>+</sup> T cell immune response primed to antigen using any of a variety of different priming compositions and also eliciting an antibody response.

Remarkably, the experimental work described below demonstrates that use of embodiments of the present invention allows for recombinant MVA virus expressing an HIV antigen to boost a CD8<sup>+</sup> T cell immune response primed by a DNA vaccine and also eliciting an antibody response. The MVA was found to induce a CD8<sup>+</sup> T cell response after intradermal, intramuscular or mucosal immunization. Recombinant MVA has also been shown to prime an immune response that is boosted by one or more inoculations of recombinant MVA.

Non-human primates immunized with plasmid DNA and boosted with the MVA were effectively protected against intramucosal challenge with live virus. Advantageously, the inventors found that a vaccination regime used intradermal, intramuscular or mucosal immunization for both prime and boost can be employed, constituting a general immunization regime suitable for inducing CD8<sup>+</sup> T cells and also eliciting an antibody response, e.g. in humans.

The present invention in various aspects and embodiments employs an MVA vector encoding an HIV antigen for boosting a CD8<sup>+</sup> T cell immune response to the antigen primed by previous administration of nucleic acid encoding the antigen and also eliciting an antibody response.

A general aspect of the present invention provides for the use of an MVA vector for boosting a CD8<sup>+</sup> T cell immune response to an HIV antigen and also eliciting an antibody response.

One aspect of the present invention provides a method of boosting a CD8<sup>+</sup> T cell immune response to an HIV antigen in an individual, and also eliciting an antibody response, the method including provision in the individual of an MVA vector including nucleic acid encoding the antigen operably linked to regulatory sequences for production of antigen in the individual by expression from the nucleic acid, whereby a CD8<sup>+</sup> T cell immune response to the antigen previously primed in the individual is boosted.

An immune response to an HIV antigen may be primed by immunization with plasmid DNA or by infection with an infectious agent.

A further aspect of the invention provides a method of inducing a CD8<sup>+</sup> T cell immune response to an HIV antigen in an individual, and also eliciting an antibody response, the method comprising administering to the individual a priming composition comprising nucleic acid encoding the antigen and then administering a boosting composition which comprises an MVA vector including nucleic acid encoding the antigen operably linked to regulatory sequences for production of antigen in the individual by expression from the nucleic acid.

A further aspect provides for use of an MVA vector, as disclosed, in the manufacture of a medicament for administration to a mammal to boost a CD8<sup>+</sup> T cell immune response to an HIV antigen, and also eliciting an antibody response. Such a medicament is generally for administration following prior administration of a priming composition comprising nucleic acid encoding the antigen.

The priming composition may comprise any viral vector, such as a vaccinia virus vector such as a replication-deficient strain such as modified vaccinia Ankara (MVA) or NYVAC (Tartaglia *et al.* 1992 *Virology* 118:217-232), an avipox vector such as fowlpox or canarypox, e.g. the strain known as ALVAC (Paoletti *et al.* 1994 *Dev Biol Stand* 82:65-69), or an adenovirus vector or a vesicular stomatitis virus vector or an alphavirus vector.

The priming composition may comprise DNA encoding the antigen, such DNA preferably being in the form of a circular plasmid that is not capable of replicating in mammalian cells. Any selectable marker should not be resistance to an antibiotic used clinically, so for example Kanamycin resistance is preferred to Ampicillin resistance. Antigen expression should be driven by a promoter which is active in mammalian cells, for instance the cytomegalovirus immediate early (CMV IE) promoter.

In particular embodiments of the various aspects of the present invention, administration of a priming composition is followed by boosting with a boosting composition, or first and second boosting compositions, the first and second boosting compositions being the same or different from one another. Still further boosting compositions may be employed without departing from the present invention. In one embodiment, a triple immunization regime employs DNA, then adenovirus as a first boosting composition, then MVA as a second boosting composition, optionally followed by a further (third) boosting composition or subsequent boosting administration of one or other or both of the same or different vectors. Another option is DNA then MVA then adenovirus, optionally followed by subsequent boosting administration of one or other or both of the same or different vectors.

The antigen to be encoded in respective priming and boosting compositions (however many boosting compositions are employed) need not be identical, but should share at least one CD8<sup>+</sup> T cell epitope. The antigen may correspond to a complete antigen, or a fragment thereof. Peptide epitopes or artificial strings of epitopes may be employed, more efficiently cutting out unnecessary protein sequence in the antigen and encoding sequence in the vector or vectors. One or more additional epitopes may be included, for instance epitopes which are recognized by T helper cells, especially epitopes recognized in individuals of different HLA types.

An HIV antigen of the invention to be encoded by a recombinant MVA virus includes polypeptides having immunogenic activity elicited by an amino acid sequence of an HIV Env, Gag, Pol, Vif, Vpr, Tat, Rev, Vpu, or Nef amino acid sequence as at least one CD8<sup>+</sup> T cell epitope. This amino acid sequence substantially corresponds to at least one 10-900 amino acid fragment and/or consensus sequence of a known HIV Env or Pol; or at least one 10-450 amino acid fragment and/or consensus sequence of a known HIV Gag; or at

least one 10-100 amino acid fragment and/or consensus sequence of a known HIV Vif, Vpr, Tat, Rev, Vpu, or Nef.

Although a full length Env precursor sequence is presented for use in the present invention, Env is optionally deleted of subsequences. For example, regions of the gp120 surface and gp41 transmembrane cleavage products can be deleted.

Although a full length Gag precursor sequence is presented for use in the present invention, Gag is optionally deleted of subsequences. For example, regions of the matrix protein (p17), regions of the capsid protein (p24), regions of the nucleocapsid protein (p7), and regions of p6 (the C-terminal peptide of the Gag polyprotein) can be deleted.

Although a full length Pol precursor sequence is presented for use in the present invention, Pol is optionally deleted of subsequences. For example, regions of the protease protein (p10), regions of the reverse transcriptase protein (p66/p51), and regions of the integrase protein (p32) can be deleted.

Such an HIV Env, Gag, or Pol can have overall identity of at least 50% to a known Env, Gag, or Pol protein amino acid sequence, such as 50-99% identity, or any range or value therein, while eliciting an immunogenic response against at least one strain of an HIV.

Percent identity can be determined, for example, by comparing sequence information using the GAP computer program, version 6.0, available from the University of Wisconsin Genetics Computer Group (UWGCG). The GAP program utilizes the alignment method of Needleman and Wunsch (*J Mol Biol* 1970 48:443), as revised by Smith and Waterman (*Adv Appl Math* 1981 2:482). Briefly, the GAP program defines identity as the number of aligned symbols (i.e., nucleotides or amino acids) which are identical, divided by the total number of symbols in the shorter of the two sequences. The preferred default parameters for the GAP program include: (1) a unitary comparison matrix (containing a value of 1 for identities and 0 for non-identities) and the weighted comparison matrix of Gribskov and Burgess (*Nucl Acids Res* 1986 14:6745), as described by Schwartz and Dayhoff (eds., *Atlas of Protein Sequence and Structure*, National Biomedical Research Foundation, Washington, D.C. 1979, pp. 353-358); (2) a penalty of 3.0 for each gap and an additional 0.10 penalty for each symbol in each gap; and (3) no penalty for end gaps.

In a preferred embodiment, an Env of the present invention is a variant form of at least one HIV envelope protein. Preferably, the Env is composed of gp120 and the



membrane-spanning and ectodomain of gp41 but lacks part or all of the cytoplasmic domain of gp41.

Known HIV sequences are readily available from commercial and institutional HIV sequence databases, such as GENBANK, or as published compilations, such as Myers *et al.* eds., *Human Retroviruses and AIDS, A Compilation and Analysis of Nucleic Acid and Amino Acid Sequences*, Vol. I and II, Theoretical Biology and Biophysics, Los Alamos, N. Mex. (1993), or <http://hiv-web.lanl.gov/>.

Substitutions or insertions of an HIV Env, Gag, or Pol to obtain an additional HIV Env, Gag, or Pol, encoded by a nucleic acid for use in a recombinant MVA virus of the present invention, can include substitutions or insertions of at least one amino acid residue (e.g., 1-25 amino acids). Alternatively, at least one amino acid (e.g., 1-25 amino acids) can be deleted from an HIV Env, Gag, or Pol sequence. Preferably, such substitutions, insertions or deletions are identified based on safety features, expression levels, immunogenicity and compatibility with high replication rates of MVA.

Amino acid sequence variations in an HIV Env, Gag, or Pol of the present invention can be prepared e.g., by mutations in the DNA. Such HIV Env, Gag, or Pol include, for example, deletions, insertions or substitutions of nucleotides coding for different amino acid residues within the amino acid sequence. Obviously, mutations that will be made in nucleic acid encoding an HIV Env, Gag, or Pol must not place the sequence out of reading frame and preferably will not create complementary domains that could produce secondary mRNA structures.

HIV Env, Gag, or Pol-encoding nucleic acid of the present invention can also be prepared by amplification or site-directed mutagenesis of nucleotides in DNA or RNA encoding an HIV Env, Gag, or Pol and thereafter synthesizing or reverse transcribing the encoding DNA to produce DNA or RNA encoding an HIV Env, Gag, or Pol, based on the teaching and guidance presented herein.

Recombinant MVA viruses expressing HIV Env, Gag, or Pol of the present invention, include a finite set of HIV Env, Gag, or Pol-encoding sequences as substitution nucleotides that can be routinely obtained by one of ordinary skill in the art, without undue experimentation, based on the teachings and guidance presented herein. For a detailed description of protein chemistry and structure, see Schulz, G.E. *et al.*, 1978 *Principles of Protein Structure*, Springer-Verlag, New York, N.Y., and Creighton, T.E., 1983 *Proteins*:

*Structure and Molecular Properties*, W. H. Freeman & Co., San Francisco, CA. For a presentation of nucleotide sequence substitutions, such as codon preferences, see Ausubel *et al.* eds. *Current Protocols in Molecular Biology*, Greene Publishing Assoc., New York, N.Y. 1994 at §§ A.1.1-A.1.24, and Sambrook, J. *et al.* 1989 *Molecular Cloning: A Laboratory Manual*, Second Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. at Appendices C and D.

Thus, one of ordinary skill in the art, given the teachings and guidance presented herein, will know how to substitute other amino acid residues in other positions of an HIV *env*, *gag*, or *pol* DNA or RNA to obtain alternative HIV Env, Gag, or Pol, including substitutional, deletional or insertional variants.

Within the MVA vector, regulatory sequences for expression of the encoded antigen will include a natural, modified or synthetic poxvirus promoter. By "promoter" is meant a sequence of nucleotides from which transcription may be initiated of DNA operably linked downstream (i.e. in the 3' direction on the sense strand of double-stranded DNA). "Operably linked" means joined as part of the same nucleic acid molecule, suitably positioned and oriented for transcription to be initiated from the promoter. DNA operably linked to a promoter is "under transcriptional initiation regulation" of the promoter. Other regulatory sequences including terminator fragments, polyadenylation sequences, marker genes and other sequences may be included as appropriate, in accordance with the knowledge and practice of the ordinary person skilled in the art: see, for example, Moss, B. (2001). Poxviridae: the viruses and their replication. In Fields Virology, D.M. Knipe, and P.M. Howley, eds. (Philadelphia, Lippincott Williams & Wilkins), pp. 2849-2883. Many known techniques and protocols for manipulation of nucleic acid, for example in preparation of nucleic acid constructs, mutagenesis, sequencing, introduction of DNA into cells and gene expression, and analysis of proteins, are described in detail in *Current Protocols in Molecular Biology*, 1998 Ausubel *et al.* eds., John Wiley & Sons.

Promoters for use in aspects and embodiments of the present invention must be compatible with poxvirus expression systems and include natural, modified and synthetic sequences.

Either or both of the priming and boosting compositions may include an adjuvant, such as granulocyte macrophage-colony stimulating factor (GM-CSF) or encoding nucleic acid therefor.

Administration of the boosting composition is generally about 1 to 6 months after administration of the priming composition, preferably about 1 to 3 months.

Preferably, administration of priming composition, boosting composition, or both priming and boosting compositions, is intradermal, intramuscular or mucosal immunization.

Administration of MVA vaccines may be achieved by using a needle to inject a suspension of the virus. An alternative is the use of a needleless injection device to administer a virus suspension (using, e.g., Biojector™ needleless injector) or a resuspended freeze-dried powder containing the vaccine, providing for manufacturing individually prepared doses that do not need cold storage. This would be a great advantage for a vaccine that is needed in rural areas of Africa.

MVA is a virus with an excellent safety record in human immunizations. The generation of recombinant viruses can be accomplished simply, and they can be manufactured reproducibly in large quantities. Intradermal, intramuscular or mucosal administration of recombinant MVA virus is therefore highly suitable for prophylactic or therapeutic vaccination of humans against AIDS which can be controlled by a CD8<sup>+</sup> T cell response.

The individual may have AIDS such that delivery of the antigen and generation of a CD8<sup>+</sup> T cell immune response to the antigen is of benefit or has a therapeutically beneficial effect.

Most likely, administration will have prophylactic aim to generate an immune response against HIV or AIDS before infection or development of symptoms.

Components to be administered in accordance with the present invention may be formulated in pharmaceutical compositions. These compositions may comprise a pharmaceutically acceptable excipient, carrier, buffer, stabilizer or other materials well known to those skilled in the art. Such materials should be non-toxic and should not interfere with the efficacy of the active ingredient. The precise nature of the carrier or other material may depend on the route of administration, e.g. intravenous, cutaneous or subcutaneous, nasal, intramuscular, intraperitoneal routes.

As noted, administration is preferably intradermal, intramuscular or mucosal.

Physiological saline solution, dextrose or other saccharide solution or glycols such as ethylene glycol, propylene glycol or polyethylene glycol may be included.

For intravenous, cutaneous, subcutaneous, intramuscular or mucosal injection, or injection at the site of affliction, the active ingredient will be in the form of a parenterally acceptable aqueous solution which is pyrogen-free and has suitable pH, isotonicity and stability. Those of relevant skill in the art are well able to prepare suitable solutions using, for example, isotonic vehicles such as Sodium Chloride Injection, Ringer's Injection, Lactated Ringer's Injection. Preservatives, stabilizers, buffers, antioxidants and/or other additives may be included as required.

A slow-release formulation may be employed.

Following production of MVA particles and optional formulation of such particles into compositions, the particles may be administered to an individual, particularly human or other primate. Administration may be to another mammal, e.g. rodent such as mouse, rat or hamster, guinea pig, rabbit, sheep, goat, pig, horse, cow, donkey, dog or cat.

Administration is preferably in a "prophylactically effective amount" or a "therapeutically effective amount" (as the case may be, although prophylaxis may be considered therapy), this being sufficient to show benefit to the individual. The actual amount administered, and rate and time-course of administration, will depend on the nature and severity of what is being treated. Prescription of treatment, e.g. decisions on dosage etc, is within the responsibility of general practitioners and other medical doctors, or in a veterinary context a veterinarian, and typically takes account of the disorder to be treated, the condition of the individual patient, the site of delivery, the method of administration and other factors known to practitioners. Examples of the techniques and protocols mentioned above can be found in *Remington's Pharmaceutical Sciences*, 16th edition, 1980, Osol, A. (ed.).

In one preferred regimen, DNA is administered at a dose of 250  $\mu$ g to 2.5 mg/injection, followed by MVA at a dose of  $10^6$  to  $10^9$  infectious virus particles/injection.

A composition may be administered alone or in combination with other treatments, either simultaneously or sequentially dependent upon the condition to be treated.

Delivery to a non-human mammal need not be for a therapeutic purpose, but may be for use in an experimental context, for instance in investigation of mechanisms of immune responses to an antigen of interest, e.g. protection against HIV or AIDS.

Further aspects and embodiments of the present invention will be apparent to those of ordinary skill in the art, in view of the above disclosure and following experimental

exemplification, included by way of illustration and not limitation, and with reference to the attached figures.

### EXAMPLE 1

#### Control of a Mucosal Challenge and Prevention of AIDS by a Multiprotein DNA/MVA Vaccine

Here we tested DNA priming and poxvirus boosting for the ability to protect against a highly pathogenic mucosal challenge. The 89.6 chimera of simian and human immunodeficiency viruses (SHIV-89.6) was used for the construction of immunogens and its highly pathogenic derivative, SHIV-89.6P, for challenge (G.B. Karlsson *et al.* 1997 *J Virol* 71:4218). SHIV-89.6 and SHIV-89.6P do not generate cross-neutralizing antibody (D.C... Montefiori *et al.* 1998 *J Virol* 72:3427) and allowed us to address the ability of vaccine-raised T cells and non-neutralizing antibodies to control an immunodeficiency virus challenge. Modified vaccinia Ankara (MVA) was used for the construction of the recombinant poxvirus. MVA has been highly effective at boosting DNA-primed CD8 T cells and enjoys the safety feature of not replicating efficiently in human or monkey cells (H.L. Robinson *et al.* 2000 *AIDS Reviews* 2:105).

To ensure a broad immune response both the DNA and recombinant MVA (rMVA) components of the vaccine expressed multiple immunodeficiency virus proteins. The DNA prime (DNA/89.6) expressed simian immunodeficiency virus (SIV) Gag, Pol, Vif, Vpx, and Vpr and human immunodeficiency virus-1 (HIV-1) Env, Tat, and Rev from a single transcript (R.J. Gorelick *et al.* 1999 *Virology* 253:259; M.M. Sauter *et al.* 1996 *J Cell Biol* 132:795).

Molecularly cloned SHIV-89.6 sequences were cloned into the vector pGA2 using ClaI and RsrII sites. This cloning deleted both long terminal repeats (LTRs) and *nef*. The SHIV-89.6 sequences also were internally mutated for a 12-base pair region encoding the first four amino acids of the second zinc finger in nucleocapsid. This mutation renders SHIV viruses noninfectious (R.J. Gorelick *et al.* 1999 *Virology* 253:259). A mutation in gp41 converted the tyrosine at position 710 to cysteine to achieve better expression of Env on the plasma membrane of DNA-expressing cells (M.M. Sauter *et al.* 1996 *J Cell Biol* 132:795). pGA2 uses the CMV immediate early promoter without intron A and the bovine growth hormone polyadenylation sequence to express vaccine inserts. Vaccine DNA was



produced by Althea (San Diego, CA). In transient transfections of 293T cells, DNA/89.6 produced about 300 ng of Gag and 85 ng of Env per  $1 \times 10^6$  cells.

The rMVA booster (MVA/89.6) expressed SIV Gag, Pol, and HIV-1 Env under the control of vaccinia virus early/late promoters.

The MVA double recombinant virus expressed both the HIV 89.6 Env and the SIV 239 Gag-Pol, which were inserted into deletion II and deletion III of MVA, respectively. The 89.6 Env protein was truncated for the COOH-terminal 115 amino acids of gp41. The modified H5 promoter controlled the expression of both foreign genes.

Vaccination was accomplished by priming with DNA at 0 and 8 weeks and boosting with rMVA at 24 weeks (Fig. 1A).

I.d. and i.m. DNA immunizations were delivered in phosphate-buffered saline (PBS) with a needleless jet injector (Bioject, Portland, OR) to deliver five i.d. 100- $\mu$ l injections to each outer thigh for the 2.5-mg dose of DNA or one i.d. 100- $\mu$ l injection to the right outer thigh for the 250- $\mu$ g dose of plasmid. I.m. deliveries of DNA were done with one 0.5-ml injection of DNA in PBS to each outer thigh for the 2.5-mg dose and one 100- $\mu$ l injection to the right outer thigh for the 250- $\mu$ g dose.  $1 \times 10^8$  pfu of MVA/89.6 was administered both i.d. and i.m. with a needle. One 100- $\mu$ l dose was delivered to each outer thigh for the i.d. dose and one 500- $\mu$ l dose to each outer thigh for the i.m. dose. Control animals received 2.5 mg of the pGA2 vector without vaccine insert with the Bioject device to deliver five 100- $\mu$ l doses i.d. to each outer thigh. The control MVA booster immunization consisted of  $2 \times 10^8$  pfu of MVA without an insert delivered i.d. and i.m. as described for MVA/89.6.

Four groups of six rhesus macaques each were primed with either 2.5 mg (high-dose) or 250  $\mu$ g (low-dose) of DNA by intradermal (i.d.) or intramuscular (i.m.) routes using a needleless jet injection device (Bioject, Portland, OR) (T.M. Allen *et al.* 2000 *J Immunol* 164:4968).

Young adult rhesus macaques from the Yerkes breeding colony were cared for under guidelines established by the Animal Welfare Act and the NIH "Guide for the Care and Use of Laboratory Animals" with protocols approved by the Emory University Institutional Animal Care and Use Committee. Macaques were typed for the *Mamu-A\*01* allele with polymerase chain reaction (PCR) analyses (M.A. Egan *et al.* 2000 *J Virol* 74:7485; I. Ourmanov *et al.* 2000 *J Virol* 74:2740). Two or more animals containing at

least one *Mamu-A\*01* allele were assigned to each group. Animal numbers are as follows: 1, RBr-5\*; 2, RIm-5\*; 3, RQf-5\*; 4, RZe-5; 5, ROm-5; 6, RDm-5; 7, RAj-5\*; 8, RJI-5\*; 9, RAI-5\*; 10, RDe-5\*; 11, RAI-5; 12, RPr-5; 13, RKw-4\*; 14, RWz-5\*; 15, RGo-5; 16, RLp-4; 17, RWd-6; 18, RAt-5; 19, RPb-5\*; 20, RLi-5\*; 21, RIq-5; 22, RSp-4; 23, RSn-5; 24, RGd-6; 25, RMb-5\*; 26, Rgy-5\*; 27, RU-4; and 28, RPM-5. Animals with the *A\*01* allele are indicated with asterisks.

Gene gun deliveries of DNA were not used because these had primed non-protective immune responses in a 1996 - 98 trial (H.L. Robinson *et al.* 1999 *Nat Med* 5:526). The MVA/89.6 booster immunization ( $2 \times 10^8$  plaque-forming units, pfu) was injected with a needle both i.d. and i.m. A control group included two mock immunized animals and two naive animals. The challenge was given at 7 months after the rMVA booster to test for the generation of long-term immunity. Because most HIV-1 infections are transmitted across mucosal surfaces, an intrarectal challenge was administered.

DNA priming followed by rMVA boosting generated high frequencies of virus-specific T cells that peaked at one week following the rMVA booster (Fig. 1). The frequencies of T cells recognizing the Gag-CM9 epitope were assessed by means of Mamu-A\*01 tetramers, and the frequencies of T cells recognizing epitopes throughout Gag were assessed with pools of overlapping peptides and an enzyme-linked immunospot (ELISPOT) assay (C.A. Power *et al.* 1999 *J Immunol Methods* 227:99).

For tetramer analyses, about  $1 \times 10^6$  peripheral blood mononuclear cells (PBMC) were surface-stained with antibodies to CD3 conjugated to fluorescein isothiocyanate (FITC) (FN-18; Biosource International, Camarillo, CA), CD8 conjugated to peridinin chlorophyll protein (PerCP) (SK1; Becton Dickinson, San Jose, CA), and Gag-CM9 (CTPYDINQM)-*Mamu-A\*01* tetramer (SEQ ID NO: 6) conjugated to allophycocyanin (APC), in a volume of 100  $\mu$ l at 8° to 10°C for 30 min. Cells were washed twice with cold PBS containing 2% fetal bovine serum (FBS), fixed with 1% paraformaldehyde in PBS, and analyzed within 24 hrs on a FACScaliber (Becton Dickinson, San Jose, CA). Cells were initially gated on lymphocyte populations with forward scatter and side scatter and then on CD3 cells. The CD3 cells were then analyzed for CD8 and tetramer-binding cells. About 150,000 lymphocytes were acquired for each sample. Data were analyzed using FloJo software (Tree Star, San Carlos, CA).

For interferon- $\gamma$  (IFN- $\gamma$ ) ELISPOTs, MULTISCREEN 96 well filtration plates (Millipore Inc. Bedford, MA) were coated overnight with antibody to human IFN- $\gamma$  (Clone B27, Pharmingen, San Diego, CA) at a concentration of 2  $\mu\text{g/ml}$  in sodium bicarbonate buffer (pH 9.6) at 8° to 10°C. Plates were washed two times with RPMI medium and then blocked for 1 hour with complete medium (RPMI containing 10% FBS) at 37°C. Plates were washed five more times with plain RPMI medium, and cells were seeded in duplicate in 100  $\mu\text{l}$  complete medium at numbers ranging from  $2 \times 10^4$  to  $5 \times 10^5$  cells per well. Peptide pools were added to each well to a final concentration of 2  $\mu\text{g/ml}$  of each peptide in a volume of 100  $\mu\text{l}$  in complete medium. Cells were cultured at 37°C for about 36 hrs under 5%  $\text{CO}_2$ . Plates were washed six times with wash buffer (PBS with 0.05% Tween-20) and then incubated with 1  $\mu\text{g}$  of biotinylated antibody to human IFN- $\gamma$  per milliliter (clone 7-86-1; Diapharma Group, West Chester, OH) diluted in wash buffer containing 2% FBS. Plates were incubated for 2 hrs at 37°C and washed six times with wash buffer. Avidin-horseradish peroxidase (Vector Laboratories, Burlingame, CA) was added to each well and incubated for 30 to 60 min at 37°C. Plates were washed six times with wash buffer and spots were developed using stable DAB as substrate (Research Genetics, Huntsville, AL). Spots were counted with a stereo dissecting microscope. An ovalbumin peptide (SIINFEKL) (SEQ ID NO: 7) was included as a control in each analysis. Background spots for the ovalbumin peptide were generally  $<5$  for  $5 \times 10^5$  PBMCs. This background when normalized for  $1 \times 10^6$  PBMC was  $<10$ . Only ELISPOT counts of twice the background ( $\geq 20$ ) were considered significant. The frequencies of ELISPOTs are approximate because different dilutions of cells have different efficiencies of spot formation in the absence of feeder cells (C.A. Power *et al.* 1999 *J Immunol Methods* 227: 99). The same dilution of cells was used for all animals at a given time point, but different dilutions were used to detect memory and acute responses.

Gag-CM9 tetramer analyses were restricted to macaques that expressed the *Mamu-A\*01* histocompatibility type, whereas ELISPOT responses did not depend on a specific histocompatibility type. As expected, the DNA immunizations raised low levels of memory cells that expanded to high frequencies within 1 week of the rMVA booster (Fig. 1 and 6). In *Mamu-A\*01* macaques, CD8 cells specific to the Gag-CM9 epitope expanded to frequencies as high as 19% of total CD8 T cells (Fig. 6). This peak of specific cells underwent a 10- to 100-fold contraction into the DNA/MVA memory pool (Fig. 1A and 6).

ELISPOTs for three pools of Gag peptides also underwent a major expansion (frequencies up to 4000 spots for  $1 \times 10^6$  PBMC) before contracting from 5- to 20-fold into the DNA/MVA memory response (Fig. 1B). The frequencies of ELISPOTs were the same in macaques with and without the *A\*01* histocompatibility type ( $P > 0.2$ ).

Simple linear regression was used to estimate correlations between postbooster and postchallenge ELISPOT responses, between memory and postchallenge ELISPOT responses, and between logarithmically transformed viral loads and ELISPOT frequencies. Comparisons between vaccine and control groups and *A\*01* and non *A\*01* macaques were performed by means of two-sample *t* tests with logarithmically transformed viral load and ELISPOT responses. Two-way analyses of variance were used to examine the effects of dose and route of administration on peak DNA/MVA ELISPOTs, on memory DNA/MVA ELISPOTs, and on logarithmically transformed Gag antibody data.

At both peak and memory phases of the vaccine response, the rank order for the height of the ELISPOTs in the vaccine groups was 2.5 mg i.d. > 2.5 mg i.m. > 250  $\mu$ g i.d. > 250  $\mu$ g i.m. (Fig. 1B). The IFN- $\gamma$  ELISPOTs included both CD4 and CD8 cells. Gag-CM9-specific CD8 cells had good lytic activity after restimulation with peptide.

The highly pathogenic SHIV-89.6P challenge was administered intrarectally at 7 months after the rMVA booster, when vaccine-raised T cells were in memory (Fig. 1).

The challenge stock ( $5.7 \times 10^9$  copies of viral RNA per milliliter) was produced by one intravenous followed by one intrarectal passage in rhesus macaques of the original SHIV-89.6P stock (G.B. Karlsson *et al.* 1997 *J Virol* 71:4218). Lymphoid cells were harvested from the intrarectally infected animal at peak viremia, CD8-depleted, and mitogen-stimulated for stock production. Before intrarectal challenge, fasted animals were anesthetized (ketamine, 10 mg/kg) and placed on their stomach with the pelvic region slightly elevated. A feeding tube (8Fr (2.7 mm) x 16 inches (41 cm); Sherwood Medical, St. Louis, MO) was inserted into the rectum for a distance of 15 to 20 cm. Following insertion of the feeding tube, a syringe containing 20 intrarectal infectious doses in 2 ml of RPMI-1640 plus 10% FBS was attached to the tube and the inoculum was slowly injected into the rectum. After delivery of the inoculum, the feeding tube was flushed with 3.0 ml of RPMI without FBS and then slowly withdrawn. Animals were left in place, with pelvic regions slightly elevated, for a period of ten minutes after the challenge.

The challenge infected all of the vaccinated and control animals (Fig. 2). However, by 2 weeks after challenge, titers of plasma viral RNA were at least 10-fold lower in the vaccine groups (geometric means of  $1 \times 10^7$  to  $5 \times 10^7$ ) than in the control animals (geometric mean of  $4 \times 10^8$ ) (Fig. 2A) (S. Staprans *et al.* in: *Viral Genome Methods* K. Adolph, ed. CRC Press, Boca Raton, FL, 1996 pp. 167-184; R. Hofmann-Lehmann *et al.* 2000 *AIDS Res Hum Retroviruses* 16:1247).

For the determination of SHIV copy number, viral RNA from 150  $\mu$ l of ACD anticoagulated plasma was directly extracted with the QIAamp Viral RNA kit (Qiagen), eluted in 60  $\mu$ l of AVE buffer, and frozen at  $-80^\circ\text{C}$  until SHIV RNA quantitation was performed. Five microliters of purified plasma RNA was reverse-transcribed in a final 20- $\mu$ l volume containing 50 mM KCl, 10 mM Tris-HCl (pH 8.3), 4 mM  $\text{MgCl}_2$ , 1 mM each deoxynucleotide triphosphate (dNTP), 2.5  $\mu$ M random hexamers, 20 units MultiScribe RT, and 8 units ribonuclease inhibitor. Reactions were incubated at  $25^\circ\text{C}$  for 10 min, followed by incubation at  $42^\circ\text{C}$  for 20 min, and inactivation of reverse transcriptase at  $99^\circ\text{C}$  for 5 min. The reaction mix was adjusted to a final volume of 50  $\mu$ l containing 50 mM KCl, 10 mM Tris-HCl (pH 8.3), 4 mM  $\text{MgCl}_2$ , 0.4 mM each dNTP, 0.2  $\mu$ M forward primer, 0.2  $\mu$ M reverse primer, 0.1  $\mu$ M probe, and 5 units AmpliTaq Gold DNA polymerase (all reagents from PerkinElmer Applied Biosystems, Foster City, CA). The primer sequences within a conserved portion of the SIV *gag* gene are the same as those described previously (S. Staprans *et al.* in: *Viral Genome Methods* K. Adolph, ed. CRC Press, Boca Raton, FL, 1996 pp. 167-184). A PerkinElmer Applied Biosystems 7700 Sequence Detection System was used with the PCR profile:  $95^\circ\text{C}$  for 10 min, followed by 40 cycles at  $93^\circ\text{C}$  for 30 s, and  $59.5^\circ\text{C}$  for 1 min. PCR product accumulation was monitored with the 7700 sequence detector and a probe to an internal conserved *gag* gene sequence: 6FAM-CTGTCTGCGTCATTTGGTGC-Tamra (SEQ ID NO: 8), where FAM and Tamra denote the reporter and quencher dyes. SHIV RNA copy number was determined by comparison with an external standard curve consisting of virion-derived SIVmac239 RNA quantified by the SIV bDNA method (Bayer Diagnostics, Emeryville, CA). All specimens were extracted and amplified in duplicate, with the mean result reported. With a 0.15-ml plasma input, the assay has a sensitivity of  $10^3$  RNA copies per milliliter of plasma and a linear dynamic range of  $10^3$  to  $10^8$  RNA copies ( $R^2 = 0.995$ ). The intraassay coefficient of variation was  $<20\%$  for samples containing  $>10^4$  SHIV RNA copies per milliliter, and



<25% for samples containing  $10^3$  to  $10^4$  SHIV RNA copies per milliliter. To more accurately quantitate low SHIV RNA copy number in vaccinated animals at weeks 16 and 20, we made the following modifications to increase the sensitivity of the SHIV RNA assay: (i) Virions from  $\leq 1$  ml of plasma were concentrated by centrifugation at 23,000g at  $10^\circ\text{C}$  for 150 min before viral RNA extraction, and (ii) a one-step reverse transcriptase PCR method was used (R. Hofmann-Lehmann *et al.* 2000 *AIDS Res Hum Retroviruses* 16:1247). These changes provided a reliable quantification limit of 300 SHIV RNA copies per milliliter, and gave SHIV RNA values that were highly correlated to those obtained by the first method used ( $r = 0.91$ ,  $P < 0.0001$ ).

By 8 weeks after challenge, both high-dose DNA-primed groups and the low-dose i.d. DNA-primed group had reduced their geometric mean loads to about 1000 copies of viral RNA per milliliter. At this time, the low-dose i.m. DNA-primed group had a geometric mean of  $6 \times 10^3$  copies of viral RNA and the nonvaccinated controls had a geometric mean of  $2 \times 10^6$ . By 20 weeks after challenge, even the low-dose i.m. group had reduced its geometric mean copies of viral RNA to 1000. Among the 24 vaccinated animals, only one animal, animal number 22 in the low-dose i.m. group, had intermittent viral loads above  $1 \times 10^4$  copies per milliliter (Fig 2D).

By 5 weeks after challenge, all of the nonvaccinated controls had undergone a profound depletion of CD4 cells (Fig 2B). All of the vaccinated animals maintained their CD4 cells, with the exception of animal 22 in the low dose i.m. group (see above), which underwent a slow CD4 decline (Fig. 2E). By 23 weeks after challenge, three of the four control animals had succumbed to AIDS (Fig. 2C). These animals had variable degrees of enterocolitis with diarrhea, cryptosporidiosis, colicystitis, enteric campylobacter infection, splenomegaly, lymphadenopathy, and SIV-associated giant cell pneumonia. In contrast, all 24 vaccinated animals maintained their health.

Containment of the viral challenge was associated with a burst of antiviral T cells (Fig. 1 and 3A). At one week after challenge, the frequency of tetramer<sup>+</sup> cells in the peripheral blood had decreased, potentially reflecting the recruitment of specific T cells to the site of infection (Fig. 3A). However, by two weeks after challenge, tetramer<sup>+</sup> cells in the peripheral blood had expanded to frequencies as high as, or higher than, after the rMVA booster (Fig. 1 and 3A). The majority of the tetramer<sup>+</sup> cells produced IFN- $\gamma$  in response to a 6-hour peptide stimulation (Fig. 3B) (S.L. Waldrop *et al.* 1997 *J Clin Invest* 99:1739) and

did not have the “stunned” IFN- $\gamma$  negative phenotype sometimes observed in viral infections (F. Lechner *et al.* 2000 *J Exp Med* 191:1499).

For intracellular cytokine assays, about  $1 \times 10^6$  PBMC were stimulated for 1 hour at 37°C in 5 ml polypropylene tubes with 100  $\mu$ g of Gag-CM9 peptide (CTPYDINQM) (SEQ ID NO: 6) per milliliter in a volume of 100  $\mu$ l RPMI containing 0.1% bovine serum albumin (BSA) and 1  $\mu$ g of antibody to human CD28 and 1  $\mu$ g of antibody to human CD49d (Pharmingen, San Diego, CA) per milliliter. Then, 900  $\mu$ l of RPMI containing 10% FBS and monensin (10  $\mu$ g/ml) was added, and the cells were cultured for an additional 5 hrs at 37°C at an angle of 5° under 5% CO<sub>2</sub>. Cells were surface stained with antibodies to CD8 conjugated to PerCP (clone SK1, Becton Dickinson) at 8° to 10°C for 30 min, washed twice with cold PBS containing 2% FBS, and fixed and permeabilized with Cytofix/Cytoperm solution (Pharmingen). Cells were then incubated with antibodies to human CD3 (clone FN-18; Biosource International, Camarillo, CA) and IFN- $\gamma$  (Clone B27; Pharmingen) conjugated to FITC and phycoerythrin, respectively, in Perm wash solution (Pharmingen) for 30 min at 4°C. Cells were washed twice with Perm wash, once with plain PBS, and resuspended in 1% paraformaldehyde in PBS. About 150,000 lymphocytes were acquired on the FACScaliber and analyzed with FloJo software.

The postchallenge burst of T cells contracted concomitant with the decline of the viral load. By 12 weeks after challenge, virus-specific T cells were present at about one-tenth of their peak height (Figs. 1A and 3A). In contrast to the vigorous secondary response in the vaccinated animals, the naive animals mounted a modest primary response (Fig. 1B and 3A). Tetramer<sup>+</sup> cells peaked at less than 1% of total CD8 cells (Fig. 3A), and IFN- $\gamma$ -producing ELISPOTs were present at a mean frequency of about 300 as opposed to the much higher frequencies of 1000 to 6000 in the vaccine groups (Fig. 1B) ( $P < 0.05$ ).

The tetramer<sup>+</sup> cells in the control group, like those in the vaccine group, produced IFN- $\gamma$  after peptide stimulation (Fig. 3B). By 12 weeks after challenge, three of the four controls had undetectable levels of IFN- $\gamma$ -producing ELISPOTs. This rapid loss of antiviral T cells in the presence of high viral loads may reflect the lack of CD4 help.

T cell proliferative responses demonstrated that virus-specific CD4 cells had survived the challenge and were available to support the antiviral immune response (Fig. 3C).

About 0.2 million PBMC were stimulated in triplicate for 5 days with the indicated antigen in 200  $\mu$ l of RPMI at 37°C under 5% CO<sub>2</sub>. Supernatants from 293T cells transfected with DNA expressing either SHIV-89.6 Gag and Pol or SHIV-89.6 Gag, Pol and Env were used directly as antigens (final concentration of ~0.5  $\mu$ g of p27 Gag per milliliter). Supernatants from mock DNA (vector alone)-transfected cells served as negative controls. On day six, cells were pulsed with 1  $\mu$ Ci of tritiated thymidine per well for 16 to 20 hours. Cells were harvested with an automated cell harvester (TOMTEC, Harvester 96, Model 1010, Hamden, CT) and counted with a Wallac 1450 MICROBETA Scintillation counter (Gaithersburg, MD). Stimulation indices are the counts of tritiated thymidine incorporated in PBMC stimulated with 89.6 antigens divided by the counts of tritiated thymidine incorporated by the same PBMC stimulated with mock antigen.

At 12 weeks after challenge, mean stimulation indices for Gag-Pol-Env or Gag-Pol proteins ranged from 35 to 14 in the vaccine groups but were undetectable in the control group. Consistent with the proliferation assays, intracellular cytokine assays demonstrated the presence of virus-specific CD4 cells in vaccinated but not control animals. The overall rank order of the vaccine groups for the magnitude of the proliferative response was 2.5 mg i.d. > 2.5 mg i.m. > 250  $\mu$ g i.d. > 250  $\mu$ g i.m.

At 12 weeks after challenge, lymph nodes from the vaccinated animals were morphologically intact and responding to the infection, whereas those from the infected controls had been functionally destroyed (Fig. 4). Nodes from vaccinated animals contained large numbers of reactive secondary follicles with expanded germinal centers and discrete dark and light zones (Fig. 4A). By contrast, lymph nodes from the non-vaccinated control animals showed follicular and paracortical depletion (Fig. 4B), while those from unvaccinated and unchallenged animals displayed normal numbers of minimally reactive germinal centers (Fig. 4C). Germinal centers occupied < 0.05% of total lymph node area in the infected controls, 2% of the lymph node area in the uninfected controls, and up to 18% of the lymph node area in the vaccinated groups (Fig. 4D). More vigorous immune reactivity in the low-dose than the high-dose DNA-primed animals was suggested by more extensive germinal centers in the low dose group (Fig. 4D). At 12 weeks after challenge, *in situ* hybridization for viral RNA revealed rare virus-expressing cells in lymph nodes from 3 of the 24 vaccinated macaques, whereas virus-expressing cells were readily detected in lymph nodes from each of the infected control animals. In the controls, which had

undergone a profound depletion in CD4 T cells, the cytomorphology of infected lymph node cells was consistent with a macrophage phenotype.

The prime/boost strategy raised low levels of antibody to Gag and undetectable levels of antibody to Env (Fig. 5). Postchallenge, antibodies to both Env and Gag underwent anamnestic responses with total Gag antibody reaching heights approaching 1 mg/ml and total Env antibody reaching heights of up to 100 µg/ml.

Enzyme-linked immunosorbent assays (ELISAs) for total antibody to Gag used bacterially produced SIV gag p27 to coat wells (2 µg per milliliter in bicarbonate buffer). ELISAs for antibody to Env antibody used 89.6 Env produced in transiently transfected 293T cells and captured with sheep antibody against Env (catalog number 6205; International Enzymes, Fairbrook CA). Standard curves for Gag and Env ELISAs were produced with serum from a SHIV-89.6-infected macaque with known amounts of immunoglobulin G (IgG) specific for Gag or Env. Bound antibody was detected with peroxidase-conjugated goat antibody to macaque IgG (catalog # YNGMOIGGFCP; Accurate Chemical, Westbury, NY) and TMB substrate (Catalog # T3405; Sigma, St. Louis, MO). Sera were assayed at threefold dilutions in duplicate wells. Dilutions of test sera were performed in whey buffer (4% whey and 0.1% tween 20 in 1X PBS). Blocking buffer consisted of whey buffer plus 0.5% nonfat dry milk. Reactions were stopped with 2M H<sub>2</sub>SO<sub>4</sub> and the optical density read at 450 nm. Standard curves were fitted and sample concentrations were interpolated as µg of antibody per ml of serum using SOFTmax 2.3 software (Molecular Devices, Sunnyvale, CA).

By 2 weeks after challenge, neutralizing antibodies for the 89.6 immunogen, but not the SHIV-89.6P challenge, were present in the high-dose DNA-primed groups (geometric mean titers of 352 in the i.d. and 303 in the i.m. groups) (Fig. 5C) (D.C. Montefiori *et al.* 1988 *J Clin Microbiol* 26:231). By 5 weeks after challenge, neutralizing antibody to 89.6P had been generated (geometric mean titers of 200 in the high-dose i.d. and 126 in the high-dose i.m. group) (Fig. 5D) and neutralizing antibody to 89.6 had started to decline. By 16 to 20 weeks after challenge, antibodies to Gag and Env had fallen in most animals.

Our results demonstrate that a multiprotein DNA/MVA vaccine can raise a memory immune response capable of controlling a highly virulent mucosal immunodeficiency virus challenge. Our levels of viral control were more favorable than have been achieved using only DNA (M.A. Egan *et al.* 2000 *J Virol* 74:7485) or rMVA vaccines (I. Ourmanov *et al.*



2000 *J Virol* 74:2740) and were comparable to those obtained for DNA immunizations adjuvanted with interleukin-2 (D.H. Barouch *et al.* 2000 *Science* 290:486). All of these previous studies have used more than three vaccine inoculations, none have used mucosal challenges, and most have challenged at peak effector responses and not allowed a prolonged post vaccination period to test for "long term" efficacy.

The dose of DNA had statistically significant effects on both cellular and humoral responses ( $P < 0.05$ ), whereas the route of DNA administration affected only humoral responses. Intradermal DNA delivery was about 10 times more effective than i.m. inoculations for generating antibody to Gag ( $P = 0.02$ ). Neither route nor dose of DNA appeared to have a significant effect on protection. At 20 weeks after challenge, the high-dose DNA-primed animals had slightly lower geometric mean levels of viral RNA ( $7 \times 10^2$  and  $5 \times 10^2$ ) than the low-dose DNA-primed animals ( $9 \times 10^2$  and  $1 \times 10^3$ ).

The DNA/MVA vaccine controlled the infection, rapidly reducing viral loads to near or below 1000 copies of viral RNA per milliliter of blood. Containment, rather than prevention of infection, affords the opportunity to establish a chronic infection (H.L. Robinson *et al.* 1999 *Nat Med* 5:526). By rapidly reducing viral loads, a multiprotein DNA/MVA vaccine will extend the prospect for long-term non-progression and limit HIV transmission. (J.W. Mellors *et al.* 1996 *Science* 272:1167; T.C. Quinn *et al.* 2000 *N Engl J Med* 342:921).

## EXAMPLE 2

### MVA Expressing Modified HIV Env, Gag, and Pol Genes

This disclosure describes the construction of a modified vaccinia Ankara (MVA) recombinant virus, MVA/HIV clade B recombinant virus expressing the HIV strain ADA env and the HXB2 gag pol (MVA/HIV ADA env + HXB2 gag pol). For amplification, the lab name of MVA/HIV 48 will be used, which denotes the plasmid from which the construct comes.

The HIV *gag-pol* genes were derived from the Clade B infectious HXB2 virus. The *gag-pol* gene was truncated so that most of the integrase coding sequences were removed and amino acids 185, 266, and 478 were mutated to inactivate reverse transcriptase, inhibit strand transfer activity, and inhibit the RNaseH activity, respectively. The Clade B CCR5 tropic envelope gene was derived from the primary ADA isolate; TTTTNT sequences were mutated without changing coding capacity to prevent premature transcription



termination and the cytoplasmic tail was truncated in order to improve surface expression, immunogenicity, and stability of the MVA vector. The HIV genes were inserted into a plasmid transfer vector so that *gag-pol* gene was regulated by the modified H5 early/late vaccinia virus promoter and the *env* gene was regulated by the newly designed early/late Psyn II promoter to provide similar high levels of expression. A self-deleting GUS reporter gene was included to allow detection and isolation of the recombinant virus. The HIV genes were flanked by MVA sequences to allow homologous recombination into the deletion 3 site so that the recombinant MVA would remain TK positive for stability and high expression in resting cells. The recombinant MVA was isolated and shown to express abundant amounts of *gag-pol-env* and to process *gag*. Production of HIV-like particles was demonstrated by centrifugation and by electron microscopy. The presence of *env* in the HIV-like particles was demonstrated by immunoelectron microscopy.

**Table of Sequences**

| Description            | SEQ ID NO | FIG. NO |
|------------------------|-----------|---------|
| pLW-48                 | 1         | A       |
| pLW-48                 | 1         | B       |
| Psyn II promoter       | 2         | B       |
| ADA envelope truncated | 3         | B       |
| PmH5 promoter          | 4         | B       |
| HXB2 <i>gag pol</i>    | 5         | B       |

#### Plasmid Transfer Vector

The plasmid transfer vector used to make the MVA recombinant virus, pLW-48, (Figure C) by homologous recombination was constructed as follows:

1. From the commercially obtained plasmid, pGem-4Z (Promega), flanking areas on either side of deletion III, designated flank 1 and flank 2, containing 926 and 520 base pairs respectively, were amplified by PCR from the MVA strains of vaccinia virus. Within these flanks, a promoter, the mH5, which had been modified from the originally published sequence by changing two bases that had been shown by previously published work to increase the expression of the cloned gene, was added.

2. A clade B gag pol (Figure D) was truncated so that the integrase was removed and was cloned into the plasmid so that it was controlled by the mH5 promoter. This gene contained the complete HXB2 sequence of the gag. The pol gene has reverse transcriptase safety mutations in amino acid 185 within the active site of RT, in amino acid 266 which inhibits strand transfer activity, and at amino acid 478 which inhibits the RNaseH activity. In addition, the integrase gene was deleted past EcoRI site.

3. A direct repeat of 280 basepairs, corresponding to the last 280 base pairs of MVA flank 1, was added after flank 1.

4. The p11 promoter and GUS reporter gene were added between the two direct repeats of flank 1 so that this screening marker could initially be used for obtaining the recombinant virus, yet deleted out in the final recombinant virus (Scheiflinger, F. *et al.* 1998 *Arch Virol* 143:467-474; Carroll, M.W. and B. Moss 1995 *BioTechniques* 19:352-355).

5. A new promoter, Psyn II, was designed to allow for increased expression of the ADA env. The sequence of this new early/late promoter is given in Figure E.

6. A truncated version of the ADA envelope with a silent STNT mutation was obtained by PCR and inserted in the plasmid under the control of the Psyn II promoter. The envelope was truncated in the cytoplasmic tail of the gp41 gene, deleting 115 amino acids of the cytoplasmic tail. This truncation was shown to increase the amount of envelope protein on the surface of infected cells and enhance immunogenicity of the envelope protein in mice, and stability of the recombinant virus in tissue culture.

#### Recombinant MVA Construction

1. MVA virus, which may be obtained from ATCC Number VR-1508, was plaque purified three times by terminal dilutions in chicken embryo fibroblasts (CEF), which were made from 9 day old SPF Premium SPAFAS fertile chicken eggs, distributed by B and E Eggs, Stevens, PA.

2. Secondary CEF cells were infected at an MOI of 0.05 of MVA and transfected with 2  $\mu$ g of pLW-48, the plasmid described above. Following a two day incubation at 37°C, the virus was harvested, frozen and thawed 3x, and plated out on CEF plates.

3. At 4 days, those foci of infection that stained blue after addition of X-gluc substrate, indicating that recombination had occurred between the plasmid and the infecting

virus, were picked and inoculated on CEF plates. Again, those foci that stained blue were picked.

4. These GUS containing foci were plated out in triplicate and analyzed for GUS staining (which we wanted to now delete) and ADA envelope expression. Individual foci were picked from the 3rd replicate plates of those samples that had about equal numbers of mixed populations of GUS staining and nonstaining foci as well as mostly envelope staining foci.

5. These foci were again plated out in triplicate, and analyzed the same way. After 5 passages, a virus was derived which expressed the envelope protein but which had deleted the GUS gene because of the double repeat. By immunostaining, this virus also expressed the gag pol protein.

#### Characterization of MVA Recombinant Virus, MVA/HIV 48

1. Aliquots of MVA/HIV 48 infected cell lysates were analyzed by radioimmunoprecipitation and immunostaining with monoclonal antibodies for expression of both the envelope and gag pol protein. In both of these tests, each of these proteins was detected.

2. The recombinant virus was shown to produce gag particles in the supernatant of infected cells by pelleting the <sup>35</sup>S-labeled particles on a 20% sucrose cushion.

3. Gag particles were also visualized both outside and budding from cells as well as within vacuoles of cells in the electron microscope in thin sections. These gag particles had envelope protein on their surface.

Unless otherwise indicated, all nucleotide sequences determined by sequencing a DNA molecule herein were determined using an automated DNA sequencer, and all amino acid sequences of polypeptides encoded by DNA molecules determined herein were predicted by translation of a DNA sequence determined as above. Therefore, as is known in the art for any DNA sequence determined by this automated approach, any nucleotide sequence determined herein may contain some errors. Nucleotide sequences determined by automation are typically at least about 90% identical, more typically at least about 95% to at least about 99.9% identical to the actual nucleotide sequence of the sequenced DNA molecule. The actual sequence can be more precisely determined by other approaches including manual DNA sequencing methods well known in the art. As is also known in the art, a single insertion or deletion in a determined nucleotide sequence compared to the

actual sequence will cause a frame shift in translation of the nucleotide sequence such that the predicted amino acid sequence encoded by a determined nucleotide sequence will be completely different from the amino acid sequence actually encoded by the sequenced DNA molecule, beginning at the point of such an insertion or deletion.

#### Summary

In summary, we have made a recombinant MVA virus, MVA/HIV 48, which has high expression of the ADA truncated envelope and the HXB2 gag pol. The MVA recombinant virus is made using a transiently expressed GUS marker that is deleted in the final virus. High expression of the ADA envelope is possible because of a new hybrid early/late promoter, Psyn II. In addition, the envelope has been truncated because we have shown truncation of the envelope enhances the amount of protein on the surface of the infected cells, and hence enhances immunogenicity; stability of the recombinant is also enhanced. The MVA recombinant makes gag particles which has been shown by pelleting the particles through sucrose and analyzing by PAGE. Gag particles with envelope protein on the surface have also been visualized in the electron microscope.

#### EXAMPLE 3

##### Additional Modified or Synthetic Promoters Designed for Gene Expression in MVA Or Other Poxviruses

Additional modified or synthetic promoters were designed for gene expression in MVA or other poxviruses. Promoters were modified to allow expression at early and late times after infection and to reduce possibility of homologous recombination between identical sequences when multiple promoters are used in same MVA vector. Promoters are placed upstream of protein coding sequence.

##### **m7.5 promoter (SEQ ID NO:10):**

CGCTTTTATAGTAAGTTTTTCACCCATAAATAATAACAATAATTAATTCT  
CGTAAAAATTGAAAAACTATTCTAATTTATTGCACGGT

##### **Psyn II promoter (SEQ ID NO:2):**

TAAAAAATGAAAAAATATTCTAATTTATAGGACGGTTTTGATTTTCTTTTTTCT  
ATGCTATAAATAATAATA

**Psyn III promoter (SEQ ID NO:11):**

TAAAAATTGAAAAAATATTCTAATTTATAGGACGGTTTTGATTTTCTTTTTTTCT  
ATACTATAAATAATAAATA

**Psyn IV promoter (SEQ ID NO:12):**

TAAAAATTGAAAAACTATTCTAATTTATAGGACGGTTTTGATTTTCTTTTTTTCT  
ATACTATAAATAATAAATA

**Psyn V promoter (SEQ ID NO:13):**

AAAAAATGATAAAGTAGGTTTCAGTTTTATTGCTGGTTTAAAATCACGCTTTCGA  
GTAAAAACTACGAATATAAAT

**EXAMPLE 4****Tables A-F****Table A: MVA/48 immunization – guinea pigs.**

Groups of guinea pigs were immunized at days 0 and 30 with  $1 \times 10^8$  infectious units of MVA/48 by either the intramuscular (IM) or intradermal (ID) route. As a control another group was immunized IM with the same dose of non-recombinant MVA. Sera taken before as well as after each immunization was analyzed for neutralizing activity against HIV-1-MN. Titers are the reciprocal serum dilution at which 50% of MT-2 cells were protected from virus-induced killing. Significant neutralizing activity was observed in all animals after the second immunization with MVA/48 (day 49).

**Table B: Frequencies of HIV-1 gag-specific T cells following immunization of mice with MVA/48.**

Groups of BalbC mice were immunized at days 0 and 21 with  $1 \times 10^7$  infectious units of MVA/48 by one of three routes: intraperitoneal (IP), intradermal (ID), or intramuscular (IM). A control group was immunized with non-recombinant MVA. At 5 weeks after the last immunization, splenocytes were prepared and stimulated *in vitro* with an immunodominant peptide from HIV-1 p24 for 7 days. The cells were then mixed either with peptide-pulsed P815 cells or with soluble peptide. Gamma interferon-producing cells were enumerated in an ELISPOT assay. A value of >500 was assigned to wells containing too many spots to count. Strong T cell responses have been reported in mice immunized IP



with other viruses. In this experiment, IP immunization of mice with MVA/48 elicited very strong HIV-1 gag-specific T cell responses.

Table C: DNA prime and MVA/48 boost – total ELISPOTS per animal.

Ten rhesus macaques were primed (weeks 0 and 8) with a DNA vaccine expressing HIV-1 antigens including Ada envelope and HXB2 gagpol. At week 24 the animals were boosted intramuscularly with  $1 \times 10^8$  infectious units of MVA/48. Fresh peripheral blood mononuclear cells (PBMC) were analyzed for production of gamma interferon in an ELISPOT assay as follows: PBMC were incubated for 30-36 hours in the presence of pools of overlapping peptides corresponding to the individual HIV-1 antigens in the vaccines. The total number of gamma interferon-producing cells from each animal is shown in the table. T cell responses to DNA vaccination were limited (weeks 2-20). However, boosting with MVA/48 resulted in very strong HIV-1-specific T cell responses in all animals (week 25).

Table D: Antibody response following immunization of macaques with MVA/SHIV KB9.

Groups of rhesus macaques were immunized with  $2 \times 10^8$  infectious units of MVA/SHIV-KB9 at weeks 0 and 4 by one of several routes: Tonsillar, intradermal (ID), or intramuscular (IM). Another group was immunized with non-recombinant MVA using the same routes. Serum samples from 2 weeks after the second immunization were analyzed for binding to KB9 envelope protein by ELISA and for neutralization of SHIV-89.6P and SHIV-89.6. In the ELISA assay, soluble KB9 envelope protein was captured in 96 well plates using an antibody to the C-terminus of gp120. Serial dilutions of sera were analyzed and used to determine the endpoint titers. Neutralization of SHIV-89.6P and SHIV-89.6 was determined in an MT-2 cell assay. Titers are the reciprocal serum dilution at which 50% of the cells were protected from virus-induced killing. In *in vitro* neutralization assays, SHIV-89.6P and SHIV-89.6 are heterologous, i.e. sera from animals infected with one of the viruses does not neutralize the other virus. Thus, two immunizations with MVA/SHIV-KB9 elicited good ELISA binding antibodies in all animals and neutralizing antibodies to the homologous virus (SHIV-89.6P) in some animals. In addition, heterologous neutralizing antibodies were observed in a subset of animals.

Table E: Frequencies of gag CM-9-specific CD3/CD8 T cells following immunization of macaques with MVA/SHIV-KB9.

Groups of MamuA\*01 positive rhesus macaques were immunized with  $2 \times 10^8$  infectious units of MVA/SHIV-KB9 at weeks 0 and 4 by one of several routes: tonsillar, intradermal (ID), or intramuscular (IM). Another group was immunized with non-recombinant MVA. The frequencies of CD3+/CD8+ T cells that bound tetrameric complex containing the SIV gag-specific peptide CM9 were determined by flow cytometry at various times after each immunization. Time intervals were as follows: 1a, 1b, and 1d were one, two, and four weeks after the first immunization, respectively; 2a, 2b, 2c, and 2d were one, two, three, and twelve weeks after the second immunization, respectively. Values above background are shown in bold face. Strong SIV gag-specific responses were observed after a single immunization with MVA/SHIV-KB9 in all immunized animals. Boosting was observed in most animals following the second immunization. In addition, measurable tetramer binding was still found twelve weeks after the second immunization.

Table F: Frequencies of specific T cells following immunization of macaques with MVA/SHIV KB9.

Groups of macaques were immunized with MVA/SHIV-KB9 as described above. MVA/SHIV-KB9 expresses 5 genes from the chimeric virus, SHIV-89.6P: envelope, gag, polymerase, tat, and nef. Thus, the frequencies of T cells specific for each of the 5 antigens was analyzed using pools of peptides corresponding to each individual protein. Fresh PBMC were stimulated with pools of peptides for 30-36 hours in vitro. Gamma interferon-producing cells were enumerated in an ELISPOT assay. The total number of cells specific for each antigen is given as "total # spots". In addition, the number of responding animals and average # of spots per group is shown. PBMC were analyzed at one week after the first immunization (1a) and one week after the second immunization (2a). Another group of 7 animals was immunized with non-recombinant MVA. In these animals, no spots above background levels were detected. Thus, a single immunization with MVA/SHIV-KB9 elicited strong SHIV-specific T cell responses in all animals. Gag and envelope responses were the strongest; most animals had responses to gag, all animals had responses to envelope. The Elispot responses were also observed after the second immunization with MVA/SHIV-KB9, albeit at lower levels. At both times, the rank order of responses was: tonsillar > ID > IM. We show good immune response to nef and some immune response to tat.

**TABLE A**

**MVA/48 immunization – guinea pigs**  
**HIV-MN neutralizing antibody - reciprocal titer**

| Animal # | Group  | Route | day 0 | Day 4<br>MVA #1 | day 30 | day 33<br>MVA#2 | day 49 |
|----------|--------|-------|-------|-----------------|--------|-----------------|--------|
| 885      | MVA    | I.M.  | <20   | I.M.            | 31     | I.M.            | 24     |
| 891      | "      | "     | <20   | "               | 85     | "               | <20    |
| 882      | MVA/48 | I.M.  | <20   | I.M.            | <20    | I.M.            | 5,524  |
| 883      | "      | "     | <20   | "               | 68     | "               | 691    |
| 886      | "      | "     | <20   | "               | <20    | "               | 4,249  |
| 890      | "      | "     | <20   | "               | 180    | "               | 89     |
| 879      | MVA/48 | I.D.  | <20   | I.D.            | <20    | I.D.            | 817    |
| 881      | "      | "     | <20   | "               | <20    | "               | 234    |
| 888      | "      | "     | <20   | "               | 24     | "               | 112    |
| 889      | "      | "     | <20   | "               | 22     | "               | 376    |

**TABLE B**

**Frequencies of HIV-gag-specific T cells following immunization of mice**  
**with MVA/48**

| <u>Group</u> | <u>P815 cells + gag peptide</u> |      | <u>gag peptide</u> |      | <u>no stimulation</u> |   |
|--------------|---------------------------------|------|--------------------|------|-----------------------|---|
| MVA control  | 0                               | 2    | 0                  | 4    | 1                     | 2 |
| MVA/48 (IP)  | >500                            | >500 | >500               | >500 | 8                     | 8 |
| MVA/48 (ID)  | 12                              | 5    | 49                 | 33   | 4                     | 2 |
| MVA/48 (IM)  | 22                              | 18   | 66                 | 49   | 12                    | 8 |

TABLE C

**DNA prime and MVA/48 boost  
Total ELISPOTS per Animal**

| Animal # | WEEKS          |       |     |                 |                 |                 |                 |
|----------|----------------|-------|-----|-----------------|-----------------|-----------------|-----------------|
|          | -2             | 2     | 6   | 10 <sup>2</sup> | 14 <sup>2</sup> | 20 <sup>2</sup> | 25 <sup>2</sup> |
| RLw      | 4              | 731*  | <   | 47              | 43              | 50              | 3905            |
| RVl      | 5              | 997*  | <   | <               | <               | 8               | 205             |
| Roa      | < <sup>1</sup> | <     | 1   | <               | <               | <               | 245             |
| RHc      | <              | <     | <   | <               | <               | <               | 535             |
| Ryl      | <              | <     | <   | <               | <               | <               | 4130            |
| RQk      | <              | 46    | <   | <               | <               | <               | 630             |
| RDr      | <              | <     | <   | 14              | <               | <               | 1965            |
| RZc      | <              | 5     | <   | 58              | <               | <               | 925             |
| RSf      | <              | 118   | <   | <               | <               | 20              | 5570            |
| Ras      | <              | 69    | <   | <               | <               | <               | 1435            |
| Total    | 9              | 1966  | 1   | 119             | 43              | 78              | 19545           |
| Geo Mean | 4.5            | 105.3 | 1.0 | 33.7            | 43.0            | 20.0            | 1147.7          |

DNA primes were at 0 and 8 weeks and MVA/48 boost was at 24 weeks

<sup>1</sup> < = Background (2x the number of ELISPOTs in the unstimulated control + 10)

<sup>2</sup>Costimulatory antibodies were added to the ELISPOT incubations

\* Animals from this bleed date exhibited higher than usual ELISPOTs.

**TABLE D****Antibody response following immunization of macaques with MVA/SHIV KB9**

| Animal # | Route   | KB9 env     | KB9 env elisa |          | SHIV-89.6 | SHIV-89.6P | SHIV-89.6     | SHIV-89.6P    |
|----------|---------|-------------|---------------|----------|-----------|------------|---------------|---------------|
|          |         | ELISA titer | average       | std dev. | Nab titer | Nab titer  | # pos animals | # pos animals |
| 598      | tonsil  | 25,600      | 31,086        | 20,383   | <20       | <20        | 3             | 2             |
| 601      | "       | 51,200      |               |          | <20       | <20        |               |               |
| 606      | "       | 25,600      |               |          | <20       | <20        |               |               |
| 642      | "       | 51,200      |               |          | 75        | 31         |               |               |
| 646      | "       | 51,200      |               |          | 61        | 48         |               |               |
| 653      | "       | 6,400       |               |          | <20       | <20        |               |               |
| 654      | "       | 6,400       |               |          | 22        | <20        |               |               |
| 602      | i.d.    | 25,600      | 18,800        | 15,341   | 38        | <20        | 2             | 4             |
| 604      | "       | 12,800      |               |          | <20       | 262        |               |               |
| 608      | "       | 3,200       |               |          | 20        | 66         |               |               |
| 637      | "       | 12,800      |               |          | <20       | 35         |               |               |
| 638      | "       | 51,200      |               |          | <20       | <20        |               |               |
| 645      | "       | 25,600      |               |          | <20       | <20        |               |               |
| 647      | "       | 12,800      |               |          | 32        | 162        |               |               |
| 650      | "       | 6,400       |               |          | <20       | <20        |               |               |
| 599      | i.m.    | 6,400       | 17,000        | 16,516   | <20       | <20        | 0             | 3             |
| 600      | "       | 6,400       |               |          | <20       | 29         |               |               |
| 609      | "       | 6,400       |               |          | <20       | <20        |               |               |
| 639      | "       | 51,200      |               |          | <20       | 85         |               |               |
| 640      | "       | 12,800      |               |          | <20       | <20        |               |               |
| 641      | "       | 25,600      |               |          | <20       | 41         |               |               |
| 649      | "       | 1,600       |               |          | <20       | <20        |               |               |
| 651      | "       | 25,600      |               |          | 20        | <20        |               |               |
| 603      | Control | <100        | <100          |          | <20       | <20        | 0             | 0             |
| 605      | "       | <100        |               |          | <20       | <20        |               |               |
| 607      | "       | <100        |               |          | <20       | <20        |               |               |
| 643      | "       | <100        |               |          | <20       | <20        |               |               |
| 644      | "       | <100        |               |          | <20       | <20        |               |               |
| 648      | "       | <100        |               |          | <20       | <20        |               |               |
| 652      | "       | <100        |               |          | <20       | <20        |               |               |



**TABLE E**

**Frequencies of gag CM9-specific CD3/CD8 T cells following immunization of macaques with MVA/SHIV KB9**

| Animal # | Route  | Virus    | pre-bleed | 1a    | 1b    | 1d    | 2a    | 2b    | 2c    | 2d    |
|----------|--------|----------|-----------|-------|-------|-------|-------|-------|-------|-------|
| 598      | Tonsil | MVA/K B9 | 0.018     | 0.41  | 0.79  | 0.25  | 2.64  | 1.13  | 0.51  | 0.21  |
| 601      | "      | "        | 0.071     | 0.34  | 0.38  | 0.27  | 0.83  | 0.7   | 0.36  | 0.039 |
| 646      | "      | "        | 0.022     | 0.68  | 0.76  | 0.43  | 1.12  | 0.91  | 0.53  | 0.15  |
| 653      | "      | "        | 0.041     | 0.69  | 0.85  | 0.53  | 0.68  | 0.49  | 0.47  | 0.3   |
| 648      | "      | MVA      |           | 0.033 | 0.039 |       | 0.022 | 0.058 | 0.033 | 0.013 |
| 602      | i.d.   | MVA/K B9 | 0.019     | 0.17  | 0.92  | 0.5   | 0.95  | 0.59  | 0.5   | 0.2   |
| 604      | "      | "        | 0.013     | 0.11  | 0.38  | 0.32  | 0.44  | 0.38  | 0.19  | 0.25  |
| 650      | "      | "        | 0.095     | 0.17  | 0.6   | 0.23  | 2.87  | 1.12  | 0.9   | 0.16  |
| 647      | "      | "        | 0.032     | 0.22  | 0.38  | 0.14  | 0.84  | 0.91  | 0.34  | 0.17  |
| 652      | "      | MVA      |           | 0.041 | 0.038 | 0.059 | 0.025 | 0.022 | 0.026 | 0.055 |
| 599      | i.m.   | MVA/K B9 |           | 0.081 | 0.31  | 0.082 |       | 0.12  | 0.054 | 0.11  |
| 600      | "      | "        | 0.034     | 0.15  | 0.41  | 0.17  | 0.29  | 0.27  | 0.16  | 0.049 |
| 649      | "      | "        | 0.00486   | 0.35  | 1.34  | 0.56  | 2.42  | 0.77  | 0.69  | 0.22  |
| 651      | "      | "        | 0.049     | 0.12  | 0.69  | 0.25  | 1.01  | 0.32  | 0.24  | 0.22  |
| 603      | "      | MVA      |           | 0.024 | 0.087 | 0.073 |       | 0.082 | 0.027 | 0.17  |

TABLE F

Frequencies of specific T cells following immunization of macaques with MVA/SHIV KB9

| Study groups | Gag specific         |               |                 |                      | Tat specific         |               |                 |                      | Nef specific         |               |                 |                      | Env specific |                 |                      | Total |
|--------------|----------------------|---------------|-----------------|----------------------|----------------------|---------------|-----------------|----------------------|----------------------|---------------|-----------------|----------------------|--------------|-----------------|----------------------|-------|
|              | # responding animals | Total # spots | average # spots | # responding animals | # responding animals | total # spots | average # spots | # responding animals | # responding animals | total # spots | average # spots | # responding animals | total spots  | Average # spots | # responding animals | Total |
| tonsil 1a    | 4/6                  | 1325          | 221             | 0/6                  | 0                    | 0             | 0               | 3/6                  | 195                  | 33            | 6/6             | 8760                 | 1460         | 6/6             | 6/6                  |       |
| tonsil 2a    | 5/6                  | 1405          | 234             | 0/6                  | 0                    | 0             | 0               | 1/6                  | 560                  | 93            | 6/6             | 4485                 | 748          | 6/6             | 6/6                  |       |
| i.d. 1a      | 7/7                  | 1335          | 191             | 0/7                  | 0                    | 0             | 0               | 2/7                  | 215                  | 31            | 7/7             | 7320                 | 1046         | 7/7             | 7/7                  |       |
| i.d. 2a      | 4/7                  | 755           | 108             | 0/7                  | 0                    | 0             | 0               | 1/7                  | 55                   | 8             | 7/7             | 2700                 | 386          | 7/7             | 7/7                  |       |
| i.m. 1a      | 7/7                  | 925           | 132             | 1/7                  | 60                   | 9             | 3/7             | 180                  |                      | 26            | 7/7             | 5490                 | 784          | 7/7             | 7/7                  |       |
| i.m. 2a      | 4/7                  | 250           | 36              | 0/7                  | 0                    | 0             | 0/7             | 0                    |                      | 0             | 6/7             | 2205                 | 315          | 6/7             | 6/7                  |       |

\*\*\*\*\*

While the present invention has been described in some detail for purposes of clarity and understanding, one skilled in the art will appreciate that various changes in form and detail can be made without departing from the true scope of the invention. All patents, patent applications and publications referred to above are hereby incorporated by reference.

WHAT IS CLAIMED IS:

1. A pharmaceutical composition comprising a recombinant MVA virus expressing an HIV *env*, *gag*, and *pol* gene or modified gene thereof for production of an HIV Env, Gag, and Pol antigen by expression from said recombinant MVA virus, wherein said HIV *env* gene is modified to encode an HIV Env protein composed of gp120 and the membrane-spanning and ectodomain of gp41 but lacking part or all of the cytoplasmic domain of gp41, and a pharmaceutically acceptable carrier.
2. The pharmaceutical composition of claim 1, wherein said HIV *pol* gene or modified gene thereof is modified to inactivate reverse transcriptase and integrase.
3. The pharmaceutical composition of claim 1, wherein said HIV *env*, *gag*, or *pol* gene or modified gene thereof is taken from clade A.
4. The pharmaceutical composition of claim 1, wherein said HIV *env*, *gag*, or *pol* gene or modified gene thereof is taken from clade B.
5. The pharmaceutical composition of claim 1, wherein said HIV *env*, *gag*, or *pol* gene or modified gene thereof is taken from clade C.
6. The pharmaceutical composition of claim 1, wherein said HIV *env*, *gag*, or *pol* gene or modified gene thereof is taken from clade D.
7. The pharmaceutical composition of claim 1, wherein said HIV *env*, *gag*, or *pol* gene or modified gene thereof is taken from clade E.
8. The pharmaceutical composition of claim 1, wherein said HIV *env*, *gag*, or *pol* gene or modified gene thereof is taken from clade F.
9. The pharmaceutical composition of claim 1, wherein said HIV *env*, *gag*, or *pol* gene or modified gene thereof is taken from clade G.
10. The pharmaceutical composition of claim 1, wherein said HIV *env*, *gag*, or *pol* gene or modified gene thereof is taken from clade H.
11. The pharmaceutical composition of claim 1, wherein said HIV *env*, *gag*, or *pol* gene or modified gene thereof is taken from clade J.
12. The pharmaceutical composition of claim 1 wherein said HIV *env*, *gag*, or *pol* gene or modified gene thereof is inserted at the site of deletion III within the MVA genome.

13. The pharmaceutical composition of claim 1 wherein said HIV *env*, *gag*, or *pol* gene or modified gene thereof is under transcriptional initiation regulation of a H5-like early/late vaccinia virus promoter.

14. The pharmaceutical composition of claim 1 wherein recombinant MVA virus additionally expresses an additional HIV gene or modified gene thereof for production of an HIV antigen by expression from said recombinant MVA virus, wherein said additional HIV gene is a member selected from the group consisting of *vif*, *vpr*, *tat*, *rev*, *vpu*, and *nef*.

15. MVA/HIV48 comprising SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, and SEQ ID NO:5.

16. pLW-48 having SEQ ID NO:1.

17. A plasmid transfer vector having the sequence of pLW-48 (SEQ ID NO:1) excluding the HIV *env*, *gag*, and *pol* genes.

18. pLW-48 (SEQ ID NO:1) wherein the HIV *env*, *gag*, and *pol* genes have a sequence taken from another clade.

19. A poxvirus comprising a promoter selected from the group consisting of m7.5 promoter having SEQ ID NO:10, Psyn II promoter having SEQ ID NO:2, Psyn III promoter having SEQ ID NO:11, Psyn IV promoter having SEQ ID NO:12, and Psyn V promoter having SEQ ID NO:13.

20. A method of boosting a CD8<sup>+</sup> T cell immune response to an HIV Env, Gag, or Pol antigen in a primate, the method comprising provision in the primate of a composition of any of claims 1-15, whereby a CD8<sup>+</sup> T cell immune response to the antigen previously primed in the primate is boosted.

21. A method of inducing a CD8<sup>+</sup> T cell immune response to an HIV Env, Gag, or Pol antigen in a primate, the method comprising provision in the primate of a composition of any of claims 1-15, whereby a CD8<sup>+</sup> T cell immune response to the antigen in the primate is induced.

22. A method of inducing a CD8<sup>+</sup> T cell immune response to an HIV Env, Gag, or Pol antigen in a primate, the method comprising provision in the primate of a priming composition comprising nucleic acid encoding said antigen and then provision in the primate of a boosting composition which comprises any of claims 1-15, whereby a CD8<sup>+</sup> T cell immune response to the antigen is induced.



23. The method of any of Claims 20-22, wherein the primate is a human.
24. The method of any of Claims 20-22, wherein administration of the recombinant MVA virus is by needleless injection.
25. The method of Claim 22, wherein the priming composition comprises plasmid DNA encoding said antigen.
26. A method of making a composition of any of claims 1-15 comprising preparing a plasmid transfer vector encoding an HIV *env*, *gag*, and *pol* gene or modified gene thereof, wherein said HIV *env* gene is modified to encode an HIV Env protein composed of gp120 and the membrane-spanning and ectodomain of gp41 but lacking part or all of the cytoplasmic domain of gp41, and recombining said plasmid transfer vector with a MVA virus to produce a composition of any of claims 1-15.




Figure I




Figure II

| Chemokine<br>coreceptor used | PBMC<br>replication | Macrophage<br>replication | T-cell-line<br>replication | Replicative<br>phenotype | Syncytium-inducing<br>phenotype |
|------------------------------|---------------------|---------------------------|----------------------------|--------------------------|---------------------------------|
| X4                           | +                   | -                         | +                          | Rapid/high               | ++                              |
| R5                           | +                   | +                         | -                          | Slow/low                 | -                               |
| R5/X4                        | +                   | +                         | +                          | Rapid/high               | +                               |

Figure III




Figure IV






Figure V





Figure VI






Figure 2








Figure 4




Figure 5

12/54





Figure 6



*FIG. A,*

1 GAATTCGTTG GTGGTCGCCA TGGATGGTGT TATTGTATAC TGCTAAACG CGTTAGTAA ACATGCCGAG  
CTAAGCAAC CACCAGCGT ACCTACCACA ATACATATG ACAGATTGC GCAATCATTT TGTACCGCTC

71 GAAATAATC ATATAAAA TGATTTCATG ATTAAACCAT GTTGTAAGAA AGTCAAGAAC GTTCACATTG  
CTTTATTAG TATATTTT ACTAAAGTAC TAATTGGTA CAACACTTTT TCAGTTCTTG CAAGTGTAAC

141 GCGGACAATC TAAACAAT ACAGGATTG CAGATTGCC ATATATGGAT AATGCGGTAT CCGATGTATG  
CGCTGTTAG ATTTTGTG TGCTACTAAC GTCTAAACGG TATATACCTA TTACGCCATA GGCTACATAC

211 CAATTCACCTG TATAAAGA ATGTATCAAG AATATCCAGA TTTGCTAATT TGATAAAGAT AGATGACGAT  
GTTAAGTGAC ATATTTTCT TACATAGTCT TTATAGGTCT AAACGATTAA ACTATTCTA TCTACTGCTA

281 GACAAGACTC CTAAGTGTGT ATATAATTAT TTAAACCTA AAGATGCCAT TCCGTATTAT ATATCCATAG  
CTGTTCTGAG GATGACCACA TATATTAATA AAATTGGAT TTCTACGGTA AGGACAAATA TATAGGTATC

351 GAAAGGATAG AGATGTTGT GAACTATTAA TCTCATCTGA TAAAGCGTGT CCGGTATAG AGTTAAATTC  
CTTCCCTATC TCTACAAACA CTTGATAATT AGAGTAGACT ATTTCCGACA CGCACATATC TCAATTTAAG

*FIG. A<sub>2</sub>*



421 ATATAAAGTA GCCATTCTTC CCATGGATGT TTCCTTTTTT ACCAAAGGAA ATGCATCATT GATTATTCTC  
TATAITTCAT CCGTAAGAAG GGTACCCTACA AAGGAAAAAA TGGTTTCCTT TACGTAGTAA CTAATAAGAG

491 CTGTTTGATT TCTCTATCGA TCGGGCACCT CTCTTAAGAA GTGTAACCGA TAATAATGTT ATTATATCTA  
GACAAACTAA AGAGATAGCT ACGCCGTGGA GAGAATTCCT CACATTGGCT ATTATTACAA TAATATAGAT

561 GACACCAGCG TCTACATGAC GAGCTTCCGA GTTCCAATTG GTTCAAGTTT TACATAAGTA TAAAGTCCGA  
CTGTGGTCGC AGATGTACTG CTCGAAGGCT CAAGTTAAC CAAGTTCAAA ATGTATTCAT ATTCAGGCT

631 CTATTGTTCT ATATTATATA TGGTTGTTGA TGGATCTGTG ATGCATGCAA TAGCTGATAA TAGAACTTAC  
GATAACAAGA TATAATATAT ACCAACAACT ACCTAGACAC TAGGTACGTT ATCGACTATT ATCTTGAATG

701 GCAAATATTA GCAAATAT ATTACACAAT ACTACAATTA ACGATGAGTG TAGATGCTGT TATTTTGAAC  
CGTTTATAAT CGTTTTTATA TAATCTGTTA TGATCTTAAT TGCTACTCAC ATCTACGACA ATAAAACTTG

*FIG. A<sub>2</sub> cont.*

771 CACAGATTAG GATTCTTGAT AGAGATGAGA TGCTCAATCG ATCATCGTGT GATATGAACA GACATTGTAT  
GTGCTAATC CTAAGAACTA TCTCTACTCT ACGAGTTACC TAGTAGCACA CTATACTTGT CTGTAACATA

841 TATGATGAAT TTACCTGATG TAGGCCAATT TGGATCTAGT ATGTTGGGA AATATGAACC TGACATGATT  
ATACTACTTA AATGGACTAC ATCCGCTTAA ACCTAGATCA TACAACCCCT TTATACTTGG ACTGTACTAA

911 AAGATTGCTC TTTCGGTGGC TGGGTACCAG GCGCGCCTTT CATTTTGTTT TTTTCTATGC TATAAATGGT  
TTCTAACGAG AAAGCCACCG ACCCATGGTC CGCGCGGAAA GTAAACAAA AAAAGATACG ATATTACCA

981 ACGTCCTGTA GAAACCCCA CCGTGAAAT CAAAAACTC GACGGCCTGT GGCATTCAG TCTGGATCGC  
TGCAGGACAT CTTTGGGGT GGGCACTTA GTTTTTGAG CTGCGGACA CCCGTAAGTC AGACCTAGCG

1051 GAAAACTGTG GAATTGATCA GCGTTGCTCG GAAAGCCCGT TACAAGAAAG CCGGCCAATT CCGTGCCAG  
CTTTTGACAC CTTAACTAGT CGCAACCACC CTTTCGGCA ATGTTCTTC GCGCCGTAA CGACACGGTC

*FIG. A<sub>2</sub> cont.*

1121 GCAGTTTTAA CGATCAGTTC GCCGATGCCAG ATATTCCCTAA TTATGCGGGC AACGTCTGGT ATCAGCGCGCA  
CGTCAAAATT GCTAGTCAAG CCGCTACGTC TATAAGCATT AATACGCCCG TTCCAGACCA TAGTCCGCGCT

1191 ACTCTTTATA CCGAAAGGTT GGCAGGGCCA GCGTATCGTG CTGCGTTTCG ATGCGGTCAC TCATTACGGC  
TCAGAAATAT GGCTTTCCAA CCCGTCCGGT CCGATAGCAC GACGCCAAGC TACGCCAGTG AGTAAATGCCG

1261 AAAGTCTGGG TCAATAATCA GGAAGTGATG GAGCATCAGG GCGGCTATAC GCCATTGAA GCCGATGTCA  
TTTCACACCC AGTTATTAGT CCTTCACTAC CTCGTAGTCC GCGCGATATG CCGTAAACTT CCGCTACAGT

1331 CGCCGTATGT TATTGCCGGG AAAAGTGATG GTATCACCGT TTGTGTGAAC AACGAACGA ACTGCCAGAC  
GCGGCATACA ATACGGCCC TTTTCACATG CATAGTGCCA AACACACTG TTGCTTGACT TGACCGTCTG

1401 TATCCCGCCG GGAATGGTGA TTACCGACGA AACGGCAAG AAAAGCAGT CTTACTTCCA TGATTCTTT  
ATAGGGCCGC CCTTACCACT AATGGCTGCT TTTGCCGTTT TTTTCGTCA GAATGAAGGT ACTAAAGAAA

1471 AACTATGCCG GAATCCATCG CAGCGTAATG CTCTACACCA CGCCGAACAC CTGGGTGGAC GATATCACCG  
TTCATACGGC CTTAGGTAGC GTCGCATTAC GAGATGTGGT CCGGCTTGTC GACCCACCTG CTATAGTGCC

*FIG. A<sub>2</sub> cont.*

1541 TGGTGACGCA TGTGCGGCAA GACTGTAAACC ACGCGTCTGT TGA CTGGCAG GTGGTGCCCA ATGGTGATGT  
ACCACTGCCGT ACAGCGCGGT CTGACATTGG TGGCAGACA ACTGACCCGC CACCACCGGT TACCACTACA

1611 CAGCGTTGAA CTGCGTGATG CGGATCAACA GGTGGTTGCA ACTGGACAAG GCACTAGCGG GACTTTGCAA  
GTCCGAACTT GACGCACTAC GCCTAGTTGT CCACCAACGT TGACCTGTTC CGTGATCGCC CTGAAACGTT

1681 GTGGTGAATC CGCACCTCTG GCAACCGGGT GAAGTTATC TCTATGAACT GTGCGTCACA GCCAAAAGCC  
CACCACCTAG GCGTGGAGAC CGTTGGCCCA CTCCAATAG AGATACTTGA CAGGCAGTGT CGGTTTTCGG

1751 AGACAGAGTG TGATATCTAC CCGCTTCGG TCGGCATCCG GTCAGTGGCA GTGAAGGCG AACAGTTCCT  
TCTGTCTCAC ACTATAGATG GCGGAAGCG AGCCGTAGGC CAGTCACCGT CACTTCCCG TTGTCAAGGA

1821 GATTAAACCAC AAACCGTTCT ACTTTACTGG CTTTGGTCGT CATGAAGATG CGGACTTGCG TGGCAAAGGA  
CTAATTGGTG TTTGGCAAGA TGAATGACC GAAACCAGCA GTACTTCTAC GCCTGAACGC ACCGTTTCCT

1891 TTCCGATAACG TGCTGATGGT GCACGACCAC GCATTAATGG ACTGGATTGG GGCCAACTCC TACCGTACCT  
AAGCTATTGC ACGACTACCA CGTGCTGGTG CGTAATTACC TGACCTAACC CCGGTTGAGG ATGGCATGGA

*FIG. A<sub>2</sub> cont.*



1961 CGCATTACCC TTACGCTGAA GAGATGCTCG ACTGGGCAGA TGAACATGGC ATCGTGGTGA TTGATGAAAC  
GCGTAATGGG AATGCCACTT CTCTACGAGC TGACCCGCTCT ACTTGTAACG TAGCACCACT AACTACTTTC

2031 TGCTGCTGTC GGCTTTAACC TCTCTTTAGG CATTTGTTTC GAAGCGGCA ACAAGCCGAA AGAACTGTAC  
ACGACGACAG CCGAAATTGG AGAGAAATCC GTAACCAAAG CTTCGCCCGT TGTTCGGCTT TCTTGACATG

2101 ACCGAAGAGG CAGTCAACGG GAAACTCAG CAAGCCGACT TACAGGCGAT TAAAGAGCTG ATAGCGCGTG  
TCGCTTCTCC GTCAGTTGCC CCTTTGAGTC GTTCGCGTCA ATGTCCGCTA ATTTCTCGAC TATCGCGCAC

2171 ACAAAAACCA CCCAAGCGTG GTGATGTGGA GTATTGCCAA CGAACC GGAT ACCCGTCCGC AAGTGCCACG  
TGTTTTTGGT GGGTTCGCAC CACTACACCT CATAACGGTT GCTTGGCCTA TGGGCAGGCG TTCCACGTCG

2241 GGAATATTTC GCGCCACTGG CGGAAGCAAC GCGTAACTC GACCCGACGC GTCCGATCAC CTGCGTCAAT  
CCTTATAAG CCGCGTGACC GCCTTCGTTG CGCATTTGAG CTGGGCTGCG CAGGCTAGTG GACGCAGTTA

2311 GTAATGTTCT GCGACGCTCA CACCGATACC ATCAGCGATC TCCTTGATGT GCTGTGCCCTG AACCGTTATT  
CATTACAAGA CGCTCGGAGT GTGGCTATGG TAGTCGCTAG AGAACTACA CGACACGGAC TTGGCAATAA

*FIG. A<sub>2</sub> cont.*

2381 ACGGATGGTA TGTCCAAAGC GCGATTGGA AACGGCAGA GAAGTACTG GAAAAGAAC TTCTGGCCCTG  
TGCCTACCAT ACAGGTTTCG CCGCTAAACC TTGCGCTCT CTTCCATGAC CTTTTCCTTG AAGACCGGAC  
=====

2451 GCAGGAGAAA CTGCATCAGC CGATTATCAT CACCGAATAC GCGTGGATA CGTTAGCCCG GCTGCACTCA  
CGTCCTCTTT GACGTAGTCG GCTAATAGTA GTGGCTTATG CCGCACCTAT GCAATCGGCC CGACGTGAGT  
=====

2521 ATGTACACCG ACATGTGGAG TGAAGAGTAT CAGTGTGCAT GGCTGGATAT GTATCACCGC GTCTTTGATC  
TACATGTGGC TGTACACCTC ACTTCTCATA GTCACACGTA CCGACCTATA CATAGTGGCG CAGAACTAG  
=====

2591 GCGTCAGCGC CGTCGTCCGT GAACAGGTAT GGAATTTCGC CGATTTTGGC ACCTCGCAAG GCATATTGCG  
CGCAGTCGCG GCAGCAGCCA CTGTCTCATA CCTAAAGCG GCTAAACGC TGGAGCGTTC CGTATAACGC  
=====

2661 CGTTGGCGGT AACAGAAAG GGATCTTCAC TCGCGACCGC AAACCGAAGT CCGCGGCTTT TCTGCTGCAA  
GCAACCGCCA TTGTTCTTTC CCTAGAAGTG AGCGCTGGCG TTGCGCTTCA GCCGCCGAAA ACACGACGTT  
=====

2731 AAACGCTGGA CTGGCATGAA CTTCCGTGAA AAACCGCAGC AGGAGGCAA ACAATGAGAG CTCGGTTGTT  
TTTGCGACCT GACCGTACTT GAAGCCACTT TTGCGCGTCG TCCCTCCGTT TGTACTCTC GAGCCAACAA  
=====

*FIG. A<sub>2</sub> cont.*



2801 GATGGATCTG TGATGCATGC AATAGCTGAT AATAGAACTT ACGCAAATAT TAGCAAAAT ATATTAGACA  
CTACCTAGAC ACTACGTACG TTATCGACTA TTATCTTGAA TCGCTTTATA ATCGTTTTTA TATAATCTGT  
=====

2871 ATACTACAAT TAACGATGAG TGTAGATGCT GTTATTTTGA ACCACAGATT AGGATTCTTG ATAGAGATGA  
TATGATGTTA ATTGCTACTC ACATCTACGA CAATAAACT TGGTGCTAA TCCTAAGAAC TATCTCTACT  
=====

2941 GATGCTCAAT GGATCATCGT GTGATATGAA CAGACATGT ATTATGATGA ATTTACCTGA TGTAGGCGAA  
CTACGAGTTA CCTAGTAGCA CACTATACTT GTCTGTAACA TAATACTACT TAAATGGACT ACATCCGCTT  
=====

3011 TTTGGATCTA GTATGTTGGG GAAATATGAA CCTGACATGA TTAAGATTGC TCTTTCGGTG CCTGGCGGCC  
AAACCTAGAT CATACAACCC CTTTATACTT GGACTGTACT AATTCCTAAG AGAAGCCAC CGACCGCCGG  
=====

3081 CGCTCGACTA AAAATGAAA AAATATTCTA ATTTATAGGA CCGTTTTCAT TTTCTTTTTT TCTATGCTAT  
GCGAGCTCAT TTTTACTTT TTTATAAGAT TAAATATCCT GCCAAACTA AAAGAAAAA AGATACGATA  
=====

3151 AAATAATAAA TAGCGGCCCG ACCATGAAAG TGAAGGGAT CAGGAAGAT TATCAGCACT TGTGGAATC  
TTTATTATTT ATCGCCCGCG TGTACTTTC ACTTCCCCTA GTCCTTCTTA ATAGTCCTGA ACACCTTAC  
=====

*FIG. A<sub>2</sub> cont.*

3221 GGGCATCATG CTCCTTGGGA TGTGATGAT CTGTAGTGCT GTAGAAATT TGTGGGTCAC AGTTATTAT  
CCCGTAGTAC GAGGAACCCCT ACAACTACTA GACATCACGA CATCTTTTAA ACACCCAGTG TCAAATAATA

3291 GGGGTACCTG TGTGGAAAGA AGCAACCACC ACTCTATTTT GTGCATCAGA TGCTAAAGCA TATGATACAG  
CCCCATGGAC ACACCTTTCT TCGTTGGTGG TGAGATAAAA CACGTAGTCT ACGATTTCTG ATACTATGTC

3361 AGGTACATAA TGTTTGGGCC ACACATGCCT GTGTACCCAC AGACCCCAAC CCACAAGAAG TAGTATTGGA  
TCCATGTATT ACAAAACCCGG TGTGTACGGA CACATGGCTG TCTGGGGTGG GGTGTTCTTC ATCATAAACCT

3431 AAATGTGACA GAAATTTTA ACATGTGGAA AAATAACATG GTAGAACAGA TGCATGAGGA TATAATCAGT  
TTTACACTGT CTTTAAAT TGTACACCTT TTTATTGTAC CATCTTGCT ACGTACTCCT ATATTAGTCA

3501 TTATGGGATC AAAGCCTAAA GCCATGTGTA AAATTAACCC CACTCTGTGT TACTTTAAAT TGCACGTATT  
AATACCCCTAG TTTCCGATT CCGTACACAT TTTAATTGGG GTGAGACACA ATGAAATTTA ACGTGACTAA

3571 TGAGGAATCT TACTAATATC AATAATAGTA GTGAGGGAAT GAGAGAGAA ATAAAAACT GCTCTTTCAA  
ACTCCTTACA ATGATTATAG TTATTATCAT CACTCCCTTA CTCTCCTCTT TATTTTTTGA CGAGAAAGTT

*FIG. A<sub>2</sub> cont.*

3641 TATCACCACA AGCATAAGAG ATAAGGTGAA GAAAGACTAT GCACCTTTCT ATAGACTTGA TCTAGTACCA  
ATAGTGGTGT TCGTATTCTC TATCCACTT CTTTCTGATA CGTGAAAACA TATCTGAACT ACATCATGGT

3711 ATAGATAATG ATAATACTAG CTATAGGTTG ATAAATTGTA ATACCTCAAC CATTACACAG GCCTGTCCAA  
TATCTATTAC TATTATGATC GATATCCAAC TATTTAACAT TATGGAGTTG GTAATGTGTC CCGACACGTT

3781 AGGTATCCCTT TGAGCCCAATT CCCATACATT ATTGTACCCC GGCTGGTTT GCGATTCTAA AGTGTAAGA  
TCCATAGGAA ACTCGGTTAA GGGTATGTAA TAACATGGGG CCGACCAAAA CGCTAAGATT TCACATTCT

3851 CAAGAAGTTC AATGGAACAG GGCCATGTAA AAATGTCAGC ACAGTACAAT GTACACATGG AATTAGGCCA  
GTTCTTCAAG TTACCTTGTC CCGGTACATT TTTACAGTCC TGTCATGTTA CATGTGTACC TTAATCCGGT

3921 GTAGTGTCAA CTCAACTGCT GTTAAATGGC AGCTAGCAG AAGAAGAGGT AGTAATTAGA TCTAGTAATT  
CATCACAGTT GACTTGACCA CAATTTACCG TCAGATCGTC TTCTTCTCCA TCATTAACT AGATCATTA

3991 TCACAGACAA TGCAAAAAC ATAATAGTAC AGTTGAAAGA ATCTGTAGAA ATTAATTGTA CAAGACCCAA  
AGTGTCTGTT ACGTTTTTG TATTATCATG TCAACTTCT TAGACATCTT TAATTAACAT GTTCTGGGTT

*FIG. A<sub>2</sub> cont.*

4061 CAACAATACA AGGAAAAGTA TACATATAGG ACCAGGAAGA GCATTTTATA CAACAGGAGA AATAATAGGA  
GTTGTTATGT TCCTTTTTCAT ATGTATATCC TGGTCCCTCT CGTAAATAT GTTGTCTCTT TTATTATCCT

4131 GATAAAGAC AAGCACATTG CAACATTAGT AGAACAAAAT GGAATAACAC TTAAATCAA ATAGCTACAA  
CTATATTCTG TTCGTGTAAC GTTGTAATCA TCTTGTTTA CCTTATTGTG AAATTAGTT TATCGATGTT

4201 AATTAAAAGA ACAATTGGG AATAATAAA CAATAGTCTT TAATCAATCC TCAGGAGGGG ACCCAGAAAT  
TTAATTTTCT TGTAAACCC TTATTATTT GTTATCAGAA ATTAGTTAGG AGTCTCTCCC TGGGTCTTTA

4271 TGTAATGCAC AGTTTAAATT GTGAGGGGA ATTCTTCTAC TGTAATTCAA CAACTGTT TAATAGTACT  
ACATTACGTG TCAAAATTAA CACCTCCCC TAAAGAGATG ACATTAAGTT GTGTGACAA ATTATCATGA

4341 TGGAATTTTA ATGGTACTTG GAATTTAACA CAATCGAATG GTACTGAAGG AAATGACACT ATCACACTCC  
ACCTTAAAT TACCATGAAC CTAAATTGT GTTAGCTTAC CATGACTTCC TTTACTGTGA TAGTGTGAGG

4411 CATGTAGAAT AAAACAAATT ATAAATATGT GGCAGGAAGT AGGAAAAGCA ATGTATGCCC CTCCCATCAG  
GTACATCTTA TTTTGTTTAA TATTATACA CCGTCTTCA TCCTTTTCGT TACATACGGG GAGGGTAGTC

*FIG. A<sub>2</sub> cont.*



4481 AGGACAAATT AGATGCTCAT CAAATATTAC AGGCTAATA TTAACAAGAG ATGCTGGAAC TAACAGTAGT  
TCCTGTTTAA TCTACGAGTA GTTTATAATG TCCCGATTAT AATTGTTCTC TACCACCTTG ATTGTCATCA

4551 GGGTCCGAGA TCTTCAGACC TGGGGGAGGA GATATGAGG ACAATTGGAG AAGTGAATTA TATAAATATA  
CCCAGGCTCT AGAAGTCTGG ACCCCCTCCT CTATACTCCC TGTTAACCTC TTCACCTAAT ATATTATAT

4621 AAGTAGTAA AATTGAACCA TTAGGAGTAG CACCACCACAA GGCAAAAGA AGAGTGGTGC AGAGAGAAA  
TTCATCATTT TTAAGTTGGT AATCCTCATC GTGGGTGGTT CCGTTTCTCT TCTCACCACG TCTCTCTTT

4691 AAGAGCAGTG GGAACGATAG GAGCTATGTT CCTTGGGTTC TTGGGAGCAG CAGGAAGCAC TATGGGCGCA  
TTCTCGTCAC CCTTGCTATC CTCGATACAA GGAACCCAAAG AACCTCGTC GTCTTCGTG ATACCCCGGT

4761 GCGTCAATAA CGCTGACGGT ACAGGCCAGA CTATTATTGT CTGGTATAGT GCAACAGCAG AACAAATTGC  
CGCAGTTATT GCGACTGCCA TGTCCGGTCT GATAATAACA GACCATATCA CGTTGTCGTC TTGTTAAACG

4831 TGAGGGCTAT TGAGGGCGAA CAGCATCTGT TGCAACTCAC AGTCTGGGGC ATCAAGCAGC TCCAGGCAAG  
ACTCCCGATA ACTCCGCGTT GTCGTAGACA ACGTTGAGTG TCAGACCCCG TAGTTCCGTC AGGTCCGTC

*FIG. A<sub>2</sub> cont.*

4901 AGTCCTGGCT GTGGAAGAT ACCTAAGGA TCAACAGCTC CTAGGGATT GGGTTGCTC TGGAAACTC  
TCAGGACCGA CACCTTTCTA TGGATTCCCT AGTGTGAG GATCCCTAAA CCCCAACGAG ACCTTTTGAG

4971 ATCTGCACCA CTGCTGTGCC TTGGAATGCT AGTTGGAGTA ATAAACTCT GGATATGATT TGGATAACA  
TAGACGTGGT GACGACACGG AACCTTACGA TCAACCTCAT TATTTGAGA CCTATACTAA ACCCTATTGT

5041 TGACCTGGAT GGAGTGGGAA AGAGAAATCG AAAATTACAC AGGCTTAATA TACACCTTAA TTGAGCAATC  
ACTGGACCTA CCTCACCCCT TCTCTTTAGC TTTTAATGTG TCCGAATTAT ATGTGGAATT AACTCCTTAG

5111 GCAGAACCAA CAAGAAAGA ATGAACAAGA CTTATTAGCA TTAGATAAGT GGCAAAGTT GTGGAATTGG  
CGTCTTGGT GTTCTTTTCT TACTGTCT GAATAATCGT AATCTATTCA CCCGTTCAAA CACCTTAACC

5181 TTTGACATAT CAAATTGGCT GTGGTATGTA AAAATCTTCA TAATGATAGT AGGAGGCTG ATAGTTTAA  
AAACTGTATA GTTTAACCGA CACCATACAT TTTTAGAAGT ATTACTATCA TCCTCGGAAC TATCCAAATT

5251 GAATAGTTT TACTGTACTT TCTATAGTAA ATAGAGTAG GCAGGATAC TCACCATGT CATTTCAGAC  
CTTATCAAAA ATGACATGAA AGATATCATT TATCTCAATC CGTCCCTATG AGTGGTAACA GTAAAGTCTG

*FIG. A<sub>2</sub> cont.*



5321 CCACCTCCCA GCCCGGAGGG GACCCGACAG GCCCGAAGGA ATCGAAGAAG AAGGTGGAGA CAGAGACTAA  
GGTGGAGGGT CCGGGCTCCC CTGGCTGTC CCGGCTCCT TAGCTTCTC TTCCACCTCT GTCTCTGATT

5391 TTTTATGCG GCCGCTGGTA CCAACCTAA AATTGAAA TAAATACAA GGTCTTGAG GGTGTGTTA  
AAAAATACGC CCGCGACCAT GGTGGATT TTAACTTT ATTTATGTT CCAAGAATC CCAACACAAT

5461 AATTGAAAGC GAGAAATAAT CATAATAAG CCCGGGATC CTCTAGAGTC GACACCATGG GTCCGAGAGC  
TTAACTTTCG CTCATTATTA GTATTATTC GGGCCCTAG GAGATCTCAG CTGTGGTACC CACGCTCTCG

5531 GTCAGTATTA AGCGGGGAG AATTAGATCG ATGGGAAAA ATTGGTTAA GGCCAGGGG AAAGAAAAA  
CAGTCATAAT TCGCCCCCTC TTAATCTAGC TACCCTTTT TAAGCCAAT CCGGTCCCCC TTCTTTTTT

5601 TATAAATTAA AACATATAGT ATGGGCAAGC AGGAGCTAG AACGATTCC AGTTAATCCT GGCCTGTAG  
ATATTTAATT TTGTATATCA TACCCGTTCC TCCCTCGATC TTGCTAAGCG TCAATTAGGA CCGGACAATC

5671 AACATCAGA AGGCTGTAGA CAAATACTGG GACAGCTACA ACCATCCCTT CAGACAGGAT CAGAAGAACT  
TTTGTAATCT TCCGACATCT GTTATGACC CTGTCGATGT TGCTAGGGA GTCTGTCTTA GTCTTCTTGA

*FIG. A<sub>2</sub> cont.*

5741 TAGATCATT TATAATACAG TAGCAACCCT CTATTGTGTG CATCAAGGA TAGAGATAAA AGACACCAAG  
ATCTAGTAAT ATATTATGTC ATCGTTGGGA GATAACACAC GTAGTTTCCT ATCTCTATTT TCTGTGGTTC

5811 GAAGCTTTAG ACAAGATAGA GGAAGAGCAA AACAAAAGTA AGAAAAAGC ACAGCAAGCA GCAGCTGACA  
CTTCGAAATC TGTCTATCT CTTCTCGTT TTGTTTTCAT TCTTTTTCG TGTGTTTCGT CGTCGACTGT

5881 CAGGACACAG CAATCAGGTC AGCCAAAATT ACCCTATAGT GCAGAACATC CAGGGGCAAA TGGTACATCA  
GTCCTGTGC GTTAGTCCAG TCGGTTTTAA TGGGATATCA CGTCTTCTAG GTCCCCGTTT ACCATGTAGT

5951 GCCCATATCA CCTAGAACTT TAAATGCATG GGTAAAAGTA GTAGAAGAGA AGGCTTTCAG CCCAGAAGTG  
CCGGTATAGT GGATCTTGAA ATTTACGTAC CCATTTTTCAT CATCTTCTCT TCCGAAAGTC GGGTCTTCAC

6021 ATACCCATGT TTTCAGCATT ATCAGAAGGA GCCACCCAC AAGATTTAA CACCATGCTA AACACAGTGG  
TATCGGTACA AAAGTCGTAA TAGTCTTCCT CGGTGGGTG TTCTAAATTT GTGCTACCAT TTGTGTCACC

6091 GGGGACATCA AGCAGCCATG CAAATGTAA AAGAGACCAT CAATGAGGA GCTGCAGAAT GGGATAGAGT  
CCCCGTAGT TCGTCGGTAC GTTACAATT TTCTCTGGTA GTTACTCCTT CGACGTCTTA CCTATCTCA

*FIG. A<sub>2</sub> cont.*

6161 GCATCCAGTG CATGCAGGGC CTATTGCACC AGGCCAGATG AGAGAACCAA GGGGAAGTGA CATAGCAGGA  
CGTAGGTCAC GTACGTCCCG GATAACGTGG TCCGGTCTAC TCTCTTGGTT CCCCTTCACT GTATCGTCCT

6231 ACTACTAGTA CCCTTCAGGA ACAATACGA TCGATGACAA ATAATCCACC TATCCCAGTA GGAGAAATTT  
TGATGATCAT GCGAAGTCCT TGTTTATCCT ACCTACTGTT TATTAGGTGG ATAGGGTCAT CCTCTTTAAA

6301 ATAAAGATG GATAATCCTG GGATTAATA AATAGTAAG AATGTATAGC CCTACCAGCA TTCTGGACAT  
TATTTTCTAC CTATTAGGAC CCTAATTAT TTTATCATTC TTACATATCG GGATGGTCGT AAGACCTGTA

6371 AAGACAAGGA CCAAAGAAC CCTTTAGAGA CTATGTAGAC CGTTCTATA AACTCTAAG AGCCGAGCAA  
TTCTGTTCTT GGTTCCTT GCGAATCTCT GATACATCTG GCCAAGATAT TTTGAGATTC TCGGCTCGTT

6441 GCTTCACAGG AGGTAAAAA TTGGATGACA GAAACCTTGT TGGTCCAAA TCGGAACCCA GATTGTAAGA  
CGAAGTGTC TCCATTTTTT AACCTACTGT CTTTGGAACA ACCAGGTTT ACCTTGGGT CTAACATTCT

6511 CTATTTTAAA AGCATTCGGA CCAGCGGCTA CACTAGAAGA AATGATGACA GCATGTCAGG GAGTAGGAGG  
GATAAAATT TCGTAACCTT GTCGCCGAT GTGATCTTCT TTACTIONGT CGTACAGTCC CTCATCCTCC

*FIG. A<sub>2</sub> cont.*

6581 ACCCGGCCAT AAGGCAAGAG TTTTGGCTGA AGCAATGAGC CAAGTAACAA ATTTCAGCTAC CATAATGATG  
TGGGCCCGTA TTCCGTTCTC AAACCGACT TCGTTACTCG GTTCATTGTT TAAAGTCGATG GTATTACTAC

6651 CAGAGAGGCA ATTTTAGGAA CCAAGAAAG ATTGTTAAGT GTTTCAAATG TGGCAAAGAA GGGCACACAG  
GTCCTCCGT TAAATCCTT GGTTCCTTC TAACAATTCA CAAAGTTAAC ACCGTTTCTT CCCGTGTGTC

6721 CCAGAAATTG CAGGGCCCCT AGGAAAAGG CCTGTTGGAA ATGTTGGAAAG GAAGGACACC AAATGAAAGA  
GGTCTTTAAC GTCCCCGCGA TCCTTTTTC CGACAACCTT TACACCTTTC CTTCCTGTGG TTTACTTTCT

6791 TTGTACTGAG AGACAGGCTA ATTTTATTAG GAAGATCTGG CCTTCCTACA AGGGAAGGCC AGGGAATTTT  
AACATGACTC TCTGTCCGAT TAAAAATCC CTTCAGACC GGAAGGATGT TCCCTTCCGG TCCCTTAAAA

6861 CTTCAGAGCA GACCAGAGCC AACAGCCCCA CCAGAAGAGA GCTTCAGGTC TGGGGTAGAG ACAACAATC  
GAAGTCTCGT CTGGTCTCGG TTGTCCGGGT GGTCTTCTCT CGAAGTCCAG ACCCCATCTC TGTGTGTGAG

6931 CCCCTCAGAA GCAGGAGCCG ATAGACAAGG AACTGTATCC TTAACTTCC CTCAGATCAC TCCTTGGCAA  
GGGAGTCTT CGTCCCTCGC TATCTGTTCC TTGACATAGG AAATTGAAGG GAGTCTAGTG AGAAACCGTT

*FIG. A<sub>2</sub> cont.*

7001 CGACCCCTCG TCACAATAA CAGAGGGGG CAACTAAAGG AAGCTCTATT AGATACAGGA GCAGATGATA  
GCTGGGGACC AGTGTTATT CTATCCCCC GTTGATTTC TTCGAGATAA TCTATGTCCT CGTCTACTAT

7071 CAGTATTAGA AGAAATGACT TTGCCAGGAA GATGGAACC AAAATGATA GGGGGAATTG GAGGTTTTAT  
GTCATAATCT TCTTTACTCA ACGGTCCTT CTACCTTTGG TTTTACTAT CCCCCTTAAC CTCCAAAATA

7141 CAAAGTAAGA CAGTATGATC AGATACTCAT AGAAATCTGT GGACATAAAG CTATAGGTAC AGTATTAGTA  
GTTTCATTCT GTCATACTAG TCTATGAGTA TCTTTAGACA CCTGTATTTC GATATCCATG TCATAATCAT

7211 GGACCTACAC CTGTCAACAT AATTGGAAGA AATCTGTTGA CTCAGATTGG TTGCACTTTA AATTTCCCA  
CCTGGATGTG GACAGTTGTA TTAACCTTCT TTAGACAACT GAGCTAACC AACGTGAAAT TTAAGAAGGT

7281 TTAGCCCTAT TGAGACTGTA CCAGTAAAT TAAAGCCAGG AATGGATGG CCAAAGTTA AACATGGCC  
AATCGGGATA ACTCTGACAT GGTCAATTTA ATTTCGGTCC TTACCTACCG GGTTTTCAAT TTGTTACCGG

7351 ATTGACAGAA GAAAAATAA AAGCATTAGT AGAAATTGT ACAGAAATGG AAAAGGAAGG GAAATTTCA  
TAACTGTCTT CTTTTTTATT TTCGTAATCA TCTTTAAACA TGCTTTTACC TTTTCCTTCC CTTTTAAGT

*FIG. A<sub>2</sub> cont.*



7421 AAAATTGGGC CTGAGATCC ATACAATACT CCAGTATTTG CCATAAGAA AAAAGACAGT ACTAAATGGA  
TTTTAACCCG CACTCTTAGG TATGTTATGA GGTCAATAAC GGTATTTCTT TTTTCTGTCA TGATTTACCT

7491 GGAATTAGT AGATTTTCAGA GAACTTAATA AGAGAACTCA AGACTTCTGG GAAGTTCAAT TAGGAATACC  
CTTTAATCA TCTAAAGTCT CTTGAATTAT TCTCTTGAGT TCTGAAGACC CTTCAAGTTA ATCCTTATGG

7561 ACATCCCGCA GGGTTAAAA AGAAAAATC AGTAACAGTA CTGGATGTGG GTGATGCATA TTTTTCAGTT  
TGTAGGGCGT CCCAATTTT TCTTTTITAG TCATTGTCAAT GACCTACACC CACTACGTAT AAAAAGTCAA

7631 CCCTTAGATG AAGACTTCAG GAAGTATACT GCATTTACCA TACCTAGTAT AACAAATGAG ACACCAGGGA  
GGGAATCTAC TTCGGAAGTC CTTCATATGA CGTAAATGGT ATGGATCATA TTTGTTACTC TGTGGTCCCT

7701 TTAGATATCA GTACAATGTG CTTCCACAGG GATGGAAGG ATCACCAGCA ATATTCCAAA GTAGCATGAC  
AATCTATAGT CATGTTACAC GAAGGTCTCC CTACCCTTCC TAGTGGTCGT TATAAGGTTT CATCGTACTG

7771 AAAAATCTTA GAGCCTTTTA AAAACAATA TCCAGACATA GTTATCTATC AATACATGAA CGATTTGTAT  
TTTTTAGAAT CTCGGAAAT TTTTGTGTTT AGCTCTGTAT CAATAGATAG TTATGTACTT GCTAAACATA

*FIG. A<sub>2</sub> cont.*



7841 GTAGGATCTG ACTTAGAAAT AGGCGAGCAT AGAACAAAA TAGAGGAGCT GAGACAACAT CTGTTGAGGT  
CATCCTAGAC TGAATCTTTA TCCCGTCGTA TCTTGTTTT ATCTCCTCGA CTCGTGTGTA GACAACTCCA

7911 GGGGACTTAC CACACCAGAC AAAAACATC AGAAGAACC TCCATTCCCTT TGGATGGGTT ATGAACCTCCA  
CCCCCTGAATG GTGTGGTCTG TTTTGTGTAG TCTTCTTGG AGTAAGGAA ACCTACCCAA TACTTGAGGT

7981 TCCTGATAAA TGGACAGTAC AGCCTATAGT GCTGCCAGAA AAAGACAGCT GGACTGTCAA TGACATACAG  
AGGACTATTT ACCTGTCA TGCGATATCA CGACGGTCTT TTTCTGTGGA CCTGACAGTT ACTGTATGTC

8051 AAGTTAGTGG GGAAATTGAA TACCGCAAGT CAGATTACC CAGGGATTAA AGTAAGGCAA TTATGTAAAC  
TTCAATCACC CCTTAACTT ATGGCGTTCA GTCTAAATGG GTCCCTAATT TCATTCCGTT AATACATTG

8121 TCCTTAGAGG AACCAAGCA CTAACAGAAG TAATACCACT AACAGAAGAA GCAGAGCTAG AACTGGCAGA  
AGGAATCTCC TTGGTTTCGT GATTGTCTTC ATTATGCTGA TTGTCTTCTT CGTCTCGATC TTGACCGTCT

8191 AACAGAGAG ATTCTAAAAG AACCACTACA TGGAGTGTAT TATGACCCAT CAAAGACTT AATAGCAGAA  
TTTGTCTCTC TAAGATTTC TTGGTCATGT ACCTCACATA ATACTGGGTA GTTTTCTGAA TTATCGTCTT

*FIG. A<sub>2</sub> cont.*

8261 ATACAGAAGC AGGGGCAAGG CCAATGGACA TATCAAATTT ATCAAGAGCC ATTTAAAAAT CTGAAAACAG  
TATGTCCTCG TCCCCGTTCC GGTACCCTGT ATAGTTTAA TAGTCTCGG TAAATTTTA GACTTTTGTC

8331 GAAAATATGC AAGAATGAGG GGTGCCCACA CTAATGATGT AAACAATTA ACAGAGCCAG TGCAAAAAAT  
CTTTTATACG TTCTTACTCC CCACGGGTGT GATTACTACA TTTTGTTAAT TGTCTCCGTC ACGTTTTTAA

8401 AACCACAGAA ACCATAGTAA TATGGGGAAA GACTCCTAAA TTAAACTAC CCATACAAA GGAACATGG  
TTGGTGCTT TCGTATCAT ATACCCCTTT CTGAGGATTT AAATTGATG GGTATGTTT CCTTGTACC

8471 GAAACATGGT GGACAGAGTA TTGGCAAGCC ACCTGGATTC CTGAGTGGGA GTTTGTTAAT ACCCTCCTT  
CTTTGTACCA CCTGTCTCAT AACCCTTCGG TGGACCTAAG GACTCACCTT CAAACAATTA TGGGGAGGAA

8541 TAGTGAAATT ATGGTACCAG TTAGAGAAAG AACCCATAGT AGGAGCAGAA ACCTTCTATG TAGATGGGGC  
ATCACTTTAA TACCATGGTC AATCTCTTTC TTGGGTATCA TCCTCGTCTT TCGAAGATAC ATCTACCCCG

8611 ACCTAACAGG GAGACTAAAT TAGGAAAAGC AGGATATGTT ACTAACAAAG GAAGACAAA GGTGTGCCCC  
TCGATTGTCC CTCTGATTTA ATCCTTTTCG TCCTATACAA TGATTGTTT CTTCTGTTT CCAACAGGGG

*FIG. A<sub>2</sub> cont.*

8681 CTAAC TAACA CAACAAATCA GAAAACTCAG TTACAAGCAA TTTATCTAGC TTTGCAGGAT TCAGGATTAG  
GATTGATTGT GTTGTTTAGT CTTTGAGTC AATGTTTCGT AAATAGATCG AAACGTCCTA AGTCCTAATC

8751 AACTAAACAT AGTAACAGAC TCACAATATG CATTAGGAAT CATTCAAGCA CAACCAGATA AAAGTGAATC  
TTCATTTTGT TCAATTGCTG AGTGTATAC GTAATCCTTA GTAAGTTTCGT GTTGCTCTAT TTTCACCTTAG

8821 AGAGTTAGTC AATCAAAATA TAGAGCAGTT AATAAAAAG GAAAAGGTCT ATCTGGCATG GGTACCAGCA  
TCTCAATCAG TTAGTTTATT ATCTCGTCAA TTATTTTTC CTTTCCAGA TAGACCGTAC CCATGCTCCT

8891 CACAAAGGAA TTGGAGGAAA TGAACAAGTA GATAAATTAG TCAGTGCTGG AATCAGGAAA ATACTATTTT  
GTGTTTCCTT AACCTCCTTT ACTTGTTTAT CTATTTAATC AGTCACGACC TTAGTCCTTT TATGATAAAA

8961 TAGATGGAAT AGATAAGGCC CAAGATGAAC ATTAGTTTTT ATGTCGACCT GCAGGGAAG TTTTATAGGT  
ATCTACCTTA TCTATTCCGG GTTCTACTTG TAATCAAAAA TACAGCTGGA CGTCCCCTTC AAAATATCCA

9031 AGTTGATAGA ACAAATACA TAATTTTCTA AAAATAAATC ACTTTTATA CTAATATGAC ACGATTACCA  
TCAACTATCT TGTTTTATGT ATTAAACAT TTTTATTAG TGAATAATAT GATTATACTG TGCTAATGCT

*FIG. A<sub>2</sub> cont.*

9101 ATACTTTTGT TACTAATATC ATTAGTATAC GCTACACCTT TTCTCAGAC ATCTAAAAA ATAGTGATC  
TATGAAAAA ATGATTATAG TAATCATATG CGATCTGGAA AAGGAGTCTG TAGATTTT TATCCACTAC

9171 ATGCAACTTT ATCATGTAAT CGAAATAATA CAAATGACTA CGTTGTTATG AGTGCTTGGT ATAAGGAGCC  
TACCTTGAAA TAGTACATTA GCTTTATTAT GTTACTGAT GCAACAATAC TCACGAACCA TATTCCTCGG

9241 CAATTCCATT ATTCTTTTAG CTGCTAAAG CGACGCTTG TATTTTGATA ATTATACCAA GGATAAATA  
CTTAAGGTAA TAAGAAATC GACGATTTTC GCTGCAGAAC ATAAACTAT TAATATGGT CCTATTTAT

9311 TCCTACGACT CTCCATACGA TGATCTAGT ACAACTATCA CAATTAAATC ATTGACTGCT AGAGATGCCG  
AGAAATGCTGA GAGGTATGCT ACTAGATCAA TGTTGATAG GTTAATTAG TAACTGACCA TCTCTACGGC

9381 GTACTTATGT ATGTGCATTC TTTATGACAT CGCCTACAA TGACACTGAT AAAGTAGATT ATGAAGAATA  
CATGAATACA TACACGTAAG AAATACTGA GCGGATGTT ACTGTGACTA TTTCATCTAA TACTTCTTAT

9451 CTCCACAGAG TTGATTGTAA ATACAGATAG TGAATCGACT ATAGACATAA TACTATCTGG ATCTACACAT  
GAGGTGCTC AACTAACATT TATGCTATC ACTTAGCTGA TATCTGTATT ATGATAGACC TAGATGTGA

*FIG. A<sub>2</sub> cont.*

**Abstract** The purpose of this study was to determine whether there were differences in the prevalence of risk factors for coronary artery disease between men who had been exposed to asbestos and those who had not. A case-control study was conducted among men aged 60 years or older who had been employed in asbestos-related occupations before age 60. The cases were men who had been diagnosed with coronary artery disease by a physician. The controls were men who had not been diagnosed with coronary artery disease by a physician. The results showed that the prevalence of risk factors for coronary artery disease was higher among men who had been exposed to asbestos than among men who had not been exposed to asbestos. The results also showed that the prevalence of risk factors for coronary artery disease was higher among men who had been exposed to asbestos at a younger age than among men who had been exposed to asbestos at an older age.

9591 CCTGTTTCCT GTCTGAAATT GTATCCGCT CACAATTCCA CACAACATAC GAGCCGGAAG CATAAAGTGT  
CGACAAAGGA CACACTTAA CAATAGCGCA GTCTTAAGGT GTGTTGTATG CTCGGCCCTTC GTATTTCACA

9661 AAGCCTGGG GTGCCTAATG AGTGAGCTAA CTCACATTAA TTGCGTTGCG CTCACTGCCC GCTTTCGAGT  
TTTCGGACCC CACGGATTAC TCACTCGATT GAGTGTAATT AACGCAACGC GAGTGACGGG CGAAAGCTCA

9731 CCGGAACCT CTCGTGCCAG CTGCATTAAAT GAATCGGCCA ACCGCGCGG AGAGCGGTT TCGCTATTGG  
GCCCTTTGGA CAGCACGGTC GACGTAATTA CTTAGCCGGT TCGCGCGCCCC TCTCCGCCAA ACGCATAAACC

9801 CCGCTCTCC CTTCTCTCG TCACTGACTC CTTCCGCTCG GTCTTCGGC TCGGGGAGC GGTATCAGCT  
CGCGAGAAGC CGAAGGAGCG ACTCACTGAG CGACGGGAGC CAGCAAGCCG ACGCCGCTCG CCATAGTCTGA

9871 CACTCAAAGG CCGTAATACG GTATCCACA GAATCAGGGG ATAACGCAGG AAGAACATG TGAGCAAAG  
GTGAGTTTCC GCCATTATGC CAATAGGTGT CTTAGTCCCC TATTGCGTCC TTTCTTGAC ACTCGTTTTC

9941 GCCAGCAAA GCCAGGAAC CGTAAAAGG CCGCGTTGCT GCGCTTTTC CATAAGCTCC GCCCCCCCTGA  
CGCTCGTTT CCGCTCCTTG GCATTTTCC GCGCAACGA CCGCAAAAAG CTATCCGAGG CCGGGGGGACT

**FIG. A<sub>2</sub> cont.**



10011 CGAGCATCAC AAAATCGAC GCTCAAGTCA GAGGTGGCGA AACCCGACAG GACTATAAAG ATACCAGGCG  
GCTCGTAGTG TTTTTAGCTG CGAGTTCAGT CTCCACCGCT TTGGGCTGTC CTGATATTTC TATGGTCCGC

10081 TTTCCCCCTG GAAGCTCCCT CGTCCGCTCT CCTGTTCGA CCTGCCGCT TACCGGATAC CTGTCCGCT  
AAAGGGGAC CTTCCGAGGA GCACCGGAGA GGACAAGGCT GGGACGGCGA ATGCCCTATG GACAGGCGGA

10151 TTCTCCCTTC GGGAAGCGTG CCGCTTTCTC ATAGCTCAG CTGTAGGTAT CTCAGTTCGG TGTAGGTCGT  
AAGAGGAAG CCTTCCGCAC CGCGAAGAG TATCGAGTGC GACATCCATA GAGTCAAGCC ACATCCAGCA

10221 TCGCTCCAAG CTGGGCTGTG TGCACGAACC CCCCCTTCAG CCCGACCGCT GCGCCTTATC CCGTAACTAT  
AGCGAGGTTT GACCCGACAC ACGTGCTTGG GGGGCAAGTC GGGCTGGCGA CGCGGAATAG GCCATTGATA

10291 CCTCTTCAGT CCAACCCGGT AAGACACCAC TTATCGCCAC TGGCAGCAG CACTGGTAAC AGGATTAGCA  
GCAGAACTCA GGTGGGCCA TTCTGTGCTG AATAGCGGTG ACCGTGCTCG GTGACCAATTG TCCTAATCGT

10361 GAGCGAGGTA TGTAGGCGGT GCTACAGAGT TCTTGAAGTG GTGGCCTAAC TACGGCTACA CTAGAAGGAC  
CTCGCTCCAT ACATCCGCCA CGATGTCTCA AGAACTTCAC CACCGGATTG ATGCCGATGT GATCTTCCTG

10431 AGTATTGGT ATCTGCGCTC TGCTGAAGCC AGTTACCTTC GGAAAAGAG TTGGTAGCTC TTGATCCGGC  
TCATAAACCA TAGACGCGAG ACGACTTCGG TCAATGGAAG CCTTTTCTC AACCATCGAG AACTAGGCCG

*FIG. A<sub>2</sub> cont.*



10501 AAACAAACCA CCGCTGGTAG CCGTGGTTT TTTGTTTCCA AGCAGCAGAT TACCGGCAGA AAAAAAGGAT  
TTTGTTTGCT GCGGACCATC GCCACCAAAA AACAAACGT TCGTCGTCTA ATCGCGCTCT TTTTTCCTA

10571 CTCAAGAAGA TCCTTTGATC TTTTCTACGG GGTCTGACGC TCAGTGGAAC GAAACTCAC GTTAAGGGAT  
GAGTCTTCT AGGAAACTAG AAAAGATGCC CCAGACTGCC AGTCACCTTG CTTTGAGTG CAATTCCCTA

10641 TTTGTCATG AGATTATCAA AAAGATCTT CACCTAGATC CTTTAAATT AAAATGAAG TTTTAAATCA  
AAACCAGTAC TCTAATAGTT TTTCTAGAA GTGGATCTAG GAAATTAA TTTTACTTC AAAATTAGT

10711 ATCTAAAGTA TATATGAGTA AACTTGGTCT GACAGTTACC AATGCTTAAT CAGTGAGGCA CCTATCTCAG  
TAGATTTTCAT ATATACTCAT TTGAACCAGA CTGTCAATGG TTACGAATTA GTCACTCCGT GGATAGAGTC

10781 CGATCTGTCT ATTTCTGTCA TCCATAGTTG CCTGACTCCC CGTCTGTAG ATAACTACGA TACGGAGGG  
GCTAGACAGA TAAAGCAAGT AGTATCAAC GCACTGAGGG GCACCATC TATTGATGCT ATGCCCTCCC

10851 CTTACCATCT GGCCCCAGTG CTGCAATGAT ACCGGAGAC CCACGCTCAC CGGCTCCAGA TTTATCAGCA  
GAATGCTAGA CCGGGGTCAC GACGTTACTA TGCGGCTCTG GGTGCGAGTG GCCAGGTCT AAATAGTCCT

10921 ATAAACCAGC CAGCCGGAAG GGCCGAGCGC AGAAGTGGTC CTGCAACTTT ATCCGCCCTCC ATCCAGTCTA  
TATTGGTCC GTCGGCCCTC CCGGCTCGCG TCTTCACCAG GACGTTGAAA TAGCCGGAGG TAGGTCAGAT

*FIG. A<sub>2</sub> cont.*

10991 TTAATTGTTG CCGGGAAGCT AGAGTAAGTA GTTCGCCAGT TAATAGTTG CGCAACGTTG TTGGCATTGC  
AATTAAACAAC GCGCCCTTCGA TCTCATTCTAT CAAGCGGTCA ATTATCAAC GCGTTGCAAC AACCGTAACG

11061 TACAGGCATC GTGGTGTCAC GCTCGTCGTT TGGTATGGCT TCATTCAGCT CCGGTTCCCA ACGATCAAGG  
ATGTCGGTAG CACCACAGTG CGAGCAGCAA ACCATACCGA AGTAAGTCGA GGCCAAGGGT TGCTAGTTCC

11131 CGAGTTACAT GATCCCCCAT GTTGTCAAA AAAGCGGTTA GCTCCTTCGG TCCTCCGATC GTTGTGAGAA  
GCTCAATGTA CTAGCGGGTA CAACACGTTT TTTCGCCAAT CGAGGAAGCC AGGAGGCTAG CAACAGTCTT

11201 GTAAGTTGGC CGCAGTGTTA TCACTCATGG TTATGGCAGC ACTGCATAAT TCTCTTACTG TCATGCCATC  
CATTCAACCG GCGTCACAAT AGTGAGTACC AATACCGTCG TGACGTATTA AGAGAATGAC AGTACGGTAG

11271 CGTAAGATGC TTTTCTGTGA CTGGTGAGTA CTCAACCAAG TCATTCTGAG AATAGTGTAT CCGGCGACCG  
GCATTCTACG AAAAGACACT GACCACTCAT GAGTTGGTTC AGTAAGACTC TTATCACATA CCGCCGCTGCC

11341 AGTTGCTCTT GCGCGGCGTC AATACGGGAT AATACCGCGC CACATAGCAG AACTTTAAA GTGCTCATCA  
TCAACGAGAA CCGGCGGCAG TTATGCCCTA TTATGCGCGG GTGTATCGTC TTGAAATTTT CACGAGTAGT

*FIG. A<sub>2</sub> cont.*

11411 TTGGAACG TTCCTCGGG CGAAACTCT CAAGGATCTT ACCGCTGTTG AGATCCAGTT CGATGTAACC  
AACCTTTTC AAGAAGCCCC GCTTTTGAGA GTTCCTAGAA TGGCGACAAC TCTAGTCAA GCTACATTGG

11481 CACTCGTGCA CCCAACTGAT CTTCAGCATC TTTTACTTTC ACCAGCGTTT CTGGGTGAGC AAAACAGGA  
GTGAGCACGT GGGTTGACTA GAAGTCGTAG AAATGAAAG TGGTCGCAA GACCCACTCG TTTTGTCTCT

11551 AGGCAAAATG CCGCAAAAA GGAATAAGG GCGACACGGA AATGTTGAAT ACTCATACTC TTCCTTTTTC  
TCCGTTTAC GCGGTTTTT CCCTTATTCC CGCTGTCCCT TTACAACCTA TGAGTATGAG AAGCAAAAAAG

11621 AATATTATTC AAGCATTAT CAGGGTTATT GTCTCATGAG CGCATACATA TTTGAATGTA TTTACAAAA  
TTATAATAAC TTCGTAAATA GTCCCAATA CAGAGTACTC GCCTATGTAT AAACCTACAT AAATCTTTT

11691 TAAACAAATA GGGGTTCCGC GCACATTTCC CCGAAAAGTG CCACCTGACG TCTAAGAAAC CATTATTATC  
ATTTGTTTAT CCCCAGGCG CGTGTAAGG GCGTTTTCAC GGTGGACTGC AGATTCTTTG GTAATAATA

11761 ATGACATTAA CCTATAAAA TAGCGTATC ACGAGGCCCT TTCGTCTCGC GCGTTTCGGT GATGACGGTG  
TACTGTAATT GGATATTTT ATCCGCATAG TGCTCCGGGA AAGCAGAGCG CGCAAAGCCA CTACTGCCAC

*FIG. A<sub>2</sub> cont.*

11831 AAACCTCTG ACACATGCAG CTCCCGGAGA CCGTCACAGC TTGTCTGTAA GCGGATGCCG GGAGCAGACA  
TTTGGAGAC TGTGTACGTC GAGGGCCTCT GCCAGTGTCC AACAGACATT CGCCTACGGC CCTCGTCTGT

11901 AGCCCGTCAG GCGCGCTCAG CCGGTGTTGG CCGGTGTCCG GGCTGGCTTA ACTATGCCGC ATCAGAGCAG  
TCGGGCAGTC CCGCGCAGTC GCGGCACAACC GCGCACAGCC CCGACCGAAT TGATACGCCG TAGTCTCGTC

11971 ATTGTACTGA GAGTGCACCA TATCGGCTGT GAAATACCGC ACAGATCCGT AAGGAGAAA TACCGCATCA  
TAACATGACT CTCACGTGGT ATACGCCACA CTTTATGGCG TGTCTACGCA TTCCTCTTTT ATGGCGTAGT

12041 GCGGCCATTG CCATTCAGG CTGCGCAACT GTTGGGAAGG GCGATCGGTG CCGGCCCTCTT CGCTATTACG  
CCGCGGTAAG CCGTAAGTCC GACGCGTTGA CAACCCCTCC CGCTAGCCAC GCGCGGAGAA GCGATAATGC

12111 CCAGCTGGCG AAAGGGGGAT GTGCTGCAAG GCGATTAAGT TGGGTAACGC CAGGGTTTTC CCAGTCACGA  
GGTCGACCGC TTTCCCCCTA CACGACGTTT CCGTAATTCA ACCCATTTCC GTCCCAAAG GGTCAAGTGT

12181 CGTTGTAAA CGACGGCCAG TGAATTGGAT TTAGGTGACA CTATA  
GCAACATTT GCTGCCGGTC ACTTAACCTA AATCCACTGT GATAT

*FIG. A<sub>2</sub> cont.*

**Text File of pLW-48 and the Included Individual HIV Genes and Their Promoters**

**Entire pLW-48 plasmid sequence:**

GAATTCGTTGGTGGTCGCCATGGATGGTGTATTGTATACTGTCTAAACGCG  
TTAGTAAAACATGGCGAGGAAATAAATCATATAAAAAATGATTTTCATGATTAA  
ACCATGTTGTGAAAAAGTCAAGAACGTTTCACATTGGCGGACAATCTAAAAAC  
AATACAGTGATTGCAGATTTGCCATATATGGATAATGCGGTATCCGATGTAT  
GCAATTCAGTGTATAAAAAGAATGTATCAAGAATATCCAGATTTGCTAATTTG  
ATAAAGATAGATGACGATGACAAGACTCCTACTGGTGTATATAATTATTTTAA  
ACCTAAAGATGCCATTCCTGTTATTATATCCATAGGAAAGGATAGAGATGTTT  
GTGAACTATTAATCTCATCTGATAAAGCGTGTGCGTGTATAGAGTTAAATTCA  
TATAAAGTAGCCATTCTTCCCATGGATGTTTCCTTTTTTACCAAAGGAAATGC  
ATCATTGATTATTCTCCTGTTTGATTCTCTATCGATGCGGCACCTCTCTTAA  
GAAGTGTAACCGATAATAATGTTATTATATCTAGACACCAGCGTCTACATGA  
CGAGCTTCCGAGTTCCAATTGGTTCAAGTTTTACATAAGTATAAAGTCCGAC  
TATTGTTCTATATTATATATGGTTGTTGATGGATCTGTGATGCATGCAATAGC  
TGATAATAGAACTTACGCAAATATTAGCAAAAATATATTAGACAATACTACAA  
TTAACGATGAGTGTAGATGCTGTTATTTTGAACCACAGATTAGGATTCTTGAT  
AGAGATGAGATGCTCAATGGATCATCGTGTGATATGAACAGACATTGTATTA  
TGATGAATTTACCTGATGTAGGCGAATTTGGATCTAGTATGTTGGGGAAATA  
TGAACCTGACATGATTAAGATTGCTCTTTCGGTGGCTGGGTACCAGGCGCG  
CCTTTCATTTTGTTTTTTCTATGCTATAAATGGTACGTCCTGTAGAAACCCC  
AACCCGTGAAATCAAAAAACTCGACGGCCTGTGGGCATTCAAGTCTGGATCG  
CGAAACTGTGGAATTGATCAGCGTTGGTGGGAAAGCGCGTTACAAGAAAG  
CCGGGCAATTGCTGTGCCAGGCAGTTTTAACGATCAGTTCGCCGATGCAGA  
TATTCGTAATTATGCGGGCAACGTCTGGTATCAGCGCGAAGTCTTTATACCG  
AAAGGTTGGGCAGGCCAGCGTATCGTGCTGCGTTTTCGATGCGGTCACTCAT  
TACGGCAAAGTGTGGGTCAATAATCAGGAAGTGATGGAGCATCAGGGCGG  
CTATACGCCATTTGAAGCCGATGTCACGCCGTATGTTATTGCCGGGAAAG  
TGTACGTATCACCGTTTGTGTGAACAACGAAGTGAAGTGGCAGACTATCCC  
GCCGGGAATGGTGATTACCGACGAAAACGGCAAGAAAAAGCAGTCTTACTT  
CCATGATTTCTTTAACTATGCCGGAATCCATCGCAGCGTAATGCTCTACACC  
ACGCCGAACACCTGGGTGGACGATATCACCGTGGTGACGCATGTCGCGCA  
AGACTGTAACCACGCGTCTGTTGACTGGCAGGTGGTGGCCAATGGTGATGT  
CAGCGTTGAACTGCGTGATGCGGATCAACAGGTGGTTGCAACTGGACAAG  
GCACTAGCGGGACTTTGCAAGTGGTGAATCCGCACCTCTGGCAACCGGGT  
GAAGGTTATCTCTATGAACTGTGCGTCACAGCCAAAAGCCAGACAGAGTGT  
GATATCTACCCGCTTCGCGTCGGCATCCGGTCAGTGGCAGTGAAGGGCGA  
ACAGTTCCTGATTAACCACAAACCGTTCTACTTTACTGGCTTTGGTCGTCAT  
GAAGATGCGGACTTGCGTGGCAAAGGATTCGATAACGTGCTGATGGTGCAC  
GACCACGCATTAATGGACTGGATTGGGGCCAACTCCTACCGTACCTCGCAT  
TACCCTTACGCTGAAGAGATGCTCGACTGGGCAGATGAACATGGCATCGTG

Figure B<sub>1</sub>



GTGATTGATGAAACTGCTGCTGTCGGCTTTAACCTCTCTTTAGGCATTGGTT  
TCGAAGCGGGCAACAAGCCGAAAGAACTGTACAGCGAAGAGGCAGTCAAC  
GGGGAAACTCAGCAAGCGCACTTACAGGCGATTAAAGAGCTGATAGCGCGT  
GACAAAAACCACCCAAGCGTGGTGATGTGGAGTATTGCCAACGAACCGGAT  
ACCCGTCCGCAAGGTGCACGGGAATATTTTCGCGCCACTGGCGGAAGCAAC  
GCGTAAACTCGACCCGACGCGTCCGATCACCTGCGTCAATGTAATGTTCTG  
CGACGCTCACACCGATACCATCAGCGATCTCTTTGATGTGCTGTGCCTGAA  
CCGTTATTACGGATGGTATGTCCAAAGCGGCGATTGGAACGGCAGAGAA  
GGTACTGGAAAAAGAACTTCTGGCCTGGCAGGAGAACTGCATCAGCCGAT  
TATCATCACCGAATACGGCGTGGATACGTTAGCCGGGCTGCACTCAATGTA  
CACCGACATGTGGAGTGAAGAGTATCAGTGTGCATGGCTGGATATGTATCA  
CCGCGTCTTTGATCGCGTCAGCGCCGTCGTCGGTGAACAGGTATGGAATTT  
CGCCGATTTTGCGACCTCGCAAGGCATATTGCGCGTTGGCGGTAACAAGAA  
AGGGATCTTCACTCGCGACCGCAAACCGAAGTCGGCGGCTTTTCTGCTGCA  
AAAACGCTGGACTGGCATGAACTTCGGTGAAAAACCGCAGCAGGGAGGCA  
AACAAATGAGAGCTCGGTTGTTGATGGATCTGTGATGCATGCAATAGCTGATA  
ATAGAACTTACGCAAATATTAGCAAAAATATATTAGACAATACTACAATTAAC  
GATGAGTGTAGATGCTGTTATTTGAACCACAGATTAGGATTCTTGATAGAG  
ATGAGATGCTCAATGGATCATCGTGTGATATGAACAGACATTGTATTATGAT  
GAATTTACCTGATGTAGGCGAATTTGGATCTAGTATGTTGGGGAAATATGAA  
CCTGACATGATTAAGATTGCTCTTTTCGGTGGCTGGCGGCCCCGCTCGAGTAA  
AAAATGAAAAAATATTCTAATTTATAGGACGGTTTTGATTTTCTTTTTTCTAT  
GCTATAAATAATAAATAGCGGCCCGCACCATGAAAGTGAAGGGGATCAGGAA  
GAATTATCAGCACTTGTGGAAATGGGGCATCATGCTCCTTGGGATGTTGATG  
ATCTGTAGTGCTGTAGAAAATTTGTGGGTCACAGTTTATTATGGGGTACCTG  
TGTGGAAAGAAGCAACCACCACTCTATTTTGTGCATCAGATGCTAAAGCATA  
TGATACAGAGGTACATAATGTTTGGGCCACACATGCCTGTGTACCCACAGA  
CCCCAACCCACAAGAAGTAGTATTGGAAAATGTGACAGAAAATTTTAACATG  
TGGA AAAAATAACATGGTAGAACAGATGCATGAGGATATAATCAGTTTATGGG  
ATCAAAGCCTAAAGCCATGTGTAAAATTAACCCCACTCTGTGTTACTTTAAAT  
TGCACTGATTTGAGGAATGTTACTAATATCAATAATAGTAGTGAGGGAATGA  
GAGGAGAAATAAAAAACTGCTCTTTCAATATCACCAACAAGCATAAGAGATAA  
GGTGAAGAAAGACTATGCACTTTTCTATAGACTTGATGTAGTACCAATAGATA  
ATGATAATACTAGCTATAGGTTGATAAATTGTAATACCTCAACCAATTACACAG  
GCCTGTCCAAAGGTATCCTTTGAGCCAATTCCCATACATTATTGTACCCCGG  
CTGGTTTTGCGATTCTAAAGTGTAAGACAAGAAGTTCAATGGAACAGGGCC  
ATGTAAAAATGTCAGCACAGTACAATGTACACATGGAATTAGGCCAGTAGTG  
TCAACTCAACTGCTGTAAATGGCAGTCTAGCAGAAGAAGAGGTAGTAATTA  
GATCTAGTAATTTACAGACAATGCAAAAAACATAATAGTACAGTTGAAAGAA  
TCTGTAGAAATTAATTGTACAAGACCCAACAACAATACAAGGAAAAGTATAC  
ATATAGGACCAGGAAGAGCATTTTATACAACAGGAGAAATAATAGGAGATAT  
AAGACAAGCACATTGCAACATTAGTAGAACAAAATGGAATAACACTTTAAAT  
CAAATAGCTACAAAATTAAGAACAATTTGGGAATAATAAACAATAGTCTT  
TAATCAATCCTCAGGAGGGGACCCAGAAATTGTAATGCACAGTTTAAATTGT  
GGAGGGGAATTCTTCTACTGTAATTCAACACAACCTGTTTAATAGTACTTGGA  
ATTTTAATGGTACTTGGAATTTAACACAATCGAATGGTACTGAAGGAAATGA

Figure B<sub>2</sub>



CACTATCACACTCCCATGTAGAATAAAACAAATTATAAATATGTGGCAGGAA  
GTAGGAAAAGCAATGTATGCCCCTCCCATCAGAGGACAAATTAGATGCTCAT  
CAAATATTACAGGGGCTAATATTAACAAGAGATGGTGGAACTAACAGTAGTGG  
GTCCGAGATCTTCAGACCTGGGGGAGGAGATATGAGGGACAATTGGAGAA  
GTGAATTATATAAATATAAAGTAGTAAAAATTGAACCATTAGGAGTAGCACCC  
ACCAAGGC AAAAAGAAGAGTGGTGCAGAGAGAAAAAAGAGCAGTGGGAAC  
GATAGGAGCTATGTTCTTGGGTTCTTGGGAGCAGCAGGAAGCACTATGGG  
CGCAGCGTCAATAACGCTGACGGTACAGGCCAGACTATTATTGTCTGGTAT  
AGTGCAACAGCAGAACAAATTTGCTGAGGGCTATTGAGGGCGCAACAGCATCT  
GTTGCAACTCACAGTCTGGGGCATCAAGCAGCTCCAGGCAAGAGTCCTGG  
CTGTGGAAAGATACCTAAGGGATCAACAGCTCCTAGGGATTTGGGGTTGCT  
CTGGAAAACCTCATCTGCACCACTGCTGTGCCTTGAATGCTAGTTGGAGTA  
ATAAACTCTGGATATGATTTGGGATAACATGACCTGGATGGAGTGGGAAA  
GAGAAATCGAAAATTACACAGGCTTAATATACACCTTAATTGAGGAATCGCA  
GAACCAACAAGAAAAGAATGAACAAGACTTATTAGCATTAGATAAGTGGGCA  
AGTTTGTGGAATTGGTTTGACATATCAAATTGGCTGTGGTATGTAAAAATCTT  
CATAATGATAGTAGGAGGCTTGATAGGTTTAAGAATAGTTTTTACTGTACTTT  
CTATAGTAAATAGAGTTAGGCAGGGGATACTCACCATTGTCATTTTCAGACCCA  
CCTCCCAGCCCCGAGGGGACCCGACAGGCCCGAAGGAATCGAAGAAGAAG  
GTGGAGACAGAGACTAATTTTTATGCGGGCGCTGGTACCCAACCTAAAAATT  
GAAAATAAATACAAAGGTTCTTGAGGGTTGTGTTAAATTGAAAGCGAGAAAT  
AATCATAAATAAGCCCGGGGATCCTCTAGAGTCGACACCATGGGTGCGAGA  
GCGTCAGTATTAAGCGGGGGGAGAATTAGATCGATGGGAAAAAATTCGGTTA  
AGGCCAGGGGGGAAAGAAAAAATATAAATTA AAACATATAGTATGGGCAAGCA  
GGGAGCTAGAACGATTTCGCAGTTAATCCTGGCCTGTTAGAAACATCAGAAG  
GCTGTAGACAAATACTGGGACAGCTACAACCATCCCTTCAGACAGGATCAG  
AAGAACTTAGATCATTATATAATACAGTAGCAACCTCTATTGTGTGCATCAA  
AGGATAGAGATAAAAGACACCAAGGAAGCTTTAGACAAGATAGAGGAAGAG  
CAAAACAAAAGTAAGAAAAAAGCACAGCAAGCAGCAGCTGACACAGGACAC  
AGCAATCAGGTCAGCCAAAATTACCCTATAGTGCAGAACATCCAGGGGGCAA  
ATGGTACATCAGGCCATATCACCTAGAACTTTAAATGCATGGGTAAAAGTAG  
TAGAAGAGAAGGCTTTCAGCCCAGAAGTGATACCCATGTTTTTCAGCATTATC  
AGAAGGAGCCACCCCAAGATTTAAACACCATGCTAAACACAGTGGGGGG  
ACATCAAGCAGCCATGCAAATGTTAAAAGAGACCATCAATGAGGAAGCTGC  
AGAATGGGATAGAGTGCATCCAGTGCATGCAGGGCCTATTGCACCAGGCCA  
GATGAGAGAACCAAGGGGAAGTGACATAGCAGGAAGTACTAGTACCCTTCA  
GGAACAAATAGGATGGATGACAAATAATCCACCTATCCCAGTAGGAGAAATT  
TATAAAAGATGGATAATCCTGGGATTAAATAAAATAGTAAGAATGTATAGCCC  
TACCAGCATTCTGGACATAAGACAAGGACCAAAAGAACCCTTTAGAGACTAT  
GTAGACCGGTTCTATAAACTCTAAGAGCCGAGCAAGCTTCACAGGAGGTA  
AAAAATTGGATGACAGAAACCTTGTTGGTCCAAAATGCGAACCCAGATTGTA  
AGACTATTTTAAAAGCATTGGGACCAGCGGCTACACTAGAAGAAATGATGAC  
AGCATGTCAGGGAGTAGGAGGACCCGGCCATAAGGCAAGAGTTTTGGCTG  
AAGCAATGAGCCAAGTAACAAATTCAGCTACCATAATGATGCAGAGAGGCA  
ATTTTAGGAACCAAGAAAGATTGTTAAGTGTTTCAATTGTGGCAAAGAAGG  
GCACACAGCCAGAAATTGCAGGGCCCCTAGGAAAAAGGGCTGTTGAAAT

Figure B<sub>3</sub>

GTGGAAAGGAAGGACACCAAATGAAAGATTGTACTGAGAGACAGGCTAATT  
TTTTAGGGAAGATCTGGCCTTCCTACAAGGGAAGGCCAGGGAATTTTCTTCA  
GAGCAGACCAGAGCCAACAGCCCCACCAGAAGAGAGCTTCAGGTCTGGGG  
TAGAGACAACAACCTCCCCCTCAGAAGCAGGAGCCGATAGACAAGGAACTGT  
ATCCTTTAACTTCCCTCAGATCACTCTTTGGCAACGACCCCTCGTCACAATA  
AAGATAGGGGGGGCAACTAAAGGAAGCTCTATTAGATACAGGAGCAGATGAT  
ACAGTATTAGAAGAAATGAGTTTGCCAGGAAGATGGAAACCAAAAATGATAG  
GGGGAATTGGAGGTTTTATCAAAGTAAGACAGTATGATCAGATACTCATAGA  
AATCTGTGGACATAAAGCTATAGGTACAGTATTAGTAGGACCTACACCTGTC  
AACATAATTGGAAGAAATCTGTTGACTCAGATTGGTTGCACTTTAAATTTTCC  
CATTAGCCCTATTGAGACTGTACCAGTAAAATTAAGGCCAGGAATGGATGGC  
CCAAAAGTTAAACAATGGCCATTGACAGAAGAAAAAATAAAAGCATTAGTAG  
AAATTTGTACAGAAATGGAAAAGGAAGGGGAAAATTTCAAAAATTGGGCCTGA  
GAATCCATACAATACTCCAGTATTTGCCATAAAGAAAAAAGACAGTACTAAAT  
GGAGGAAATTAGTAGATTTTCAGAGAACTTAATAAGAGAACTCAAGACTTCTG  
GGAAGTTCAATTAGGAATACCACATCCCGCAGGGTTAAAAAAGAAAAAATCA  
GTAACAGTACTGGATGTGGGTGATGCATATTTTTCAGTTCCCTTAGATGAAG  
ACTTCAGGAAGTATACTGCATTTACCATACCTAGTATAAACAATGAGACACC  
AGGGATTAGATATCAGTACAATGTGCTTCCACAGGGATGGAAAGGATCACC  
AGCAATATTCCAAAGTAGCATGACAAAAATCTTAGAGCCTTTTAAAAAACAAA  
ATCCAGACATAGTTATCTATCAATACATGAACGATTTGTATGTAGGATCTGAC  
TTAGAAATAGGGCAGCATAGAACAAAAATAGAGGAGCTGAGACAACATCTG  
TTGAGGTGGGGACTTACCACACCAGACAAAAAACATCAGAAAGAACCTCCA  
TTCCTTTGGATGGGTATGAACTCCATCCTGATAAATGGACAGTACAGCCTA  
TAGTGCTGCCAGAAAAAGACAGCTGGACTGTCAATGACATACAGAAGTTAG  
TGGGGAAATTGAATACCGCAAGTCAGATTTACCCAGGGATTAAAGTAAGGC  
AATTATGTAACTCCTTAGAGGAACCAAAGCACTAACAGAAGTAATACCACT  
AACAGAAGAAGCAGAGCTAGAACTGGCAGAAAACAGAGAGATTCTAAAAGA  
ACCAGTACATGGAGTGTATTATGACCCATCAAAAGACTTAATAGCAGAAATA  
CAGAAGCAGGGGCAAGGCCAATGGACATATCAAATTTATCAAGAGCCATTT  
AAAAATCTGAAAACAGGAAAATATGCAAGAATGAGGGGTGCCCCACACTAAT  
GATGTAAAACAATTAACAGAGGCAGTGCAAAAAATAACCACAGAAAGCATAG  
TAATATGGGGAAAGACTCCTAAATTTAACTACCCATACAAAAGGAAACATG  
GGAAACATGGTGGACAGAGTATTGGCAAGCCACCTGGATTCTCTGAGTGGGA  
GTTTGTTAATACCCCTCCTTTAGTGAAATTATGGTACCAGTTAGAGAAAGAA  
CCCATAGTAGGAGCAGAAACCTTCTATGTAGATGGGGCAGCTAACAGGGAG  
ACTAAATTAGGAAAAGCAGGATATGTTACTAACAAAGGAAGACAAAAGGTTG  
TCCCCCTAACTAACACAACAAATCAGAAAACCTCAGTTACAAGCAATTTATCTA  
GCTTTGCAGGATTCAGGATTAGAAGTAAACATAGTAACAGACTCACAATATG  
CATTAGGAATCATTCAAGCACAACCAGATAAAAGTGAATCAGAGTTAGTCAA  
TCAAATAATAGAGCAGTTAATAAAAAAGGAAAAGGTCTATCTGGCATGGGTA  
CCAGCACACAAAGGAATTGGAGGAAATGAACAAGTAGATAAATTAGTCAGT  
GCTGGAATCAGGAAAATACTATTTTTAGATGGAATAGATAAGGCCCAAGATG  
AACATTAGTTTTTATGTCGACCTGCAGGGAAAGTTTTATAGGTAGTTGATAG  
AACAAAATACATAATTTTGTA AAAAATAAATCACTTTTTATACTAATATGACACG  
ATTACCAATACTTTTGTTACTAATATCATTAGTATACGCTACACCTTTTCCTCA

Figure B<sub>4</sub>

GACATCTAAAAAATAGGTGATGATGCAACTTTATCATGTAATCGAAATAATA  
CAAATGACTACGTTGTTATGAGTGCTTGGTATAAGGAGCCCAATTCCATTAT  
TCTTTTAGCTGCTAAAAGCGACGTCTTGATTTTGATAATTATACCAAGGATA  
AAATATCTTACGACTCTCCATACGATGATCTAGTTACAACATCACAATTAAA  
TCATTGACTGCTAGAGATGCCGGTACTTATGTATGTGCATTCTTTATGACATC  
GCCTACAAATGACACTGATAAAGTAGATTATGAAGAATACTCCACAGAGTTG  
ATTGTAAATACAGATAGTGAATCGACTATAGACATAATACTATCTGGATCTAC  
ACATTCACCAGAACTAGTTAAGCTTGTCTCCCTATAGTGAGTCGTATTAGA  
GCTTGGCGTAATCATGGTCATAGCTGTTTCCTGTGTGAAATTGTTATCCGCT  
CACAATTCCACACAACATACGAGCCGGAAGCATAAAGTGTAAGCCTGGGG  
TGCCTAATGAGTGAGCTAACTCACATTAATTGCGTTGCGCTCACTGCCCGCT  
TTCGAGTCGGGAAACCTGTCGTGCCAGCTGCATTAATGAATCGGCCAACGC  
GCGGGGAGAGGGCGGTTTGCGTATTGGGCGCTCTTCCGCTTCCTCGCTCAC  
TGACTCGCTGCGCTCGGTCTGTTCCGGCTGCGGCGAGCGGTATCAGCTCACT  
CAAAGGCGGTAAATACGGTTATCCACAGAATCAGGGGATAACGCAGGAAAGA  
ACATGTGAGCAAAAGGCCAGCAAAAGGCCAGGAACCGTAAAAAGGCCGCG  
TTGCTGGCGTTTTTCGATAGGCTCCGCCCCCTGACGAGCATCACAAAAT  
CGACGCTCAAGTCAGAGGTGGCGAAACCCGACAGGACTATAAAGATACCAG  
GCGTTTCCCCCTGGAAGCTCCCTCGTGCGCTCTCCTGTTCCGACCCTGCCG  
CTTACCGGATACCTGTCCGCTTTCTCCCTTCGGGAAGCGTGGCGCTTTCT  
CATAGCTCACGCTGTAGGTATCTCAGTTCGGTGTAAGTTCGTTCCGCTCCAAG  
CTGGGCTGTGTGCACGAACCCCCCGTTACAGCCCGACCGCTGCGCCTTATC  
CGGTAACATATCGTCTTGAGTCCAACCCGGTAAGACACGACTTATCGCCACT  
GGCAGCAGCCACTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGCGGTG  
CTACAGAGTTCTTGAAGTGGTGGCCTAACTACGGCTACACTAGAAGGACAG  
TATTTGGTATCTGCGCTCTGCTGAAGCCAGTTACCTTCGGAAAAAGAGTTGG  
TAGCTCTTGATCCGGCAAACAAACCCAGCTGGTAGCGGTGGTTTTTTTGT  
TGCAAGCAGCAGATTACGCGCAGAAAAAAGGATCTCAAGAAGATCCTTTG  
ATCTTTTCTACGGGGTCTGACGCTCAGTGGAACGAAAACCTCACGTTAAGGG  
ATTTTGGTCATGAGATTATCAAAAAGGATCTTCACCTAGATCCTTTTAAATTA  
AAAATGAAGTTTTTAAATCAATCTAAAGTATATATGAGTAACTTGGTCTGACA  
GTTACCAATGCTTAATCAGTGAGGCACCTATCTCAGCGATCTGTCTATTTG  
TTCATCCATAGTTGCCTGACTCCCCGTCGTGTAGATAACTACGATACGGGAG  
GGCTTACCATCTGGCCCCAGTGCTGCAATGATACCGCGAGACCCACGCTCA  
CCGGCTCCAGATTTATCAGCAATAAACCAGCCAGCCGGAAGGGCCGAGCG  
CAGAAGTGGTCCTGCAACTTTATCCGCCTCCATCCAGTCTATTAATTGTTGC  
CGGGAAGCTAGAGTAAGTAGTTCGCCAGTTAATAGTTTGCGCAACGTTGTT  
GGCATTGCTACAGGCATCGTGGTGTACGCTCGTCGTTTGGTATGGCTTCA  
TTCAGCTCCGGTTCCCAACGATCAAGGCGAGTTACATGATCCCCCATGTTGT  
GCAAAAAAGCGGTTAGCTCCTTCGGTCCTCCGATCGTTGTCAGAAGTAAGT  
TGGCCGCAGTGTTATCACTCATGGTTATGGCAGCACTGCATAATTCTCTTAC  
TGTCATGCCATCCGTAAGATGCTTTTCTGTGACTGGTGAGTACTCAACCAAG  
TCATTCTGAGAATAGTGTATGCGGCGACCGAGTTGCTCTTGCCCGGCGTCA  
ATACGGGATAATACCGCGCCACATAGCAGAACTTTAAAGTGCTCATCATTG  
GAAAACGTTCTTCGGGGCGAAAACCTCTCAAGGATCTTACCGCTGTTGAGAT  
CCAGTTCGATGTAACCCACTCGTGCACCCAACTGATCTTCAGCATCTTTTAC

Figure B<sub>5</sub>



TTTCACCAGCGTTTCTGGGTGAGCAAAAACAGGAAGGCAAAATGCCGCAAA  
AAAGGGAATAAGGGGCGACACGGAAATGTTGAATACTCATACTCTTCCTTTT  
CAATATTATTGAAGCATTTATCAGGGTTATTGTCTCATGAGCGGATACATATT  
TGAATGTATTTAGAAAAATAAACAAATAGGGGTTCGCGGCACATTTCCCCGA  
AAAGTGCCACCTGACGTCTAAGAAACCATTATTATCATGACATTAACCTATAA  
AAATAGGCGTATCACGAGGCCCTTTCTGTCTCGCGCGTTTCGGTGATGACGG  
TGAAAACCTCTGACACATGCAGCTCCCGGAGACGGTCACAGCTTGTCTGTA  
AGCGGATGCCGGGAGCAGACAAGCCCGTCAGGGGCGCGTCAGCGGGGTGTT  
GGCGGGTGTCTGGGGGCTGGCTTAACCTATGCGGGCATCAGAGCAGATTGTACT  
GAGAGTGCACCATATGCGGTGTGAAATACCGCACAGATGCGTAAGGAGAAA  
ATACCGCATCAGGCGCCATTGCGCATTCAGGCTGCGCAACTGTTGGGAAGG  
GCGATCGGTGCGGGCCTCTTCGCTATTACGCCAGCTGGCGAAAGGGGGAT  
GTGCTGCAAGGCGATTAAGTTGGGTAAACGCCAGGGTTTTCCAGTCACGAC  
GTTGTAAAACGACGGCCAGTGAATTGGATTAGGTGACACTATA

**New Psyn II Promoter which controls ADA envelope expression:**

TAAAAAATGAAAAAATATTCTAATTTATAGGACGGTTTTGATTTTCTTTTTTTC  
TATGCTATAAATAATAATA

**ADA envelope truncated:**

ATGAAAGTGAAGGGGATCAGGAAGAATTATCAGCACTTGTGGAAATGGGGC  
ATCATGCTCCTTGGGATGTTGATGATCTGTAGTGCTGTAGAAAATTTGTGGG  
TCACAGTTTATTATGGGGTACCTGTGTGGAAAGAAGCAACCACCACTCTATT  
TTGTGCATCAGATGCTAAAGCATATGATACAGAGGTACATAATGTTTGGGCC  
ACACATGCCTGTGTACCCACAGACCCCAACCCACAAGAAGTAGTATTGGAA  
AATGTGACAGAAAATTTTAACATGTGGAAAAATAACATGGTAGAACAGATGC  
ATGAGGATATAATCAGTTTATGGGATCAAAGCCTAAAGCCATGTGTAAATT  
AACCCCACTCTGTGTTACTTTAAATTGCACTGATTTGAGGAATGTTACTAATA  
TCAATAATAGTAGTGAGGGAATGAGAGGAGAAATAAAAAACTGCTCTTTCAA  
TATCACCACAAGCATAAGAGATAAGGTGAAGAAAGACTATGCACTTTTCTAT  
AGACTTGATGTAGTACCAATAGATAATGATAATACTAGCTATAGGTTGATAAA  
TTGTAATACCTCAACCATTACACAGGCCTGTCCAAAGGTATCCTTTGAGCCA  
ATTCCCATACATTATTGTACCCCGGCTGGTTTTTGCGATTCTAAAGTGTAAG  
ACAAGAAGTTCAATGGAACAGGGCCATGTAAAAATGTCAGCACAGTACAAT  
GTACACATGGAATTAGGCCAGTAGTGCAACTCAACTGCTGTAAATGGCAG  
TCTAGCAGAAGAAGAGGTAGTAATTAGATCTAGTAATTTACAGACAATGCA  
AAAAACATAATAGTACAGTTGAAAGAATCTGTAGAAATTAATTGTACAAGACC  
CAACAACAATACAAGGAAAAGTATACATATAGGACCAGGAAGAGCATTTTAT  
ACAACAGGAGAAATAATAGGAGATATAAGACAAGCACATTGCAACATTAGTA  
GAACAAAATGGAATAACACTTTAAATCAAATAGCTACAAAATTAAGAACA  
TTTGGGAATAATAAAACAATAGTCTTTAATCAATCCTCAGGAGGGGACCCAG  
AAATTGTAATGCACAGTTTTAATTGTGGAGGGGAATTCTTCTACTGTAATTCA  
ACACAACCTGTTTAATAGTACTTGGAATTTAATGGTACTTGGAATTTAACACA

Figure B<sub>6</sub>

ATCGAATGGTACTGAAGGAAATGACACTATCACACTCCCATGTAGAATAAAA  
CAAATTATAAATATGTGGCAGGAAGTAGGAAAAGCAATGTATGCCCCTCCCA  
TCAGAGGACAAATTAGATGCTCATCAAATATTACAGGGCTAATATTAACAAG  
AGATGGTGGAACTAACAGTAGTGGGTCCGAGATCTTCAGACCTGGGGGAG  
GAGATATGAGGGACAATTGGAGAAGTGAATTATATAAATATAAAGTAGTAAA  
AATTGAACCATTAGGAGTAGCACCCACCAAGGCCAAAAAGAAGAGTGGTGCA  
GAGAGAAAAAGAGCAGTGGGAACGATAGGAGCTATGTTCTTGGGGTTCTT  
GGGAGCAGCAGGAAGCACTATGGGCGCAGCGTCAATAACGCTGACGGTAC  
AGGCCAGACTATTATTGTCTGGTATAGTGCAACAGCAGAACAATTTGCTGAG  
GGCTATTGAGGCGCAACAGCATCTGTTGCAACTCACAGTCTGGGGCATCAA  
GCAGCTCCAGGCAAGAGTCCTGGCTGTGGAAAGATACCTAAGGGATCAACA  
GCTCCTAGGGATTTGGGGTTGCTCTGGAAACTCATCTGCACCACTGCTGT  
GCCTTGGAATGCTAGTTGGAGTAATAAACTCTGGATATGATTTGGGATAAC  
ATGACCTGGATGGAGTGGGAAAGAGAAATCGAAAATTACACAGGCTTAATAT  
ACACCTTAATTGAGGAATCGCAGAACCAACAAGAAAAGAATGAACAAGACTT  
ATTAGCATTAGATAAGTGGGCAAGTTTGTGGAATTGGTTTGACATATCAAATT  
GGCTGTGGTATGTAAAAATCTTCATAATGATAGTAGGAGGCTTGATAGGTTT  
AAGAATAGTTTTTACTGTACTTTCTATAGTAAATAGAGTTAGGCAGGGATACT  
CACCATTGTCATTTTCAGACCCACCTCCCAGCCCCGAGGGGACCCGACAGG  
CCCGAAGGAATCGAAGAAGAAGGTGGAGACAGAGAC

**PmH5 promoter (which controls HXB2 gag pol expression):**

AAAAATTGAAAATAAATACAAAGGTTCTTGAGGGTTGTGTTAAATTGAAAGC  
GAGAAATAATCATAAATA

**HXB2 gag pol (with safety mutations,  $\Delta$  integrase):**

ATGGGTGCGAGAGCGTCAGTATTAAGCGGGGGGAGAATTAGATCGATGGGA  
AAAAATTCGGTTAAGGCCAGGGGGGAAAGAAAAAATATAAATTAAACATATA  
GTATGGGCAAGCAGGGAGCTAGAACGATTTCGCAGTTAATCCTGGCCTGTTA  
GAAACATCAGAAGGCTGTAGACAAATACTGGGACAGCTACAACCATCCCTT  
CAGACAGGATCAGAAGAAGCTTAGATCATTATATAATACAGTAGCAACCCTCT  
ATTGTGTGCATCAAAGGATAGAGATAAAAGACACCAAGGAAGCTTTAGACAA  
GATAGAGGAAGAGCAAAACAAAAGTAAGAAAAAAGCACAGCAAGCAGCAGC  
TGACACAGGACACAGCAATCAGGTCAGCCAAAATTACCCTATAGTGCAGAA  
CATCCAGGGGCAAATGGTACATCAGGCCATATCACCTAGAACTTTAAATGCA  
TGGGTAAAAGTAGTAGAAGAGAAGGCTTTCAGCCCAGAAGTGATACCCATG  
TTTTCAGCATTATCAGAAGGAGCCACCCCAAGATTTAAACACCATGCTAA  
ACACAGTGGGGGGACATCAAGCAGCCATGCAAATGTTAAAAGAGACCATCA  
ATGAGGAAGCTGCAGAATGGGATAGAGTGCATCCAGTGCATGCAGGGCCT  
ATTGCACCAGGCCAGATGAGAGAACCAAGGGGAAGTGACATAGCAGGAAC  
TACTAGTACCCTTCAGGAACAAATAGGATGGATGACAAATAATCCACCTATC  
CCAGTAGGAGAAATTTATAAAAGATGGATAATCCTGGGATTAAATAAATAG  
TAAGAATGTATAGCCCTACCAGCATTCTGGACATAAGACAAGGACCAAAAGA  
ACCCTTTAGAGACTATGTAGACCGGTTCTATAAACTCTAAGAGCCGAGCAA

Figure B<sub>7</sub>

GCTTCACAGGAGGTAAAAAATTGGATGACAGAAACCTTGTTGGTCCAAAATG  
CGAACCCAGATTGTAAGACTATTTTAAAAGCATTGGGACCAGCGGCTACACT  
AGAAGAAATGATGACAGCATGTCAGGGAGTAGGAGGACCCGGCCATAAGG  
CAAGAGTTTTGGCTGAAGCAATGAGCCAAGTAACAAATTCAGCTACCATAAT  
GATGCAGAGAGGCAATTTTAGGAACCAAGAAAGATTGTTAAGTGTTTCAAT  
TGTGGCAAAGAAGGGGCACACAGCCAGAAATTGCAGGGCCCCCTAGGAAAAA  
GGGCTGTTGGAAATGTGGAAAGGAAGGACACCAAATGAAAGATTGTACTGA  
GAGACAGGCTAATTTTTTAGGGGAAGATCTGGCCTTCCTACAAGGGAAGGCC  
AGGGAATTTTCTTCAGAGCAGACCAGAGCCAACAGCCCCACCAGAAGAGAG  
CTTCAGGTCTGGGGTAGAGACAACAACCTCCCCCTCAGAAGCAGGAGCCGAT  
AGACAAGGAACTGTATCCTTTAACTTCCCTCAGATCACTCTTTGGCAACGAC  
CCCTCGTCACAATAAAGATAGGGGGGGCAACTAAAGGAAGCTCTATTAGATA  
CAGGAGCAGATGATACAGTATTAGAAGAAATGAGTTTGCCAGGAAGATGGA  
AACCAAAAATGATAGGGGGGAATTGGAGGTTTTATCAAAGTAAGACAGTATGA  
TCAGATACTCATAGAAATCTGTGGACATAAAGCTATAGGTACAGTATTAGTA  
GGACCTACACCTGTCAACATAATTGGAAGAAATCTGTTGACTCAGATTGGTT  
GCACTTTAAATTTTCCCATTAGCCCTATTGAGACTGTACCAGTAAAATTAAG  
CCAGGAATGGATGGCCCAAAGTTAAACAATGGCCATTGACAGAAGAAAAA  
ATAAAAGCATTAGTAGAAATTTGTACAGAAATGGAAAAGGAAGGGAAAAATT  
CAAAAATTGGGCCTGAGAATCCATACAATACTCCAGTATTTGCCATAAAGAA  
AAAAGACAGTACTAAATGGAGGAAATTAGTAGATTTTCAGAGAACTTAATAAG  
AGAACTCAAGACTTCTGGGAAGTTCAATTAGGAATACCACATCCCGCAGGG  
TTAAAAAAGAAAAAATCAGTAACAGTACTGGATGTGGGTGATGCATATTTTC  
AGTTCCCTTAGATGAAGACTTCAGGAAGTATACTGCATTTACCATACCTAGT  
ATAACAATGAGACACCAGGGATTAGATATCAGTACAATGTGCTTCCACAGG  
GATGGAAAGGATCACCAGCAATATTCCAAAGTAGCATGACAAAAATCTTAGA  
GCCTTTTAAAAAACAAAATCCAGACATAGTTATCTATCAATACATGAACGATT  
TGTATGTAGGATCTGACTTAGAAATAGGGGCAGCATAGAACAAAAATAGAGGA  
GCTGAGACAACATCTGTTGAGGTGGGGACTTACCACACCAGACAAAAACA  
TCAGAAAGAACCTCCATTCTTTGGATGGGTATGAACTCCATCCTGATAAA  
TGGACAGTACAGCCTATAGTGCTGCCAGAAAAAGACAGCTGGACTGTCAAT  
GACATACAGAAGTTAGTGGGGAAATTGAATACCGCAAGTCAGATTTACCCA  
GGGATTAAAGTAAGGCAATTATGTAAACTCCTTAGAGGAACCAAAGCACTAA  
CAGAAGTAATACCACTAACAGAAGAAGCAGAGCTAGAACTGGCAGAAAACA  
GAGAGATTCTAAAAGAACCAGTACATGGAGTGTATTATGACCCATCAAAAGA  
CTTAATAGCAGAAATACAGAAGCAGGGGCAAGGCCAATGGACATATCAAAT  
TTATCAAGAGCCATTTAAAAATCTGAAAACAGGAAAATATGCAAGAATGAGG  
GGTGCCCACTAATGATGTAAACAATTAACAGAGGCAGTGCAAAAAATAA  
CCACAGAAAGCATAGTAATATGGGGAAAGACTCCTAAATTTAAACTACCCAT  
ACAAAAGGAAACATGGGAAACATGGTGGACAGAGTATTGGCAAGCCACCTG  
GATTCCTGAGTGGGAGTTTGTAAATACCCCTCCTTTAGTGAAATTATGGTAC  
CAGTTAGAGAAAGAACCCATAGTAGGAGCAGAAACCTTCTATGTAGATGGG  
GCAGCTAACAGGGAGACTAAATTAGGAAAAGCAGGATATGTTACTAACAAA  
GGAAGACAAAAGGTTGTCCCCCTAACTAACACAACAAATCAGAAAACCTCAGT  
TACAAGCAATTTATCTAGCTTTGCAGGATTCAGGATTAGAAGTAAACATAGTA  
ACAGACTCACAATATGCATTAGGAATCATTCAAGCACACCAGATAAAAGTG

Figure B<sub>8</sub>




AATCAGAGTTAGTCAATCAAATAATAGAGCAGTTAATAAAAAAGGAAAAGGT  
CTATCTGGCATGGGTACCAGCACACAAAGGAATTGGAGGAAATGAACAAGT  
AGATAAATTAGTCAGTGCTGGAATCAGGAAAATACTATTTT TAGATGGAATA  
GATAAGGCCCAAGATGAACATTAG

O:\DOCS\MXG\NIH211A.001PR\PLW-48 AND HIV GENES SEQ.DOC  
022602

Figure B<sub>9</sub>

## Plasmid pLW-48



## Virus MVA/HIV 48




Figure C




Figure D

## Sequence of new Psyn II promoter:

### Early part of promoter

|                                      |                  |
|--------------------------------------|------------------|
| <u>Critical region</u>               | Early start site |
| TAAAAAATGAAAAAATATTCTAATTTATAGGACGGT |                  |

### Late part of promoter

TTTGATTTTCTTTTTTCTATGCTATAAATAATAAATA

Figure E

## SEQUENCE LISTING

<110> THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE  
SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES

Moss, Bernard  
Wyatt, Linda  
Earl, Patricia

<120> MVA EXPRESSING MODIFIED HIV ENVELOPE,  
GAG, AND POL GENES

<130> NIH211.001PCT

<150> US 60/274,434

<151> 2001-03-08

<160> 13

<170> FastSEQ for Windows Version 4.0

<210> 1

<211> 12225

<212> DNA

<213> Artificial Sequence

<220>

<223> Plasmid pLW-48

<400> 1

|             |             |             |             |             |             |      |
|-------------|-------------|-------------|-------------|-------------|-------------|------|
| gaattcgttg  | gtggtcgcca  | tggatgggtgt | tattgtatac  | tgtctaaacg  | cgtttagtaaa | 60   |
| acatggcgag  | gaaataaaatc | atataaaaaa  | tgatttcatg  | attaaacccat | gttgtgaaaa  | 120  |
| agtcaagaac  | gttcacattg  | gcggacaatc  | taaaaacaat  | acagtgattg  | cagatttgcc  | 180  |
| atatatggat  | aatgcggtat  | ccgatgtatg  | caattcactg  | tataaaaaga  | atgtatcaag  | 240  |
| aatatccaga  | tttgctaatt  | tgataaagat  | agatgacgat  | gacaagactc  | ctactgggtgt | 300  |
| atataattat  | tttaaaccta  | aagatgccat  | tcctgttatt  | atatccatag  | gaaaggatag  | 360  |
| agatgtttgt  | gaactattaa  | tctcatctga  | taaagcgtgt  | gcgtgtatag  | agttaaattc  | 420  |
| atataaagta  | gccattcttc  | ccatggatgt  | ttcctttttt  | accaaaggaa  | atgcatcatt  | 480  |
| gattattctc  | ctgtttgatt  | tctctatcga  | tgcggcacct  | ctcttaagaa  | gtgtaaccga  | 540  |
| taataatggt  | attatatcta  | gacaccagcg  | tctacatgac  | gagcttccga  | gttccaattg  | 600  |
| gttcaagttt  | tacataagta  | taaagtccga  | ctattgttct  | atattatata  | tggttggtga  | 660  |
| tggtatctgtg | atgcatgcaa  | tagctgataa  | tagaacttac  | gcaaatatta  | gcaaaaatat  | 720  |
| attagacaat  | actacaatta  | acgatgagtg  | tagatgctgt  | tattttgaac  | cacagattag  | 780  |
| gattccttgat | agagatgaga  | tgctcaatgg  | atcatcgtgt  | gatatgaaca  | gacattgtat  | 840  |
| tatgatgaat  | ttacctgatg  | taggcgaatt  | tggatctagt  | atggtgggga  | aatatgaacc  | 900  |
| tgacatgatt  | aagattgctc  | tttcgggtggc | tgggtaccag  | gcgcgccttt  | cattttgttt  | 960  |
| ttttctatgc  | tataaatggt  | acgtcctgta  | gaaaccccaa  | cccgtgaaat  | caaaaaactc  | 1020 |
| gacggcctgt  | gggcattcag  | tctggatcgc  | gaaaactgtg  | gaattgatca  | gcgttggtgg  | 1080 |
| gaaagcgcgt  | tacaagaaag  | ccgggcaatt  | gctgtgccag  | gcagttttta  | cgatcagttc  | 1140 |
| gccgatgcag  | atattcgtaa  | ttatgcgggc  | aacgtctggt  | atcagcgcga  | agtctttata  | 1200 |
| ccgaaagggt  | gggcaggcca  | gcgtatcgtg  | ctgcgtttcg  | atgcgggtcac | tcattacggc  | 1260 |
| aaagtgtggg  | tcaataatca  | ggaagtgatg  | gagcatcagg  | gcggctatac  | gccatttgaa  | 1320 |
| gccgatgtca  | cgccgtatgt  | tattgccggg  | aaaagtgtac  | gtatcaccgt  | ttgtgtgaac  | 1380 |
| aacgaactga  | actggcagac  | tatcccgcgc  | ggaatggtga  | ttaccgacga  | aaacggcaag  | 1440 |
| aaaaagcagt  | cttacttcca  | tgatttcttt  | aactatgccg  | gaatccatcg  | cagcgtaatg  | 1500 |
| ctctacacca  | cgccgaacac  | ctgggtggac  | gatatcaccg  | tggtgacgca  | tgctcgcgcaa | 1560 |
| gactgtaacc  | acgcgtctgt  | tgactggcag  | gtgggtggcca | atggtgatgt  | cagcgttgaa  | 1620 |
| ctgcgtgatg  | cggatcaaca  | ggtgggttgca | actggacaag  | gcactagcgg  | gactttgcaa  | 1680 |



|             |             |             |             |             |             |      |
|-------------|-------------|-------------|-------------|-------------|-------------|------|
| gtggtgaatc  | cgcacctctg  | gcaaccgggt  | gaaggttatc  | tctatgaact  | gtgcgtcaca  | 1740 |
| gccaaaagcc  | agacagagtg  | tgatatctac  | ccgcttcgcg  | tcggcatccg  | gtcagtggca  | 1800 |
| gtgaagggcg  | aacagttcct  | gattaaccac  | aaaccgttct  | actttactgg  | ctttggtcgt  | 1860 |
| catgaagatg  | cggacttgcg  | tggcaaagga  | ttcgataacg  | tgctgatggg  | gcacgaccac  | 1920 |
| gcattaatgg  | actggattgg  | ggccaactcc  | taccgtacct  | cgcattaccc  | ttacgctgaa  | 1980 |
| gagatgctcg  | actgggcaga  | tgaacatggc  | atcgtgggtga | ttgatgaaac  | tgctgctgtc  | 2040 |
| ggctttaacc  | tctctttagg  | cattggtttc  | gaagcgggca  | acaagccgaa  | agaactgtac  | 2100 |
| agcgaagagg  | cagtcaacgg  | ggaaactcag  | caagcgcact  | tacaggcgat  | taaagagctg  | 2160 |
| atagcgcgtg  | acaaaaacca  | cccaagcgtg  | gtgatgtgga  | gtattgcca   | cgaaccggat  | 2220 |
| acccgtccgc  | aaggtgcacg  | ggaatatctc  | gcgccactgg  | cggagcaac   | gcgtaaactc  | 2280 |
| gacccgacgc  | gtccgatcac  | ctgctcaat   | gtaatgttct  | gcgacgctca  | caccgatacc  | 2340 |
| atcagcgcgc  | tctttgatgt  | gctgtgcctg  | aaccgttatt  | acggatggta  | tgtccaaagc  | 2400 |
| ggcgatttgg  | aaacggcaga  | gaaggactct  | gaaaaagaac  | ttctggcctg  | gcaggagaaa  | 2460 |
| ctgcatcagc  | cgattatcat  | caccgaatac  | ggcgtggata  | cgtagccggg  | gctgcactca  | 2520 |
| atgtacaccg  | acatgtggag  | tgaagagtat  | cagtgtgcat  | ggctggatat  | gtatcaccgc  | 2580 |
| gtctttgatc  | gcgtcagcgc  | cgctcgcgtg  | gaacagggtat | ggaatttcgc  | cgattttgcg  | 2640 |
| acctcgcaag  | gcataattgcg | cgttggcggg  | aacaagaaag  | ggatcttcac  | tcgcgaccgc  | 2700 |
| aaaccgaagt  | cggcggcttt  | tctgctgcaa  | aaacgctgga  | ctggcatgaa  | cttcgggtgaa | 2760 |
| aaaccgcagc  | agggaggcaa  | acaatgagag  | ctcggttgtt  | gatggatctg  | tgatgcatgc  | 2820 |
| aatagctgat  | aatagaactt  | acgcaaatat  | tagcaaaaat  | atattagaca  | atactacaat  | 2880 |
| taacgatgag  | tgtagatgct  | gttattttga  | accacagatt  | aggattcttg  | atagagatga  | 2940 |
| gatgctcaat  | ggatcatcgt  | gtgatatgaa  | cagacattgt  | attatgatga  | atttacctga  | 3000 |
| tgtaggcgaa  | tttggatcta  | gtatgttggg  | gaaatatgaa  | cctgacatga  | ttaagattgc  | 3060 |
| tctttcgggtg | gctggcggcc  | cgctcgagta  | aaaaatgaaa  | aaatatctta  | atttatagga  | 3120 |
| cggttttgat  | tttctttttt  | tctatgctat  | aaataataaa  | tagcggccgc  | accatgaaag  | 3180 |
| tgaaggggat  | caggaagaat  | tatcagcact  | tgtggaaatg  | gggcatcatg  | ctccttggga  | 3240 |
| tgttgatgat  | ctgtagtgct  | gtagaaaatt  | tgtgggtcac  | agtttattat  | ggggtacctg  | 3300 |
| tgtggaaaga  | agcaaccacc  | actctatctt  | gtgcatcaga  | tgctaaagca  | tatgatacag  | 3360 |
| aggtacataa  | tgtttgggccc | acacatgcct  | gtgtaccac   | agaccccaac  | ccacaagaag  | 3420 |
| tagtatttga  | aaatgtgaca  | gaaaatttta  | acatgtggaa  | aaataacatg  | gtagaacaga  | 3480 |
| tgcatgagga  | tataatcagt  | ttatgggatc  | aaagcctaaa  | gccatgtgta  | aaattaaccc  | 3540 |
| cactctgtgt  | tactttaaat  | tgactgatt   | tgagggaatgt | tactaatatc  | aataatagta  | 3600 |
| gtgaggggat  | gagaggagaa  | ataaaaaact  | gctctttcaa  | tatcaccaca  | agcataagag  | 3660 |
| ataaggtgaa  | gaaagactat  | gcacttttct  | atagacttga  | tgtagtacca  | atagataatg  | 3720 |
| ataatactag  | ctataggttg  | ataaattgta  | atacctcaac  | cattacacag  | gcctgtccaa  | 3780 |
| aggtatcctt  | tgagccaatt  | cccatacatt  | attgtacccc  | ggctgggttt  | gcgattctaa  | 3840 |
| agtgtaaaga  | caagaagtcc  | aatggaacag  | ggccatgtaa  | aaatgtcagc  | acagtacaat  | 3900 |
| gtacacatgg  | aattaggcca  | gtagtgtcaa  | ctcaactgct  | gttaaattggc | agtctagcag  | 3960 |
| aagaagaggt  | agtaattaga  | tctagtaatt  | tcacagacaa  | tgcaaaaaaac | ataatagtag  | 4020 |
| agttgaaaga  | atctgtagaa  | attaattgta  | caagacccaa  | caacaataca  | aggaaaagta  | 4080 |
| tacatatagg  | accaggaaga  | gcattttata  | caacaggaga  | aataatagga  | gatataagac  | 4140 |
| aagcacattg  | caacattagt  | agaacaaaat  | ggaataaacac | tttaaatcaa  | atagctacaa  | 4200 |
| aattaaaaga  | acaatttggg  | aataataaaa  | caatagtctt  | taatcaatcc  | tcaggagggg  | 4260 |
| acccagaaat  | tgtaatgcac  | agttttaatt  | gtggagggga  | attcttctac  | tgtaattcaa  | 4320 |
| cacaactgtt  | taatagtact  | tggaaatttta | atgggtactg  | gaatttaaca  | caatcgaatg  | 4380 |
| gtactgaagg  | aaatgacact  | atcacactcc  | catgtagaat  | aaaacaaatt  | ataaatatgt  | 4440 |
| ggcaggaagt  | aggaaaagca  | atgtatgccc  | ctcccatcag  | aggacaaatt  | agatgctcat  | 4500 |
| caaatattac  | agggctaata  | ttaacaagag  | atgggtggaac | taacagtagt  | gggtccgaga  | 4560 |
| tcttcagacc  | tgggggagga  | gatatgaggg  | acaattggag  | aagtgaatta  | tataaatata  | 4620 |
| aagtagtaaa  | aattgaacca  | ttaggagtag  | caccacccaa  | ggcaaaaaga  | agagtgggtgc | 4680 |
| agagagaaaa  | aagagcagtg  | ggaacgatag  | gagctatgtt  | ccttgggttc  | ttgggagcag  | 4740 |
| caggaagcac  | tatgggcgca  | gcgtcaataa  | cgctgacggg  | acaggccaga  | ctattattgt  | 4800 |
| ctgggtatagt | gcaacagcag  | aacaattttg  | tgagggtctat | tgaggcgcaa  | cagcatctgt  | 4860 |
| tgcaactcac  | agtctggggc  | atcaagcagc  | tccaggcaag  | agtcctgggt  | gtggaaagat  | 4920 |
| acctaaggga  | tcaacagctc  | ctagggatct  | ggggttgctc  | tggaaaactc  | atctgcacca  | 4980 |
| ctgctgtgcc  | ttggaatgct  | agttggagta  | ataaaaactc  | ggatatgatt  | tgggataaca  | 5040 |
| tgacctggat  | ggagtgggaa  | agagaaatcg  | aaaattacac  | aggcttaata  | tacaccttaa  | 5100 |
| ttgaggaatc  | gcagaaccaa  | caagaaaaga  | atgaacaaga  | cttattagca  | ttagataagt  | 5160 |
| gggcaagtct  | gtggaattgg  | tttgacatat  | caaattgggt  | gtgggtatgta | aaaatcttca  | 5220 |

|             |             |             |             |             |             |      |
|-------------|-------------|-------------|-------------|-------------|-------------|------|
| taatgatagt  | aggaggcttg  | ataggtttaa  | gaatagtttt  | tactgtactt  | tctatagtaa  | 5280 |
| atagagttag  | gcagggatac  | tcaccattgt  | catttcagac  | ccacctccca  | gccccgaggg  | 5340 |
| gacccgacag  | gcccgaagga  | atcgaagaag  | aaggtggaga  | cagagactaa  | tttttatgcg  | 5400 |
| gccgctggta  | cccaacctaa  | aaattgaaaa  | taaatacaaa  | ggttcttgag  | ggttgtgtta  | 5460 |
| aattgaaagc  | gagaaataat  | cataaataag  | cccggggatc  | ctctagagtc  | gacaccatgg  | 5520 |
| gtgcgagagc  | gtcagtatta  | agcgggggag  | aattagatcg  | atgggaaaaa  | attcggttaa  | 5580 |
| ggtcaggggg  | aaagaaaaaa  | tataaattaa  | aacatatagt  | atgggcaagc  | agggagctag  | 5640 |
| aacgattcgc  | agttaatcct  | ggcctgttag  | aaacatcaga  | aggctgtaga  | caaatactgg  | 5700 |
| gacagctaca  | accatccctt  | cagacaggat  | cagaagaact  | tagatcatta  | tataatacag  | 5760 |
| tagcaaccct  | ctattgtgtg  | catcaaagga  | tagagataaa  | agacaccaag  | gaagctttag  | 5820 |
| acaagataga  | ggaagagcaa  | aacaaaagta  | agaaaaaagc  | acagcaagca  | gcagctgaca  | 5880 |
| caggacacag  | caatcaggtc  | agccaaaatt  | accctatagt  | gcagaacatc  | caggggcaaa  | 5940 |
| tggtagatca  | ggccatatca  | cctagaactt  | taaatgcatg  | ggtaaaagta  | gtagaagaga  | 6000 |
| aggctttcag  | cccagaagtg  | atacccatgt  | tttcagcatt  | atcagaagga  | gccacccccc  | 6060 |
| aagattttaa  | caccatgcta  | aacacagtgg  | ggggacatca  | agcagccatg  | caaattgttaa | 6120 |
| aagagaccat  | caatgaggaa  | gctgcagaat  | gggatagagt  | gcatccagtg  | catgcagggc  | 6180 |
| ctattgcacc  | aggccagatg  | agagaaccaa  | ggggaagtga  | catagcagga  | actactagta  | 6240 |
| cccttcagga  | acaaatagga  | tggatgacaa  | ataatccacc  | tatcccagta  | ggagaaattt  | 6300 |
| ataaaagatg  | gataatcctg  | ggattaaata  | aaatagtaag  | aatgtatagc  | cctaccagca  | 6360 |
| ttctggacat  | aagacaagga  | ccaaaagaac  | ccttttagaga | ctatgtagac  | cggttctata  | 6420 |
| aaactctaag  | agccgagcaa  | gcttcacagg  | aggtaaaaaa  | ttggatgaca  | gaaaccttgt  | 6480 |
| tgggtccaaa  | tgcgaaccca  | gattgtgaag  | ctatttttaa  | agcattggga  | ccagcggcta  | 6540 |
| cactagaaga  | aatgatgaca  | gcatgtcagg  | gagtaggagg  | acccggccat  | aaggcaagag  | 6600 |
| ttttggctga  | agcaatgagc  | caagtaacaa  | attcagctac  | cataatgatg  | cagagaggca  | 6660 |
| atttttaggaa | ccaaagaaag  | attgttaagt  | gtttcaattg  | tggcaaagaa  | gggcacacag  | 6720 |
| ccagaaattg  | cagggccctt  | aggaaaaagg  | gctgtttggaa | atgtggaaag  | gaaggacacc  | 6780 |
| aaatgaaaga  | ttgtactgag  | agacaggcta  | atttttttag  | gaagatctgg  | ccttcctaca  | 6840 |
| agggaaggcc  | agggaatttt  | cttcagagca  | gaccagagcc  | aacagcccca  | ccagaagaga  | 6900 |
| gcttcaggtc  | tggggtagag  | acaacaactc  | cccctcagaa  | gcaggagccg  | atagacaagg  | 6960 |
| aactgtatcc  | tttaacttcc  | ctcagatcac  | tctttggcaa  | cgacccctcg  | tcacaataaa  | 7020 |
| gatagggggg  | caactaaagg  | aagctctatt  | agatacagga  | gcagatgata  | cagtattaga  | 7080 |
| agaaatgagt  | ttgccaggaa  | gatggaaacc  | aaaaatgata  | gggggaattg  | gaggttttat  | 7140 |
| caaagtaaga  | cagtatgatc  | agatactcat  | agaaatctgt  | ggacataaag  | ctataggtac  | 7200 |
| agtattagta  | ggacctacac  | ctgtcaacat  | aattggaaga  | aatctgttga  | ctcagattgg  | 7260 |
| ttgcacttta  | aattttccca  | ttagccctat  | tgagactgta  | ccagtaaaat  | taaagccagg  | 7320 |
| aatggatggc  | ccaaaagtta  | aacaatggcc  | attgacagaa  | gaaaaaataa  | aagcattagt  | 7380 |
| agaaatttgt  | acagaaatgg  | aaaagggaagg | gaaaatttca  | aaaattgggc  | ctgagaatcc  | 7440 |
| atacaatact  | ccagtatttg  | ccataaagaa  | aaaagacagt  | actaaatgga  | ggaaattagt  | 7500 |
| agatttcaga  | gaacttaata  | agagaactca  | agacttctgg  | gaagttcaat  | taggaatacc  | 7560 |
| acatcccgc   | gggttaaaaa  | agaaaaaatc  | agtaacagta  | ctggatgtgg  | gtgatgcata  | 7620 |
| tttttcagtt  | cccttagatg  | aagacttcag  | gaagtatact  | gcatttacca  | tacctagtat  | 7680 |
| aaacaatgag  | acaccaggga  | ttagatatca  | gtacaatgtg  | cttccacagg  | gatggaaagg  | 7740 |
| atcaccagca  | atattccaaa  | gtagcatgac  | aaaaatctta  | gagcctttta  | aaaaacaaaa  | 7800 |
| tccagacata  | gttatctatc  | aatacatgaa  | cgatttgtat  | gtaggatctg  | acttagaaat  | 7860 |
| agggcagcat  | agaacaaaaa  | tagaggagct  | gagacaacat  | ctgttgagggt | ggggacttac  | 7920 |
| cacaccagac  | aaaaaacatc  | agaaagaacc  | tccattcctt  | tggatggggt  | atgaactcca  | 7980 |
| tcctgataaa  | tggacagtac  | agcctatagt  | gctgccagaa  | aaagacagct  | ggactgtcaa  | 8040 |
| tgacatacag  | aagttagtgg  | ggaaattgaa  | taccgcaagt  | cagatttacc  | cagggattaa  | 8100 |
| agtaaggcaa  | ttatgtaaac  | tccttagagg  | aaccaaagca  | ctaacagaag  | taataccact  | 8160 |
| aacagaagaa  | gcagagctag  | aactggcaga  | aaacagagag  | attctaaaag  | aaccagtaca  | 8220 |
| tggagtgtat  | tatgacccat  | caaaagactt  | aatagcagaa  | atacagaagc  | aggggcaagg  | 8280 |
| ccaatggaca  | tatcaaattt  | atcaagagcc  | atttaaaaaa  | ctgaaaacag  | gaaaatatgc  | 8340 |
| aagaatgagg  | ggtgccccaca | ctaagtatgt  | aaaacaatta  | acagaggcag  | tgcaaaaaat  | 8400 |
| aaccacagaa  | agcatagtaa  | tatggggaaa  | gactcctaaa  | tttaaactac  | ccatacaaaa  | 8460 |
| ggaaacatgg  | gaaacatggg  | ggacagagta  | ttggcaagcc  | acctggattc  | ctgagtggga  | 8520 |
| gtttgttaat  | acccttcctt  | tagtgaaatt  | atggtaccag  | ttagagaaag  | aacccatagt  | 8580 |
| aggagcagaa  | accttctatg  | tagatggggc  | agctaacagg  | gagactaaat  | taggaaaagc  | 8640 |
| aggatatgtt  | actaacaag   | gaagacaaaa  | ggttgtcccc  | ctaactaaca  | caacaaatca  | 8700 |
| gaaaactcag  | ttacaagcaa  | tttatctagc  | tttgcaggat  | tcaggattag  | aagtaaacad  | 8760 |

agtaacagac tcacaatatg cattaggaat cattcaagca caaccagata aaagtgaatc 8820  
agagttagtc aatcaaataa tagagcagtt aataaaaaag gaaaagggtct atctggcatg 8880  
ggtaccagca cacaaaggaa ttggaggaaa tgaacaagta gataaattag tcagtgtctgg 8940  
aatcaggaaa atactatttt tagatggaat agataaggcc caagatgaac attagttttt 9000  
atgtcgacct gcagggaag ttttataggt agttgataga acaaaatata taattttgta 9060  
aaaataaatc actttttata ctaatatgac acgattacca atacttttgt tactaatatc 9120  
attagtatac gctacacctt ttcctcagac atctaaaaaa atagggtgatg atgcaacttt 9180  
atcatgtaat cgaaataata caaatgacta cgttgttatg agtgcttggg ataaggagcc 9240  
caattccatt attcttttag ctgctaaaag cgacgtcttg tattttgata attataccaa 9300  
ggataaaata tcttacgact ctccatacga tgatctagtt acaactatca caattaaatc 9360  
attgactgct agagatgccg gtacttatgt atgtgcattc tttatgacat cgcctacaaa 9420  
tgacactgat aaagtagatt atgaagaata ctccacagag ttgattgtaa atacagatag 9480  
tgaatcgact atagacataa tactatctgg atctacacat tcaccagaaa ctagttaagc 9540  
ttgtctccct atagtgaagc gtattagagc ttggcgtaat catggtcata gctgtttcct 9600  
gtgtgaaatt gttatccgct cacaattcca cacaacatac gagccggaag cataaagtgt 9660  
aaagcctggg gtgcctaag agtgagctaa ctcacattaa ttgcgttgcg ctactgccc 9720  
gctttcgagt cgggaaacct gtcgtgccag ctgcattaat gaatcgcca acgcgcggg 9780  
agaggcggtt tgcgtattgg gcgctcttcc gcttcctcgc tcaetgactc gctgcgctcg 9840  
gtcgttcggc tgcggcgagc ggtatcagct cactcaaagg cggtaatacg gttatccaca 9900  
gaatcagggg ataacgcagg aaagaacatg tgagcaaaa ggcagcaaaa ggccaggaac 9960  
cgtaaaaagg ccgcttgct ggcgtttttc gataggctcc gccccctga cgagcatcac 10020  
aaaaatcgac gctcaagtc gaggtggcga aaccgcagag gactataaag ataccaggcg 10080  
tttccccctg gaagctccct cgtgcgctct cctgttccga ccctgccgt tactcgatc 10140  
ctgtccgctt ttctcccttc ggaagcgtg gcgctttctc atagctcacg ctgtaggtat 10200  
ctcagttcgg tgtaggctcg tgcgtccaag ctgggctgtg tgcacgaacc ccccgttcag 10260  
cccgaccgct gcgccttatc cggtaactat cgtcttgagt ccaaccggg aagacacgac 10320  
ttatcgccac tggcagcagc cactggtaac aggattagca gagcgaggta tgtaggcggt 10380  
gctacagagt tcttgaagtg gtggcctaac tacggctaca ctagaaggac agtatttggt 10440  
atctgcgctc tgcgtgaagc agttaccttc ggaaaaagag ttggtagctc ttgatccggc 10500  
aaacaaacca ccgctggtag cgggtggttt tttgtttgca agcagcagat tacgcgcaga 10560  
aaaaaaggat ctcaagaaga tcttttgatc ttttctacgg ggtctgacgc tcagtggaa 10620  
gaaaactcac gttaagggat tttgggtcatg agattatcaa aaaggatctt cacctagatc 10680  
cttttaaat aaaaatgaag ttttaaatca atctaaagta tatatgagta aacttggtct 10740  
gacagttacc aatgcttaat cagtgaggca cctatctcag cgatctgtct atttcgttca 10800  
tccatagttg cctgactccc cgtcgtgtag ataactacga tacgggaggg cttaccatct 10860  
ggccccagtg ctgcaatgat accgcgagac ccacgctcac cggctccaga tttatcagca 10920  
ataaaccagc cagccggaag ggccgagcgc agaagtggc ctgcaacttt atccgcctcc 10980  
atccagttca ttaattggtg ccgggaagct agagtaagta gttcgccagt taatagtttg 11040  
cgcaacggtt ttggcattgc tacaggcacc gtgggtgtcac gctcgtcgtt tgggtatggc 11100  
tcattcagct ccggttccca acgatcaagg cgagttacat gatcccccac gttgtgcaaa 11160  
aaagcgggta gctccttcgg tctccgac cgtgtcagaa gtaagttggc cgcagtgtta 11220  
tcaetcatgg ttatggcagc actgcataat tctcttactg tcatgccatc cgtaagatgc 11280  
ttttctgtga ctgggtgagta ctcaaccaag tcatcttgag aatagtgtat gcggcgaccg 11340  
agttgctctt gcccggcgtc aatacgggat aataccgcgc cacatagcag aactttaaaa 11400  
gtgctcatca ttggaaaacg tcttcgggg cgaaaactct caaggatctt accgctgttg 11460  
agatccagtt cgatgtaacc cactcgtgca cccaactgat cttcagcatc ttttactttc 11520  
accagcgttt ctgggtgagc aaaaacagga aggcaaatg ccgcaaaaaa gggaataagg 11580  
gcgacacgga aatggtgaat actcactc ttcctttttc aatattattg aagcatttat 11640  
cagggttatt gtctcatgag cggatacata tttgaatgta tttagaaaaa taaacaaata 11700  
ggggttccgc gcacatttcc ccgaaaagtg ccacctgacg tctaagaaac cattattatc 11760  
atgacattaa cctataaaaa taggcgtatc acgaggccct ttcgtctcgc gcgtttcggg 11820  
gatgacgggtg aaaacctctg acacatgcag ctcccggaga cgggtcacagc ttgtctgtaa 11880  
gcggatgccg ggagcagaca agcccgtcag ggcgcgtcag cgggtgttg cgggtgtcgg 11940  
ggctggctta actatgcggc atcagagcag attgtactga gagtgcacca tatgcggtgt 12000  
gaaataccgc acagatgcgt aaggagaaaa taccgcatca ggcgccattc gccattcagg 12060  
ctgcgcaact gttgggaagg gcgatcgggt cgggcctctt cgctattacg ccagctggcg 12120  
aaagggggat gtgctgcaag gcgattaagt tgggtaacgc cagggttttc ccagtcacga 12180  
cgttgtaaaa cgacggccag tgaattggat ttaggtgaca ctata 12225  
<210> 2



<211> 74  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Psyn II promoter

<400> 2  
 taaaaaatga aaaaatattc taatttatag gacgggtttg attttctttt tttctatgct 60  
 ataaataata aata 74

<210> 3  
 <211> 2214  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> HIV env gene

<400> 3  
 atgaaagtga aggggatcag gaagaattat cagcacttgt ggaaatgggg catcatgctc 60  
 cttgggatgt tgatgatctg tagtgctgta gaaaatttgt gggtcacagt ttattatggg 120  
 gtacctgtgt ggaaagaagc aaccaccact ctatttttgt catcagatgc taaagcatat 180  
 gatacagagg tacataatgt ttgggccaca catgcctgtg taccacaga cccaaccca 240  
 caagaagtag tattggaaaa tgtgacagaa aattttaaca tgtggaaaaa taacatggta 300  
 gaacagatgc atgaggatat aatcagttta tgggatcaaa gcctaaagcc atgtgtaaaa 360  
 ttaaccccac tctgtgttac tttaaattgc actgatttga ggaatgttac taatatcaat 420  
 aatagtagtg agggaatgag aggagaaata aaaaactgct ctttcaatat caccacaagc 480  
 ataagagata aggtgaagaa agactatgca cttttctata gacttgatgt agtaccaata 540  
 gataatgata atactagcta taggttgata aattgtaata cctcaaccat tacacaggcc 600  
 tgtccaaagg tatcctttga gccaatccc atacattatt gtaccccggc tggttttgcy 660  
 attctaaagt gtaaagacaa gaagttcaat ggaacagggc catgtaaaaa tgtcagcaca 720  
 gtacaatgta cacatggaat taggccagta gtgtcaactc aactgctgtt aaatggcagt 780  
 ctacgagaag aagaggtagt aattagatct agtaatttca cagacaatgc aaaaaacata 840  
 atagtacagt tgaaagaatc tgtagaaatt aattgtacaa gacccaacaa caatacaagg 900  
 aaaagtatac atataggacc aggaagagca ttttatacaa caggagaaat aataggagat 960  
 ataagacaag cacattgcaa cattagtaga acaaaatgga ataacacttt aaatcaaata 1020  
 gctacaaaat taaaagaaca attcgggaat aataaaacaa tagtctttaa tcaatcctca 1080  
 ggaggggacc cagaaattgt aatgcacagt tttaattgtg gaggggaatt cttctactgt 1140  
 aattcaacac aactgtttta tagtacttgg aattttaatg gtacttgga tttaacacaa 1200  
 tcgaatggta ctgaaggaaa tgacactatc acactcccat gtagaataaa acaaattata 1260  
 aatatgtggc aggaagtagg aaaagcaatg tatgcccctc ccatcagagg acaaattaga 1320  
 tgctcatcaa atattacagg gctaattatta acaagagatg gtggaactaa cagtagtggg 1380  
 tccgagatct tcagacctgg gggaggagat atgagggaca attggagaag tgaattatat 1440  
 aaatataaag tagtaaaaat tgaaccatta ggagtagcac ccaccaaggc aaaaagaaga 1500  
 gtgggtgcaga gagaaaaaag agcagtggga acgataggag ctatgttcct tgggttcttg 1560  
 ggagcagcag gaagcactat gggcgagcg tcaataacgc tgacggtaca ggccagacta 1620  
 ttattgtctg gtatagtga acagcagaac aatttgctga gggctattga ggcgcaacag 1680  
 catctgttgc aactcacagt ctggggcatc aagcagctcc aggcaagagt cctggctgtg 1740  
 gaaagatacc taagggatca acagctccta gggatttggg gttgctctgg aaaactcatc 1800  
 tgcaccactg ctgtgccttg gaatgctagt tggagtaata aaactctgga tatgatttgg 1860  
 gataacatga cctggatgga gtgggaaaga gaaatcgaaa attacacagg cttaatatac 1920  
 accttaattg aggaatcgca gaaccaacaa gaaaagaatg aacaagactt attagcatta 1980  
 gataagtggg caagtttgtg gaattggttt gacatatcaa attggctgtg gtatgtaaaa 2040  
 atcttcataa tgatagtagg aggccttgata ggtttaagaa tagtttttac tgtactttct 2100  
 atagtaaata gagttaggca gggatactca ccattgtcat ttcagacca cctcccagcc 2160  
 ccgaggggac ccgacaggcc cgaaggaatc gaagaagaag gtggagacag agac 2214

<210> 4

<211> 70  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> PmH5 promoter

<400> 4  
aaaaattgaa aataaataca aaggttcttg agggtttgtt taaattgaaa gcgagaaata 60  
atcataaata 70

<210> 5  
<211> 3479  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> HIV genes

<400> 5  
atgggtgcga gagcgtcagt attaagcggg ggagaattag atcgatggga aaaaattcgg 60  
ttaaggccag ggggaaagaa aaaatataaa ttaaaacata tagtatgggc aagcagggag 120  
ctagaacgat tcgcagttaa tcctggcctg ttagaaacat cagaaggctg tagacaaata 180  
ctgggacagc tacaaccatc ccttcagaca ggatcagaag aacttagatc attatataat 240  
acagtagcaa ccctctattg tgtgcatcaa aggatagaga taaaagacac caaggaagct 300  
ttagacaaga tagaggaaga gcaaaacaaa agtaagaaaa aagcacagca agcagcagct 360  
gacacaggac acagcaatca ggtcagccaa aattacccta tagtgcagaa catccagggg 420  
caaattggtac atcaggccat atcacctaga actttaaatg catgggtaaa agtagtagaa 480  
gagaaggctt tcagcccaga agtgataccc atgttttcag cattatcaga aggagccacc 540  
ccacaagatt taaacaccat gctaaacaca gtgggggggac atcaagcagc catgcaaatg 600  
ttaaaagaga ccatcaatga ggaagctgca gaattgggata gaggatgcatc agtgcagca 660  
gggcctattg caccaggcca gatgagagaa ccaaggggaa gtgacatagc aggaactact 720  
agtacccttc aggaacaaat aggatggatg acaataatc cacctatccc agtaggagaa 780  
atttataaaa gatggataat cctgggatta aataaaatag taagaatgta tagccctacc 840  
agcattctgg acataagaca aggacccaaa gaacccttta gagactatgt agaccggttc 900  
tataaaactc taagagccga gcaagcttca caggaggtaa aaaattggat gacagaaacc 960  
ttgttggtcc aaaatgcgaa cccagattgt aagactatct taaaagcatt gggaccagcg 1020  
gctacactag aagaaatgat gacagcatgt caggagtag gaggaccgag ccataaggca 1080  
agagtttttg ctgaagcaat gagccaagta acaaattcag ctaccataat gatgcagaga 1140  
ggcaatttta ggaaccaaag aaagattggt aagtgtttca attgtggcaa agaagggcac 1200  
acagccagaa attgcagggc ccctaggaaa aagggtgtgt ggaaatgtgg aaaggaagga 1260  
caccaaatga aagattgtac tgagagacag gctaattttt tagggaagat ctggccttcc 1320  
tacaagggaa ggccagggaa ttttcttcag agcagaccag agccaacagc cccaccagaa 1380  
gagagcttca ggtctggggg agagacaaca actccccctc agaagcagga gccgatagac 1440  
aaggaactgt atcctttaac ttccctcaga tcaactcttg gcaacgaccc ctcgtcaca 1500  
taaagatagg ggggcaacta aaggaagctc tattagatac aggagcagat gatacagtat 1560  
tagaagaaat gaggtttgcca ggaagatgga aacccaaaat gataggggga attggaggtt 1620  
ttatcaaagt aagacagtat gatcagatac tcatagaaat ctgtggacat aaagctatag 1680  
gtacagtatt agtaggacct acacctgtca acataattgg aagaaatctg ttgactcaga 1740  
ttggttgcac tttaaatttt cccattagcc ctattgagac tgtaccagta aaattaaagc 1800  
caggaatgga tggcccaaaa gttaaacaat ggccattgac agaagaaaaa ataaaagcat 1860  
tagtagaaat ttgtacagaa atggaaaagg aagggaatatt ttcaaaaatt gggcctgaga 1920  
atccatacaa tactccagta ttgcccataa agaaaaaaga cagtactaaa tggaggaaat 1980  
tagtagattt cagagaactt aataagagaa ctcaagactt ctgggaagtt caattaggaa 2040  
taccacatcc cgcagggtta aaaaagaaaa aatcagtaac agtactggat gtgggtgatg 2100  
catatttttc agttccctta gatgaagact tcaggaagta tactgcattt accataccta 2160  
gtataaacia tgagacacca gggattagat atcagtacaa tgtgcttcca cagggatgga 2220  
aaggatcacc agcaatattc caaagtagca tgacaaaaat cttagagcct tttaaaaaac 2280  
aaaatccaga catagttatc tatcaataca tgaacgatct gtatgtagga tctgacttag 2340



aaatagggca gcatagaaca aaaatagagg agctgagaca acatctgttg aggtggggac 2400  
ttaccacacc agacaaaaaa catcagaaag aacctccatt cctttggatg gggtatgaac 2460  
tccatcctga taaatggaca gtacagccta tagtgctgcc agaaaaagac agctggactg 2520  
tcaatgacat acagaagtta gtgggggaaat tgaataccgc aagtcagatt taccagaggga 2580  
ttaaagtaag gcaattatgt aaactcctta gaggaaccaa agcactaaca gaagtaatac 2640  
cactaacaga agaagcagag ctagaactgg cagaaaacag agagattcta aaagaaccag 2700  
tacatggagt gtattatgac ccatcaaaag acttaatagc agaaatacag aagcaggggc 2760  
aaggccaatg gacatatcaa atttatcaag agccatttaa aaatctgaaa acaggaaaat 2820  
atgcaagaat gaggggtgcc cacactaatg atgtaaaaca attaacagag gcagtgc aaa 2880  
aaataaccac agaaagcata gtaatatggg gaaagactcc taaattttaa ctaccatac 2940  
aaaaggaaac atgggaaaca tgggtggacag agtattggca agccacctgg attcctgagt 3000  
gggagtttgt taataccctt ccttttagtg aattatggta ccagttagag aaagaaccca 3060  
tagtaggagc agaaaccttc tatgtagatg gggcagctaa caggagagact aaattaggaa 3120  
aagcaggata tggtactaac aaaggaagac aaaagggtgt cccctaact aacacaacaa 3180  
atcagaaaac tcagttacaa gcaatttatc tagctttgca ggattcagga ttagaagtaa 3240  
acatagtaac agactcacia tatgcattag gaatcattca agcacaacca gataaaagt 3300  
aatcagagtt agtcaatcaa ataatagagc agttaataaa aaaggaaaag gtctatctgg 3360  
catgggtacc agcacacaaa ggaattggag gaaatgaaca agtagataaa ttagtcagt 3420  
ctggaatcag gaaaatacta tttttagatg gaatagataa ggccaagat gaacattag 3479

<210> 6

<211> 9

<212> PRT

<213> Simian Immunodeficiency virus

<400> 6

Cys Thr Pro Tyr Asp Ile Asn Gln Met

1

5

<210> 7

<211> 8

<212> PRT

<213> Chicken

<400> 7

Ser Ile Ile Asn Phe Glu Lys Leu

1

5

<210> 8

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> probe

<400> 8

ctgtctgcgt catttggtgc

20

<210> 9

<211> 4

<212> PRT

<213> Human immunodeficiency Virus

<220>

<221> VARIANT

<222> (1)...(4)

<223> Xaa = Any Amino Acid

<400> 9

Tyr Xaa Xaa Leu

1

<210> 10

<211> 93

<212> DNA

<213> Artificial Sequence

<220>

<223> m7.5 promoter

<400> 10

cgcttttttat agtaagtttt tcacccataa ataataaata caataattaa tttctcgtaa 60

aaattgaaaa actattctaa tttattgcac ggt 93

<210> 11

<211> 74

<212> DNA

<213> Artificial Sequence

<220>

<223> Psyn III promoter

<400> 11

taaaaattga aaaaatattc taatttatag gacggttttg attttctttt tttctatact 60

ataaataata aata 74

<210> 12

<211> 74

<212> DNA

<213> Artificial Sequence

<220>

<223> Psyn IV promoter

<400> 12

taaaaattga aaaactattc taatttatag gacggttttg attttctttt tttctatact 60

ataaataata aata 74

<210> 13

<211> 75

<212> DNA

<213> Artificial Sequence

<220>

<223> Psyn V promoter

<400> 13

aaaaaatgat aaagtaggtt cagttttatt gctggtttaa aatcacgctt tcgagtaaaa 60

actacgaata taaat 75

CORRECTED VERSION

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
19 September 2002 (19.09.2002)

PCT

(10) International Publication Number  
**WO 02/072754 A2**

(51) International Patent Classification<sup>7</sup>: **C12N**

(21) International Application Number: PCT/US02/06713

(22) International Filing Date: 1 March 2002 (01.03.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/274,434 8 March 2001 (08.03.2001) US

(71) Applicant (*for all designated States except US*): **THE GOVERNMENT OF THE UNITED STATES OF AMERICA**, as represented by **THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES** [US/US]; National Institutes of Health, Office of Technology Transfer, Suite 325, 6011 Executive Boulevard, Rockville, MD 20852-3804 (US).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **MOSS, Bernard** [US/US]; 10301 Dickens Avenue, Bethesda, MD 20814 (US). **WYATT, Linda** [US/US]; 11201 Huntover Drive, Rockville, MD 20852 (US). **EARL, Patricia** [US/US]; 3520 Woodbine Street, Chevy Chase, MD 20815 (US).

(74) Agent: **ALTMAN, Daniel, E.**; Knobbe, Martens, Olson And Bear, LLP, 16th floor, 620 Newport Center Drive, Newport Beach, CA 92660 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT (utility model), AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA,

CH, CN, CO, CR, CU, CZ (utility model), CZ, DE (utility model), DE, DK (utility model), DK, DM, DZ, EC, EE (utility model), EE, ES, FI (utility model), FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK (utility model), SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Declaration under Rule 4.17:**

— *of inventorship (Rule 4.17(iv)) for US only*

**Published:**

— *without international search report and to be republished upon receipt of that report*

(48) Date of publication of this corrected version:

3 January 2003

**(15) Information about Correction:**

see PCT Gazette No. 01/2003 of 3 January 2003, Section II

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: **MVA EXPRESSING MODIFIED HIV ENVELOPE, GAG, AND POL GENES**

(57) Abstract: The invention provides modified virus Ankara (MVA), a replication-deficient strain of vaccinia virus, expressing human immunodeficiency virus (HIV) *env*, *gag*, and *pol* genes.



WO 02/072754 A2

## MVA EXPRESSING MODIFIED HIV ENVELOPE, GAG, AND POL GENES

### Field of the Invention

The invention provides modified vaccinia Ankara (MVA), a replication-deficient strain of vaccinia virus, expressing human immunodeficiency virus (HIV) *env*, *gag*, and *pol* genes.

### Background of the Invention

Cellular immunity plays an important role in the control of immunodeficiency virus infections (P.J. Goulder *et al.* 1999 *AIDS* 13:S121). Recently, a DNA vaccine designed to enhance cellular immunity by cytokine augmentation successfully contained a highly virulent immunodeficiency virus challenge (D.H. Barouch *et al.* 2000 *Science* 290:486). Another promising approach to raising cellular immunity is DNA priming followed by recombinant poxvirus boosters (H.L. Robinson *et al.* 2000 *AIDS Rev* 2:105). This heterologous prime/boost regimen induces 10- to 100-fold higher frequencies of T cells than priming and boosting with DNA or recombinant poxvirus vaccines alone. Previously, investigators showed that boosting a DNA-primed response with a poxvirus was superior to boosting with DNA or protein for the control of a non-pathogenic immunodeficiency virus (H.L. Robinson *et al.* 1999 *Nat Med* 5:526). There is a need for the control of a pathogenic immunodeficiency virus.

### Summary of the Invention

Here we report that DNA priming followed by a recombinant modified vaccinia Ankara (rMVA) booster has controlled a highly pathogenic immunodeficiency virus challenge in a rhesus macaque model. Both the DNA and rMVA components of the vaccine expressed multiple immunodeficiency virus proteins. Two DNA inoculations at 0 and 8 weeks and a single rMVA booster at 24 weeks effectively controlled an intrarectal challenge administered seven months after the booster. These findings are envisioned as indicating that a relatively simple multiprotein DNA/MVA vaccine can help to control the acquired immune deficiency syndrome (AIDS) epidemic. We also report that inoculations of rMVA induce good immune responses even without DNA priming.

### Brief Description of the Drawings

**Figure I.** Phylogenetic relationships of HIV-1 and HIV-2 based on identity of *pol* gene sequences. SIV<sub>cpz</sub> and SIV<sub>smm</sub> are subhuman primate lentiviruses recovered from a chimpanzee and sooty mangabey monkey, respectively.

**Figure II.** Phylogenetic relationships of HIV-1 groups M, N and O with four different SIV<sub>cpz</sub> isolates based on full-length *pol* gene sequences. The bar indicates a genetic distance of 0.1 (10% nucleotide divergence) and the *asterisk* positions group N HIV-1 isolates based on *env* sequences.

**Figure III.** Tropic and biologic properties of HIV-1 isolates.

**Figure IV.** HIV-encoded proteins. The location of the HIV genes, the sizes of primary translation products (in some cases polyproteins), and the processed mature viral proteins are indicated.

**Figure V.** Schematic representation of a mature HIV-1 virion.

**Figure VI.** Linear representation of the HIV-1 Env glycoprotein. The *arrow* indicates the site of gp160 cleavage to gp120 and gp41. In gp120, *cross-hatched* areas represent variable domains (V<sub>1</sub> to V<sub>5</sub>) and *open boxes* depict conserved sequences (C<sub>1</sub> to C<sub>5</sub>). In the gp41 ectodomain, several domains are indicated: the N-terminal fusion peptide, and the two ectodomain helices (N- and C-helix). The membrane-spanning domain is represented by a *black box*. In the gp41 cytoplasmic domain, the Tyr-X-X-Leu (YXXL) endocytosis motif (SEQ ID NO: 9) and two predicted helical domains (helix-1 and -2) are shown. Amino acid numbers are indicated.

**Figure 1.** Temporal frequencies of Gag-specific T cells. (A) Gag-specific CD8 T cell responses raised by DNA priming and rMVA booster immunizations. The schematic presents mean Gag-CM9-tetramer data generated in the high-dose i.d. DNA-immunized animals. (B) Gag-specific IFN- $\gamma$  ELISPOTs in A\*01 (open bars) and non-A\*01 (filled bars) macaques at various times before challenge and at two weeks after challenge. Three pools of 10 to 13 Gag peptides (22-mers overlapping by 12) were used for the analyses. The numbers above data bars represent the arithmetic mean  $\pm$  SD for the ELISPOTs within each group. The numbers at the top of the graphs designate individual animals. \*, data not available; #, <20 ELISPOTs per  $1 \times 10^6$  peripheral blood mononuclear cells (PBMC). Temporal data for Gag-CM9-Mamu-A\*01 tetramer-specific T cells can be found in Figure 6.

**Figure 2.** Temporal viral loads, CD4 counts, and survival after challenge of vaccinated and control animals. (A) Geometric mean viral loads and (B) geometric mean CD4 counts. (C) Survival curve for vaccinated and control animals. The dotted line represents all 24 vaccinated animals. (D) Viral loads and (E) CD4 counts for individual animals in the vaccine and control groups. The key to animal numbers is presented in (E). Assays for the first 12 weeks after challenge had a detection level of 1000 copies of RNA per milliliter of plasma. Animals with loads below 1000 were scored with a load of 500. For weeks 16 and 20, the detection level was 300 copies of RNA per milliliter. Animals with levels of virus below 300 were scored at 300.

**Figure 3.** Postchallenge T cell responses in vaccine and control groups. (A) Temporal tetramer<sup>+</sup> cells (dashed line) and viral loads (solid line). (B) Intracellular cytokine assays for IFN- $\gamma$  production in response to stimulation with the Gag-CM9 peptide at two weeks after challenge. This *ex vivo* assay allows evaluation of the functional status of the peak postchallenge tetramer<sup>+</sup> cells displayed in Figure 1A. (C) Proliferation assay at 12 weeks after challenge. Gag-Pol-Env (open bars) and Gag-Pol (hatched bars) produced by transient transfections were used for stimulation. Supernatants from mock-transfected cultures served as control antigen. Stimulation indices are the growth of cultures in the presence of viral antigens divided by the growth of cultures in the presence of mock antigen.

**Figure 4.** Lymph node histomorphology at 12 weeks after challenge. (A) Typical lymph node from a vaccinated macaque showing evidence of follicular hyperplasia characterized by the presence of numerous secondary follicles with expanded germinal centers and discrete dark and light zones. (B) Typical lymph node from an infected control animal showing follicular depletion and paracortical lymphocellular atrophy. (C) A representative lymph node from an age-matched, uninfected macaque displaying nonreactive germinal centers. (D) The percentage of the total lymph node area occupied by germinal centers was measured to give a non-specific indicator of follicular hyperplasia. Data for uninfected controls are for four age-matched rhesus macaques.

**Figure 5.** Temporal antibody responses. Micrograms of total Gag (A) or Env (B) antibody were determined with ELISAs. The titers of neutralizing antibody for SHIV-89.6 (C) and SHIV-89.6P (D) were determined with MT-2 cell killing and neutral red staining (D.C. Montefiori *et al.* 1988 *J Clin Microbiol* 26:231). Titers are the reciprocal of the



serum dilution giving 50% neutralization of the indicated viruses grown in human PBMC. Symbols for animals are the same as in Figure 2.

**Figure 6.** Gag-CM9-Mamu-A\*01 tetramer-specific T cells in *Mamu-A\*01* vaccinated and control macaques at various times before challenge and at two weeks after challenge. The number at the upper right corner of each plot represents the frequency of tetramer-specific CD8 T cells as a % of total CD8 T cells. The numbers above each column of FACS data designate individual animals.

**Figure A.** Map and sequence of plasmid transfer vector pLW-48.

**Figure B.** Sequences of plasmid transfer vector pLW-48, Psy II promoter (which controls ADA envelope expression), ADA envelope truncated, PmH5 promoter (which controls HXB2 gag pol expression), and HXB2 gag pol (with safety mutations,  $\Delta$  integrase).

**Figure C.** Plasmid transfer vector pLW-48 and making MVA recombinant virus MVA/HIV 48.

**Figure D.** A clade B gag pol.

**Figure E.** Sequence of new Psyn II promoter.

#### Detailed Description of the Preferred Embodiment

##### Recombinant MVA Virus

Vaccinia virus, a member of the genus Orthopoxvirus in the family of Poxviridae, was used as live vaccine to immunize against the human smallpox disease. Successful worldwide vaccination with vaccinia virus culminated in the eradication of variola virus, the causative agent of the smallpox (The global eradication of smallpox. Final report of the global commission for the certification of smallpox eradication. History of Public Health, No. 4, Geneva: World Health Organization, 1980). Since that WHO declaration, vaccination has been universally discontinued except for people at high risk of poxvirus infections (e.g. laboratory workers).

More recently, vaccinia viruses have also been used to engineer viral vectors for recombinant gene expression and for the potential use as recombinant live vaccines (Mackett, M. *et al.* 1982 *PNAS USA* 79:7415-7419; Smith, G.L. *et al.* 1984 *Biotech Genet Engin Rev* 2:383-407). This entails DNA sequences (genes) which code for foreign antigens being introduced, with the aid of DNA recombination techniques, into the genome of the vaccinia viruses. If the gene is integrated at a site in the viral DNA which is non-

essential for the life cycle of the virus, it is possible for the newly produced recombinant vaccinia virus to be infectious, that is to say able to infect foreign cells and thus to express the integrated DNA sequence (EP Patent Applications No. 83,286 and No. 110,385). The recombinant vaccinia viruses prepared in this way can be used, on the one hand, as live vaccines for the prophylaxis of infectious diseases, on the other hand, for the preparation of heterologous proteins in eukaryotic cells.

For vector applications health risks would be lessened by the use of a highly attenuated vaccinia virus strain. Several such strains of vaccinia virus were especially developed to avoid undesired side effects of smallpox vaccination. Thus, the modified vaccinia Ankara (MVA) has been generated by long-term serial passages of the Ankara strain of vaccinia virus (CVA) on chicken embryo fibroblasts (for review see Mayr, A. *et al.* 1975 *Infection* 3:6-14; Swiss Patent No. 568,392). The MVA virus is publicly available from American Type Culture Collection as ATCC No. VR-1508. MVA is distinguished by its great attenuation, that is to say by diminished virulence and ability to replicate in primate cells while maintaining good immunogenicity. The MVA virus has been analyzed to determine alterations in the genome relative to the parental CVA strain. Six major deletions of genomic DNA (deletion I, II, III, IV, V, and VI) totaling 31,000 base pairs have been identified (Meyer, H. *et al.* 1991 *J Gen Virol* 72:1031-1038). The resulting MVA virus became severely host cell restricted to avian cells.

Furthermore, MVA is characterized by its extreme attenuation. When tested in a variety of animal models, MVA was proven to be avirulent even in immunosuppressed animals. More importantly, the excellent properties of the MVA strain have been demonstrated in extensive clinical trials (Mayr A. *et al.* 1978 *Zentralbl Bakteriol [B]* 167:375-390; Stickl *et al.* 1974 *Dtsch Med Wschr* 99:2386-2392). During these studies in over 120,000 humans, including high-risk patients, no side effects were associated with the use of MVA vaccine.

MVA replication in human cells was found to be blocked late in infection preventing the assembly to mature infectious virions. Nevertheless, MVA was able to express viral and recombinant genes at high levels even in non-permissive cells and was proposed to serve as an efficient and exceptionally safe gene expression vector (Sutter, G. and Moss, B. 1992 *PNAS USA* 89:10847-10851). Additionally, novel vaccinia vector vaccines were established on the basis of MVA having foreign DNA sequences inserted at

the site of deletion III within the MVA genome (Sutter, G. *et al.* 1994 *Vaccine* 12:1032-1040).

The recombinant MVA vaccinia viruses can be prepared as set out hereinafter. A DNA-construct which contains a DNA-sequence which codes for a foreign polypeptide flanked by MVA DNA sequences adjacent to a naturally occurring deletion, e.g. deletion III, or other non-essential sites, within the MVA genome, is introduced into cells infected with MVA, to allow homologous recombination. Once the DNA-construct has been introduced into the eukaryotic cell and the foreign DNA has recombined with the viral DNA, it is possible to isolate the desired recombinant vaccinia virus in a manner known per se, preferably with the aid of a marker. The DNA-construct to be inserted can be linear or circular. A plasmid or polymerase chain reaction product is preferred. The DNA-construct contains sequences flanking the left and the right side of a naturally occurring deletion, e.g. deletion III, within the MVA genome. The foreign DNA sequence is inserted between the sequences flanking the naturally occurring deletion. For the expression of a DNA sequence or gene, it is necessary for regulatory sequences, which are required for the transcription of the gene, to be present on the DNA. Such regulatory sequences (called promoters) are known to those skilled in the art, and include for example those of the vaccinia 11 kDa gene as are described in EP-A-198,328, and those of the 7.5 kDa gene (EP-A-110,385). The DNA-construct can be introduced into the MVA infected cells by transfection, for example by means of calcium phosphate precipitation (Graham *et al.* 1973 *Virol* 52:456-467; Wigler *et al.* 1979 *Cell* 16:777-785), by means of electroporation (Neumann *et al.* 1982 *EMBO J* 1:841-845), by microinjection (Graessmann *et al.* 1983 *Meth Enzymol* 101:482-492), by means of liposomes (Straubinger *et al.* 1983 *Meth Enzymol* 101:512-527), by means of spheroplasts (Schaffner 1980 *PNAS USA* 77:2163-2167) or by other methods known to those skilled in the art.

#### HIVs and Their Replication

The etiological agent of acquired immune deficiency syndrome (AIDS) is recognized to be a retrovirus exhibiting characteristics typical of the lentivirus genus, referred to as human immunodeficiency virus (HIV). The phylogenetic relationships of the human lentiviruses are shown in Figure I. HIV-2 is more closely related to SIV<sub>smm</sub>, a virus isolated from sooty mangabey monkeys in the wild, than to HIV-1. It is currently believed

that HIV-2 represents a zoonotic transmission of SIV<sub>smm</sub> to man. A series of lentiviral isolates from captive chimpanzees, designated SIV<sub>cpz</sub>, are close genetic relatives of HIV-1.

The earliest phylogenetic analyses of HIV-1 isolates focused on samples from Europe/North America and Africa; discrete clusters of viruses were identified from these two areas of the world. Distinct genetic subtypes or clades of HIV-1 were subsequently defined and classified into three groups: M (major); O (outlier); and N (non-M or O) (Fig. II). The M group of HIV-1, which includes over 95% of the global virus isolates, consists of at least eight discrete clades (A, B, C, D, F, G, H, and J), based on the sequence of complete viral genomes. Members of HIV-1 group O have been recovered from individuals living in Cameroon, Gabon, and Equatorial Guinea; their genomes share less than 50% identity in nucleotide sequence with group M viruses. The more recently discovered group N HIV-1 strains have been identified in infected Cameroonians, fail to react serologically in standard whole-virus enzyme-linked immunosorbent assay (ELISA), yet are readily detectable by conventional Western blot analysis.

Most current knowledge about HIV-1 genetic variation comes from studies of group M viruses of diverse geographic origin. Data collected during the past decade indicate that the HIV-1 population present within an infected individual can vary from 6% to 10% in nucleotide sequence. HIV-1 isolates within a clade may exhibit nucleotide distances of 15% in *gag* and up to 30% in *gp120* coding sequences. Interclade genetic variation may range between 30% and 40% depending on the gene analyzed.

All of the HIV-1 group M subtypes can be found in Africa. Clade A viruses are genetically the most divergent and were the most common HIV-1 subtype in Africa early in the epidemic. With the rapid spread of HIV-1 to southern Africa during the mid to late 1990s, clade C viruses have become the dominant subtype and now account for 48% of HIV-1 infections worldwide. Clade B viruses, the most intensively studied HIV-1 subtype, remain the most prevalent isolates in Europe and North America.

High rates of genetic recombination are a hallmark of retroviruses. It was initially believed that simultaneous infections by genetically diverse virus strains were not likely to be established in individuals at risk for HIV-1. By 1995, however, it became apparent that a significant fraction of the HIV-1 group M global diversity included interclade viral recombinants. It is now appreciated that HIV-1 recombinants will be found in geographic areas such as Africa, South America, and Southeast Asia, where multiple HIV-1 subtypes

coexist and may account for more than 10% of circulating HIV-1 strains. Molecularly, the genomes of these recombinant viruses resemble patchwork mosaics, with juxtaposed diverse HIV-1 subtype segments, reflecting the multiple crossover events contributing to their generation. Most HIV-1 recombinants have arisen in Africa and a majority contain segments originally derived from clade A viruses. In Thailand, for example, the composition of the predominant circulating strain consists of a clade A *gag* plus *pol* gene segment and a clade E *env* gene. Because the clade E *env* gene in Thai HIV-1 strains is closely related to the clade E *env* present in virus isolates from the Central African Republic, it is believed that the original recombination event occurred in Africa, with the subsequent introduction of a descendent virus into Thailand. Interestingly, no full-length HIV-1 subtype E isolate (i.e., with subtype E *gag*, *pol*, and *env* genes) has been reported to date.

The discovery that  $\alpha$  and  $\beta$  chemokine receptors function as coreceptors for virus fusion and entry into susceptible CD4<sup>+</sup> cells has led to a revised classification scheme for HIV-1 (Fig. III). Isolates can now be grouped on the basis of chemokine receptor utilization in fusion assays in which HIV-1 gp120 and CD4<sup>+</sup> coreceptor proteins are expressed in separate cells. As indicated in Figure III, HIV-1 isolates using the CXCR4 receptor (now designated X4 viruses) are usually T cell line (TCL)-tropic syncytium inducing (SI) strains, whereas those exclusively utilizing the CCR5 receptor (R5 viruses) are predominantly macrophage (M)-tropic and non-syncytium inducing (NSI). The dual-tropic R5/X4 strains, which may comprise the majority of patient isolates and exhibit a continuum of tropic phenotypes, are frequently SI.

As is the case for all replication-competent retroviruses, the three primary HIV-1 translation products, all encoding structural proteins, are initially synthesized as polyprotein precursors, which are subsequently processed by viral or cellular proteases into mature particle-associated proteins (Fig. IV). The 55-kd Gag precursor Pr55<sup>Gag</sup> is cleaved into the matrix (MA), capsid (CA), nucleocapsid (NC), and p6 proteins. Autocatalysis of the 160-kd Gag-Pol polyprotein, Pr160<sup>Gag-Pol</sup>, gives rise to the protease (PR), the heterodimeric reverse transcriptase (RT), and the integrase (IN) proteins, whereas proteolytic digestion by a cellular enzyme(s) converts the glycosylated 160-kd Env precursor gp160 to the gp120 surface (SU) and gp41 transmembrane (TM) cleavage products. The remaining six HIV-1-



encoded proteins (Vif, Vpr, Tat, Rev, Vpu, and Nef) are the primary translation products of spliced mRNAs.

### Gag

The Gag proteins of HIV, like those of other retroviruses, are necessary and sufficient for the formation of noninfectious, virus-like particles. Retroviral Gag proteins are generally synthesized as polyprotein precursors; the HIV-1 Gag precursor has been named, based on its apparent molecular mass, Pr55<sup>Gag</sup>. As noted previously, the mRNA for Pr55<sup>Gag</sup> is the unspliced 9.2-kb transcript (Fig. IV) that requires Rev for its expression in the cytoplasm. When the *pol* ORF is present, the viral protease (PR) cleaves Pr55<sup>Gag</sup> during or shortly after budding from the cell to generate the mature Gag proteins p17 (MA), p24 (CA), p7 (NC), and p6 (see Fig. IV). In the virion, MA is localized immediately inside the lipid bilayer of the viral envelope, CA forms the outer portion of the cone-shaped core structure in the center of the particle, and NC is present in the core in a ribonucleoprotein complex with the viral RNA genome (Fig. V).

The HIV Pr55<sup>Gag</sup> precursor oligomerizes following its translation and is targeted to the plasma membrane, where particles of sufficient size and density to be visible by EM are assembled. Formation of virus-like particles by Pr55<sup>Gag</sup> is a self-assembly process, with critical Gag-Gag interactions taking place between multiple domains along the Gag precursor. The assembly of virus-like particles does not require the participation of genomic RNA (although the presence of nucleic acid appears to be essential), *pol*-encoded enzymes, or Env glycoproteins, but the production of infectious virions requires the encapsidation of the viral RNA genome and the incorporation of the Env glycoproteins and the Gag-Pol polyprotein precursor Pr160<sup>Gag-Pol</sup>.

### Pol

Downstream of *gag* lies the most highly conserved region of the HIV genome, the *pol* gene, which encodes three enzymes: PR, RT, and IN (see Fig. IV). RT and IN are required, respectively, for reverse transcription of the viral RNA genome to a double-stranded DNA copy, and for the integration of the viral DNA into the host cell chromosome. PR plays a critical role late in the life cycle by mediating the production of mature, infectious virions. The *pol* gene products are derived by enzymatic cleavage of a 160-kd Gag-Pol fusion protein, referred to as Pr160<sup>Gag-Pol</sup>. This fusion protein is produced by ribosomal frameshifting during translation of Pr55<sup>Gag</sup> (see Fig. IV). The frame-shifting

mechanism for Gag-Pol expression, also utilized by many other retroviruses, ensures that the *pol*-derived proteins are expressed at a low level, approximately 5% to 10% that of Gag. Like Pr55<sup>Gag</sup>, the N-terminus of Pr160<sup>Gag-Pol</sup> is myristylated and targeted to the plasma membrane.

### Protease

Early pulse-chase studies performed with avian retroviruses clearly indicated that retroviral Gag proteins are initially synthesized as polyprotein precursors that are cleaved to generate smaller products. Subsequent studies demonstrated that the processing function is provided by a viral rather than a cellular enzyme, and that proteolytic digestion of the Gag and Gag-Pol precursors is essential for virus infectivity. Sequence analysis of retroviral PRs indicated that they are related to cellular "aspartic" proteases such as pepsin and renin. Like these cellular enzymes, retroviral PRs use two apposed Asp residues at the active site to coordinate a water molecule that catalyzes the hydrolysis of a peptide bond in the target protein. Unlike the cellular aspartic proteases, which function as pseudodimers (using two folds within the same molecule to generate the active site), retroviral PRs function as true dimers. X-ray crystallographic data from HIV-1 PR indicate that the two monomers are held together in part by a four-stranded antiparallel  $\beta$ -sheet derived from both N- and C-terminal ends of each monomer. The substrate-binding site is located within a cleft formed between the two monomers. Like their cellular homologs, the HIV PR dimer contains flexible "flaps" that overhang the binding site and may stabilize the substrate within the cleft; the active-site Asp residues lie in the center of the dimer. Interestingly, although some limited amino acid homology is observed surrounding active-site residues, the primary sequences of retroviral PRs are highly divergent, yet their structures are remarkably similar.

### Reverse Transcriptase

By definition, retroviruses possess the ability to convert their single-stranded RNA genomes into double-stranded DNA during the early stages of the infection process. The enzyme that catalyzes this reaction is RT, in conjunction with its associated RNaseH activity. Retroviral RTs have three enzymatic activities: (a) RNA-directed DNA polymerization (for minus-strand DNA synthesis), (b) RNaseH activity (for the degradation of the tRNA primer and genomic RNA present in DNA-RNA hybrid intermediates), and (c) DNA-directed DNA polymerization (for second- or plus-strand DNA synthesis).

The mature HIV-1 RT holoenzyme is a heterodimer of 66 and 51 kd subunits. The 51-kd subunit (p51) is derived from the 66-kd (p66) subunit by proteolytic removal of the C-terminal 15-kd RNaseH domain of p66 by PR (see Fig. IV). The crystal structure of HIV-1 RT reveals a highly asymmetric folding in which the orientations of the p66 and p51 subunits differ substantially. The p66 subunit can be visualized as a right hand, with the polymerase active site within the palm, and a deep template-binding cleft formed by the palm, fingers, and thumb subdomains. The polymerase domain is linked to RNaseH by the connection subdomain. The active site, located in the palm, contains three critical Asp residues (110, 185, and 186) in close proximity, and two coordinated  $Mg^{2+}$  ions. Mutation of these Asp residues abolishes RT polymerizing activity. The orientation of the three active-site Asp residues is similar to that observed in other DNA polymerases (e.g., the Klenow fragment of *E. coli* DNA polI). The p51 subunit appears to be rigid and does not form a polymerizing cleft; Asp 110, 185, and 186 of this subunit are buried within the molecule. Approximately 18 base pairs of the primer-template duplex lie in the nucleic acid binding cleft, stretching from the polymerase active site to the RNaseH domain.

In the RT-primer-template-dNTP structure, the presence of a dideoxynucleotide at the 3' end of the primer allows visualization of the catalytic complex trapped just prior to attack on the incoming dNTP. Comparison with previously obtained structures suggests a model whereby the fingers close in to trap the template and dNTP prior to nucleophilic attack of the 3'-OH of the primer on the incoming dNTP. After the addition of the incoming dNTP to the growing chain, it has been proposed that the fingers adopt a more open configuration, thereby releasing the pyrophosphate and enabling RT to bind the next dNTP. The structure of the HIV-1 RNaseH has also been determined by x-ray crystallography; this domain displays a global folding similar to that of *E. coli* RNaseH.

### Integrase

A distinguishing feature of retrovirus replication is the insertion of a DNA copy of the viral genome into the host cell chromosome following reverse transcription. The integrated viral DNA (the provirus) serves as the template for the synthesis of viral RNAs and is maintained as part of the host cell genome for the lifetime of the infected cell. Retroviral mutants deficient in the ability to integrate generally fail to establish a productive infection.

The integration of viral DNA is catalyzed by integrase, a 32-kd protein generated by PR-mediated cleavage of the C-terminal portion of the HIV-1 Gag-Pol polyprotein (see Fig. IV).

Retroviral IN proteins are composed of three structurally and functionally distinct domains: an N-terminal, zinc-finger-containing domain, a core domain, and a relatively nonconserved C-terminal domain. Because of its low solubility, it has not yet been possible to crystallize the entire 288-amino-acid HIV-1 IN protein. However, the structure of all three domains has been solved independently by x-ray crystallography or NMR methods. The crystal structure of the core domain of the avian sarcoma virus IN has also been determined. The N-terminal domain (residues 1 to 55), whose structure was solved by NMR spectroscopy, is composed of four helices with a zinc coordinated by amino acids His-12, His-16, Cys-40, and Cys-43. The structure of the N-terminal domain is reminiscent of helical DNA binding proteins that contain a so-called helix-turn-helix motif; however, in the HIV-1 structure this motif contributes to dimer formation. Initially, poor solubility hampered efforts to solve the structure of the core domain. However, attempts at crystallography were successful when it was observed that a Phe-to-Lys change at IN residue 185 greatly increased solubility without disrupting *in vitro* catalytic activity. Each monomer of the HIV-1 IN core domain (IN residues 50 to 212) is composed of a five-stranded  $\beta$ -sheet flanked by helices; this structure bears striking resemblance to other polynucleotidyl transferases including RNaseH and the bacteriophage MuA transposase. Three highly conserved residues are found in analogous positions in other polynucleotidyl transferases; in HIV-1 IN these are Asp-64, Asp-116 and Glu-152, the so-called D,D-35-E motif. Mutations at these positions block HIV IN function both *in vivo* and *in vitro*. The close proximity of these three amino acids in the crystal structure of both avian sarcoma virus and HIV-1 core domains supports the hypothesis that these residues play a central role in catalysis of the polynucleotidyl transfer reaction that is at the heart of the integration process. The C-terminal domain, whose structure has been solved by NMR methods, adopts a five-stranded  $\beta$ -barrel folding topology reminiscent of a Src homology 3 (SH3) domain. Recently, the x-ray structures of SIV and Rous sarcoma virus IN protein fragments encompassing both the core and C-terminal domains have been solved.

## Env

The HIV Env glycoproteins play a major role in the virus life cycle. They contain the determinants that interact with the CD4 receptor and coreceptor, and they catalyze the fusion reaction between the lipid bilayer of the viral envelope and the host cell plasma membrane. In addition, the HIV Env glycoproteins contain epitopes that elicit immune responses that are important from both diagnostic and vaccine development perspectives.

The HIV Env glycoprotein is synthesized from the singly spliced 4.3-kb Vpu/Env bicistronic mRNA (see Fig. IV); translation occurs on ribosomes associated with the rough endoplasmic reticulum (ER). The 160-kd polyprotein precursor (gp160) is an integral membrane protein that is anchored to cell membranes by a hydrophobic stop-transfer signal in the domain destined to be the mature TM Env glycoprotein, gp41 (Fig. VI). The gp160 is cotranslationally glycosylated, forms disulfide bonds, and undergoes oligomerization in the ER. The predominant oligomeric form appears to be a trimer, although dimers and tetramers are also observed. The gp160 is transported to the Golgi, where, like other retroviral envelope precursor proteins, it is proteolytically cleaved by cellular enzymes to the mature SU glycoprotein gp120 and TM glycoprotein gp41 (see Fig. VI). The cellular enzyme responsible for cleavage of retroviral Env precursors following a highly conserved Lys/Arg-X-Lys/Arg-Arg motif is furin or a furin-like protease, although other enzymes may also catalyze gp160 processing. Cleavage of gp160 is required for Env-induced fusion activity and virus infectivity. Subsequent to gp160 cleavage, gp120 and gp41 form a noncovalent association that is critical for transport of the Env complex from the Golgi to the cell surface. The gp120-gp41 interaction is fairly weak, and a substantial amount of gp120 is shed from the surface of Env-expressing cells.

The HIV Env glycoprotein complex, in particular the SU (gp120) domain, is very heavily glycosylated; approximately half the molecular mass of gp160 is composed of oligosaccharide side chains. During transport of Env from its site of synthesis in the ER to the plasma membrane, many of the side chains are modified by the addition of complex sugars. The numerous oligosaccharide side chains form what could be imagined as a sugar cloud obscuring much of gp120 from host immune recognition. As shown in Figure VI, gp120 contains interspersed conserved ( $C_1$  to  $C_5$ ) and variable ( $V_1$  to  $V_5$ ) domains. The Cys residues present in the gp120s of different isolates are highly conserved and form disulfide bonds that link the first four variable regions in large loops.



A primary function of viral Env glycoproteins is to promote a membrane fusion reaction between the lipid bilayers of the viral envelope and host cell membranes. This membrane fusion event enables the viral core to gain entry into the host cell cytoplasm. A number of regions in both gp120 and gp41 have been implicated, directly or indirectly, in Env-mediated membrane fusion. Studies of the HA<sub>2</sub> hemagglutinin protein of the orthomyxoviruses and the F protein of the paramyxoviruses indicated that a highly hydrophobic domain at the N-terminus of these proteins, referred to as the fusion peptide, plays a critical role in membrane fusion. Mutational analyses demonstrated that an analogous domain was located at the N-terminus of the HIV-1, HIV-2, and SIV TM glycoproteins (see Fig. VI). Nonhydrophobic substitutions within this region of gp41 greatly reduced or blocked syncytium formation and resulted in the production of noninfectious progeny virions.

C-terminal to the gp41 fusion peptide are two amphipathic helical domains (see Fig. VI) which play a central role in membrane fusion. Mutations in the N-terminal helix (referred to as the N-helix), which contains a Leu zipper-like heptad repeat motif, impair infectivity and membrane fusion activity, and peptides derived from these sequences exhibit potent antiviral activity in culture. The structure of the ectodomain of HIV-1 and SIV gp41, the two helical motifs in particular, has been the focus of structural analyses in recent years. Structures were determined by x-ray crystallography or NMR spectroscopy either for fusion proteins containing the helical domains, a mixture of peptides derived from the N- and C-helices, or in the case of the SIV structure, the intact gp41 ectodomain sequence from residue 27 to 149. These studies obtained fundamentally similar trimeric structures, in which the two helical domains pack in an antiparallel fashion to generate a six-helix bundle. The N-helices form a coiled-coil in the center of the bundle, with the C-helices packing into hydrophobic grooves on the outside.

In the steps leading to membrane fusion CD4 binding induces conformation changes in Env that facilitate coreceptor binding. Following the formation of a ternary gp120/CD4/coreceptor complex, gp41 adopts a hypothetical conformation that allows the fusion peptide to insert into the target lipid bilayer. The formation of the gp41 six-helix bundle (which involves antiparallel interactions between the gp41 N- and C-helices) brings the viral and cellular membranes together and membrane fusion takes place.

Use of Recombinant MVA Virus To Boost CD+8 Cell Immune Response

The present invention relates to generation of a CD8<sup>+</sup> T cell immune response against an antigen and also eliciting an antibody response. More particularly, the present invention relates to "prime and boost" immunization regimes in which the immune response induced by administration of a priming composition is boosted by administration of a boosting composition. The present invention is based on inventors' experimental demonstration that effective boosting can be achieved using modified vaccinia Ankara (MVA) vectors, following priming with any of a variety of different types of priming compositions including recombinant MVA itself.

A major protective component of the immune response against a number of pathogens is mediated by T lymphocytes of the CD8<sup>+</sup> type, also known as cytotoxic T lymphocytes (CTL). An important function of CD8<sup>+</sup> cells is secretion of gamma interferon (IFN $\gamma$ ), and this provides a measure of CD8<sup>+</sup> T cell immune response. A second component of the immune response is antibody directed to the proteins of the pathogen.

The present invention employs MVA which, as the experiments described below show, has been found to be an effective means for providing a boost to a CD8<sup>+</sup> T cell immune response primed to antigen using any of a variety of different priming compositions and also eliciting an antibody response.

Remarkably, the experimental work described below demonstrates that use of embodiments of the present invention allows for recombinant MVA virus expressing an HIV antigen to boost a CD8<sup>+</sup> T cell immune response primed by a DNA vaccine and also eliciting an antibody response. The MVA was found to induce a CD8<sup>+</sup> T cell response after intradermal, intramuscular or mucosal immunization. Recombinant MVA has also been shown to prime an immune response that is boosted by one or more inoculations of recombinant MVA.

Non-human primates immunized with plasmid DNA and boosted with the MVA were effectively protected against intramucosal challenge with live virus. Advantageously, the inventors found that a vaccination regime used intradermal, intramuscular or mucosal immunization for both prime and boost can be employed, constituting a general immunization regime suitable for inducing CD8<sup>+</sup> T cells and also eliciting an antibody response, e.g. in humans.

The present invention in various aspects and embodiments employs an MVA vector encoding an HIV antigen for boosting a CD8<sup>+</sup> T cell immune response to the antigen primed by previous administration of nucleic acid encoding the antigen and also eliciting an antibody response.

A general aspect of the present invention provides for the use of an MVA vector for boosting a CD8<sup>+</sup> T cell immune response to an HIV antigen and also eliciting an antibody response.

One aspect of the present invention provides a method of boosting a CD8<sup>+</sup> T cell immune response to an HIV antigen in an individual, and also eliciting an antibody response, the method including provision in the individual of an MVA vector including nucleic acid encoding the antigen operably linked to regulatory sequences for production of antigen in the individual by expression from the nucleic acid, whereby a CD8<sup>+</sup> T cell immune response to the antigen previously primed in the individual is boosted.

An immune response to an HIV antigen may be primed by immunization with plasmid DNA or by infection with an infectious agent.

A further aspect of the invention provides a method of inducing a CD8<sup>+</sup> T cell immune response to an HIV antigen in an individual, and also eliciting an antibody response, the method comprising administering to the individual a priming composition comprising nucleic acid encoding the antigen and then administering a boosting composition which comprises an MVA vector including nucleic acid encoding the antigen operably linked to regulatory sequences for production of antigen in the individual by expression from the nucleic acid.

A further aspect provides for use of an MVA vector, as disclosed, in the manufacture of a medicament for administration to a mammal to boost a CD8<sup>+</sup> T cell immune response to an HIV antigen, and also eliciting an antibody response. Such a medicament is generally for administration following prior administration of a priming composition comprising nucleic acid encoding the antigen.

The priming composition may comprise any viral vector, such as a vaccinia virus vector such as a replication-deficient strain such as modified vaccinia Ankara (MVA) or NYVAC (Tartaglia *et al.* 1992 *Virology* 118:217-232), an avipox vector such as fowlpox or canarypox, e.g. the strain known as ALVAC (Paoletti *et al.* 1994 *Dev Biol Stand* 82:65-69), or an adenovirus vector or a vesicular stomatitis virus vector or an alphavirus vector.

The priming composition may comprise DNA encoding the antigen, such DNA preferably being in the form of a circular plasmid that is not capable of replicating in mammalian cells. Any selectable marker should not be resistance to an antibiotic used clinically, so for example Kanamycin resistance is preferred to Ampicillin resistance. Antigen expression should be driven by a promoter which is active in mammalian cells, for instance the cytomegalovirus immediate early (CMV IE) promoter.

In particular embodiments of the various aspects of the present invention, administration of a priming composition is followed by boosting with a boosting composition, or first and second boosting compositions, the first and second boosting compositions being the same or different from one another. Still further boosting compositions may be employed without departing from the present invention. In one embodiment, a triple immunization regime employs DNA, then adenovirus as a first boosting composition, then MVA as a second boosting composition, optionally followed by a further (third) boosting composition or subsequent boosting administration of one or other or both of the same or different vectors. Another option is DNA then MVA then adenovirus, optionally followed by subsequent boosting administration of one or other or both of the same or different vectors.

The antigen to be encoded in respective priming and boosting compositions (however many boosting compositions are employed) need not be identical, but should share at least one CD8<sup>+</sup> T cell epitope. The antigen may correspond to a complete antigen, or a fragment thereof. Peptide epitopes or artificial strings of epitopes may be employed, more efficiently cutting out unnecessary protein sequence in the antigen and encoding sequence in the vector or vectors. One or more additional epitopes may be included, for instance epitopes which are recognized by T helper cells, especially epitopes recognized in individuals of different HLA types.

An HIV antigen of the invention to be encoded by a recombinant MVA virus includes polypeptides having immunogenic activity elicited by an amino acid sequence of an HIV Env, Gag, Pol, Vif, Vpr, Tat, Rev, Vpu, or Nef amino acid sequence as at least one CD8<sup>+</sup> T cell epitope. This amino acid sequence substantially corresponds to at least one 10-900 amino acid fragment and/or consensus sequence of a known HIV Env or Pol; or at least one 10-450 amino acid fragment and/or consensus sequence of a known HIV Gag; or at

least one 10-100 amino acid fragment and/or consensus sequence of a known HIV Vif, Vpr, Tat, Rev, Vpu, or Nef.

Although a full length Env precursor sequence is presented for use in the present invention, Env is optionally deleted of subsequences. For example, regions of the gp120 surface and gp41 transmembrane cleavage products can be deleted.

Although a full length Gag precursor sequence is presented for use in the present invention, Gag is optionally deleted of subsequences. For example, regions of the matrix protein (p17), regions of the capsid protein (p24), regions of the nucleocapsid protein (p7), and regions of p6 (the C-terminal peptide of the Gag polyprotein) can be deleted.

Although a full length Pol precursor sequence is presented for use in the present invention, Pol is optionally deleted of subsequences. For example, regions of the protease protein (p10), regions of the reverse transcriptase protein (p66/p51), and regions of the integrase protein (p32) can be deleted.

Such an HIV Env, Gag, or Pol can have overall identity of at least 50% to a known Env, Gag, or Pol protein amino acid sequence, such as 50-99% identity, or any range or value therein, while eliciting an immunogenic response against at least one strain of an HIV.

Percent identify can be determined, for example, by comparing sequence information using the GAP computer program, version 6.0, available from the University of Wisconsin Genetics Computer Group (UWGCG). The GAP program utilizes the alignment method of Needleman and Wunsch (*J Mol Biol* 1970 48:443), as revised by Smith and Waterman (*Adv Appl Math* 1981 2:482). Briefly, the GAP program defines identity as the number of aligned symbols (i.e., nucleotides or amino acids) which are identical, divided by the total number of symbols in the shorter of the two sequences. The preferred default parameters for the GAP program include: (1) a unitary comparison matrix (containing a value of 1 for identities and 0 for non-identities) and the weighted comparison matrix of Gribskov and Burgess (*Nucl Acids Res* 1986 14:6745), as described by Schwartz and Dayhoff (eds., *Atlas of Protein Sequence and Structure*, National Biomedical Research Foundation, Washington, D.C. 1979, pp. 353-358); (2) a penalty of 3.0 for each gap and an additional 0.10 penalty for each symbol in each gap; and (3) no penalty for end gaps.

In a preferred embodiment, an Env of the present invention is a variant form of at least one HIV envelope protein. Preferably, the Env is composed of gp120 and the



membrane-spanning and ectodomain of gp41 but lacks part or all of the cytoplasmic domain of gp41.

Known HIV sequences are readily available from commercial and institutional HIV sequence databases, such as GENBANK, or as published compilations, such as Myers *et al.* eds., *Human Retroviruses and AIDS, A Compilation and Analysis of Nucleic Acid and Amino Acid Sequences*, Vol. I and II, Theoretical Biology and Biophysics, Los Alamos, N. Mex. (1993), or <http://hiv-web.lanl.gov/>.

Substitutions or insertions of an HIV Env, Gag, or Pol to obtain an additional HIV Env, Gag, or Pol, encoded by a nucleic acid for use in a recombinant MVA virus of the present invention, can include substitutions or insertions of at least one amino acid residue (e.g., 1-25 amino acids). Alternatively, at least one amino acid (e.g., 1-25 amino acids) can be deleted from an HIV Env, Gag, or Pol sequence. Preferably, such substitutions, insertions or deletions are identified based on safety features, expression levels, immunogenicity and compatibility with high replication rates of MVA.

Amino acid sequence variations in an HIV Env, Gag, or Pol of the present invention can be prepared e.g., by mutations in the DNA. Such HIV Env, Gag, or Pol include, for example, deletions, insertions or substitutions of nucleotides coding for different amino acid residues within the amino acid sequence. Obviously, mutations that will be made in nucleic acid encoding an HIV Env, Gag, or Pol must not place the sequence out of reading frame and preferably will not create complementary domains that could produce secondary mRNA structures.

HIV Env, Gag, or Pol-encoding nucleic acid of the present invention can also be prepared by amplification or site-directed mutagenesis of nucleotides in DNA or RNA encoding an HIV Env, Gag, or Pol and thereafter synthesizing or reverse transcribing the encoding DNA to produce DNA or RNA encoding an HIV Env, Gag, or Pol, based on the teaching and guidance presented herein.

Recombinant MVA viruses expressing HIV Env, Gag, or Pol of the present invention, include a finite set of HIV Env, Gag, or Pol-encoding sequences as substitution nucleotides that can be routinely obtained by one of ordinary skill in the art, without undue experimentation, based on the teachings and guidance presented herein. For a detailed description of protein chemistry and structure, see Schulz, G.E. *et al.*, 1978 *Principles of Protein Structure*, Springer-Verlag, New York, N.Y., and Creighton, T.E., 1983 *Proteins*:

*Structure and Molecular Properties*, W. H. Freeman & Co., San Francisco, CA. For a presentation of nucleotide sequence substitutions, such as codon preferences, see Ausubel *et al.* eds. *Current Protocols in Molecular Biology*, Greene Publishing Assoc., New York, N.Y. 1994 at §§ A.1.1-A.1.24, and Sambrook, J. *et al.* 1989 *Molecular Cloning: A Laboratory Manual*, Second Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. at Appendices C and D.

Thus, one of ordinary skill in the art, given the teachings and guidance presented herein, will know how to substitute other amino acid residues in other positions of an HIV *env*, *gag*, or *pol* DNA or RNA to obtain alternative HIV Env, Gag, or Pol, including substitutional, deletional or insertional variants.

Within the MVA vector, regulatory sequences for expression of the encoded antigen will include a natural, modified or synthetic poxvirus promoter. By "promoter" is meant a sequence of nucleotides from which transcription may be initiated of DNA operably linked downstream (i.e. in the 3' direction on the sense strand of double-stranded DNA). "Operably linked" means joined as part of the same nucleic acid molecule, suitably positioned and oriented for transcription to be initiated from the promoter. DNA operably linked to a promoter is "under transcriptional initiation regulation" of the promoter. Other regulatory sequences including terminator fragments, polyadenylation sequences, marker genes and other sequences may be included as appropriate, in accordance with the knowledge and practice of the ordinary person skilled in the art: see, for example, Moss, B. (2001). Poxviridae: the viruses and their replication. In Fields Virology, D.M. Knipe, and P.M. Howley, eds. (Philadelphia, Lippincott Williams & Wilkins), pp. 2849-2883. Many known techniques and protocols for manipulation of nucleic acid, for example in preparation of nucleic acid constructs, mutagenesis, sequencing, introduction of DNA into cells and gene expression, and analysis of proteins, are described in detail in *Current Protocols in Molecular Biology*, 1998 Ausubel *et al.* eds., John Wiley & Sons.

Promoters for use in aspects and embodiments of the present invention must be compatible with poxvirus expression systems and include natural, modified and synthetic sequences.

Either or both of the priming and boosting compositions may include an adjuvant, such as granulocyte macrophage-colony stimulating factor (GM-CSF) or encoding nucleic acid therefor.

Administration of the boosting composition is generally about 1 to 6 months after administration of the priming composition, preferably about 1 to 3 months.

Preferably, administration of priming composition, boosting composition, or both priming and boosting compositions, is intradermal, intramuscular or mucosal immunization.

Administration of MVA vaccines may be achieved by using a needle to inject a suspension of the virus. An alternative is the use of a needleless injection device to administer a virus suspension (using, e.g., Biojector™ needleless injector) or a resuspended freeze-dried powder containing the vaccine, providing for manufacturing individually prepared doses that do not need cold storage. This would be a great advantage for a vaccine that is needed in rural areas of Africa.

MVA is a virus with an excellent safety record in human immunizations. The generation of recombinant viruses can be accomplished simply, and they can be manufactured reproducibly in large quantities. Intradermal, intramuscular or mucosal administration of recombinant MVA virus is therefore highly suitable for prophylactic or therapeutic vaccination of humans against AIDS which can be controlled by a CD8<sup>+</sup> T cell response.

The individual may have AIDS such that delivery of the antigen and generation of a CD8<sup>+</sup> T cell immune response to the antigen is of benefit or has a therapeutically beneficial effect.

Most likely, administration will have prophylactic aim to generate an immune response against HIV or AIDS before infection or development of symptoms.

Components to be administered in accordance with the present invention may be formulated in pharmaceutical compositions. These compositions may comprise a pharmaceutically acceptable excipient, carrier, buffer, stabilizer or other materials well known to those skilled in the art. Such materials should be non-toxic and should not interfere with the efficacy of the active ingredient. The precise nature of the carrier or other material may depend on the route of administration, e.g. intravenous, cutaneous or subcutaneous, nasal, intramuscular, intraperitoneal routes.

As noted, administration is preferably intradermal, intramuscular or mucosal.

Physiological saline solution, dextrose or other saccharide solution or glycols such as ethylene glycol, propylene glycol or polyethylene glycol may be included.

For intravenous, cutaneous, subcutaneous, intramuscular or mucosal injection, or injection at the site of affliction, the active ingredient will be in the form of a parenterally acceptable aqueous solution which is pyrogen-free and has suitable pH, isotonicity and stability. Those of relevant skill in the art are well able to prepare suitable solutions using, for example, isotonic vehicles such as Sodium Chloride Injection, Ringer's Injection, Lactated Ringer's Injection. Preservatives, stabilizers, buffers, antioxidants and/or other additives may be included as required.

A slow-release formulation may be employed.

Following production of MVA particles and optional formulation of such particles into compositions, the particles may be administered to an individual, particularly human or other primate. Administration may be to another mammal, e.g. rodent such as mouse, rat or hamster, guinea pig, rabbit, sheep, goat, pig, horse, cow, donkey, dog or cat.

Administration is preferably in a "prophylactically effective amount" or a "therapeutically effective amount" (as the case may be, although prophylaxis may be considered therapy), this being sufficient to show benefit to the individual. The actual amount administered, and rate and time-course of administration, will depend on the nature and severity of what is being treated. Prescription of treatment, e.g. decisions on dosage etc, is within the responsibility of general practitioners and other medical doctors, or in a veterinary context a veterinarian, and typically takes account of the disorder to be treated, the condition of the individual patient, the site of delivery, the method of administration and other factors known to practitioners. Examples of the techniques and protocols mentioned above can be found in *Remington's Pharmaceutical Sciences*, 16th edition, 1980, Osol, A. (ed.).

In one preferred regimen, DNA is administered at a dose of 250  $\mu$ g to 2.5 mg/injection, followed by MVA at a dose of  $10^6$  to  $10^9$  infectious virus particles/injection.

A composition may be administered alone or in combination with other treatments, either simultaneously or sequentially dependent upon the condition to be treated.

Delivery to a non-human mammal need not be for a therapeutic purpose, but may be for use in an experimental context, for instance in investigation of mechanisms of immune responses to an antigen of interest, e.g. protection against HIV or AIDS.

Further aspects and embodiments of the present invention will be apparent to those of ordinary skill in the art, in view of the above disclosure and following experimental

exemplification, included by way of illustration and not limitation, and with reference to the attached figures.

### EXAMPLE 1

#### Control of a Mucosal Challenge and Prevention of AIDS by a Multiprotein DNA/MVA Vaccine

Here we tested DNA priming and poxvirus boosting for the ability to protect against a highly pathogenic mucosal challenge. The 89.6 chimera of simian and human immunodeficiency viruses (SHIV-89.6) was used for the construction of immunogens and its highly pathogenic derivative, SHIV-89.6P, for challenge (G.B. Karlsson *et al.* 1997 *J Virol* 71:4218). SHIV-89.6 and SHIV-89.6P do not generate cross-neutralizing antibody (D.C... Montefiori *et al.* 1998 *J Virol* 72:3427) and allowed us to address the ability of vaccine-raised T cells and non-neutralizing antibodies to control an immunodeficiency virus challenge. Modified vaccinia Ankara (MVA) was used for the construction of the recombinant poxvirus. MVA has been highly effective at boosting DNA-primed CD8 T cells and enjoys the safety feature of not replicating efficiently in human or monkey cells (H.L. Robinson *et al.* 2000 *AIDS Reviews* 2:105).

To ensure a broad immune response both the DNA and recombinant MVA (rMVA) components of the vaccine expressed multiple immunodeficiency virus proteins. The DNA prime (DNA/89.6) expressed simian immunodeficiency virus (SIV) Gag, Pol, Vif, Vpx, and Vpr and human immunodeficiency virus-1 (HIV-1) Env, Tat, and Rev from a single transcript (R.J. Gorelick *et al.* 1999 *Virology* 253:259; M.M. Sauter *et al.* 1996 *J Cell Biol* 132:795).

Molecularly cloned SHIV-89.6 sequences were cloned into the vector pGA2 using ClaI and RsrII sites. This cloning deleted both long terminal repeats (LTRs) and *nef*. The SHIV-89.6 sequences also were internally mutated for a 12-base pair region encoding the first four amino acids of the second zinc finger in nucleocapsid. This mutation renders SHIV viruses noninfectious (R.J. Gorelick *et al.* 1999 *Virology* 253:259). A mutation in gp41 converted the tyrosine at position 710 to cysteine to achieve better expression of Env on the plasma membrane of DNA-expressing cells (M.M. Sauter *et al.* 1996 *J Cell Biol* 132:795). pGA2 uses the CMV immediate early promoter without intron A and the bovine growth hormone polyadenylation sequence to express vaccine inserts. Vaccine DNA was



produced by Althea (San Diego, CA). In transient transfections of 293T cells, DNA/89.6 produced about 300 ng of Gag and 85 ng of Env per  $1 \times 10^6$  cells.

The rMVA booster (MVA/89.6) expressed SIV Gag, Pol, and HIV-1 Env under the control of vaccinia virus early/late promoters.

The MVA double recombinant virus expressed both the HIV 89.6 Env and the SIV 239 Gag-Pol, which were inserted into deletion II and deletion III of MVA, respectively. The 89.6 Env protein was truncated for the COOH-terminal 115 amino acids of gp41. The modified H5 promoter controlled the expression of both foreign genes.

Vaccination was accomplished by priming with DNA at 0 and 8 weeks and boosting with rMVA at 24 weeks (Fig. 1A).

I.d. and i.m. DNA immunizations were delivered in phosphate-buffered saline (PBS) with a needleless jet injector (Bioject, Portland, OR) to deliver five i.d. 100- $\mu$ l injections to each outer thigh for the 2.5-mg dose of DNA or one i.d. 100- $\mu$ l injection to the right outer thigh for the 250- $\mu$ g dose of plasmid. I.m. deliveries of DNA were done with one 0.5-ml injection of DNA in PBS to each outer thigh for the 2.5-mg dose and one 100- $\mu$ l injection to the right outer thigh for the 250- $\mu$ g dose.  $1 \times 10^8$  pfu of MVA/89.6 was administered both i.d. and i.m. with a needle. One 100- $\mu$ l dose was delivered to each outer thigh for the i.d. dose and one 500- $\mu$ l dose to each outer thigh for the i.m dose. Control animals received 2.5 mg of the pGA2 vector without vaccine insert with the Bioject device to deliver five 100- $\mu$ l doses i.d. to each outer thigh. The control MVA booster immunization consisted of  $2 \times 10^8$  pfu of MVA without an insert delivered i.d. and i.m. as described for MVA/89.6.

Four groups of six rhesus macaques each were primed with either 2.5 mg (high-dose) or 250  $\mu$ g (low-dose) of DNA by intradermal (i.d.) or intramuscular (i.m.) routes using a needleless jet injection device (Bioject, Portland, OR) (T.M. Allen *et al.* 2000 *J Immunol* 164:4968).

Young adult rhesus macaques from the Yerkes breeding colony were cared for under guidelines established by the Animal Welfare Act and the NIH "Guide for the Care and Use of Laboratory Animals" with protocols approved by the Emory University Institutional Animal Care and Use Committee. Macaques were typed for the *Mamu-A\*01* allele with polymerase chain reaction (PCR) analyses (M.A. Egan *et al.* 2000 *J Virol* 74:7485; I. Ourmanov *et al.* 2000 *J Virol* 74:2740). Two or more animals containing at

least one *Mamu-A\*01* allele were assigned to each group. Animal numbers are as follows: 1, RBr-5\*; 2, RIm-5\*; 3, RQf-5\*; 4, RZe-5; 5, ROm-5; 6, RDm-5; 7, RAj-5\*; 8, Rji-5\*; 9, RAl-5\*; 10, RDe-5\*; 11, RAi-5; 12, RPr-5; 13, RKw-4\*; 14, RWz-5\*; 15, RGo-5; 16, RLp-4; 17, RWd-6; 18, RAi-5; 19, RPb-5\*; 20, Rli-5\*; 21, RIq-5; 22, RSp-4; 23, RSn-5; 24, RGd-6; 25, RMb-5\*; 26, RGy-5\*; 27, RUs-4; and 28, RPm-5. Animals with the *A\*01* allele are indicated with asterisks.

Gene gun deliveries of DNA were not used because these had primed non-protective immune responses in a 1996 - 98 trial (H.L. Robinson *et al.* 1999 *Nat Med* 5:526). The MVA/89.6 booster immunization ( $2 \times 10^8$  plaque-forming units, pfu) was injected with a needle both i.d. and i.m. A control group included two mock immunized animals and two naive animals. The challenge was given at 7 months after the rMVA booster to test for the generation of long-term immunity. Because most HIV-1 infections are transmitted across mucosal surfaces, an intrarectal challenge was administered.

DNA priming followed by rMVA boosting generated high frequencies of virus-specific T cells that peaked at one week following the rMVA booster (Fig. 1). The frequencies of T cells recognizing the Gag-CM9 epitope were assessed by means of Mamu-A\*01 tetramers, and the frequencies of T cells recognizing epitopes throughout Gag were assessed with pools of overlapping peptides and an enzyme-linked immunospot (ELISPOT) assay (C.A. Power *et al.* 1999 *J Immunol Methods* 227:99).

For tetramer analyses, about  $1 \times 10^6$  peripheral blood mononuclear cells (PBMC) were surface-stained with antibodies to CD3 conjugated to fluorescein isothiocyanate (FITC) (FN-18; Biosource International, Camarillo, CA), CD8 conjugated to peridinin chlorophyll protein (PerCP) (SK1; Becton Dickinson, San Jose, CA), and Gag-CM9 (CTPYDINQM)-*Mamu-A\*01* tetramer (SEQ ID NO: 6) conjugated to allophycocyanin (APC), in a volume of 100  $\mu$ l at 8° to 10°C for 30 min. Cells were washed twice with cold PBS containing 2% fetal bovine serum (FBS), fixed with 1% paraformaldehyde in PBS, and analyzed within 24 hrs on a FACScaliber (Becton Dickinson, San Jose, CA). Cells were initially gated on lymphocyte populations with forward scatter and side scatter and then on CD3 cells. The CD3 cells were then analyzed for CD8 and tetramer-binding cells. About 150,000 lymphocytes were acquired for each sample. Data were analyzed using FloJo software (Tree Star, San Carlos, CA).

For interferon- $\gamma$  (IFN- $\gamma$ ) ELISPOTs, MULTISCREEN 96 well filtration plates (Millipore Inc. Bedford, MA) were coated overnight with antibody to human IFN- $\gamma$  (Clone B27, Pharmingen, San Diego, CA) at a concentration of 2  $\mu\text{g/ml}$  in sodium bicarbonate buffer (pH 9.6) at 8° to 10°C. Plates were washed two times with RPMI medium and then blocked for 1 hour with complete medium (RPMI containing 10% FBS) at 37°C. Plates were washed five more times with plain RPMI medium, and cells were seeded in duplicate in 100  $\mu\text{l}$  complete medium at numbers ranging from  $2 \times 10^4$  to  $5 \times 10^5$  cells per well. Peptide pools were added to each well to a final concentration of 2  $\mu\text{g/ml}$  of each peptide in a volume of 100  $\mu\text{l}$  in complete medium. Cells were cultured at 37°C for about 36 hrs under 5%  $\text{CO}_2$ . Plates were washed six times with wash buffer (PBS with 0.05% Tween-20) and then incubated with 1  $\mu\text{g}$  of biotinylated antibody to human IFN- $\gamma$  per milliliter (clone 7-86-1; Diapharma Group, West Chester, OH) diluted in wash buffer containing 2% FBS. Plates were incubated for 2 hrs at 37°C and washed six times with wash buffer. Avidin-horseradish peroxidase (Vector Laboratories, Burlingame, CA) was added to each well and incubated for 30 to 60 min at 37°C. Plates were washed six times with wash buffer and spots were developed using stable DAB as substrate (Research Genetics, Huntsville, AL). Spots were counted with a stereo dissecting microscope. An ovalbumin peptide (SIINFELK) (SEQ ID NO: 7) was included as a control in each analysis. Background spots for the ovalbumin peptide were generally  $<5$  for  $5 \times 10^5$  PBMCs. This background when normalized for  $1 \times 10^6$  PBMC was  $<10$ . Only ELISPOT counts of twice the background ( $\geq 20$ ) were considered significant. The frequencies of ELISPOTs are approximate because different dilutions of cells have different efficiencies of spot formation in the absence of feeder cells (C.A. Power *et al.* 1999 *J Immunol Methods* 227: 99). The same dilution of cells was used for all animals at a given time point, but different dilutions were used to detect memory and acute responses.

Gag-CM9 tetramer analyses were restricted to macaques that expressed the *Mamu-A\*01* histocompatibility type, whereas ELISPOT responses did not depend on a specific histocompatibility type. As expected, the DNA immunizations raised low levels of memory cells that expanded to high frequencies within 1 week of the rMVA booster (Fig. 1 and 6). In *Mamu-A\*01* macaques, CD8 cells specific to the Gag-CM9 epitope expanded to frequencies as high as 19% of total CD8 T cells (Fig. 6). This peak of specific cells underwent a 10- to 100-fold contraction into the DNA/MVA memory pool (Fig. 1A and 6).

ELISPOTs for three pools of Gag peptides also underwent a major expansion (frequencies up to 4000 spots for  $1 \times 10^6$  PBMC) before contracting from 5- to 20-fold into the DNA/MVA memory response (Fig. 1B). The frequencies of ELISPOTs were the same in macaques with and without the *A\*01* histocompatibility type ( $P > 0.2$ ).

Simple linear regression was used to estimate correlations between postbooster and postchallenge ELISPOT responses, between memory and postchallenge ELISPOT responses, and between logarithmically transformed viral loads and ELISPOT frequencies. Comparisons between vaccine and control groups and *A\*01* and non *A\*01* macaques were performed by means of two-sample *t* tests with logarithmically transformed viral load and ELISPOT responses. Two-way analyses of variance were used to examine the effects of dose and route of administration on peak DNA/MVA ELISPOTs, on memory DNA/MVA ELISPOTs, and on logarithmically transformed Gag antibody data.

At both peak and memory phases of the vaccine response, the rank order for the height of the ELISPOTs in the vaccine groups was 2.5 mg i.d. > 2.5 mg i.m. > 250  $\mu$ g i.d. > 250  $\mu$ g i.m. (Fig. 1B). The IFN- $\gamma$  ELISPOTs included both CD4 and CD8 cells. Gag-CM9-specific CD8 cells had good lytic activity after restimulation with peptide.

The highly pathogenic SHIV-89.6P challenge was administered intrarectally at 7 months after the rMVA booster, when vaccine-raised T cells were in memory (Fig. 1).

The challenge stock ( $5.7 \times 10^9$  copies of viral RNA per milliliter) was produced by one intravenous followed by one intrarectal passage in rhesus macaques of the original SHIV-89.6P stock (G.B. Karlsson *et al.* 1997 *J Virol* 71:4218). Lymphoid cells were harvested from the intrarectally infected animal at peak viremia, CD8-depleted, and mitogen-stimulated for stock production. Before intrarectal challenge, fasted animals were anesthetized (ketamine, 10 mg/kg) and placed on their stomach with the pelvic region slightly elevated. A feeding tube (8Fr (2.7 mm) x 16 inches (41 cm); Sherwood Medical, St. Louis, MO) was inserted into the rectum for a distance of 15 to 20 cm. Following insertion of the feeding tube, a syringe containing 20 intrarectal infectious doses in 2 ml of RPMI-1640 plus 10% FBS was attached to the tube and the inoculum was slowly injected into the rectum. After delivery of the inoculum, the feeding tube was flushed with 3.0 ml of RPMI without FBS and then slowly withdrawn. Animals were left in place, with pelvic regions slightly elevated, for a period of ten minutes after the challenge.



The challenge infected all of the vaccinated and control animals (Fig. 2). However, by 2 weeks after challenge, titers of plasma viral RNA were at least 10-fold lower in the vaccine groups (geometric means of  $1 \times 10^7$  to  $5 \times 10^7$ ) than in the control animals (geometric mean of  $4 \times 10^8$ ) (Fig. 2A) (S. Staprans *et al.* in: *Viral Genome Methods* K. Adolph, ed. CRC Press, Boca Raton, FL, 1996 pp. 167-184; R. Hofmann-Lehmann *et al.* 2000 *AIDS Res Hum Retroviruses* 16:1247).

For the determination of SHIV copy number, viral RNA from 150  $\mu$ l of ACD anticoagulated plasma was directly extracted with the QIAamp Viral RNA kit (Qiagen), eluted in 60  $\mu$ l of AVE buffer, and frozen at  $-80^\circ\text{C}$  until SHIV RNA quantitation was performed. Five microliters of purified plasma RNA was reverse-transcribed in a final 20- $\mu$ l volume containing 50 mM KCl, 10 mM Tris-HCl (pH 8.3), 4 mM  $\text{MgCl}_2$ , 1 mM each deoxynucleotide triphosphate (dNTP), 2.5  $\mu$ M random hexamers, 20 units MultiScribe RT, and 8 units ribonuclease inhibitor. Reactions were incubated at  $25^\circ\text{C}$  for 10 min, followed by incubation at  $42^\circ\text{C}$  for 20 min, and inactivation of reverse transcriptase at  $99^\circ\text{C}$  for 5 min. The reaction mix was adjusted to a final volume of 50  $\mu$ l containing 50 mM KCl, 10 mM Tris-HCl (pH 8.3), 4 mM  $\text{MgCl}_2$ , 0.4 mM each dNTP, 0.2  $\mu$ M forward primer, 0.2  $\mu$ M reverse primer, 0.1  $\mu$ M probe, and 5 units AmpliTaq Gold DNA polymerase (all reagents from PerkinElmer Applied Biosystems, Foster City, CA). The primer sequences within a conserved portion of the SIV *gag* gene are the same as those described previously (S. Staprans *et al.* in: *Viral Genome Methods* K. Adolph, ed. CRC Press, Boca Raton, FL, 1996 pp. 167-184). A PerkinElmer Applied Biosystems 7700 Sequence Detection System was used with the PCR profile:  $95^\circ\text{C}$  for 10 min, followed by 40 cycles at  $93^\circ\text{C}$  for 30 s, and  $59.5^\circ\text{C}$  for 1 min. PCR product accumulation was monitored with the 7700 sequence detector and a probe to an internal conserved *gag* gene sequence: 6FAM-CTGTCTGCGTCATTTGGTGC-Tamra (SEQ ID NO: 8), where FAM and Tamra denote the reporter and quencher dyes. SHIV RNA copy number was determined by comparison with an external standard curve consisting of virion-derived SIVmac239 RNA quantified by the SIV bDNA method (Bayer Diagnostics, Emeryville, CA). All specimens were extracted and amplified in duplicate, with the mean result reported. With a 0.15-ml plasma input, the assay has a sensitivity of  $10^3$  RNA copies per milliliter of plasma and a linear dynamic range of  $10^3$  to  $10^8$  RNA copies ( $R^2 = 0.995$ ). The intraassay coefficient of variation was  $<20\%$  for samples containing  $>10^4$  SHIV RNA copies per milliliter, and



<25% for samples containing  $10^3$  to  $10^4$  SHIV RNA copies per milliliter. To more accurately quantitate low SHIV RNA copy number in vaccinated animals at weeks 16 and 20, we made the following modifications to increase the sensitivity of the SHIV RNA assay: (i) Virions from  $\leq 1$  ml of plasma were concentrated by centrifugation at 23,000g at 10°C for 150 min before viral RNA extraction, and (ii) a one-step reverse transcriptase PCR method was used (R. Hofmann-Lehmann *et al.* 2000 *AIDS Res Hum Retroviruses* 16:1247). These changes provided a reliable quantification limit of 300 SHIV RNA copies per milliliter, and gave SHIV RNA values that were highly correlated to those obtained by the first method used ( $r = 0.91$ ,  $P < 0.0001$ ).

By 8 weeks after challenge, both high-dose DNA-primed groups and the low-dose i.d. DNA-primed group had reduced their geometric mean loads to about 1000 copies of viral RNA per milliliter. At this time, the low-dose i.m. DNA-primed group had a geometric mean of  $6 \times 10^3$  copies of viral RNA and the nonvaccinated controls had a geometric mean of  $2 \times 10^6$ . By 20 weeks after challenge, even the low-dose i.m. group had reduced its geometric mean copies of viral RNA to 1000. Among the 24 vaccinated animals, only one animal, animal number 22 in the low-dose i.m. group, had intermittent viral loads above  $1 \times 10^4$  copies per milliliter (Fig 2D).

By 5 weeks after challenge, all of the nonvaccinated controls had undergone a profound depletion of CD4 cells (Fig 2B). All of the vaccinated animals maintained their CD4 cells, with the exception of animal 22 in the low dose i.m. group (see above), which underwent a slow CD4 decline (Fig. 2E). By 23 weeks after challenge, three of the four control animals had succumbed to AIDS (Fig. 2C). These animals had variable degrees of enterocolitis with diarrhea, cryptosporidiosis, colicystitis, enteric campylobacter infection, splenomegaly, lymphadenopathy, and SIV-associated giant cell pneumonia. In contrast, all 24 vaccinated animals maintained their health.

Containment of the viral challenge was associated with a burst of antiviral T cells (Fig. 1 and 3A). At one week after challenge, the frequency of tetramer<sup>+</sup> cells in the peripheral blood had decreased, potentially reflecting the recruitment of specific T cells to the site of infection (Fig. 3A). However, by two weeks after challenge, tetramer<sup>+</sup> cells in the peripheral blood had expanded to frequencies as high as, or higher than, after the rMVA booster (Fig. 1 and 3A). The majority of the tetramer<sup>+</sup> cells produced IFN- $\gamma$  in response to a 6-hour peptide stimulation (Fig. 3B) (S.L. Waldrop *et al.* 1997 *J Clin Invest* 99:1739) and

did not have the “stunned” IFN- $\gamma$  negative phenotype sometimes observed in viral infections (F. Lechner *et al.* 2000 *J Exp Med* 191:1499).

For intracellular cytokine assays, about  $1 \times 10^6$  PBMC were stimulated for 1 hour at 37°C in 5 ml polypropylene tubes with 100  $\mu$ g of Gag-CM9 peptide (CTPYDINQM) (SEQ ID NO: 6) per milliliter in a volume of 100  $\mu$ l RPMI containing 0.1% bovine serum albumin (BSA) and 1  $\mu$ g of antibody to human CD28 and 1  $\mu$ g of antibody to human CD49d (Pharmingen, San Diego, CA) per milliliter. Then, 900  $\mu$ l of RPMI containing 10% FBS and monensin (10  $\mu$ g/ml) was added, and the cells were cultured for an additional 5 hrs at 37°C at an angle of 5° under 5% CO<sub>2</sub>. Cells were surface stained with antibodies to CD8 conjugated to PerCP (clone SK1, Becton Dickinson) at 8° to 10°C for 30 min, washed twice with cold PBS containing 2% FBS, and fixed and permeabilized with Cytofix/Cytoperm solution (Pharmingen). Cells were then incubated with antibodies to human CD3 (clone FN-18; Biosource International, Camarillo, CA) and IFN- $\gamma$  (Clone B27; Pharmingen) conjugated to FITC and phycoerythrin, respectively, in Perm wash solution (Pharmingen) for 30 min at 4°C. Cells were washed twice with Perm wash, once with plain PBS, and resuspended in 1% paraformaldehyde in PBS. About 150,000 lymphocytes were acquired on the FACScaliber and analyzed with FloJo software.

The postchallenge burst of T cells contracted concomitant with the decline of the viral load. By 12 weeks after challenge, virus-specific T cells were present at about one-tenth of their peak height (Figs. 1A and 3A). In contrast to the vigorous secondary response in the vaccinated animals, the naive animals mounted a modest primary response (Fig. 1B and 3A). Tetramer<sup>+</sup> cells peaked at less than 1% of total CD8 cells (Fig. 3A), and IFN- $\gamma$ -producing ELISPOTs were present at a mean frequency of about 300 as opposed to the much higher frequencies of 1000 to 6000 in the vaccine groups (Fig. 1B) ( $P < 0.05$ ).

The tetramer<sup>+</sup> cells in the control group, like those in the vaccine group, produced IFN- $\gamma$  after peptide stimulation (Fig. 3B). By 12 weeks after challenge, three of the four controls had undetectable levels of IFN- $\gamma$ -producing ELISPOTs. This rapid loss of antiviral T cells in the presence of high viral loads may reflect the lack of CD4 help.

T cell proliferative responses demonstrated that virus-specific CD4 cells had survived the challenge and were available to support the antiviral immune response (Fig. 3C).

About 0.2 million PBMC were stimulated in triplicate for 5 days with the indicated antigen in 200  $\mu$ l of RPMI at 37°C under 5% CO<sub>2</sub>. Supernatants from 293T cells transfected with DNA expressing either SHIV-89.6 Gag and Pol or SHIV-89.6 Gag, Pol and Env were used directly as antigens (final concentration of ~0.5  $\mu$ g of p27 Gag per milliliter). Supernatants from mock DNA (vector alone)-transfected cells served as negative controls. On day six, cells were pulsed with 1  $\mu$ Ci of tritiated thymidine per well for 16 to 20 hours. Cells were harvested with an automated cell harvester (TOMTEC, Harvester 96, Model 1010, Hamden, CT) and counted with a Wallac 1450 MICROBETA Scintillation counter (Gaithersburg, MD). Stimulation indices are the counts of tritiated thymidine incorporated in PBMC stimulated with 89.6 antigens divided by the counts of tritiated thymidine incorporated by the same PBMC stimulated with mock antigen.

At 12 weeks after challenge, mean stimulation indices for Gag-Pol-Env or Gag-Pol proteins ranged from 35 to 14 in the vaccine groups but were undetectable in the control group. Consistent with the proliferation assays, intracellular cytokine assays demonstrated the presence of virus-specific CD4 cells in vaccinated but not control animals. The overall rank order of the vaccine groups for the magnitude of the proliferative response was 2.5 mg i.d. > 2.5 mg i.m. > 250  $\mu$ g i.d. > 250  $\mu$ g i.m.

At 12 weeks after challenge, lymph nodes from the vaccinated animals were morphologically intact and responding to the infection, whereas those from the infected controls had been functionally destroyed (Fig. 4). Nodes from vaccinated animals contained large numbers of reactive secondary follicles with expanded germinal centers and discrete dark and light zones (Fig. 4A). By contrast, lymph nodes from the non-vaccinated control animals showed follicular and paracortical depletion (Fig. 4B), while those from unvaccinated and unchallenged animals displayed normal numbers of minimally reactive germinal centers (Fig. 4C). Germinal centers occupied < 0.05% of total lymph node area in the infected controls, 2% of the lymph node area in the uninfected controls, and up to 18% of the lymph node area in the vaccinated groups (Fig. 4D). More vigorous immune reactivity in the low-dose than the high-dose DNA-primed animals was suggested by more extensive germinal centers in the low dose group (Fig. 4D). At 12 weeks after challenge, *in situ* hybridization for viral RNA revealed rare virus-expressing cells in lymph nodes from 3 of the 24 vaccinated macaques, whereas virus-expressing cells were readily detected in lymph nodes from each of the infected control animals. In the controls, which had

undergone a profound depletion in CD4 T cells, the cytomorphology of infected lymph node cells was consistent with a macrophage phenotype.

The prime/boost strategy raised low levels of antibody to Gag and undetectable levels of antibody to Env (Fig. 5). Postchallenge, antibodies to both Env and Gag underwent anamnestic responses with total Gag antibody reaching heights approaching 1 mg/ml and total Env antibody reaching heights of up to 100 µg/ml.

Enzyme-linked immunosorbent assays (ELISAs) for total antibody to Gag used bacterially produced SIV gag p27 to coat wells (2 µg per milliliter in bicarbonate buffer). ELISAs for antibody to Env antibody used 89.6 Env produced in transiently transfected 293T cells and captured with sheep antibody against Env (catalog number 6205; International Enzymes, Fairbrook CA). Standard curves for Gag and Env ELISAs were produced with serum from a SHIV-89.6-infected macaque with known amounts of immunoglobulin G (IgG) specific for Gag or Env. Bound antibody was detected with peroxidase-conjugated goat antibody to macaque IgG (catalog # YNGMOIGGFCP; Accurate Chemical, Westbury, NY) and TMB substrate (Catalog # T3405; Sigma, St. Louis, MO). Sera were assayed at threefold dilutions in duplicate wells. Dilutions of test sera were performed in whey buffer (4% whey and 0.1% tween 20 in 1X PBS). Blocking buffer consisted of whey buffer plus 0.5% nonfat dry milk. Reactions were stopped with 2M H<sub>2</sub>SO<sub>4</sub> and the optical density read at 450 nm. Standard curves were fitted and sample concentrations were interpolated as µg of antibody per ml of serum using SOFTmax 2.3 software (Molecular Devices, Sunnyvale, CA).

By 2 weeks after challenge, neutralizing antibodies for the 89.6 immunogen, but not the SHIV-89.6P challenge, were present in the high-dose DNA-primed groups (geometric mean titers of 352 in the i.d. and 303 in the i.m. groups) (Fig. 5C) (D.C. Montefiori *et al.* 1988 *J Clin Microbiol* 26:231). By 5 weeks after challenge, neutralizing antibody to 89.6P had been generated (geometric mean titers of 200 in the high-dose i.d. and 126 in the high-dose i.m. group) (Fig. 5D) and neutralizing antibody to 89.6 had started to decline. By 16 to 20 weeks after challenge, antibodies to Gag and Env had fallen in most animals.

Our results demonstrate that a multiprotein DNA/MVA vaccine can raise a memory immune response capable of controlling a highly virulent mucosal immunodeficiency virus challenge. Our levels of viral control were more favorable than have been achieved using only DNA (M.A. Egan *et al.* 2000 *J Virol* 74:7485) or rMVA vaccines (I. Ourmanov *et al.*



2000 *J Virol* 74:2740) and were comparable to those obtained for DNA immunizations adjuvanted with interleukin-2 (D.H. Barouch *et al.* 2000 *Science* 290:486). All of these previous studies have used more than three vaccine inoculations, none have used mucosal challenges, and most have challenged at peak effector responses and not allowed a prolonged post vaccination period to test for "long term" efficacy.

The dose of DNA had statistically significant effects on both cellular and humoral responses ( $P < 0.05$ ), whereas the route of DNA administration affected only humoral responses. Intradermal DNA delivery was about 10 times more effective than i.m. inoculations for generating antibody to Gag ( $P = 0.02$ ). Neither route nor dose of DNA appeared to have a significant effect on protection. At 20 weeks after challenge, the high-dose DNA-primed animals had slightly lower geometric mean levels of viral RNA ( $7 \times 10^2$  and  $5 \times 10^2$ ) than the low-dose DNA-primed animals ( $9 \times 10^2$  and  $1 \times 10^3$ ).

The DNA/MVA vaccine controlled the infection, rapidly reducing viral loads to near or below 1000 copies of viral RNA per milliliter of blood. Containment, rather than prevention of infection, affords the opportunity to establish a chronic infection (H.L. Robinson *et al.* 1999 *Nat Med* 5:526). By rapidly reducing viral loads, a multiprotein DNA/MVA vaccine will extend the prospect for long-term non-progression and limit HIV transmission. (J.W. Mellors *et al.* 1996 *Science* 272:1167; T.C. Quinn *et al.* 2000 *N Engl J Med* 342:921).

## EXAMPLE 2

### MVA Expressing Modified HIV Env, Gag, and Pol Genes

This disclosure describes the construction of a modified vaccinia Ankara (MVA) recombinant virus, MVA/HIV clade B recombinant virus expressing the HIV strain ADA env and the HXB2 gag pol (MVA/HIV ADA env + HXB2 gag pol). For amplification, the lab name of MVA/HIV 48 will be used, which denotes the plasmid from which the construct comes.

The HIV *gag-pol* genes were derived from the Clade B infectious HXB2 virus. The *gag-pol* gene was truncated so that most of the integrase coding sequences were removed and amino acids 185, 266, and 478 were mutated to inactivate reverse transcriptase, inhibit strand transfer activity, and inhibit the RNaseH activity, respectively. The Clade B CCR5 tropic envelope gene was derived from the primary ADA isolate; TTTTNT sequences were mutated without changing coding capacity to prevent premature transcription



termination and the cytoplasmic tail was truncated in order to improve surface expression, immunogenicity, and stability of the MVA vector. The HIV genes were inserted into a plasmid transfer vector so that *gag-pol* gene was regulated by the modified H5 early/late vaccinia virus promoter and the *env* gene was regulated by the newly designed early/late Psyn II promoter to provide similar high levels of expression. A self-deleting GUS reporter gene was included to allow detection and isolation of the recombinant virus. The HIV genes were flanked by MVA sequences to allow homologous recombination into the deletion 3 site so that the recombinant MVA would remain TK positive for stability and high expression in resting cells. The recombinant MVA was isolated and shown to express abundant amounts of *gag-pol-env* and to process *gag*. Production of HIV-like particles was demonstrated by centrifugation and by electron microscopy. The presence of *env* in the HIV-like particles was demonstrated by immunoelectron microscopy.

**Table of Sequences**

| Description            | SEQ ID NO | FIG. NO |
|------------------------|-----------|---------|
| pLW-48                 | 1         | A       |
| pLW-48                 | 1         | B       |
| Psyn II promoter       | 2         | B       |
| ADA envelope truncated | 3         | B       |
| PmH5 promoter          | 4         | B       |
| HXB2 <i>gag pol</i>    | 5         | B       |

#### Plasmid Transfer Vector

The plasmid transfer vector used to make the MVA recombinant virus, pLW-48, (Figure C) by homologous recombination was constructed as follows:

1. From the commercially obtained plasmid, pGem-4Z (Promega), flanking areas on either side of deletion III, designated flank 1 and flank 2, containing 926 and 520 base pairs respectively, were amplified by PCR from the MVA strains of vaccinia virus. Within these flanks, a promoter, the mH5, which had been modified from the originally published sequence by changing two bases that had been shown by previously published work to increase the expression of the cloned gene, was added.

2. A clade B gag pol (Figure D) was truncated so that the integrase was removed and was cloned into the plasmid so that it was controlled by the mH5 promoter. This gene contained the complete HXB2 sequence of the gag. The pol gene has reverse transcriptase safety mutations in amino acid 185 within the active site of RT, in amino acid 266 which inhibits strand transfer activity, and at amino acid 478 which inhibits the RNaseH activity. In addition, the integrase gene was deleted past EcoRI site.

3. A direct repeat of 280 basepairs, corresponding to the last 280 base pairs of MVA flank 1, was added after flank 1.

4. The p11 promoter and GUS reporter gene were added between the two direct repeats of flank 1 so that this screening marker could initially be used for obtaining the recombinant virus, yet deleted out in the final recombinant virus (Scheiflinger, F. *et al.* 1998 *Arch Virol* 143:467-474; Carroll, M.W. and B. Moss 1995 *BioTechniques* 19:352-355).

5. A new promoter, Psyn II, was designed to allow for increased expression of the ADA env. The sequence of this new early/late promoter is given in Figure E.

6. A truncated version of the ADA envelope with a silent 5TNT mutation was obtained by PCR and inserted in the plasmid under the control of the Psyn II promoter. The envelope was truncated in the cytoplasmic tail of the gp41 gene, deleting 115 amino acids of the cytoplasmic tail. This truncation was shown to increase the amount of envelope protein on the surface of infected cells and enhance immunogenicity of the envelope protein in mice, and stability of the recombinant virus in tissue culture.

#### Recombinant MVA Construction

1. MVA virus, which may be obtained from ATCC Number VR-1508, was plaque purified three times by terminal dilutions in chicken embryo fibroblasts (CEF), which were made from 9 day old SPF Premium SPAFAS fertile chicken eggs, distributed by B and E Eggs, Stevens, PA.

2. Secondary CEF cells were infected at an MOI of 0.05 of MVA and transfected with 2 µg of pLW-48, the plasmid described above. Following a two day incubation at 37°C, the virus was harvested, frozen and thawed 3x, and plated out on CEF plates.

3. At 4 days, those foci of infection that stained blue after addition of X-gluc substrate, indicating that recombination had occurred between the plasmid and the infecting

virus, were picked and inoculated on CEF plates. Again, those foci that stained blue were picked.

4. These GUS containing foci were plated out in triplicate and analyzed for GUS staining (which we wanted to now delete) and ADA envelope expression. Individual foci were picked from the 3rd replicate plates of those samples that had about equal numbers of mixed populations of GUS staining and nonstaining foci as well as mostly envelope staining foci.

5. These foci were again plated out in triplicate, and analyzed the same way. After 5 passages, a virus was derived which expressed the envelope protein but which had deleted the GUS gene because of the double repeat. By immunostaining, this virus also expressed the gag pol protein.

#### Characterization of MVA Recombinant Virus, MVA/HIV 48

1. Aliquots of MVA/HIV 48 infected cell lysates were analyzed by radioimmunoprecipitation and immunostaining with monoclonal antibodies for expression of both the envelope and gag pol protein. In both of these tests, each of these proteins was detected.

2. The recombinant virus was shown to produce gag particles in the supernatant of infected cells by pelleting the <sup>35</sup>S-labeled particles on a 20% sucrose cushion.

3. Gag particles were also visualized both outside and budding from cells as well as within vacuoles of cells in the electron microscope in thin sections. These gag particles had envelope protein on their surface.

Unless otherwise indicated, all nucleotide sequences determined by sequencing a DNA molecule herein were determined using an automated DNA sequencer, and all amino acid sequences of polypeptides encoded by DNA molecules determined herein were predicted by translation of a DNA sequence determined as above. Therefore, as is known in the art for any DNA sequence determined by this automated approach, any nucleotide sequence determined herein may contain some errors. Nucleotide sequences determined by automation are typically at least about 90% identical, more typically at least about 95% to at least about 99.9% identical to the actual nucleotide sequence of the sequenced DNA molecule. The actual sequence can be more precisely determined by other approaches including manual DNA sequencing methods well known in the art. As is also known in the art, a single insertion or deletion in a determined nucleotide sequence compared to the

actual sequence will cause a frame shift in translation of the nucleotide sequence such that the predicted amino acid sequence encoded by a determined nucleotide sequence will be completely different from the amino acid sequence actually encoded by the sequenced DNA molecule, beginning at the point of such an insertion or deletion.

### Summary

In summary, we have made a recombinant MVA virus, MVA/HIV 48, which has high expression of the ADA truncated envelope and the HXB2 gag pol. The MVA recombinant virus is made using a transiently expressed GUS marker that is deleted in the final virus. High expression of the ADA envelope is possible because of a new hybrid early/late promoter, Psyn II. In addition, the envelope has been truncated because we have shown truncation of the envelope enhances the amount of protein on the surface of the infected cells, and hence enhances immunogenicity; stability of the recombinant is also enhanced. The MVA recombinant makes gag particles which has been shown by pelleting the particles through sucrose and analyzing by PAGE. Gag particles with envelope protein on the surface have also been visualized in the electron microscope.

### EXAMPLE 3

#### Additional Modified or Synthetic Promoters Designed for Gene Expression in MVA Or Other Poxviruses

Additional modified or synthetic promoters were designed for gene expression in MVA or other poxviruses. Promoters were modified to allow expression at early and late times after infection and to reduce possibility of homologous recombination between identical sequences when multiple promoters are used in same MVA vector. Promoters are placed upstream of protein coding sequence.

#### **m7.5 promoter (SEQ ID NO:10):**

CGCTTTTATAGTAAGTTTTTCACCCATAAATAATAATACAATAATTAATTTCT  
CGTAAAAATTGAAAAACTATTCTAATTTATTGCACGGT

#### **Psyn II promoter (SEQ ID NO:2):**

TAAAAAATGAAAAAATATTCTAATTTATAGGACGGTTTTGATTTTCTTTTTTTCT  
ATGCTATAAATAATAAATA

**Psyn III promoter (SEQ ID NO:11):**

TAAAAATTGAAAAAATATTCTAATTTATAGGACGGTTTTGATTTTCTTTTTTTCT  
ATACTATAAATAATAAATA

**Psyn IV promoter (SEQ ID NO:12):**

TAAAAATTGAAAAACTATTCTAATTTATAGGACGGTTTTGATTTTCTTTTTTTCT  
ATACTATAAATAATAAATA

**Psyn V promoter (SEQ ID NO:13):**

AAAAAATGATAAAGTAGGTTTCAGTTTTATTGCTGGTTTAAAATCACGCTTTCGA  
GTAAAAACTACGAATATAAAT

**EXAMPLE 4****Tables A-F****Table A: MVA/48 immunization – guinea pigs.**

Groups of guinea pigs were immunized at days 0 and 30 with  $1 \times 10^8$  infectious units of MVA/48 by either the intramuscular (IM) or intradermal (ID) route. As a control another group was immunized IM with the same dose of non-recombinant MVA. Sera taken before as well as after each immunization was analyzed for neutralizing activity against HIV-1-MN. Titers are the reciprocal serum dilution at which 50% of MT-2 cells were protected from virus-induced killing. Significant neutralizing activity was observed in all animals after the second immunization with MVA/48 (day 49).

**Table B: Frequencies of HIV-1 gag-specific T cells following immunization of mice with MVA/48.**

Groups of BalbC mice were immunized at days 0 and 21 with  $1 \times 10^7$  infectious units of MVA/48 by one of three routes: intraperitoneal (IP), intradermal (ID), or intramuscular (IM). A control group was immunized with non-recombinant MVA. At 5 weeks after the last immunization, splenocytes were prepared and stimulated *in vitro* with an immunodominant peptide from HIV-1 p24 for 7 days. The cells were then mixed either with peptide-pulsed P815 cells or with soluble peptide. Gamma interferon-producing cells were enumerated in an ELISPOT assay. A value of >500 was assigned to wells containing too many spots to count. Strong T cell responses have been reported in mice immunized IP



with other viruses. In this experiment, IP immunization of mice with MVA/48 elicited very strong HIV-1 gag-specific T cell responses.

Table C: DNA prime and MVA/48 boost – total ELISPOTS per animal.

Ten rhesus macaques were primed (weeks 0 and 8) with a DNA vaccine expressing HIV-1 antigens including Ada envelope and HXB2 gagpol. At week 24 the animals were boosted intramuscularly with  $1 \times 10^8$  infectious units of MVA/48. Fresh peripheral blood mononuclear cells (PBMC) were analyzed for production of gamma interferon in an ELISPOT assay as follows: PBMC were incubated for 30-36 hours in the presence of pools of overlapping peptides corresponding to the individual HIV-1 antigens in the vaccines. The total number of gamma interferon-producing cells from each animal is shown in the table. T cell responses to DNA vaccination were limited (weeks 2-20). However, boosting with MVA/48 resulted in very strong HIV-1-specific T cell responses in all animals (week 25).

Table D: Antibody response following immunization of macaques with MVA/SHIV KB9.

Groups of rhesus macaques were immunized with  $2 \times 10^8$  infectious units of MVA/SHIV-KB9 at weeks 0 and 4 by one of several routes: Tonsillar, intradermal (ID), or intramuscular (IM). Another group was immunized with non-recombinant MVA using the same routes. Serum samples from 2 weeks after the second immunization were analyzed for binding to KB9 envelope protein by ELISA and for neutralization of SHIV-89.6P and SHIV-89.6. In the ELISA assay, soluble KB9 envelope protein was captured in 96 well plates using an antibody to the C-terminus of gp120. Serial dilutions of sera were analyzed and used to determine the endpoint titers. Neutralization of SHIV-89.6P and SHIV-89.6 was determined in an MT-2 cell assay. Titers are the reciprocal serum dilution at which 50% of the cells were protected from virus-induced killing. In *in vitro* neutralization assays, SHIV-89.6P and SHIV-89.6 are heterologous, i.e. sera from animals infected with one of the viruses does not neutralize the other virus. Thus, two immunizations with MVA/SHIV-KB9 elicited good ELISA binding antibodies in all animals and neutralizing antibodies to the homologous virus (SHIV-89.6P) in some animals. In addition, heterologous neutralizing antibodies were observed in a subset of animals.

Table E: Frequencies of gag CM-9-specific CD3/CD8 T cells following immunization of macaques with MVA/SHIV-KB9.

Groups of MamuA\*01 positive rhesus macaques were immunized with  $2 \times 10^8$  infectious units of MVA/SHIV-KB9 at weeks 0 and 4 by one of several routes: tonsilar, intradermal (ID), or intramuscular (IM). Another group was immunized with non-recombinant MVA. The frequencies of CD3+/CD8+ T cells that bound tetrameric complex containing the SIV gag-specific peptide CM9 were determined by flow cytometry at various times after each immunization. Time intervals were as follows: 1a, 1b, and 1d were one, two, and four weeks after the first immunization, respectively; 2a, 2b, 2c, and 2d were one, two, three, and twelve weeks after the second immunization, respectively. Values above background are shown in bold face. Strong SIV gag-specific responses were observed after a single immunization with MVA/SHIV-KB9 in all immunized animals. Boosting was observed in most animals following the second immunization. In addition, measurable tetramer binding was still found twelve weeks after the second immunization.

Table F: Frequencies of specific T cells following immunization of macaques with MVA/SHIV KB9.

Groups of macaques were immunized with MVA/SHIV-KB9 as described above. MVA/SHIV-KB9 expresses 5 genes from the chimeric virus, SHIV-89.6P: envelope, gag, polymerase, tat, and nef. Thus, the frequencies of T cells specific for each of the 5 antigens was analyzed using pools of peptides corresponding to each individual protein. Fresh PBMC were stimulated with pools of peptides for 30-36 hours in vitro. Gamma interferon-producing cells were enumerated in an ELISPOT assay. The total number of cells specific for each antigen is given as "total # spots". In addition, the number of responding animals and average # of spots per group is shown. PBMC were analyzed at one week after the first immunization (1a) and one week after the second immunization (2a). Another group of 7 animals was immunized with non-recombinant MVA. In these animals, no spots above background levels were detected. Thus, a single immunization with MVA/SHIV-KB9 elicited strong SHIV-specific T cell responses in all animals. Gag and envelope responses were the strongest; most animals had responses to gag, all animals had responses to envelope. The Elispot responses were also observed after the second immunization with MVA/SHIV-KB9, albeit at lower levels. At both times, the rank order of responses was: tonsilar > ID > IM. We show good immune response to nef and some immune response to tat.

TABLE A

MVA/48 immunization – guinea pigs  
HIV-MN neutralizing antibody - reciprocal titer

| Animal # | Group  | Route | day 0 | Day 4<br>MVA #1 | day 30 | day 33<br>MVA#2 | day 49 |
|----------|--------|-------|-------|-----------------|--------|-----------------|--------|
| 885      | MVA    | I.M.  | <20   | I.M.            | 31     | I.M.            | 24     |
| 891      | "      | "     | <20   | "               | 85     | "               | <20    |
| 882      | MVA/48 | I.M.  | <20   | I.M.            | <20    | I.M.            | 5,524  |
| 883      | "      | "     | <20   | "               | 68     | "               | 691    |
| 886      | "      | "     | <20   | "               | <20    | "               | 4,249  |
| 890      | "      | "     | <20   | "               | 180    | "               | 89     |
| 879      | MVA/48 | I.D.  | <20   | I.D.            | <20    | I.D.            | 817    |
| 881      | "      | "     | <20   | "               | <20    | "               | 234    |
| 888      | "      | "     | <20   | "               | 24     | "               | 112    |
| 889      | "      | "     | <20   | "               | 22     | "               | 376    |

TABLE B

Frequencies of HIV-gag-specific T cells following immunization of mice  
with MVA/48

| Group       | P815 cells + gag peptide |      | gag peptide |      | no stimulation |   |
|-------------|--------------------------|------|-------------|------|----------------|---|
|             | 0                        | 2    | 0           | 4    | 1              | 2 |
| MVA control | 0                        | 2    | 0           | 4    | 1              | 2 |
| MVA/48 (IP) | >500                     | >500 | >500        | >500 | 8              | 8 |
| MVA/48 (ID) | 12                       | 5    | 49          | 33   | 4              | 2 |
| MVA/48 (IM) | 22                       | 18   | 66          | 49   | 12             | 8 |

**TABLE C**

**DNA prime and MVA/48 boost  
Total ELISPOTS per Animal**

| <b>Animal #</b> | <b>WEEKS</b>   |          |          |                       |                       |                       |                       |
|-----------------|----------------|----------|----------|-----------------------|-----------------------|-----------------------|-----------------------|
|                 | <b>-2</b>      | <b>2</b> | <b>6</b> | <b>10<sup>2</sup></b> | <b>14<sup>2</sup></b> | <b>20<sup>2</sup></b> | <b>25<sup>2</sup></b> |
| <b>RLw</b>      | 4              | 731*     | <        | 47                    | 43                    | 50                    | 3905                  |
| <b>RVI</b>      | 5              | 997*     | <        | <                     | <                     | 8                     | 205                   |
| <b>Roa</b>      | < <sup>1</sup> | <        | 1        | <                     | <                     | <                     | 245                   |
| <b>RHc</b>      | <              | <        | <        | <                     | <                     | <                     | 535                   |
| <b>Ryl</b>      | <              | <        | <        | <                     | <                     | <                     | 4130                  |
| <b>RQk</b>      | <              | 46       | <        | <                     | <                     | <                     | 630                   |
| <b>RDr</b>      | <              | <        | <        | 14                    | <                     | <                     | 1965                  |
| <b>RZc</b>      | <              | 5        | <        | 58                    | <                     | <                     | 925                   |
| <b>RSf</b>      | <              | 118      | <        | <                     | <                     | 20                    | 5570                  |
| <b>Ras</b>      | <              | 69       | <        | <                     | <                     | <                     | 1435                  |
| <b>Total</b>    | 9              | 1966     | 1        | 119                   | 43                    | 78                    | 19545                 |
| <b>Geo Mean</b> | 4.5            | 105.3    | 1.0      | 33.7                  | 43.0                  | 20.0                  | 1147.7                |

DNA primes were at 0 and 8 weeks and MVA/48 boost was at 24 weeks

<sup>1</sup> < = Background (2x the number of ELISPOTs in the unstimulated control + 10)

<sup>2</sup> Costimulatory antibodies were added to the ELISPOT incubations

\* Animals from this bleed date exhibited higher than usual ELISPOTs.

TABLE D

## Antibody response following immunization of macaques with MVA/SHIV KB9

| Animal # | Route   | KB9 env     | KB9 env elisa |          | SHIV-89.6 | SHIV-89.6P | SHIV-89.6     | SHIV-89.6P    |
|----------|---------|-------------|---------------|----------|-----------|------------|---------------|---------------|
|          |         | ELISA titer | average       | std dev. | Nab titer | Nab titer  | # pos animals | # pos animals |
| 598      | tonsil  | 25,600      | 31,086        | 20,383   | <20       | <20        | 3             | 2             |
| 601      | "       | 51,200      |               |          | <20       | <20        |               |               |
| 606      | "       | 25,600      |               |          | <20       | <20        |               |               |
| 642      | "       | 51,200      |               |          | 75        | 31         |               |               |
| 646      | "       | 51,200      |               |          | 61        | 48         |               |               |
| 653      | "       | 6,400       |               |          | <20       | <20        |               |               |
| 654      | "       | 6,400       |               |          | 22        | <20        |               |               |
| 602      | i.d.    | 25,600      | 18,800        | 15,341   | 38        | <20        | 2             | 4             |
| 604      | "       | 12,800      |               |          | <20       | 262        |               |               |
| 608      | "       | 3,200       |               |          | 20        | 66         |               |               |
| 637      | "       | 12,800      |               |          | <20       | 35         |               |               |
| 638      | "       | 51,200      |               |          | <20       | <20        |               |               |
| 645      | "       | 25,600      |               |          | <20       | <20        |               |               |
| 647      | "       | 12,800      |               |          | 32        | 162        |               |               |
| 650      | "       | 6,400       |               |          | <20       | <20        |               |               |
| 599      | i.m.    | 6,400       | 17,000        | 16,516   | <20       | <20        | 0             | 3             |
| 600      | "       | 6,400       |               |          | <20       | 29         |               |               |
| 609      | "       | 6,400       |               |          | <20       | <20        |               |               |
| 639      | "       | 51,200      |               |          | <20       | 85         |               |               |
| 640      | "       | 12,800      |               |          | <20       | <20        |               |               |
| 641      | "       | 25,600      |               |          | <20       | 41         |               |               |
| 649      | "       | 1,600       |               |          | <20       | <20        |               |               |
| 651      | "       | 25,600      |               |          | 20        | <20        |               |               |
| 603      | Control | <100        | <100          |          | <20       | <20        | 0             | 0             |
| 605      | "       | <100        |               |          | <20       | <20        |               |               |
| 607      | "       | <100        |               |          | <20       | <20        |               |               |
| 643      | "       | <100        |               |          | <20       | <20        |               |               |
| 644      | "       | <100        |               |          | <20       | <20        |               |               |
| 648      | "       | <100        |               |          | <20       | <20        |               |               |
| 652      | "       | <100        |               |          | <20       | <20        |               |               |



**TABLE E**

**Frequencies of gag CM9-specific CD3/CD8 T cells following immunization of macaques with  
MVA/SHIV KB9**

| Animal # | Route  | Virus    | pre-bleed | 1a    | 1b    | 1d    | 2a    | 2b    | 2c    | 2d    |
|----------|--------|----------|-----------|-------|-------|-------|-------|-------|-------|-------|
| 598      | Tonsil | MVA/K B9 | 0.018     | 0.41  | 0.79  | 0.25  | 2.64  | 1.13  | 0.51  | 0.21  |
| 601      | "      | "        | 0.071     | 0.34  | 0.38  | 0.27  | 0.83  | 0.7   | 0.36  | 0.039 |
| 646      | "      | "        | 0.022     | 0.68  | 0.76  | 0.43  | 1.12  | 0.91  | 0.53  | 0.15  |
| 653      | "      | "        | 0.041     | 0.69  | 0.85  | 0.53  | 0.68  | 0.49  | 0.47  | 0.3   |
| 648      | "      | MVA      |           | 0.033 | 0.039 |       | 0.022 | 0.058 | 0.033 | 0.013 |
| 602      | i.d.   | MVA/K B9 | 0.019     | 0.17  | 0.92  | 0.5   | 0.95  | 0.59  | 0.5   | 0.2   |
| 604      | "      | "        | 0.013     | 0.11  | 0.38  | 0.32  | 0.44  | 0.38  | 0.19  | 0.25  |
| 650      | "      | "        | 0.095     | 0.17  | 0.6   | 0.23  | 2.87  | 1.12  | 0.9   | 0.16  |
| 647      | "      | "        | 0.032     | 0.22  | 0.38  | 0.14  | 0.84  | 0.91  | 0.34  | 0.17  |
| 652      | "      | MVA      |           | 0.041 | 0.038 | 0.059 | 0.025 | 0.022 | 0.026 | 0.055 |
| 599      | i.m.   | MVA/K B9 |           | 0.081 | 0.31  | 0.082 |       | 0.12  | 0.054 | 0.11  |
| 600      | "      | "        | 0.034     | 0.15  | 0.41  | 0.17  | 0.29  | 0.27  | 0.16  | 0.049 |
| 649      | "      | "        | 0.00486   | 0.35  | 1.34  | 0.56  | 2.42  | 0.77  | 0.69  | 0.22  |
| 651      | "      | "        | 0.049     | 0.12  | 0.69  | 0.25  | 1.01  | 0.32  | 0.24  | 0.22  |
| 603      | "      | MVA      |           | 0.024 | 0.087 | 0.073 |       | 0.082 | 0.027 | 0.17  |

TABLE F

Frequencies of specific T cells following immunization of macaques with MVA/SHIV KB9

| Study groups | Gag specific         |               |                 |                      | Tat specific  |                 |                      |               | Nef specific    |                      |             |                 | Env specific         |                      |       | Total |
|--------------|----------------------|---------------|-----------------|----------------------|---------------|-----------------|----------------------|---------------|-----------------|----------------------|-------------|-----------------|----------------------|----------------------|-------|-------|
|              | # responding animals | Total # spots | average # spots | # responding animals | total # spots | average # spots | # responding animals | total # spots | average # spots | # responding animals | total spots | Average # spots | # responding animals | # responding animals | Total |       |
| tonsil 1a    | 4/6                  | 1325          | 221             | 0/6                  | 0             | 0               | 3/6                  | 195           | 33              | 6/6                  | 8760        | 1460            | 6/6                  | 6/6                  |       |       |
| tonsil 2a    | 5/6                  | 1405          | 234             | 0/6                  | 0             | 0               | 1/6                  | 560           | 93              | 6/6                  | 4485        | 748             | 6/6                  | 6/6                  |       |       |
| i.d. 1a      | 7/7                  | 1335          | 191             | 0/7                  | 0             | 0               | 2/7                  | 215           | 31              | 7/7                  | 7320        | 1046            | 7/7                  | 7/7                  |       |       |
| i.d. 2a      | 4/7                  | 755           | 108             | 0/7                  | 0             | 0               | 1/7                  | 55            | 8               | 7/7                  | 2700        | 386             | 7/7                  | 7/7                  |       |       |
| i.m. 1a      | 7/7                  | 925           | 132             | 1/7                  | 60            | 9               | 3/7                  | 180           | 26              | 7/7                  | 5490        | 784             | 7/7                  | 7/7                  |       |       |
| i.m. 2a      | 4/7                  | 250           | 36              | 0/7                  | 0             | 0               | 0/7                  | 0             | 0               | 6/7                  | 2205        | 315             | 6/7                  | 6/7                  |       |       |

15

\*\*\*\*\*

While the present invention has been described in some detail for purposes of clarity and understanding, one skilled in the art will appreciate that various changes in form and detail can be made without departing from the true scope of the invention. All patents, patent applications and publications referred to above are hereby incorporated by reference.

WHAT IS CLAIMED IS:

1. A pharmaceutical composition comprising a recombinant MVA virus expressing an HIV *env*, *gag*, and *pol* gene or modified gene thereof for production of an HIV Env, Gag, and Pol antigen by expression from said recombinant MVA virus, wherein said HIV *env* gene is modified to encode an HIV Env protein composed of gp120 and the membrane-spanning and ectodomain of gp41 but lacking part or all of the cytoplasmic domain of gp41, and a pharmaceutically acceptable carrier.
2. The pharmaceutical composition of claim 1, wherein said HIV *pol* gene or modified gene thereof is modified to inactivate reverse transcriptase and integrase.
3. The pharmaceutical composition of claim 1, wherein said HIV *env*, *gag*, or *pol* gene or modified gene thereof is taken from clade A.
4. The pharmaceutical composition of claim 1, wherein said HIV *env*, *gag*, or *pol* gene or modified gene thereof is taken from clade B.
5. The pharmaceutical composition of claim 1, wherein said HIV *env*, *gag*, or *pol* gene or modified gene thereof is taken from clade C.
6. The pharmaceutical composition of claim 1, wherein said HIV *env*, *gag*, or *pol* gene or modified gene thereof is taken from clade D.
7. The pharmaceutical composition of claim 1, wherein said HIV *env*, *gag*, or *pol* gene or modified gene thereof is taken from clade E.
8. The pharmaceutical composition of claim 1, wherein said HIV *env*, *gag*, or *pol* gene or modified gene thereof is taken from clade F.
9. The pharmaceutical composition of claim 1, wherein said HIV *env*, *gag*, or *pol* gene or modified gene thereof is taken from clade G.
10. The pharmaceutical composition of claim 1, wherein said HIV *env*, *gag*, or *pol* gene or modified gene thereof is taken from clade H.
11. The pharmaceutical composition of claim 1, wherein said HIV *env*, *gag*, or *pol* gene or modified gene thereof is taken from clade J.
12. The pharmaceutical composition of claim 1 wherein said HIV *env*, *gag*, or *pol* gene or modified gene thereof is inserted at the site of deletion III within the MVA genome.

13. The pharmaceutical composition of claim 1 wherein said HIV *env*, *gag*, or *pol* gene or modified gene thereof is under transcriptional initiation regulation of a H5-like early/late vaccinia virus promoter.

14. The pharmaceutical composition of claim 1 wherein recombinant MVA virus additionally expresses an additional HIV gene or modified gene thereof for production of an HIV antigen by expression from said recombinant MVA virus, wherein said additional HIV gene is a member selected from the group consisting of *vif*, *vpr*, *tat*, *rev*, *vpu*, and *nef*.

15. MVA/HIV48 comprising SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, and SEQ ID NO:5.

16. pLW-48 having SEQ ID NO:1.

17. A plasmid transfer vector having the sequence of pLW-48 (SEQ ID NO:1) excluding the HIV *env*, *gag*, and *pol* genes.

18. pLW-48 (SEQ ID NO:1) wherein the HIV *env*, *gag*, and *pol* genes have a sequence taken from another clade.

19. A poxvirus comprising a promoter selected from the group consisting of m7.5 promoter having SEQ ID NO:10, Psyn II promoter having SEQ ID NO:2, Psyn III promoter having SEQ ID NO:11, Psyn IV promoter having SEQ ID NO:12, and Psyn V promoter having SEQ ID NO:13.


20. A method of boosting a CD8<sup>+</sup> T cell immune response to an HIV Env, Gag, or Pol antigen in a primate, the method comprising provision in the primate of a composition of any of claims 1-15, whereby a CD8<sup>+</sup> T cell immune response to the antigen previously primed in the primate is boosted.

21. A method of inducing a CD8<sup>+</sup> T cell immune response to an HIV Env, Gag, or Pol antigen in a primate, the method comprising provision in the primate of a composition of any of claims 1-15, whereby a CD8<sup>+</sup> T cell immune response to the antigen in the primate is induced.

22. A method of inducing a CD8<sup>+</sup> T cell immune response to an HIV Env, Gag, or Pol antigen in a primate, the method comprising provision in the primate of a priming composition comprising nucleic acid encoding said antigen and then provision in the primate of a boosting composition which comprises any of claims 1-15, whereby a CD8<sup>+</sup> T cell immune response to the antigen is induced.




23. The method of any of Claims 20-22, wherein the primate is a human.
24. The method of any of Claims 20-22, wherein administration of the combinant MVA virus is by needleless injection.
25. The method of Claim 22, wherein the priming composition comprises plasmid DNA encoding said antigen.
26. A method of making a composition of any of claims 1-15 comprising preparing a plasmid transfer vector encoding an HIV *env*, *gag*, and *pol* gene or modified portion thereof, wherein said HIV *env* gene is modified to encode an HIV Env protein composed of gp120 and the membrane-spanning and ectodomain of gp41 but lacking part all of the cytoplasmic domain of gp41, and recombining said plasmid transfer vector with a MVA virus to produce a composition of any of claims 1-15.



*FIG. 1*

(Figure I)



**FIG. 2**

(Figure II)

| Chemokine<br>coreceptor used | PBMC<br>replication | Macrophage<br>replication | T-cell-line<br>replication | REplicative<br>phenotype | Syncytium-inducing<br>phenotype |
|------------------------------|---------------------|---------------------------|----------------------------|--------------------------|---------------------------------|
| X4                           | +                   | -                         | +                          | Rapid/high               | ++                              |
| R5                           | +                   | +                         | -                          | Slow/low                 | -                               |
| R5/X4                        | +                   | +                         | +                          | Rapid/high               | +                               |

FIG. 3  
(Figure III)




FIG. 4

(Figure IV)








FIG. 5

(Figure V)



**FIG. 6**

(Figure VI)



**FIG. 7A**  
(Figure 1A)

SUBSTITUTE SHEET (RULE 26)




FIG. 7B (Figure 1B)




FIG. 8C

(Figure 2C)




FIG. 8B

(Figure 2B)





FIG. 8A


(Figure 2A)




10/63




*FIG. 8D*  
(Figure 2D)



**FIG. 8E**  
(Figure 2E)



**FIG. 9A**  
(Figure 3A)



**FIG. 9B**  
(Figure 3B)

14/63




FIG. 9C

(Figure 3C)







*FIG. 10A*  
(Figure 4A)



*FIG. 10B*  
(Figure 4B)




*FIG. 10C*  
(Figure 4C)



*FIG. 10D*


(Figure 4D)



**FIG. 11A**


(Figure 5A)

18/63



**FIG. 11B**  
(Figure 5B)

19/63



**FIG. 11C**

(Figure 5C)






FIG. 11D

(Figure 5D)

21/63

Mamu-A\*01 Gag-CM9 TETRAMER





FIG. 12

SUBSTITUTE SHEET (RULE 26)

22/63



**FIG. 13**  
(FIG. A<sub>1</sub>)

23/63

1 GAATTCCTTG GTGTCGCCCA TGGATGGTGT TATTGTATAC TGTCTAAACG CGTTAGTAAA ACATGGCGGAG  
CTTAAGCAAC CACCAGCGGT ACCTACCACA ATAACATATG ACAGATTTCG GCAATCATTT TGTACCGCTC

71 GAAATAAATC ATATAAAAA TGATTTCATG ATTAACCAT GTTGTAATA AGTCAAGAAC GTTCACATTG  
CTTTATTAG TATATTTT ACTAAAGTAC TAATTGGTA CAACACTTTT TCAGTTCTTG CAAGTGTAAC

141 GCGGACAATC TAAAAACAAT ACAGTGATTG CAGATTGGC ATATATGGAT AATGCGGTAT CCGATGTATG  
CGCTGTAG ATTTTGTTA TGCACTAAC GTCTAAACGG TATATACCTA TTACGCCATA GGCTACATAC

211 CAATTCAC TG TATAAAGA ATGATCAAG AATATCCAGA TTTGCTAATT TGATAAGAT AGATGACGAT  
GTTAAGTGAC ATATTTTCT TACATAGTTC TTATAGGTCT AAACGATTAA ACTATTCTA TCTACTGCTA

281 GACAAGACTC CACTGGTGT ATATAATTAT TTAAACCTA AAGATGCCAT TCCTGTTATT ATATCCATAG  
CTGTTCTGAG GATGACCACA TATATTAATA AAATTGGAT TTCTACGGTA AGGACAATAA TATAGGTATC

351 GAAAGGATAG AGATGTTTGT GAACTATTAA TCTCATCTGA TAAAGCGTGT GCGTGTATAG AGTTAAATTC  
CTTTCCTATC TCTACAAACA CTTGATAATT AGAGTAGACT ATTCGCACA CGACATATC TCAATTTAAG

FIG. 14 (FIG. A<sub>2</sub>)

24/63

421 ATATAAAGTA GCCATTCTTC CCATGGATGT TTCCTTTTTC ACCAAAGGAA ATGCATCATT GATTATTCTC  
TATATTTCAT CCGTAAGAAG GGTACCTACA AAGGAAAAAA TGGTTTCCTT TACGTAGTAA CTAATAAGAG

491 CTGTTTGATT TCTCTATCGA TCGGGCACCT CTCCTAAGAA GTGTAACCGA TAATAATGTT ATTATATCTA  
GACAAACTAA AGAGATAGCT ACGCCGTGGA GAGAAATTCTT CACATTGGCT ATTATTACAA TAATATAGAT

561 GACACCAGCG TCTACATGAC GAGCTTCCGA GTTCCAATTG GTTCAAGTTT TACATAAGTA TAAAGTCCGA  
CTGTGGTCCG AGATGTACTG CTCGAAGGCT CAAGTTAAC CAAGTTCAAT ATGTATTTCAT ATTTCAGGCT

631 CTATTGTTCT ATATTATATA TCGTTGTTGA TGGATCTGTG ATGCATGCAA TAGCTGATAA TAGAACTTAC  
GATAACAAGA TATAATATAT ACCAACAACT ACCTAGACAC TACGTACGTT ATCGACTATT ATCTTGAATG

701 GCAAATATTA GCAAAAATAT ATTAGACAAT ACTACAATTA ACGATGAGTG TAGATGCTGT TATTTTGAAC  
CGTTTATAAT CGTTTTATA TAATCTGTTA TGATGTTAAT TGCTACTCAC ATCTACGACA ATAAACTTG

*FIG. 15*

*(FIG. A<sub>2</sub> cont.)*



25/63

771 CACAGATTAG GATTCTTGAT AGAGATGAGA TGCTCAATGG ATCATCGTGT GATATGAACA GACATTGTAT  
GTGCTAATC CTAAGAACTA TCTCTACTCT ACGAGTTACC TAGTAGCACA CTATACTTGT CTGTAACATA

841 TATGATGAAT TTACCTGATG TAGCGGAATT TGGATCTAGT ATGTTGGGGA AATATGAACC TGACATGATT  
ATACTACTTA AATGGACTAC ATCCGCTTAA ACCTAGATCA TACAACCCCT TTATACTTGG ACTGTAATAA

911 AAGATTGCTC TTTCGGTGGC TGGGTACCAG GCGGCCCTTT CATTTGTTT TTTTCTATGC TATAAATCGT  
TTCTAACCAG AAAGCCACCG ACCCATGGTC CGCGCGGAAA GTAAAACAAA AAAAGATACG ATATTTACCA

981 ACGTCCTGTA GAAACCCCAA CCCGTGAAAT CAAAAACTC GACGGCCTGT GGGCATTAG TCTGGATCGC  
TGCAGGACAT CTTTGGGGTT GGCACATTGA GTTTTITGAG CTGCCGGACA CCCGTAAGTC AGACCTAGCG

1051 GAAAACTGTG GAATTGATCA GCGTTGCTGG GAAAGCGCGT TACAAGAAAG CCGGGCAATT GCTGTGCCAG  
CTTTTGACAC CTTAACTAGT CGCAACCACC CTTTCGGGCA ATGTTCTTTC GGCCCGTTAA CGACACGGTC

*FIG. 16*  
*(FIG. A<sub>2</sub> cont.)*

26/63

1121 GCAGTTTAA CGATCAGTTC GCCGATGCAG ATATTGTA AATGCGGGC AACGTCTGGT ATCAGCGCGA  
CGTCAAAATT GCTAGTCAAG CCGCTACGTC TATAAGCATT AATACGCCCG TTGCAGACCA TAGTCGCGCT

1191 AGTCTTTATA CCGAAAGGTT GGCAGGCCA GCGTATCGTG CTGCGTTTCG ATGCGGTCAC TCATTACGGC  
TCAGAAATAT GGCTTTCCAA CCCGTCCGGT CCGATAGCAC GACGCCAAGC TACGCCAGTG AGTAATGCCG

1261 AAAGTCTGGG TCAATAATCA GGAAGTGATG GAGCATCAGG CCGGCTATAC GCCATTGAA GCCGATGTCA  
TTTCACACCC AGTTATTAGT CCTTCACACTC CTCGTAGTCC CCGCGATATG CCGTAAACTT CCGCTACAGT

1331 CGCCGTATGT TATTGCCGGG AAAAGTGATG GTATCACCCT TTGTGTGAAC AACGAAGTGA ACTGGCAGAC  
GCGGCATACA ATAACGGCCC TTTTCACATG CATAGTGGCA AACACACTG TTGCTTGACT TGACCGTCTG

1401 TATCCCGCCG GGAATGGTGA TTACCGACGA AACGGCAAG AAAAGCAGT CTTACTTCCA TGATTCTTT  
ATAGGGCGGC CCTTACCACT AATGGCTGCT TTGCGCGTTC TTTTTCGTCA GAATGAAGGT ACTAAGAAA

1471 AACTATGCCG GAATCCATCG CAGCGTAATG CTCTACACCA CGCCGAACAC CTGGGTGGAC GATATCACCG  
TTGATACCGC CTTAGGTAGC GTCGCATTAC GAGATGTGGT GCGGCTTGTG GACCCACCTG CTATAGTGCC

FIG. 17 (FIG. A<sub>2</sub> cont.)

27/63

1541 TGGTGACGCA TGTGCGGCAA GACTGTAACC ACGCGTCTGT TGA CTGGCAG GTGGTGGCCA ATGCTGATGT  
ACCACTGCCG ACAGCGCGGT CTGACATTGG TGGCAGACA ACTGACCGTC CACCACCGGT TACCACTACA

1611 CAGCGTTGAA CTGCGTGATG CCGATCAACA GGTGGTTCCA ACTGGACAAG GCACTAGCGG GACTTTGCCAA  
GTCCCAACTT GACGCACTAC GCCTAGTTGT CCACCAACGT TGACCTGTTC CGTGATCGCC CTGAAACGTT

1681 GTGCTGAATC CGCACCTCTG GCAACCGGGT GAAGTTATC TCTATGAACT GTGCGTCACA GCCAAAAGCC  
CACCACCTAG GCGTGGAGAC CGTTGGCCCA CTTCCAATAG AGATACTTGA CACGCAGTGT CGGTTTTCGG

1751 AGACAGAGTG TGATATCTAC CCGCTTCGGG TCGGCATCCG GTCAGTGGCA GTGAAGGGCG AACAGTTCCT  
TCTGTCTCAC ACTATAGATG GCGGAAGCGC AGCCGTAGGC CAGTCACCGT CACTTCCCGC TTGTCAAGGA

1821 GATTAACCAC AAACCGTTCT ACTTTACTGG CTTTGGTCGT CATGAAGATG CGGACTTGCG TGGCAAAGGA  
CTAATTGGTG TTTGGCAAGA TGAATGACC GAAACCAGCA GTACTTCTAC GCCTGAACGC ACCGTTTCCT

1891 TTCCGATAACG TGCTGATGGT GCACGACCAC GCATTAAATGG ACTGGATTGG GGCCAACCTCC TACCGTACCT  
AAGCTATTGC ACGACTACCA CGTGCTGGTG CGTAATTACC TGACCTAACC CCGGTTGAGG ATGGCATGGA

FIG. 18 (FIG. A<sub>2</sub> cont.)

28/63

1961 CGCATTACCC TTACGCTGAA GAGATGCTCG ACTGGGCAGA TGAACATGGC ATCGTGCTGA TTGATGA AAC  
GCGTAATGGG AATCGGACTT CTCTACGAGC TGACCCCGTCT ACTGTACCG TAGCACCACT AACTACTTTG

2031 TGCTGCTGTC GGCTTTAACC TCTCTTTAGG CATTGGTTTC GAAGCGGGCA ACAAGCCGAA AGAACTGTAC  
ACGACGACAG CCGAAATTGG AGAGAAATCC GTAACCAAAG CTTCGCCCGT TGTTCGGCTT TCTTGACATG

2101 AGCCAAGAGG CAGTCAACGG GGAACTCAG CAAGCGGACT TACAGCGGAT TAAAGAGCTG ATAGCGCGTG  
TCGCTTCTCC GTCAGTTGCC CCTTTGAGTC GTTCGCCGTA ATGTCGGCTA ATTCTCGAC TATCGCGCAC

2171 ACAAAAACCA CCCAAGCGTG GTGATGTGGA GTATTGCCAA CGAACCGGAT ACCCGTCCGC AAGTGCACG  
TGTTTTTGGT GGGTTCGCAC CACTACACCT CATAACGGT GCTTGGCCCTA TGGCAGGCG TTCCACGTGC

2241 GGAATATTTC GCGCCACTGG CGGAAGCAAC GCGTAAACTC GACCCGACGC GTCCGATCAC CTGCGTCAAT  
CCTTATAAAG CCGGGTGACC GCGTTCTGTTG CGCATTTGAG CTGGGCTGCG CAGGCTAGTG GACGCAGTTA

2311 GTAATGTTCT GCGACGCTCA CACCGATACC ATCAGCGATC TCTTTGATGT GCTGTGCCCTG AACCGTTATT  
CATTACAAGA CGCTGCCAGT GTGGCTATGG TAGTCGCTAG AGAACTACA CGACACGGAC TTGGCAATAA

FIG. 19 (FIG. A<sub>2</sub> cont.)



29/63

2381 ACGGATGGTA TGTCCAAAGC GCGATTTCG AACGGCAGA GAAGTACTG GAAAAAGAAC TTCTGGCCTG  
TGCCTACCAT ACAGGTTTCG CCGCTAAACC TTGCGCGTCT CTCCATGAC CTTTCTTG AAGACCGGAC

2451 GCAGGAGAAA CTGCATCAGC CGATTATCAT CACCGAATAC GCGGTGGATA CGTAGCCGG GCTGCACTCA  
CGTCCCTCTT GACGTAGTCG GCTAATAGTA GTGGCTTATG CCGCACCTAT CCAATCGGCC CGACGTGAGT

2521 ATGTACACCG ACATGTGGAG TGAAGAGTAT CAGTGTGCAT GGCTGGATAT GTATCACCGC GTCTTTGATC  
TACATGTGGC TGTACACCTC ACTTCTCATA GTCACACGTA CCGACCTATA CATACTGGCG CAGAAACTAG

2591 GCGTCAGCGC CGTCGTCGGT GAACAGGTAT GGAATTTCCG CGATTTTGCG ACCTCGCAAG GCATATTGCG  
CGCAGTCGGC GCAGCAGCCA CTTGTCCATA CCTTAAAGCG GCTAAACGC TGGAGCGTTC CGTATAACGC

2661 CGTTGGCCGT AACAGAAAG GGATCTTCAC TCGCGACCGC AAACCGAAGT CCGCGGCTTT TCTGCTGCAA  
GCAACCGCCA TTGTTCTTTC CCTAGAAGTG AGCGTGGCG TTGGGCTTCA GCCGCCGAAA AGACGACGTT

2731 AAACGCTGGA CTGGCATGAA CTTCGGTGAA AAACCGCAGC AGGAGGCAA ACAATGAGAG CTCGGTTGTT  
TTTGGGACCT GACCGTACTT GAAGCCACTT TTTGGCGTCG TCCCTCCGTT TGTTACTCTC GAGCCAACAA

FIG. 20 (FIG. A<sub>2</sub> cont.)

30/63

2801 GATGGATCTG TGATGCATGC AATAGCTGAT AATAGAACTT ACCCAATAT TAGCAAAAT ATATTAGACA  
CTACCTAGAC ACTACGTACG TTATCGACTA TTATCTTGAA TCGGTTTATA ATCGTTTTA TATAATCTGT

2871 ATACTACAAT TAACGATGAG TGTAGATGCT GTTATTTTGA ACCACAGATT AGGATTCTTG ATAGAGATGA  
TATGATGTTA ATTGCTACTC ACATCTACGA CAATAAACT TCGTGTCTAA TCCTAAGAAC TATCTCTACT

2941 GATGCTCAAT GGATCATCGT GTGATATGAA CAGACATTGT ATTATGATGA ATTTACCTGA TGTAGCGGAA  
CTACCGAGTTA CCTAGTAGCA CACTATACTT GTCTGTAACA TAATACTACT TAAATGGACT ACATCCGCTT

3011 TTTGGATCTA GTATGTTGGG GAAATATGAA CCTGACATGA TTAAGATTGC TCTTTCGGTG GCTGGCGGCC  
AAACCTAGAT CATACAACCC CTTTATACTT GGACTGTACT AATTCTAAG AGAAAGCCAC CGACCGCCGG

3081 CGCTCGAGTA AAAAATGAAA AAATATTCTA ATTTATAGGA CGGTTTGTAT TTTCTTTTTT TCTATGCTAT  
GCGAGCTCAT TTTTACTTT TTTATAAGAT TAAATATCCT GCCAAAATA AAAGAAAAA AGATACGATA

3151 AAATAATAAA TAGCGCGCGC ACCATGAAAG TGAAGGGGAT CAGGAAGAAT TATCAGCACT TGTGAAATG  
TTTATTATT ATCGCGCGCG TGGTACTTTC ACTTCCCCTA GTCCTTCTTA ATAGTCGTGA ACACCTTTAC

FIG. 21 (FIG. A<sub>2</sub> cont.)



31/63

3221 GGGCATCATG CTCCTTGGGA TGTGATGAT CTGTAGTGCT GTAGAAAATT TGTGGGTCAC AGTTTATTAT  
CCCCGTAGTAC GAGGAACCCCT ACAACTACTA GACATCACGA CATCTTTTAA ACACCCAGTG TCAAATAATA

3291 GGGGTACCTG TGTGGAAGA AGCAACCACC ACTCTATTTT GTGCATCAGA TGCTAAAGCA TATGATACAG  
CCCCATGGAC ACACCTTTCT TCGTTGGTGG TGAGATAAAA CACGTAGTCT ACGATTTCGT ATACTATGTC

3361 AGGTACATAA TGTTTGGGCC ACACATGCCT GTGTACCCAC AGACCCCAAC CCACAAGAAG TAGTATTGGA  
TCCATGTATT ACAACCCGG TGTGTACGGA CACATGGGTG TCTGGGGTGG GGTGTTCTTC ATCATAACCT

3431 AAATGTGACA GAAATTTTA ACATGTGGAA AAATAACATG GTAGAACAGA TGCATGAGGA TATAATCAGT  
TTTACACTGT CTTTTAAAT TGTACACCCT TTTATTGTAC CATCTTGTCT ACGTACTCCT ATATTAGTCA

3501 TTATGGGATC AAAGCCTAA GCCATGTGTA AAATTAACCC CACTCTGTGT TACTTTAAAT TGCACGTATT  
AATACCCTAG TTTCGGATT CCGTACACAT TTTAATTGGG GTGAGACACA ATGAAATTTA ACGTACTAA

3571 TGAGGAATGT TACTAATATC AATAATAGTA GTGAGGGAAT GAGAGGAGAA ATAAAACT GCTCTTTCAA  
ACTCCCTTACA ATGATTATAG TTATTATCAT CACTCCCTTA CTCCTCTCTT TATTTTGA CGAGAAAGTT

*FIG. 22 (FIG. A<sub>2</sub> cont.)*

32/63

3641 TATCACCACA AGCATAAGAG ATAAGGTGAA GAAAGACTAT GCACCTTTCT ATAGACTTGA TGTAGTACCA  
ATAGTGGTGT TCGTATTCTC TATCCCACTT CTTTCTGATA CGTGAAAAGA TATCTGAAC TACATCATGGT

3711 ATAGATAATG ATAATACTAG CTATAGGTG ATAAATTGTA ATACCTCAAC CATTACACAG GCCTGTCCAA  
TATCTATTAC TATTATGATC GATATCCAAC TATTTAACAT TATGGAGTTG GTAATGTGTC CGGACACGGT

3781 AGGTATCCTT TGAGCCAAAT CCCATACATT ATTGTACCCC GGCTGGTTT GCGATTCTAA AGTGTAAGA  
TCCATAGGAA ACTCGGTAA GGGTATGTAA TAACATGGG CCGACCACAAA CGCTAAGATT TCACATTCT

3851 CAAGAAGTTC AATGGAACAG GCCCATGTAA AATGTCAGC ACAGTACAAT GTACACATGG AATTAGGCCA  
GTTCTTCAAG TTACCTTGTC CCGGTACATT TTTACAGTCG TGTCATGTTA CATGTGTACC TTAATCCGGT

3921 GTAGTGTCAA CTCAACTGCT GTTAAATGCC AGTCTAGCAG AAGAAGAGGT AGTAATTAGA TCTAGTAATT  
CATCACAGTT GAGTTGACGA CAATTACCG TCAGATCCGC TTCTTCTCCA TCATTAATCT AGATCATTA

3991 TCACAGACAA TGCAAAAAC ATAATAGTAC AGTTGAAAGA ATCTGTAGAA ATTAATTGTA CAAGAACC  
AGTGCTGTT ACGTTTTTG TATTATCATG TCAACTTTCT TAGACATCTT TAATTAACAT GTTCTGGGT

FIG. 23 (FIG. A<sub>2</sub> cont.)

33/63

4061 CAACAATACA AGGAAAAGTA TACATATAGG ACCAGGAAGA GCATTTTATA CAACAGGAGA AATAATAGGA  
GTGTTATGT TCCTTTTCAT ATGTATATCC TGGTCCTTCT CGTAAATAT GTTGTCCTCT TTATTATCCT

4131 GATAAAGAC AAGCACATTG CAACATTAGT AGAACAAAAT GGAATAACAC TTAAATCAA ATAGCTACAA  
CTATATTCTG TTCGTGTAAC GTTGTAATCA TCTTGTTTAA CCTATTGIG AAATTAGTT TATCGATGTT

4201 AATTAAAGA ACAATTGGG AATAATAAA CAATAGTCTT TAATCAATCC TCAGGAGGG ACCAGAAAT  
TTAATTCTT TGTAAACCC TTATTATTT GTTATCAGAA ATTAGTTAGG AGTCCTCCCC TGGGCTCTTA

4271 TGTAATGCAC AGTTTAAAT GTGGAGGGA ATTCTTCTAC TGTAATTCAA CAAACTGTT TAATAGTACT  
ACATTACGTG TCAAAATTAA CACCTCCCCT TAAGAAGATG ACATTAAGTT GTGTGACAA ATTATCATGA

4341 TGGAATTTTA ATGGTACTTG GAATTTAACA CAATCGAATG GTACTGAAGG AAATGACACT ATCACACTCC  
ACCTTAAAT TACCATGAAC CTAAATGT GTTAGCTTAC CATGACTTCC TTTACTGTGA TAGTGTGAGG

4411 CATGTAGAAT AAAACAAATT ATAAATATGT GGCAGGAAGT AGGAAAAGCA ATGTATGCCC CTCCCATCAG  
GTACATCTTA TTTTGTTTAA TATTATACA CCGTCCTTCA TCCTTTTCGT TACATACGGG GAGGGTAGTC

FIG. 24 (FIG. A<sub>2</sub> cont.)

34/63

4481 AGGACAAATT AGATGCTCAT CAAATATTAC AGGGCTAATA TTAACAAGAG ATGCTGGAAC TAACAGTAGT  
TCCCTGTTAA TCTACGAGTA GTTTATAATG TCCCGATTAT AATTGTTCTC TACCACCTTG ATTGTCATCA

4551 GGGTCCGAGA TCTTCAGACC TGGGGAGGA GATATGAGGG ACAATTGGAG AAGTGAATTA TATAAATATA  
CCCAGGCTCT AGAAGTCTGG ACCCCCTCCT CTATACTCCC TGTTAACCTC TTCACCTTAAT ATATTTATAT

4621 AAGTAGTAA AATTGAACCA TTAGGAGTAG CACCACCAA GGCAAAAGA AGAGTGGTGC AGAGAGAAA  
TTCATCATTT TTAACCTGGT AATCCTCATC GTGGGTGGTT CCGTTTTTCT TCTCACCACG TCTCTCTTT

4691 AAGAGCAGTG GGAACGATAG GAGCTATGTT CCTTGGGTTC TTGGGAGCAG CAGGAAGCAC TATGGGGCCA  
TTCCTCGTCAC CCTTGCTATC CTCGATACAA GGAACCCAAG AACCTTCGTC GTCCCTCGTG ATACCCCGGT

4761 GCGTCAATAA CGCTGACGGT ACAGGCCAGA CTATTATTGT CTGGTATAGT GCAACAGCAG AACAATTGTC  
CGCAGTTATT GCGACTGCCA TGTCGGGTCT GATAATAACA GACCATATCA CGTTGTCGTC TTGTTAAACG

4831 TGAGGGCTAT TGAGGGGCAA CAGCATCTGT TGCAACTCAC AGTCTGGGGC ATCAAGCAGC TCCAGGCAAG  
ACTCCCGATA ACTCCCGGTT GTCGTAGACA ACGTTGAGTG TCAGACCCCG TAGTTGCTCG AGGTCCGTC

FIG. 25 (FIG. A<sub>2</sub> cont.)



35/63

4901 AGTCCTGGCT CTGGAAAGAT ACCTAAGGA TCAACAGCTC CTAGGGATT GGGGTGCTC TGGAAACTC  
TCAGGACCGA CACCTTTCTA TGGATTCCCT AGTTGTCGAG GATCCCTAAA CCCCACGAG ACCTTTTGAG

4971 ATCTGCACCA CTGCTGTGCC TTGCAATGCT ACTTGGAGTA ATAAACTCT GGATATGATT TGGGATAACA  
TAGACGTGCT GACGACACGG AACCTTACGA TCAACCTCAT TATTTGAGA CCTATACTAA ACCCTATTGT

5041 TGACCTGGAT GGAGTGGGA AGAGAAATCG AAAATTACAC AGGCTTAATA TACACCTTAA TTGAGGAATC  
ACTGGACCTA CCTCACCCCTT TCCTTTTAGC TTTTAATGTG TCCGAATTAT ATGTGGAATT AACTCCTTAG

5111 GCAGAACCAA CAAGAAAGA ATGAACAAGA CTTATTAGCA TTAGATAAGT GGGCAAGTTT GTGGAATTGG  
CGTCTTGGTT GTTCTTTTCT TACTTGTCT GAATAATCGT AATCTATTCA CCCGTTCAAA CACCTTAACC

5181 TTTGACATAT CAAATTGGCT GTGGTATGTA AAAATCTTCA TAATGATAGT AGCAGGCTTG ATAGGTTTAA  
AAACTGTATA GTTTAACCGA CACCAATACAT TTTTAGAAGT ATTACTATCA TCCTCCGAAC TATCCAAATT

5251 CAATAGTTT TACTGTACTT TCTATAGTAA ATAGAGTTAG GCAGGGATAC TCACCATTGT CATTTCAGAC  
CTTATCAAAA ATGACATGAA AGATATCATT TATCTCAATC CGTCCCTATG AGTGTAACA GTAAAGTCTG

FIG. 26 (FIG. A<sub>2</sub> cont.)

36/63

5321 CCACCTCCCA GCCCGGAGGG GACCCGACAG GCCCGAAGGA ATCGAAGAAG AAGGTGGAGA CAGAGACTAA  
GGTGGAGGGT CGGGGCTCCC CTGGGCTGTC CGGCTTCCT TAGCTTCTTC TTCCACCTCT GTCTCTGATT

5391 TTTTATGCG GCCGCTGGTA CCAACCTAA AAATTGAAA TAAATACAAA GTTCTTGAG GTTGTGTTA  
AAAAATACGC CGCGGACCAT GGTGCGATT TTAACTTTT ATTTATGTTT CCAAGAACTC CCAACACAAT

5461 AATTGAAAGC GAGAAATAAT CATAAATAAG CCCGGGGATC CTCTAGAGTC GACACCATGG GTGCGAGAGC  
TTAACTTTCG CTCCTTATTA GTATTATTC GGGCCCCCTAG GAGATCTCAG CTGTGGTACC CACGCTCTCG

5531 GTCAGTATTA AGCGGGGGAG AATTAGATCG ATGGGAAAAA ATTCGGTTAA GCCCAGGGGG AAAGAAAAAA  
CAGTCATAAT TCGCCCCCCTC TTAATCTAGC TACCCCTTTT TAAGCCAATT CCGGTCCCCC TTTCCTTTT

5601 TATAAATTAA AACATATAGT ATGGGCAAGC AGGGAGCTAG AACGATTCCG AGTTAATCCT GGCCTGTTAG  
ATATTTAATT TTGTATATCA TACCCGTTCC TCCCTCGATC TTGCTAAGCG TCAATTAGGA CCGGACAATC

5671 AACATCAGA AGGCTGTAGA CAAATACTGG GACAGCTACA ACCATCCCTT CAGACAGGAT CAGAAGAACT  
TTTGTAATCT TCCGACATCT GTTTATGACC CTGTCGATGT TGGTAGGGA GTCTGTCTTA GTCTTCTTGA

FIG. 27 (FIG. A<sub>2</sub> cont.)



37/63

5741 TAGATCATT TATAATACAG TAGCAACCCT CTATTGTGTG CATCAAGGA TAGAGATAAA AGACACCAAG  
ATCTAGTAAT ATATTATGTC ATCGTTGGGA GATAACACAC GTAGTTTCCT ATCTCTATTT TCTGTGGTTC

5811 GAAGCTTTAG ACAAGATAGA GGAAGAGCAA AACAAAAGTA AGAAAAGC ACAGCAAGCA GCAGCTGACA  
CTTCGAAATC TGTTCATCT CTTCTCCTT TGTCTTCAT TCTTTTTCG TGTCTTCCT CGTCGACTGT

5881 CAGGACACAG CAATCAGGTC AGCCAAAATT ACCCTATAGT GCAGAACATC CAGGGGCAA TGGTACATCA  
GTCCTGTGTC GTTAGTCCAG TCGGTTTAA TGGGATATCA CGTCTGTAG GTCCCCGTTT ACCAIGTAGT

5951 GGCCATATCA CCTAGAACTT TAAATGCATG GGTAAGTA GTAGAAGAGA AGGCTTTCAG CCCAGAAGTG  
CCGGTATAGT GGATCTTGAA ATTACGTAC CCATTTCAT CATCTCTCT TCCGAAAGTC GGGTCTTCAC

6021 ATACCCATGT TTTCAGCATT ATCAGAAGGA GCCACCCAC AAGATTAA CACCATGCTA AACACAGTGG  
TATGGGTACA AAAGTCGTAA TAGCTTCCT CGGTGGGTG TTCTAAATT GTGGTACGAT TTGTGTCACC

6091 GGGGACATCA AGCAGCCATG CAAATGTTAA AAGAGACCAT CAATGAGGA CCTGCAGAA GGGATAGAGT  
CCCCGTAGT TCGTCGGTAC GTTACAATT TTCTCTGGTA GTTACTCCTT CGACGTCTTA CCCTATCTCA

FIG. 28 (FIG. A<sub>2</sub> cont.)

38/63

6161 GCATCCAGTG CATGAGGGC CTATTGCACC AGGCCAGATG AGAGAACCAA GGGGAAGTGA CATAGCAGGA  
CGTAGGTCAC GTACGTCCCG GATAACGTGG TCCGGTCTAC TCTCTTGGTT CCCCTTCACT GTATCGTCCT

6231 ACTACTAGTA CCCTTCAGGA ACAATAGGA TGGATGACAA ATAATCCACC TATCCCAGTA GGAGAAATTT  
TGATGATCAT GGGAAGTCCT TGTATTACCT ACCTACTGTT TATTAGGTGG ATAGGTCAT CCTCTTTAAA

6301 ATAAAGATG GATAATCCTG GGATTAAATA AATAGTAAG AATGTATAGC CCTACCAGCA TTCTGGACAT  
TATTTTCTAC CTATTAGGAC CCTAATTAT TTTATCATTC TTACATATCG GGATGGTCGT AAGACCTGTA

6371 AAGACAAGGA CCAAAGAAC CCTTTAGAGA CTATGTAGAC CGGTTCTATA AACTCTAAG AGCCGAGCAA  
TTCTGTTCCCT GCTTTTCTTG GCAATCTCT GATACATCTG GCCAAGATAT TTTGAGATTC TCGGCTCGTT

6441 GCTTCACAGG AGGTAAAAA TTGGATGACA GAAACCTTGT TGGTCCAAA TCGGAACCCA GATTGTAAGA  
CGAAGTGTC TCCATTTTT AACCTACTGT CTTTGGGAACA ACCAGGTTTT ACGCTTGGGT CTAACATTCT

6511 CTATTTTAAA AGCATTGGGA CCAGCGGCTA CACTAGAAGA AATGATGACA GCATGTCAGG GAGTAGGAGG  
GATAAAATT TCGTAACCCT GGTGCGCGAT CTGATCTTCT TTACTIONGT CGTACAGTCC CTCATCCTCC

FIG. 29 (FIG. A<sub>2</sub> cont.)

39/63

6581 ACCCGGCCAT AAGCAAGAG TTTGGCTGA AGCAATGAGC CAAGTAACAA ATT[CAGCTAC CATAATGATG  
TGGGCCGGTA TTCCGTTCTC AAAACCGACT TCGTTACTCG GTTCATTGTT TAA[GTCCGATG GTATTACTAC

6651 CAGAGAGGCA ATTTAGGAA CCAAAGAAAG ATTGTTAAGT GTTTCAATTG TGGCAAAGAA GGGCACACAG  
GTCTCTCCGT TAAATCCTT GTTTCTTTC TAACAATTCA CAAAGTTAAC ACCGTTTCTT CCCGTGTGTC

6721 CCAGAAATTG CAGGGCCCT AGGAAAAGG GCTGTGCAA ATGTGGAAAG GAAGCACACC AAATGAAAGA  
GGTCTTTAAC GTCCCGGGGA TCCTTTTTC CGACAACCTT TACA[CCCTTC CTTCCTGTGG TTTACTTTCT

6791 TTGTACTGAG AGACAGGCTA ATTTTTTAGG GAAGATCTGG CCTTCCTACA AGGGAAGGCC AGGGAATTTT  
AACATGACTC TCTGTCCGAT TAAAAATCC CTTCTAGACC GGAAGGATGT TCCCTTCCGG TCCCTTAAAA

6861 CTTCAGAGCA GACCAGAGCC AACAGCCCCA CCAGAAGAGA CCTTCAGGTC TGGGGTAGAG ACAACAATC  
GAAGTCTCGT CTGGTCTCGG TTGTCGGGGT GGTCTTCTCT CGAAGTCCAG ACCCCATCTC TGTGTTCAG

6931 CCCCTCAGAA GCAGGAGCCG ATAGACAAGG AACTGTATCC TTAACTTCC CTCAGATCAC TCTTTGGCAA  
GGGGAGTCTT CGTCCTCCGC TATCTGTTC TTGACATAGG AAATTGAAGG GAGTCTAGTG AGAAACCGTT

FIG. 30 (FIG. A<sub>2</sub> cont.)

40/63

7001 CGACCCCTCG TCACAATAAA GATAGGGGGG CAACTAAAGG AAGCTCTATT AGATACAGGA GCAGATGATA  
GCTGGGGAGC AGTGTTATT CTATCCCCC GTTGATTTC TCGAGATAA TCTATGTCCT CGTCTACTAT

7071 CAGTATTAGA AGAAATGAGT TTGCCAGGAA GATCGAAACC AAAATGATA GGGGGAATTG GAGTTTAT  
GTCATAATCT TCTTTACTCA AACGGTCCTT CTACCTTTGG TTTTFACTAT CCCCCTTAAC CTCCTAAATA

7141 CAAAGTAAGA CAGTATGATC AGATACTCAT AGAAATCTGT GGACATAAAG CTATAGGTAC AGTATTAGTA  
GTTTCATTCT GTCATACTAG TCTATGAGTA TCTTTAGACA CCTGTATTTC GATATCCATG TCATAATCAT

7211 GGACCTACAC CTGTCAACAT AATTGGAAGA AATCTGTTGA CTCAGATTGG TTGCACTTTA AATTTCCCA  
CCTGGATGTG GACAGTTGTA TTAACCTTCT TTAGACAACT GAGTCTAACC AACGTGAAAT TTAAAAGGGT

7281 TTAGCCCTAT TGAGACTGTA CCAGTAAAT TAAAGCCAGG AATGGATGGC CCAAAAGTTA AACAAATGGCC  
AATCGGGATA ACTCTGACAT GGTCATTTA ATTTCGGTCC TTACCTACCG GGTTTTCAAT TTGTTACCGG

7351 ATTGACAGAA GAAAAATAA AAGCATTAGT AGAAATTGT ACAGAAATGG AAAAGGAAGG GAAATTTCA  
TAACTGTCTT CTTTTTTATT TTCGTAATCA TCTTTAAACA TGCTTTTACC TTTTCTTCC CTTTTAAAGT

*FIG. 31 (FIG. A<sub>2</sub> cont.)*



41/63

7421 AAAATTGGGC CTGAGAAATCC ATACAATACT CCAGTATTTG CCATAAAGAA AAAAGACAGT ACTAAATGGA  
TTTTAACC CG GACTCTTAGG TATGTTATGA GGTCAATAAC GGTATTCTT TTTCTGTCA TGATTACCT

7491 GCAAAATTAGT AGATTTCAGA GAACTTAATA AGAGAACTCA AGACTTCTGG GAAGTTCAAT TAGGAATACC  
CCTTAATCA TCTAAAGTCT CTTGAATTAT TCTCTTGAGT TCTGAAGACC CTTCAAGTTA ATCCTTATGG

7561 ACATCCCCGA GGGTTAAAA AGAAAAATC AGTAACAGTA CTGGATGTGG GTGATGCATA TTTTTCAGTT  
TGAGGGCGT CCCAATTTT TCTTTTITAG TCATTGTCTAT GACCTACACC CACTACGTAT AAAAAGTCAA

7631 CCCTTAGATG AAGACTTCAG GAAGTATACT GCATTTACCA TACCTAGTAT AAACAATGAG ACACCAGGGA  
GGGAATCTAC TTCTGAAGTC CTTCATATGA CGTAAATGGT ATGGATCATA TTTGTTACTC TGTGCTCCCT

7701 TTAGATATCA GTACAATGTG CTTCCACAGG GATGGAAGG ATCACCAGCA ATATCCAAA GTAGCATGAC  
AATCTATAGT CATGTTACAC GAAGGTGTCC CTACCTTTCC TAGTGGTCGT TATAAGGTTT CATCGTACTG

7771 AAAATCTTA GAGCCTTTAA AAAACAAAA TCCAGACATA GTTATCTATC AATACATGAA CGATTGTAT  
TTTTTAGAAT CTCGGAAAAAT TTTTGTGTTT AGGTCTGTAT CAATAGATAG TTATGTACTT GCTAAACATA

FIG. 32 (FIG. A<sub>2</sub> cont.)



42/63

7841 GTAGGATCTG ACTTAGAAAT AGGCAGCAT AGAACAAAA TAGAGGAGCT GAGACAACAT CTGTTAGGT  
CATCCTAGAC TGAATCTTA TCCCGTCGTA TCTTGTTTT ATCTCCTCGA CTCTGTTGTA GACAACTCCA

7911 GGGGACTTAC CACACCAGAC AAAAACATC AGAAGAACC TCCATTCCCTT TGGATGGGTT ATGAACCTCA  
CCCCTGAATG GTGTGGTCTG TTTTGTGTAG TCTTCTTGG AGTAAGGAA ACCTACCCAA TACTTGAGGT

7981 TCCTGATAAA TGGACAGTAC AGCCTATAGT GCTGCCAGAA AAAGACAGCT GGAAGTCAA TGACATACAG  
AGGACTATT ACCTGTCAATG TCGGATATCA CGACGGTCTT TTTCTGTCCA CCTGACAGTT ACTGTATGTC

8051 AAGTAGTGG GGAATTGAA TACCGCAAGT CAGATTACC CAGGGATTAA AGTAAGGCAA TTATGTAAAC  
TTCAATCACC CCTTTAACTT ATGGCGTTCA GTCTAAATGG GTCCCTAATT TCATTCCGTT AATACATTG

8121 TCCTTAGAGG AACCAAAGCA CTAACAGAAG TAATACCACT AACAGAAGAA GCAGAGCTAG AACTGGCAGA  
AGGAATCTCC TTGGTTTCGT GATTGTCTTC ATTATGGTGA TTGTCTTCTT CGTCTCGATC TTGACCGTCT

8191 AACACAGAG ATTCTAAAAG AACCACTACA TGGAGTGTAT TATGACCCAT CAAAAGACTT AATAGCAGAA  
TTTGTCTCTC TAAGATTTC TTGTCATGT ACCTCACATA ATACTGGGA GTTTTCTGAA TTATCGTCTT

FIG. 33 (FIG. A<sub>2</sub> cont.)

43/63

8261 ATACAGAAGC AGGGGCAAGG CCAATGGACA TATCAAAATT ATCAAGAGCC ATTTAAAAAT CTGAAAACAG  
TATGCTCTTCG TCCCCGTTCC GGTACCTGT ATAGTTTAAA TAGTCTCGG TAAATTTTA GACTTTTGTC

8331 GAAATATGC AAGAATCAGG GGTGCCCACA CTAATGATGT AAAACAATTA ACAGAGGCAG TGCAAAAAAT  
CTTTATACG TTCTTACTCC CCACGGGTGT GATTACTACA TTTTGTTAAT TGCTCCGC ACCTTTTTA

8401 AACCACAGAA AGCATAGTAA TATGGGAAA GACTCCTAAA TTAAACTAC CCATACAAA GGAACATGG  
TTGGTGCTT TCGTATCAT ATACCCCTTT CTGAGGATT AAATTGATG GGTATGTTT CCTTTGTACC

8471 GAAACATGGT GGACAGAGTA TTGGCAAGCC ACCTGGATTC CTGAGTGGGA GTTGTTAAT ACCCCTCCTT  
CTTTGTACCA CCTGTCAT AACCGTTCG TGGACCTAAG GACTCACCT CAAACAATTA TGGGGAGGAA

8541 TAGTAAATT ATGGTACCAG TTAGAGAAAG AACCCATAGT AGGAGCAGAA ACCTTCTATG TAGATGGGGC  
ATCACTTTAA TACCATGGTC AATCTCTTC TTGGGTATCA TCCTCGTCTT TGGAGATAC ATCTACCCCG

8611 AGCTAACAGG GAGACTAAAT TAGGAAAAGC AGGATATGTT ACTAACAAAG GAAGACAAA GGTTGTCCCC  
TCGATTGTCC CTCTGATTTA ATCCTTTTCG TCCTATACAA TGATTGTTC CTCTCTTTT CCAACAGGGG

FIG. 34 (FIG. A<sub>2</sub> cont.)

44/63

8681 CTAAC TAACA CAACAATCA GAAAACTCAG TTACAAGCAA TTTATCTAGC TTTGCAGGAT TCAGGATTAG  
GATTGATTGT GTTGTTAGT CTTTGGAGTC AATGTTTCGT AAATAGATCG AAACGTCCTA AGTCCTAATC

8751 AAGTAAACAT AGTAACAGAC TCACAATATG CATTAGGAAT CATTCAAGCA CAACCAGATA AAAGTGAATC  
TTCATTTTGTA TCATTGCTCG AGTGTATAC GTAATCCTTA GTAAGTTCGT GTTGGTCTAT TTTCACCTTAG

8821 AGAGTTAGTC AATCAAAATA TAGAGCAGTT AATAAAAAG GAAAGGTCT ATCTGGCATG GGTACCAGCA  
TCTCAATCAG TTAGTTTATT ATCTCGTCAA TTATTTTTC CTTTCCAGA TAGACCGTAC CCATGGTCTGT

8891 CACAAAGGAA TTGGAGGAAA TGAACAAGTA GATAAATTAG TCAGTGCTGG AATCAGGAAA ATACTATTTT  
GTGTTTCCTT AACCTCCTTT ACTTGTTTCAT CTATTTAATC AGTCACGACC TTAGTCCCTT TATGATAAAA

8961 TAGATGGAAT AGATAAGGCC CAAGATGAAC ATTAGTTTTT ATGTCGACCT GCAGGGAAG TTTTATAGCT  
ATCTACCTTA TCTATTCCGG GTTCTACTTG TAATCAAAA TACAGCTGGA CGTCCCTTC AAAATATCCA

9031 AGTTGATAGA ACAAATACA TAATTTGTA AAAATAAATC ACTTTTATA CTAATATGAC ACGATTACCA  
TCAACTATCT TGTTTTATGT ATTAAACAT TTTTATTAG TGAAAAATAT GATTATACTG TGCTAATGCT

FIG. 35 (FIG. A<sub>2</sub> cont.)

45/63

9101 ATACTTTTGT TACTAATATC ATTAGTATAC GCTACACCTT TTCTCAGAC ATCTAAAAA ATAGTGATG  
TATGAAAACA ATGATTATAG TAATCATATG CGATGTGGA AAGAGTCTG TAGATTTTT TATCCACTAC

9171 ATGCAACTTT ATCATGTAAT CGAAATAATA CAAATGACTA CGTTGTTATG AGTGCTTGGT ATAAGGAGCC  
TACGTTGAAA TAGTACATTA GCTTTATTAT GTTACTGAT GCAACAATAC TCACGAACCA TATTCCTCGG

9241 CAATTCCATT ATTCTTTTAG CTGCTAAAG CGACGCTTG TATTTGATA ATTATACCAA GGATAAATA  
GTTAAGGTAA TAAGAAATC GACGATTTTC GCTGCAGAAC ATAAACTAT TAATATGGTT CCTATTTTAT

9311 TCTTACGACT CTCCATACGA TGATCTAGTT ACAACTATCA CAATTAAATC ATTGACTGCT AGAGATGCCG  
AGAAATGCTGA GAGGTATGCT ACTAGATCAA TGTTGATAG GTTAATTTAG TAACTGACGA TCTCTACGGC

9381 GTACTTATGT ATGTGCATTC TTTATGACAT CGCTACAAA TGACACTGAT AAAGTAGATT ATGAAGAATA  
CATGAATACA TACACGTAAG AAATACTGTA CCGGATGTTT ACTGTGACTA TTTCATCTAA TACTTCTTAT

9451 CTCCACAGAG TTGATTGTAA ATACAGATAG TGAATCGACT ATAGACATAA TACTATCTGG ATCTACACAT  
GAGGTGCTC AACTAACATT TATGTCTATC ACTTAGCTGA TATCTGTATT ATGATAGACC TAGATGTGTA

FIG. 36 (FIG. A<sub>2</sub> cont.)



46/63

9521 TCACCAGAAA CTAGTTAAGC TTGTCTCCCT ATAGTGAGTC GTATTAGAGC TTGGCGTAAT CATGGTCATA  
AGTGGTCTTT GATCAATTCC AACAGAGGGA TATCACTCAG CATAATCTCG AACCGCATTA GTACCAGTAT

9591 GCTGTTTCCT GTGTGAAATT GTTATCCGCT CACAATTCCA CACAACATAC GAGCCGGAAG CATAAAGTGT  
CGACAAAGGA CACACTTTAA CAATAGCGGA GTGTTAAGGT GTGTTGTATG CTCGGCCCTTC GTATTTCACA

9661 AAAGCCTGGG GTGCCTAATG AGTGAGCTAA CTCACATTAA TTGCGTTGGG CTCACTGCCC GCTTTCGAGT  
TTTCGGACCC CACGGATTAC TCACTCGATT GAGTGTAATT AACGCAACGC GAGTGACGGG CGAAAGCTCA

9731 CCGGAAACCT GTCGTGCCAG CTGCATTAAAT GAATCGGCCA ACGCGCGGG AGAGCGGTT TCGGTATTGG  
GCCCTTTGGA CAGCACGGTC GACGTAATTA CTTAGCCGGT TCGCGGCCCC TCTCCGCCAA ACGCATAACC

9801 GCGCTCTTCC GCTTCCTCCG TCACTGACTC GCTGCCCTCG GTCGTTCCGG TCGCGCGAGC GGTATCAGCT  
CGCGAGAAGG CGAAGGAGCG AGTGACTGAG CGACGCGAGC CAGCAAGCCG ACGCGCTCG CCATAGTCGA

9871 CACTCAAAGG CCGTAATACG GTTATCCACA GAATCAGGG ATAACGAGG AAAGAACATG TGAGCAAAAG  
GTGAGTTTCC GCCATTATCG CAATAGGTGT CTTAGTCCCC TATTGCGTCC TTTCTTGTAC ACTCGTTTTC

9941 GCCAGCAAAA GGCAGGAAC CGTAAAAGG CCGCGTTGCT GCGGTTTTC GATAGGCTCC GCCCCCTGA  
CCGTCGTTT CCGGTCCTTG GCATTTTTC GCGCAACGA CCGCAAAAAG CTATCCGAGG CGGGGGGACT

FIG. 37 (FIG. A<sub>2</sub> cont.)

SUBSTITUTE SHEET (RULE 26)



47/63

10011 CGAGCATCAC AAAATCGAC GCTCAAGTCA GAGGTGGCGA AACCCGACAG GACTATAAAG ATACCAGGCG  
GCTCCTAGTG TTTTITAGCTG CGAGTTCAGT CTCCACCGCT TTGGGCTGTC CTGATATTTC TATGGTCCGC

10081 TTTCCCCCTG GAAGCTCCCT CGTGGCTCT CCTGTTCCGA CCTGCCGCT TACCGGATAC CTGTCCGCCCT  
AAAGGGGAC CTTCCAGGGA GCACGGGAGA GGACAAGGCT GGGACGGCGA ATGGCCTATG GACAGGCGGA

10151 TTCTCCCTTC GGAAGCGTG GCGCTTTCTC ATAGCTCAGG CTGTAGGTAT CTCAGTTCGG TGTAGGTCGT  
AAGAGGGAAG CCCTTCGCAC CGCGAAGAG TATCGAGTGC GACATCCATA GAGTCAAGCC ACATCCAGCA

10221 TCGCTCCAAG CTGGGCTGTG TGCACGAACC CCCCGTTCAG CCCGACCGCT GCGCCTTATC CGGTAACAT  
AGCGAGGTTT GACCGGACAC ACGTGCTTGG GGGGCAAGTC GGGCTGGCGA CGCGGAATAG GCCATTGATA

10291 CGTCTTGAGT CCAACCCGGT AAGACACGAC TTATCGCCAC TGGCAGCAGC CACTGGTAAC AGGATTAGCA  
GCAGAACTCA GGTGGGCCA TTCTGTGCTG AATAGCGGTG ACCGTGCTCG GTGACCATTG TCCTAATCGT

10361 GAGCGAGGTA TGTAGGCGGT GCTACAGAGT TCTTGAAGTG GTGGCCTAAC TACGGCTACA CTAGAAGGAC  
CTCGCTCCAT ACATCCGCCA CGATGTCTCA AGAACTTCAC CACCGGATG ATGCCGATGT GATCTTCCTG

10431 AGTATTTCGT ATCTCGGCTC TGCTGAAGCC AGTTACCTTC GGAAAAGAG TTGGTAGCTC TTGATCCGGC  
TCATAAACCA TAGACGGGAG ACCACTTCGG TCAATGGAAG CCTTTTCTC AACCATCGAG AACTAGGCCG

FIG. 38 (FIG. A<sub>2</sub> cont.)

48/63

10501 AAACAACCA CCGCTGGTAG CCGTGGTTT TTTGTTTGA AGCAGCAGAT TACCGGCAGA AAAAAGGAT  
TTTGTTTGGT GCGGACCATC GCCACCAAAA AACAAACGT TCGTCGTCTA ATGCGCGTCT TTTTTCCTA

10571 CTCAAGAAGA TCCTTTGATC TTTTCTACGG GGTCTGACGC TCAGTGGAAC GAAACTCAC GTTAAGGGAT  
GAGTTCTTCT AGGAAACTAG AAAAGATGCC CCAGACTGCG AGTCACCTTG CTTTGTGAGTG CAATCCCTA

10641 TTTGGTCATG AGATTATCAA AAAGCATCTT CACCTAGATC CTTTAAATT AAAATGAAG TTTTAAATCA  
AAACCAGTAC TCTAATAGTT TTCCCTAGAA GTGGATCTAG GAAATTAA TTTTACTTC AAAATTAGT

10711 ATCTAAAGTA TATATGAGTA AACTTGGTCT GACAGTTACC AATGCTTAAT CAGTGAGGCA CCTATCTCAG  
TAGATTTCAT ATATACTCAT TTGAACCAGA CTGTCAATGG TTACGAATTA GTCACTCCGT GGATAGAGTC

10781 CGATCTGTCT ATTTCGTTCA TCCATAGTTG CCTGACTCCC CGTCGTGTAG ATAACTACGA TACGGGAGGG  
GCTAGACAGA TAAAGCAAGT AGGTATCAAC GGACTGAGGG GCAGCACATC TATTGATGCT ATGCCCTCCC

10851 CTTACCATCT GGGCCCAGTG CTGCAATGAT ACCGGGAGAC CCACGCTCAC CGGCTCCAGA TTTATCAGCA  
GAATGGTAGA CCGGGGTCAC GACGTTACTA TGGCGCTCTG GGTGGGAGTG GCCGAGGTCT AAATAGTCGT

10921 ATAAACCAGC CAGCCGGAAG GCGCGAGCGC AGAAGTGGTC CTGCAACTTT ATCCGCTCC ATCCAGTCTA  
TATTGGTGG GTCCGCCCTC CCGGCTCGCG TCTTCACCAG GACGTTGAAA TAGGGGAGG TAGGTCAGAT

FIG. 39 (FIG. A<sub>2</sub> cont.)

49/63

10991 TTAATTGTTG CCGGGAAGCT AGAGTAAGTA GTTCGCCAGT TAATAGTTG CGCAACGTTG TTGGCATTGC  
AATTACAAC GCCCCTTCGA TCTCATTCAT CAAGCGGTCA ATTATCAAAC GCGTTGCAAC AACCGTAACG

11061 TACAGGCATC GTGGTGTAC GCTCGTCGTT TGGTATGGCT TCATTCAGCT CCGGTTCCCA ACGATCAAGG  
ATGTCCGTAG CACCACAGTC CGAGCAGCAA ACCATACCGA AGTAAGTCCA GGCCAAGGT TGCTAGTTCC

11131 CGAGTTACAT GATCCCCCAT GTTGTCAAA AAGCGGTTA GCTCCTTCGG TCCTCCGATC GTTGTCAAG  
GCTCAATGTA CTAGGGGGTA CAACAGTTT TTTCGCCAAT CGAGGAAGCC AGGAGGCTAG CAACAGTCTT

11201 GTAAGTTGGC CGCAGTGTTA TCACTCATGG TTATGGCAGC ACTGCATAAT TCTCTTACTG TCATGCCATC  
CATTCAACCG GCGTCACAAT AGTGAGTACC AATACCGTCG TCACGTATTA AGAGAATGAC AGTACGGTAG

11271 CGTAAGATGC TTTTCTGTGA CTGGTGAGTA CTCAACCAAG TCATTCTGAG AATAGTGTAT GCGGCGACCG  
GCATTCTACG AAAAGACACT GACCACTCAT GAGTGGTTC AGTAAGACTC TTATCACATA CGCCCGCTGGC

11341 AGTTGCTCTT GCCCGGGCTC AATACGGGAT AATACCGCG CACATAGCAG AACTTTAAAA GTGCTCATCA  
TCAACGAGAA CCGGCGGCAG TTATGCCCTA TTATGGCGCG GTGTATCGTC TTGAAATTTT CACGAGTAGT

FIG. 40 (FIG. A<sub>2</sub> cont.)

50/63

11411 TTGGAACG TTCTTCGGG CGAAACTCT CAAGATCTT ACCGCTGTTG AGATCCAGTT CGATGTAACC  
AACCTTTTC AAGAAGCCCC GCTTTTGAGA GTTCTAGAA TGGCGACAAC TCTAGGTCAA GCTACATTGG

11481 CACTCGTGCA CCCAACTGAT CTTCAGCATC TTTTACTTTC ACCAGCGTTT CTGGGTGAGC AAAACAGGA  
GTGAGCACCT GGGTTGACTA GAAGTCGTAG AAATGAAAG TGGTCGCAA GACCCACTCG TTTTGTCTCT

11551 AGGCAAAATG CCGCAAAAA GGAATAAGG GCGACACGGA AATGTTGAAT ACTCATACTC TTCCCTTTTC  
TCCGTTTAC GCGCTTTT CCCTTATTCC CGCTGTCCCT TTACAACCTA TGAGTATGAG AAGGAAAAAG

11621 AATATTATTG AAGCATTAT CAGGGTTATT GTCTCATGAG CCGATACATA TTTGAATGTA TTTAGAAAA  
TTATAATAAC TTCGTAAATA GTCCCAATA CAGAGTACTC GCCTATGTAT AAATCTTTT

11691 TAAACAAATA GGGGTTCCGC GCACATTTCC CCGAAAGTG CCACCTGACG TCTAAGAAC CATTATTATC  
ATTGTATTAT CCCCAGGCG CGTGTAAGG GGCTTTTCAC GTGGACTGC AGATTCTTTG GTAATAATAG

11761 ATGACATTAA CCTATAAAA TAGCGTATC ACGAGGCCCT TTCGTCTCGC GCGTTTCGGT GATGACGGTG  
TACTGTAATT GGATATTTT ATCCGCATAG TGCTCCGGA AAGCAGAGCG CGCAAAGCCA CTACTGCCAC

FIG. 41 (FIG. A<sub>2</sub> cont.)

51/63

11831 AAACCTCTG ACACATGCAG CTCCCGGAGA CCGTCACAGC TTGTCTGTAA GCGGATGCCG GGAGCAGACA  
TTTTGGAGAC TGTGTACGTC GAGGGCCTCT GCCAGTGTG AACAGACATT CGCCTACGGC CCTCGTCTGT

11901 AGCCCGTCAG GCGCGTCAG CCGGTGTTGG CCGGTGTCCG GCTGGCTTA ACTATCGGC ATCAGAGCAG  
TCGGGCAGTC CCGGCAGTC GCCACAAACC GCCACAGCC CCGACCGAAT TGATACGCCG TAGTCTCGTC

11971 ATTGTACTGA GAGTGCACCA TATCGGTGT GAAATACCG ACAGATGCCG AAGGAGAAA TACCGCATCA  
TAACATGACT CTCACGTGGT ATACGCCACA CTTTATGGCG TGTCTACGCA TTCCTCTTTT ATGGCGTAGT

12041 GCGGCCATTG GCCATTTCAGG CTGCGCAACT GTTGGGAAGG GCGATCGGTG CCGGCCCTCTT CGCTATTACG  
CCGCGGTAAG CCGTAAGTCC GACGCGTTGA CAACCCCTTC CCGTAGCCAC GCCCGGAGAA GCGATAATGC

12111 CCAGCTGGCG AAAGGGGAT GTGCTGCAAG GCGATTAAAG TGGGTAACGC CAGGGTTTC CCAGTCACGA  
GGTCCAGCCG TTTCCCCCTA CACGACGTTT CGCTAATTCA ACCCATTCGG GTCCCAAAG GGTCAGTGCT

12181 CGTTGTAAA CGACGGCCAG TGAATTGGAT TTAGGTGACA CTATA  
GCAACATTTT GCTGCCGGTC ACTTAACCTA AATCCACTGT GATAT

FIG. 42 (FIG. A<sub>2</sub> cont.)



52/63

**Text File of pLW-48 and the Included Individual HIV Genes and Their Promoters**

**Entire pLW-48 plasmid sequence:**

GAATTCGTTGGTGGTCGCCATGGATGGTGTATTGTATACTGTCTAAACGCG  
TTAGTAAAACATGGCGAGGAAATAAATCATATAAAAAATGATTTTCATGATTAA  
ACCATGTTGTGAAAAAGTCAAGAACGTTACATTGGCGGACAATCTAAAAAC  
AATACAGTGATTGCAGATTTGCCATATATGGATAATGCGGTATCCGATGTAT  
GCAATTCAGTGTATAAAAAAGAATGTATCAAGAATATCCAGATTTGCTAATTTG  
ATAAAGATAGATGACGATGACAAGACTCCTACTGGTGTATATAATTATTTTAA  
ACCTAAAGATGCCATTCCTGTTATTATATCCATAGGAAAGGATAGAGATGTTT  
GTGAACTATTAATCTCATCTGATAAAGCGTGTGCGTGTATAGAGTTAAATTCA  
TATAAAGTAGCCATTCTTCCCATGGATGTTTCCTTTTTTACCAAAGGAAATGC  
ATCATTGATTATTCTCCTGTTTGATTTCTCTATCGATGCGGCACCTCTCTTAA  
GAAGTGTAACCGATAATAATGTTATTATATCTAGACACCAGCGTCTACATGA  
CGAGCTTCCGAGTTCCAATTGGTTCAAGTTTTACATAAGTATAAAGTCCGAC  
TATTGTTCTATATTATATATGGTTGTTGATGGATCTGTGATGCATGCAATAGC  
TGATAATAGAACTTACGCAAATATTAGCAAAAATATATTAGACAATACTACAA  
TTAACGATGAGTGTAGATGCTGTTATTTTGAACCACAGATTAGGATTCTTGAT  
AGAGATGAGATGCTCAATGGATCATCGTGTGATATGAACAGACATTGTATTA  
TGATGAATTTACCTGATGTAGGCGAATTTGGATCTAGTATGTTGGGGAAATA  
TGAACCTGACATGATTAAGATTGCTCTTTCGGTGGCTGGGTACCAGGCGCG  
CCTTTCATTTTGTTTTTTTCTATGCTATAAATGGTACGTCCTGTAGAAACCCC  
AACCCGTGAAATCAAAAAACTCGACGGCCTGTGGGCATTCAAGTCTGGATCG  
CGAAAACGTGGAATTGATCAGCGTTGGTGGGAAAGCGCGTTACAAGAAAG  
CCGGGCAATTGCTGTGCCAGGCAGTTTAAACGATCAGTTCGCCGATGCAGA  
TATTCGTAATTATGCGGGCAACGTCTGGTATCAGCGCGAAGTCTTTATACCG  
AAAGGTTGGGCAGGCCAGCGTATCGTGCTGCGTTTCGATGCGGTCACTCAT  
TACGGCAAAGTGTGGGTCAATAATCAGGAAGTGATGGAGCATCAGGGCGG  
CTATACGCCATTTGAAGCCGATGTCACGCCGTATGTTATTGCCGGGAAAAG  
TGTACGTATCACCGTTTGTGTGAACAACGAACCTGAACTGGCAGACTATCCC  
GCCGGGAATGGTGATTACCGACGAAAACGGCAAGAAAAAGCAGTCTTACTT  
CCATGATTTCTTTAACTATGCCGGAATCCATCGCAGCGTAATGCTCTACACC  
ACGCCGAACACCTGGGTGGACGATATCACCGTGGTGACGCATGTCGCGCA  
AGACTGTAACCACGCGTCTGTTGACTGGCAGGTGGTGGCCAATGGTGATGT  
CAGCGTTGAACTGCGTGATGCGGATCAACAGGTGGTTGCAACTGGACAAG  
GCACTAGCGGGACTTTGCAAGTGGTGAATCCGCACCTCTGGCAACCGGGT  
GAAGGTTATCTCTATGAACTGTGCGTCACAGCCAAAAGCCAGACAGAGTGT  
GATATCTACCCGCTTCGCGTCGGCATCCGGTCAGTGGCAGTGAAGGGCGA  
ACAGTTCCTGATTAACCACAAACCGTTCTACTTTACTGGCTTTGGTCGTCAT  
GAAGATGCGGACTTGCGTGGCAAAGGATTGATAACGTGCTGATGGTGCAC  
GACCACGCATTAATGGACTGGATTGGGGCCAACTCCTACCGTACCTCGCAT  
TACCCTTACGCTGAAGAGATGCTCGACTGGGCAGATGAACATGGCATCGTG

*FIG. 43*

(Figure B<sub>1</sub>)

SUBSTITUTE SHEET (RULE 26)

53/63

GTGATTGATGAAACTGCTGCTGTCGGCTTTAACCTCTCTTTAGGCATTGGTT  
TCGAAGCGGGCAACAAGCCGAAAGAACTGTACAGCGAAGAGGCAGTCAAC  
GGGGAAACTCAGCAAGCGCACTTACAGGCGATTAAAGAGCTGATAGCGCGT  
GACAAAAACCACCCAAGCGTGGTGATGTGGAGTATTGCCAACGAACCGGAT  
ACCCGTCCGCAAGGTGCACGGGAATATTTGCGCGCCACTGGCGGAAGCAAC  
GCGTAAACTCGACCCGACGCGTCCGATCACCTGCGTCAATGTAATGTTCTG  
CGACGCTCACACCGATAACCATCAGCGATCTCTTTGATGTGCTGTGCCTGAA  
CCGTTATTACGGATGGTATGTCCAAAGCGGCGATTTGGAAACGGCAGAGAA  
GGTACTGGAAAAAGAACTTCTGGCCTGGCAGGAGAACTGCATCAGCCGAT  
TATCATCACCGAATACGGCGTGGATACGTTAGCCGGGCTGCACTCAATGTA  
CACCGACATGTGGAGTGAAGAGTATCAGTGTGCATGGCTGGATATGTATCA  
CCGCGTCTTTGATCGCGTCAGCGCCGTCGTCGGTGAACAGGTATGGAATTT  
CGCCGATTTTGCGACCTCGCAAGGCATATTGCGCGTTGGCGGTAACAAGAA  
AGGGATCTTCACTCGCGACCGCAAACCGAAGTCGGCGGGCTTTTCTGCTGCA  
AAAACGCTGGACTGGCATGAACTTCGGTGAAAAACCGCAGCAGGGAGGCA  
AACAATGAGAGCTCGGTTGTTGATGGATCTGTGATGCATGCAATAGCTGATA  
ATAGA ACTTACGCAAATATTAGCAAAAATATATTAGACAATACTACAATTAAC  
GATGAGTGTAGATGCTGTTATTTTGAACCACAGATTAGGATTCTTGATAGAG  
ATGAGATGCTCAATGGATCATCGTGTGATATGAACAGACATTGTATTATGAT  
GAATTTACCTGATGTAGGCGAATTTGGATCTAGTATGTTGGGGAAATATGAA  
CCTGACATGATTAAGATTGCTCTTTCGGTGGCTGGCGGGCCCGCTCGAGTAA  
AAAATGAAAAAATATTCTAATTTATAGGACGGTTTTGATTTTCTTTTTTCTAT  
GCTATAAATAATAAATAGCGGGCCGCACCATGAAAGTGAAGGGGATCAGGAA  
GAATTATCAGCACTTGTGGAAATGGGGCATCATGCTCCTTGGGATGTTGATG  
ATCTGTAGTGCTGTAGAAAATTTGTGGGTCACAGTTTATTATGGGGTACCTG  
TGTGGAAAGAAGCAACCACCACTCTATTTTGTGCATCAGATGCTAAAGCATA  
TGATACAGAGGTACATAATGTTTGGGGCCACACATGCCTGTGTACCCACAGA  
CCCCAACCCACAAGAAGTAGTATTGGAAAATGTGACAGAAAATTTTAACATG  
TGGA AAAATAACATGGTAGAACAGATGCATGAGGATATAATCAGTTTATGGG  
ATCAAAGCCTAAAGCCATGTGTAAAATTAACCCCACTCTGTGTTACTTTAAAT  
TGCACTGATTTGAGGAATGTTACTAATATCAATAATAGTAGTGAGGGAATGA  
GAGGAGAAATAAAAAACTGCTCTTTCAATATCACCAACAAGCATAAGAGATAA  
GGTGAAGAAAGACTATGCACTTTTCTATAGACTTGATGTAGTACCAATAGATA  
ATGATAATACTAGCTATAGGTTGATAAATTGTAATACCTCAACCATTACACAG  
GCCTGTCCAAAGGTATCCTTTGAGCCAATTCCCATAACATTATTGTACCCCGG  
CTGGTTTTTGCGATTCTAAAGTGTAAGACAAGAAGTTCAATGGAACAGGGCC  
ATGTAAAATGTCAGCACAGTACAATGTACACATGGAATTAGGCCAGTAGTG  
TCAACTCAACTGCTGTTAAATGGCAGTCTAGCAGAAGAAGAGGTAGTAATTA  
GATCTAGTAATTTACAGACAATGCAAAAAACATAATAGTACAGTTGAAAGAA  
TCTGTAGAAATTAATTGTACAAGACCCAACAACAATAAAGGAAAAGTATAC  
ATATAGGACCAGGAAGAGCATTTTATACAACAGGAGAAATAATAGGAGATAT  
AAGACAAGCACATTGCAACATTAGTAGAACA AAATGGAATAACACTTTAAAT  
CAAATAGCTACAAAATTAAGAACAATTTGGGAATAATAAACAATAGTCTT  
TAATCAATCCTCAGGAGGGGACCCAGAAATTGTAATGCACAGTTTTTAATTGT  
GGAGGGGAATTCTTCTACTGTAATTCAACACA ACTGTTTAATAGTACTTGGA  
ATTTAATGGTACTTGGAATTTAACACAATCGAATGGTACTGAAGGAAATGA

*FIG. 44*(Figure B<sub>2</sub>)

SUBSTITUTE SHEET (RULE 26)

54/63

CACTATCACACTCCCATGTAGAATAAAACAAATTATAAATATGTGGCAGGAA  
GTAGGAAAAGCAATGTATGCCCCTCCCATCAGAGGACAAATTAGATGCTCAT  
CAAATATTACAGGGCTAATATTAACAAGAGATGGTGGAACTAACAGTAGTGG  
GTCCGAGATCTTCAGACCTGGGGGAGGAGATATGAGGGACAATTGGAGAA  
GTGAATTATATAAATATAAAGTAGTAAAAATTGAACCATTAGGAGTAGCACCC  
ACCAAGGCAAAAAGAAGAGTGGTGCAGAGAGAAAAAAGAGCAGTGGGAAC  
GATAGGAGCTATGTTCTTGGGTTCTTGGGAGCAGCAGGAAGCACTATGGG  
CGCAGCGTCAATAACGCTGACGGTACAGGCCAGACTATTATTGTCTGGTAT  
AGTGCAACAGCAGAACAATTTGCTGAGGGGCTATTGAGGCGCAACAGCATCT  
GTTGCAACTCACAGTCTGGGGCATCAAGCAGCTCCAGGCAAGAGTCCTGG  
CTGTGGAAAGATACCTAAGGGATCAACAGCTCCTAGGGATTGTTGGGGTTGCT  
CTGGAAAACCTCATCTGCACCACTGCTGTGCCTTGGAATGCTAGTTGGAGTA  
ATAAACTCTGGATATGATTTGGGATAACATGACCTGGATGGAGTGGGAAA  
GAGAAATCGAAAATTACACAGGCTTAATATACACCTTAATTGAGGAATCGCA  
GAACCAACAAGAAAAGAATGAACAAGACTTATTAGCATTAGATAAGTGGGCA  
AGTTTGTGGAATTGGTTTGACATATCAAATTGGCTGTGGTATGTAAAAATCTT  
CATAATGATAGTAGGAGGCTTGATAGGTTTAAGAATAGTTTTTACTGTACTTT  
CTATAGTAAATAGAGTTAGGCAGGGATACTCACCATTGTCATTTTCAGACCCA  
CCTCCCAGCCCCGAGGGGACCCGACAGGCCCGAAGGAATCGAAGAAGAAG  
GTGGAGACAGAGACTAATTTTTATGCGGCCGCTGGTACCCAACCTAAAAATT  
GAAAATAAATACAAAGGTTCTTGAGGGTTGTGTTAAATTGAAAGCGAGAAAT  
AATCATAAATAAGCCCCGGGGATCCTCTAGAGTCGACACCATGGGTGCGAGA  
GCGTCAGTATTAAGCGGGGGGAGAATTAGATCGATGGGAAAAAATTCGGTTA  
AGGCCAGGGGGGAAAGAAAAAATATAAATTAACATATAGTATGGGCAAGCA  
GGGAGCTAGAACGATTTCGCAGTTAATCCTGGCCTGTTAGAAACATCAGAAG  
GCTGTAGACAAATACTGGGACAGCTACAACCATCCCTTCAGACAGGATCAG  
AAGAACTTAGATCATTATATAATACAGTAGCAACCCTCTATTGTGTGCATCAA  
AGGATAGAGATAAAAGACACCAAGGAAGCTTTAGACAAGATAGAGGAAGAG  
CAAAACAAAAGTAAGAAAAAAGCACAGCAAGCAGCAGCTGACACAGGACAC  
AGCAATCAGGTCAGCCAAAATTACCCTATAGTGCAGAACATCCAGGGGGCAA  
ATGGTACATCAGGCCATATCACCTAGAACTTTAAATGCATGGGTAAAAGTAG  
TAGAAGAGAAGGCTTTTCAGCCCAGAAGTGATACCCATGTTTTTCAGCATTATC  
AGAAGGAGCCACCCCAAGATTAAACACCATGCTAAACACAGTGGGGGGG  
ACATCAAGCAGCCATGCAAATGTTAAAAGAGACCATCAATGAGGAAGCTGC  
AGAATGGGATAGAGTGCATCCAGTGCATGCAGGGGCCTATTGCACCAGGCCA  
GATGAGAGAACCAAGGGGAAGTGACATAGCAGGAACTACTAGTACCCTTCA  
GGAACAAATAGGATGGATGACAAATAATCCACCTATCCCAGTAGGAGAAATT  
TATAAAAGATGGATAATCCTGGGATTAAATAAAATAGTAAGAATGTATAGCCC  
TACCAGCATTCTGGACATAAGACAAGGACCAAAAAGAACCTTTAGAGACTAT  
GTAGACCGGTTCTATAAACTCTAAGAGCCGAGCAAGCTTCACAGGAGGTA  
AAAAATTGGATGACAGAAACCTTGTTGGTCCAAAATGCGAACCCAGATTGTA  
AGACTATTTTAAAAGCATTGGGACCAGCGGCTACACTAGAAGAAATGATGAC  
AGCATGTCAGGGAGTAGGAGGACCCGGCCATAAGGCAAGAGTTTTGGCTG  
AAGCAATGAGCCAAGTAACAAATTCAGCTACCATAATGATGCAGAGAGGCA  
ATTTTAGGAACCAAGAAAGATTGTTAAGTGTTTCAATTGTGGCAAAGAAGG  
GCACACAGCCAGAAATTGCAGGGGCCCTAGGAAAAAGGGCTGTTGGAAAT

*FIG. 45*(Figure B<sub>3</sub>)

SUBSTITUTE SHEET (RULE 26)



55/63

GTGGAAAGGAAGGACACCAAATGAAAGATTGTACTGAGAGACAGGCTAATT  
TTTTAGGGAAGATCTGGCCTTCCTACAAGGGAAGGCCAGGGAATTTTCTTCA  
GAGCAGACCAGAGCCAACAGCCCCACCAGAAGAGAGCTTCAGGTCTGGGG  
TAGAGACAACAACCTCCCCCTCAGAAGCAGGAGCCGATAGACAAGGAACTGT  
ATCCTTTAACTTCCCTCAGATCACTCTTTGGCAACGACCCCTCGTCACAATA  
AAGATAGGGGGGGCAACTAAAGGAAGCTCTATTAGATACAGGAGCAGATGAT  
ACAGTATTAGAAGAAATGAGTTTGCCAGGAAGATGGAAACCAAAAATGATAG  
GGGGAATTGGAGGTTTTATCAAAGTAAGACAGTATGATCAGATACTCATAGA  
AATCTGTGGACATAAAGCTATAGGTACAGTATTAGTAGGACCTACACCTGTC  
AACATAATTGGAAGAAATCTGTTGACTCAGATTGGTTGCACTTTAAATTTTCC  
CATTAGCCCTATTGAGACTGTACCAGTAAAATTAAAGCCAGGAATGGATGGC  
CCAAAAGTTAAACAATGGCCATTGACAGAAGAAAAAATAAAAGCATTAGTAG  
AAATTTGTACAGAAATGGAAAAGGAAGGGGAAAATTTCAAAAATTGGGCCTGA  
GAATCCATACAATACTCCAGTATTTGCCATAAAGAAAAAAGACAGTACTAAAT  
GGAGGAAATTAGTAGATTTTCAGAGAACTTAATAAGAGAACTCAAGACTTCTG  
GGAAGTTCAATTAGGAATACCACATCCCGCAGGGTTAAAAAAGAAAAAATCA  
GTAAACAGTACTGGATGTGGGTGATGCATATTTTTCAGTTCCCTTAGATGAAG  
ACTTCAGGAAGTATACTGCATTTACCATACCTAGTATAAACAATGAGACACC  
AGGGATTAGATATCAGTACAATGTGCTTCCACAGGGATGGAAAGGATCACC  
AGCAATATTCCAAAGTAGCATGACAAAAATCTTAGAGCCTTTTAAAAAACAAA  
ATCCAGACATAGTTATCTATCAATACATGAACGATTTGTATGTAGGATCTGAC  
TTAGAAATAGGGGCAGCATAGAACAAAAATAGAGGAGCTGAGACAACATCTG  
TTGAGGTGGGGACTTACCACACCAGACAAAAAACATCAGAAAGAACCTCCA  
TTCCTTTGGATGGGTATGAACTCCATCCTGATAAATGGACAGTACAGCCTA  
TAGTGCTGCCAGAAAAAGACAGCTGGACTGTCAATGACATACAGAAGTTAG  
TGGGGAAATTGAATACCGCAAGTCAGATTTACCCAGGGATTAAAGTAAGGC  
AATTATGTAACTCCTTAGAGGAACCAAAGCACTAACAGAAGTAATACCACT  
AACAGAAGAAGCAGAGCTAGAACTGGCAGAAAACAGAGAGATTCTAAAAGA  
ACCAGTACATGGAGTGTATTATGACCCATCAAAGACTTAATAGCAGAAATA  
CAGAAGCAGGGGGCAAGGCCAATGGACATATCAAATTTATCAAGAGCCATT  
AAAAATCTGAAAACAGGAAAATATGCAAGAATGAGGGGTGCCCACACTAAT  
GATGTAAAACAATTAACAGAGGCAGTGCAAAAAATAACCACAGAAAGCATAG  
TAATATGGGGAAAGACTCCTAAATTTAACTACCCATACAAAAGGAAACATG  
GGAAACATGGTGGACAGAGTATTGGCAAGCCACCTGGATTCTGAGTGGGA  
GTTTGTTAATACCCCTCCTTTAGTGAAATTATGGTACCAGTTAGAGAAAGAA  
CCCATAGTAGGAGCAGAAACCTTCTATGTAGATGGGGGCAGCTAACAGGGAG  
ACTAAATTAGGAAAAGCAGGATATGTTACTAACAAAGGAAGACAAAAGGTTG  
TCCCCCTAACTAACACAACAAATCAGAAAACCTCAGTTACAAGCAATTTATCTA  
GCTTTGCAGGATTCAGGATTAGAAGTAAACATAGTAACAGACTCACAATATG  
CATTAGGAATCATTCAAGCACACCAGATAAAAGTGAATCAGAGTTAGTCAA  
TCAAATAATAGAGCAGTTAATAAAAAAGGAAAAGGTCTATCTGGCATGGGTA  
CCAGCACACAAAGGAATTGGAGGAAATGAACAAGTAGATAAATTAGTCAGT  
GCTGGAATCAGGAAAATACTATTTTTAGATGGAATAGATAAGGCCCAAGATG  
AACATTAGTTTTTATGTCGACCTGCAGGGGAAAGTTTTATAGGTAGTTGATAG  
AACAAAATACATAATTTTGTAAAAATAAATCACTTTTTATACTAATATGACACG  
ATTACCAATACTTTTGTACTAATATCATTAGTATACGCTACACCTTTTCCTCA

*FIG. 46*(Figure B<sub>4</sub>)

SUBSTITUTE SHEET (RULE 26)

56/63

GACATCTAAAAAATAGGTGATGATGCAACTTTATCATGTAATCGAAATAATA  
CAAATGACTACGTTGTTATGAGTGCTTGGTATAAGGAGCCCAATTCCATTAT  
TCTTTTAGCTGCTAAAAGCGACGTCTTGATTTTGATAATTATACCAAGGATA  
AAATATCTTACGACTCTCCATACGATGATCTAGTTACAACCTATCACAATTAAA  
TCATTGACTGCTAGAGATGCCGGTACTTATGTATGTGCATTCTTTATGACATC  
GCCTACAAATGACACTGATAAAGTAGATTATGAAGAATACTCACAGAGTTG  
ATTGTAAATACAGATAGTGAATCGACTATAGACATAATACTATCTGGATCTAC  
ACATTCACCAGAACTAGTTAAGCTTGTCTCCCTATAGTGAGTCGTATTAGA  
GCTTGGCGTAATCATGGTCATAGCTGTTTCCTGTGTGAAATTGTTATCCGCT  
CACAATTCCACACAACATACGAGCCGGAAGCATAAAGTGTAAGCCTGGGG  
TGCCTAATGAGTGAGCTAACTCACATTAATTGCGTTGCGCTCACTGCCCGCT  
TTCGAGTCGGGAAACCTGTCGTGCCAGCTGCATTAATGAATCGGCCAACGC  
GCGGGGAGAGGCGGTTTGCGTATTGGGCGCTCTTCCGCTTCCTCGCTCAC  
TGACTCGCTGCGCTCGGTGCTTCGGCTGCGGCGAGCGGTATCAGCTCACT  
CAAAGGCGGTAATACGGTTATCCACAGAATCAGGGGATAACGCAGGAAAGA  
ACATGTGAGCAAAAGGCCAGCAAAAGGCCAGGAACCGTAAAAAGGCCGCG  
TTGCTGGCGTTTTTCGATAGGCTCCGCCCCCTGACGAGCATCACAAAAAT  
CGACGCTCAAGTCAGAGGTGGCGAAACCCGACAGGACTATAAAGATACCAG  
GCGTTTCCCCCTGGAAGCTCCCTCGTGCGCTCTCCTGTTCCGACCCTGCCG  
CTTACCGGATACCTGTCCGCTTTCTCCCTTCGGGAAGCGTGCGCGCTTTCT  
CATAGCTCACGCTGTAGGTATCTCAGTTCGGTGTAGGTGCTTCGCTCCAAG  
CTGGGCTGTGTGCACGAACCCCCCGTTTCAGCCCGACCGCTGCGCCTTATC  
CGGTAACCTATCGTCTTGAGTCCAACCCGGTAAGACACGACTTATCGCCACT  
GGCAGCAGCCACTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGCGGTG  
CTACAGAGTTCTTGAAGTGGTGGCCTAACTACGGCTACACTAGAAGGACAG  
TATTTGGTATCTGCGCTCTGCTGAAGCCAGTTACCTTCGGAAAAAGAGTTGG  
TAGCTCTTGATCCGGCAAACAACCCACCGCTGGTAGCGGTGGTTTTTTTGT  
TGCAAGCAGCAGATTACGCGCAGAAAAAAGGATCTCAAGAAGATCCTTTG  
ATCTTTTCTACGGGGTCTGACGCTCAGTGGAACGAAAACCTCACGTTAAGGG  
ATTTTGGTCATGAGATTATCAAAAAGGATCTTCACCTAGATCCTTTTAAATTA  
AAAATGAAGTTTTTAAATCAATCTAAAGTATATATGAGTAACTTGGTCTGACA  
GTTACCAATGCTTAATCAGTGAGGCACCTATCTCAGCGATCTGTCTATTTG  
TTCATCCATAGTTGCCTGACTCCCCGTCGTGTAGATAACTACGATACGGGAG  
GGCTTACCATCTGGCCCCAGTGCTGCAATGATACCGCGAGACCCACGCTCA  
CCGGCTCCAGATTTATCAGCAATAAACCAGCCAGCCGGAAGGGCCGAGCG  
CAGAAGTGGTCCTGCAACTTTATCCGCTCCATCCAGTCTATTAATTGTTGC  
CGGGAAGCTAGAGTAAGTAGTTCGCCAGTTAATAGTTTGCGCAACGTTGTT  
GGCATTGCTACAGGCATCGTGGTGTACGCTCGTCGTTTGGTATGGCTTCA  
TTCAGCTCCGGTTCCCAACGATCAAGGCGAGTTACATGATCCCCCATGTTGT  
GCAAAAAAGCGGTTAGCTCCTTCGGTCCTCCGATCGTTGTCAGAAGTAAGT  
TGGCCGCAGTGTTATCACTCATGGTTATGGCAGCACTGCATAATTCTCTTAC  
TGTCATGCCATCCGTAAGATGCTTTTCTGTGACTGGTGAGTACTCAACCAAG  
TCATTCTGAGAATAGTGTATGCGGCGACCGAGTTGCTCTTGCCCGGGCGTCA  
ATACGGGATAATACCGCGCCACATAGCAGAACTTTAAAGTGCTCATCATTG  
GAAAACGTTCTTCGGGGCGAAAACCTCTCAAGGATCTTACCGCTGTTGAGAT  
CCAGTTCGATGTAACCCACTCGTGCAACCAACTGATCTTCAGCATCTTTTAC

*FIG. 47*(Figure B<sub>5</sub>)

SUBSTITUTE SHEET (RULE 26)



57/63

TTTCACCAGCGTTTCTGGGTGAGCAAAAACAGGAAGGCCAAAATGCCGCAAA  
 AAAGGGAATAAGGGGCGACACGGAAATGTTGAATACTCATACTCTTCCTTTTT  
 CAATATTATTGAAGCATTATCAGGGTTATTGTCTCATGAGCGGATACATATT  
 TGAATGTATTTAGAAAAATAAACAAATAGGGGGTTCCGCGCACATTTCCCCGA  
 AAAGTGCCACCTGACGTCTAAGAAACCATTATTATCATGACATTAACCTATAA  
 AATAGGCGTATCACGAGGGCCCTTTCGTCTCGCGCGTTTCGGTGATGACGG  
 TGAAAACCTCTGACACATGCAGCTCCCGGAGACGGTCACAGCTTGTCTGTA  
 AGCGGATGCCGGGAGCAGACAAGCCCGTCAGGGGCGCGTCAGCGGGTGTT  
 GGCGGGTGTCGGGGGCTGGCTTAACCTATGCGGGCATCAGAGCAGATTGTACT  
 GAGAGTGCACCATATGCGGTGTGAAATACCGCACAGATGCGTAAGGAGAAA  
 ATACCGCATCAGGCGCCATTTCGCCATTCAGGCTGCGCAACTGTTGGGAAGG  
 GCGATCGGTGCGGGGCTCTTCGCTATTACGCCAGCTGGCGAAAGGGGGAT  
 GTGCTGCAAGGCGATTAAGTTGGGTAACGCCAGGGTTTTCCAGTCACGAC  
 GTTGTAACGACGGCCAGTGAATTGGATTAGGTGACACTATA

**New Psyn II Promoter which controls ADA envelope expression:**

TAAAAAATGAAAAAATATTCTAATTTATAGGACGGTTTTGATTTTCTTTTTTTC  
 TATGCTATAAATAATAATA

**ADA envelope truncated:**

ATGAAAGTGAAGGGGATCAGGAAGAATTATCAGCACTTGTGGAAATGGGGC  
 ATCATGCTCCTTGGGATGTTGATGATCTGTAGTGCTGTAGAAAATTTGTGGG  
 TCACAGTTTATTATGGGGTACCTGTGTGGAAAGAAGCAACCACCACTCTATT  
 TTGTGCATCAGATGCTAAAGCATATGATACAGAGGTACATAATGTTTGGGCC  
 ACACATGCCTGTGTACCCACAGACCCCAACCCACAAGAAGTAGTATTGGAA  
 AATGTGACAGAAAATTTTAACATGTGGAAAAATAACATGGTAGAACAGATGC  
 ATGAGGATATAATCAGTTTATGGGATCAAAGCCTAAAGCCATGTGTAAAATT  
 AACCCCACTCTGTGTTACTTTAAATTGCACTGATTTGAGGAATGTTACTAATA  
 TCAATAATAGTAGTGAGGGAATGAGAGGAGAAATAAAAAACTGCTCTTTCAA  
 TATCACCACAAGCATAAGAGATAAGGTGAAGAAAGACTATGCACTTTTCTAT  
 AGACTTGATGTAGTACCAATAGATAATGATAATACTAGCTATAGGTTGATAAA  
 TTGTAATACCTCAACCATTACACAGGCCTGTCCAAAGGTATCCTTTGAGCCA  
 ATTCCCATACATTATTGTACCCCGGCTGGTTTTGCGATTCTAAAGTGTAAG  
 ACAAGAAGTTCAATGGAACAGGGCCATGTAAAAATGTCAGCACAGTACAAT  
 GTACACATGGAATTAGGCCAGTAGTGTCAACTCAACTGCTGTTAAATGGCAG  
 TCTAGCAGAAGAAGAGGTAGTAATTAGATCTAGTAATTTACACAGACAATGCA  
 AAAACATAATAGTACAGTTGAAAGAATCTGTAGAAATTAATTGTACAAGACC  
 CAACAACAATAAAGGAAAAGTATACATATAGGACCAGGAAGAGCATTTTAT  
 ACAACAGGAGAAATAATAGGAGATATAAGACAAGCACATTGCAACATTAGTA  
 GAACAAAATGGAATAACACTTTAAATCAAATAGCTACAAAATTAAGAACA  
 TTTGGGAATAATAAAACAATAGTCTTTAATCAATCCTCAGGAGGGGACCCAG  
 AAATTGTAATGCACAGTTTTAATTGTGGAGGGGAATTCTTCTACTGTAATTCA  
 ACACAACCTGTTTAATAGTACTTGGAATTTAATGGTACTTGGAATTTAACACA

*FIG. 48*

(Figure B<sub>6</sub>)

SUBSTITUTE SHEET (RULE 26)

58/63

ATCGAATGGTACTGAAGGAAATGACACTATCACACTCCCATGTAGAATAAAA  
 CAAATTATAAATATGTGGCAGGAAGTAGGAAAAGCAATGTATGCCCTCCCA  
 TCAGAGGACAAATTAGATGCTCATCAAATATTACAGGGCTAATATTAACAAG  
 AGATGGTGGAACTAACAGTAGTGGGTCCGAGATCTTCAGACCTGGGGGAG  
 GAGATATGAGGGACAATTGGAGAAGTGAATTATATAAATATAAAGTAGTAAA  
 AATTGAACCATTAGGAGTAGCACCCACCAAGGCCAAAAAGAAGATGGTGCA  
 GAGAGAAAAAAGAGCAGTGGGAACGATAGGAGCTATGTTCTTGGGGTTCTT  
 GGGAGCAGCAGGAAGCACTATGGGCGCAGCGTCAATAACGCTGACGGTAC  
 AGGCCAGACTATTATTGTCTGGTATAGTGCAACAGCAGAACAATTTGCTGAG  
 GGCTATTGAGGCGCAACAGCATCTGTTGCAACTCACAGTCTGGGGGCATCAA  
 GCAGCTCCAGGCAAGAGTCCTGGCTGTGGAAAGATACCTAAGGGATCAACA  
 GCTCCTAGGGATTTGGGGTTGCTCTGGAAAACCTCATCTGCACCACTGCTGT  
 GCCTTGGAATGCTAGTTGGAGTAATAAACTCTGGATATGATTTGGGATAAC  
 ATGACCTGGATGGAGTGGGAAAGAGAAATCGAAAATTACACAGGCTTAATAT  
 ACACCTTAATTGAGGAATCGCAGAACCAACAAGAAAAGAATGAACAAGACTT  
 ATTAGCATTAGATAAGTGGGCAAGTTTGTGGAATTGGTTTGACATATCAAATT  
 GGCTGTGGTATGTAAAAATCTTCATAATGATAGTAGGAGGCTTGATAGGTTT  
 AAGAATAGTTTTTACTGTACTTTCTATAGTAAATAGAGTTAGGCAGGGGATACT  
 CACCATTGTCATTTAGACCCACCTCCAGCCCCGAGGGGACCCGACAGG  
 CCCGAAGGAATCGAAGAAGAAGGTGGAGACAGAGAC

**PmH5 promoter (which controls HXB2 gag pol expression):**

AAAAATTGAAAATAAATACAAAGGTTCTTGAGGGTTGTGTTAAATTGAAAGC  
 GAGAAATAATCATAAATA

**HXB2 gag pol (with safety mutations, Δ integrase):**

ATGGGTGCGAGAGCGTCAGTATTAAGCGGGGGGAGAATTAGATCGATGGGA  
 AAAAATTCGGTTAAGGCCAGGGGGGAAAGAAAAAATATAAATTAAACATATA  
 GTATGGGCAAGCAGGGAGCTAGAACGATTGCGCAGTTAATCCTGGCCTGTTA  
 GAAACATCAGAAGGCTGTAGACAAATACTGGGACAGCTACAACCATCCCTT  
 CAGACAGGATCAGAAGAAGCTTAGATCATTATATAATACAGTAGCAACCCTCT  
 ATTGTGTGCATCAAAGGATAGAGATAAAAGACACCAAGGAAGCTTTAGACAA  
 GATAGAGGAAGAGCAAAACAAAAGTAAGAAAAAAGCACAGCAAGCAGCAGC  
 TGACACAGGACACAGCAATCAGGTCAGCCAAAATTACCCTATAGTGCAGAA  
 CATCCAGGGGGCAAATGGTACATCAGGCCATATCACCTAGAACTTTAAATGCA  
 TGGGTAAAAGTAGTAGAAGAGAAGGCTTTCAGCCCAGAAGTGATACCCATG  
 TTTTCAGCATTATCAGAAGGAGCCACCCCAAGATTTAAACACCATGCTAA  
 ACACAGTGGGGGGACATCAAGCAGCCATGCAAATGTTAAAAGAGACCATCA  
 ATGAGGAAGCTGCAGAATGGGATAGAGTGCATCCAGTGCATGCAGGGCCT  
 ATTGCACCAGGCCAGATGAGAGAACCAAGGGGAAGTGACATAGCAGGAAC  
 TACTAGTACCCTTCAGGAACAAATAGGATGGATGACAAATAATCCACCTATC  
 CCAGTAGGAGAAATTTATAAAAGATGGATAATCCTGGGATTAAATAAATAG  
 TAAGAATGTATAGCCCTACCAGCATTCTGGACATAAGACAAGGACCAAAAGA  
 ACCCTTTAGAGACTATGTAGACCGGTTCTATAAACTCTAAGAGCCGAGCAA

*FIG. 49*

(Figure B<sub>7</sub>)

SUBSTITUTE SHEET (RULE 26)

59/63

GCTTCACAGGAGGTAAAAAATTGGATGACAGAAACCTTGTTGGTCCAAAATG  
CGAACCCAGATTGTAAGACTATTTTAAAAGCATTGGGACCAGCGGCTACACT  
AGAAGAAATGATGACAGCATGTCAGGGAGTAGGAGGACCCGGCCATAAGG  
CAAGAGTTTTGGCTGAAGCAATGAGCCAAGTAACAAATTCAGCTACCATAAT  
GATGCAGAGAGGCAATTTTAGGAACCAAAGAAAGATTGTTAAGTGTTTCAAT  
TGTGGCAAAGAAGGGGCACACAGCCAGAAATTGCAGGGGCCCTAGGAAAAA  
GGGCTGTTGGAAATGTGGAAAGGAAGGACACCAAATGAAAGATTGTACTGA  
GAGACAGGCTAATTTTTTAGGGAAGATCTGGCCTTCCTACAAGGGAAGGCC  
AGGGAATTTTCTTCAGAGCAGACCAGAGCCAACAGCCCCACCAGAAGAGAG  
CTTCAGGTCTGGGGTAGAGACAACAACCTCCCCCTCAGAAGCAGGAGCCGAT  
AGACAAGGAACTGTATCCTTTAACTTCCCTCAGATCACTCTTTGGCAACGAC  
CCCTCGTCACAATAAAGATAGGGGGGGCAACTAAAGGAAGCTCTATTAGATA  
CAGGAGCAGATGATACAGTATTAGAAGAAATGAGTTTGCCAGGAAGATGGA  
AACCAAAAATGATAGGGGGGAATTGGAGGTTTTATCAAAGTAAGACAGTATGA  
TCAGATACTCATAGAAATCTGTGGACATAAAGCTATAGGTACAGTATTAGTA  
GGACCTACACCTGTCAACATAATTGGAAGAAATCTGTTGACTCAGATTGGTT  
GCACTTTAAATTTTCCCATTAGCCCTATTGAGACTGTACCAGTAAAATTAAG  
CCAGGAATGGATGGCCCAAAGTTAAACAATGGCCATTGACAGAAGAAAAA  
ATAAAAGCATTAGTAGAAATTTGTACAGAAATGGAAAAGGAAGGGGAAATTT  
CAAAAATTGGGCCTGAGAATCCATACAATACTCCAGTATTTGCCATAAAGAA  
AAAAGACAGTACTAAATGGAGGAAATTAGTAGATTTTCAGAGAACTTAATAAG  
AGAACTCAAGACTTCTGGGAAGTTCAATTAGGAATACCACATCCCGCAGGG  
TTAAAAAAGAAAAAATCAGTAACAGTACTGGATGTGGGTGATGCATATTTTTC  
AGTTCCCTTAGATGAAGACTTCAGGAAGTATACTGCATTTACCATACCTAGT  
ATAACAATGAGACACCAGGGATTAGATATCAGTACAATGTGCTTCCACAGG  
GATGGAAAGGATCACCAGCAATATTCCAAAGTAGCATGACAAAAATCTTAGA  
GCCTTTTAAAAAACAATAATCCAGACATAGTTATCTATCAATACATGAACGATT  
TGTATGTAGGATCTGACTTAGAAATAGGGGCAGCATAGAACAAAAATAGAGGA  
GCTGAGACAACATCTGTTGAGGTGGGGACTTACCACACCAGACAAAAAACA  
TCAGAAAGAACCTCCATTCCTTTGGATGGGTATGAACTCCATCCTGATAAA  
TGGACAGTACAGCCTATAGTGCTGCCAGAAAAAGACAGCTGGACTGTCAAT  
GACATACAGAAGTTAGTGGGGGAAATTGAATACCGCAAGTCAGATTTACCCA  
GGGATTAAAGTAAGGCAATTATGTAAACTCCTTAGAGGAACCAAAGCACTAA  
CAGAAGTAATACCACTAACAGAAGAAGCAGAGCTAGAACTGGCAGAAAAACA  
GAGAGATTCTAAAAGAACCAGTACATGGAGTGTATTATGACCCATCAAAAGA  
CTTAATAGCAGAAATACAGAAGCAGGGGGCAAGGCCAATGGACATATCAAAT  
TTATCAAGAGCCATTTAAAAATCTGAAAACAGGAAAATATGCAAGAATGAGG  
GGTGCCACACTAATGATGTAAACAATTAACAGAGGCAGTGCAAAAAATAA  
CCACAGAAAGCATAGTAATATGGGGGAAAGACTCCTAAATTTAAACTACCCAT  
ACAAAAGGAAACATGGGAAACATGGTGGACAGAGTATTGGCAAGCCACCTG  
GATTCCTGAGTGGGAGTTTGTTAATACCCCTCCTTTAGTGAAATTATGGTAC  
CAGTTAGAGAAAGAACCCATAGTAGGAGCAGAAACCTTCTATGTAGATGGG  
GCAGCTAACAGGGGAGACTAAATTAGGAAAAGCAGGATATGTTACTAACAAA  
GGAAGACAAAAGGTTGTCCCCCTAACTAACACAACAAATCAGAAAACCTCAGT  
TACAAGCAATTTATCTAGCTTTGCAGGATTCAGGATTAGAAGTAAACATAGTA  
ACAGACTCACAATATGCATTAGGAATCATTCAAGCACAACCAGATAAAAGTG

*FIG. 50*(Figure B<sub>8</sub>)

SUBSTITUTE SHEET (RULE 26)


60/63

AATCAGAGTTAGTCAATCAAATAATAGAGCAGTTAATAAAAAAGGAAAAGGT  
CTATCTGGCATGGGTACCAGCACACAAAGGAATTGGAGGAAATGAACAAGT  
AGATAAATTAGTCAGTGCTGGAATCAGGAAAATACTATTTTATAGATGGAATA  
GATAAGGCCCAAGATGAACATTAG

*FIG. 51*(Figure B<sub>9</sub>)

SUBSTITUTE SHEET (RULE 26)





**FIG. 52**

(Figure C)






FIG. 53

(Figure D)

63/63

Sequence of new Psyn II promoter:

Early part of promoter

Critical region

Early start site

TAAAAATGAAAAATATTCTAATTTATAGGACGGT

Late part of promoter

TTTGATTTTCITTTTTCTATGCTATAAATAATAAATA

**FIG. 54**

(Figure E)

## SEQUENCE LISTING

<110> THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE  
SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES  
Moss, Bernard  
Wyatt, Linda  
Earl, Patricia

<120> MVA EXPRESSING MODIFIED HIV ENVELOPE,  
GAG, AND POL GENES

<130> NIH211.001PCT

<150> US 60/274,434

<151> 2001-03-08

<160> 13

<170> FastSEQ for Windows Version 4.0

<210> 1

<211> 12225

<212> DNA

<213> Artificial Sequence

<220>

<223> Plasmid pLW-48

<400> 1

|            |            |             |             |            |            |      |
|------------|------------|-------------|-------------|------------|------------|------|
| gaattcggtg | gtggtcgcca | tggatggtgt  | tattgtatac  | tgtctaaacg | cgtagtaaaa | 60   |
| acatggcgag | gaaataaatc | atataaaaaa  | tgatttcacg  | attaaaccat | gttgtgaaaa | 120  |
| agtcagaac  | gttcacattg | gcggacaatc  | taaaaacaat  | acagtgattg | cagatttgcc | 180  |
| atatatggat | aatgcggtat | ccgatgtatg  | caattcactg  | tataaaaaga | atgtatcaag | 240  |
| aatatccaga | tttgctaatt | tgataaagat  | agatgacgat  | gacaagactc | ctactggtgt | 300  |
| atataattat | tttaaacctc | aagatgccat  | tcctgttatt  | atatccatag | gaaaggatag | 360  |
| agatgtttgt | gaactattaa | tctcatctga  | taaagcgtgt  | gcgtgtatag | agttaaattc | 420  |
| atataaagta | gccattcttc | ccatggatgt  | ttcctttttt  | accaaaggaa | atgcatcatt | 480  |
| gattattctc | ctgtttgatt | tctctatcga  | tgccggcacct | ctcttaagaa | gtgtaaccga | 540  |
| taataatggt | attatatcta | gacaccagcg  | tctacatgac  | gagcttccga | gttccaattg | 600  |
| gttcaagttt | tacataagta | taaagtccga  | ctattgttct  | atattatata | tggttggtga | 660  |
| tggatctgtg | atgcatgcaa | tagctgataa  | tagaacttac  | gcaaatatta | gcaaaaatat | 720  |
| attagacaat | actacaatta | acgatgagtg  | tagatgctgt  | tatttttgaa | cacagattag | 780  |
| gattcttgat | agagatgaga | tgctcaatgg  | atcatcgtgt  | gatatgaaca | gacattgtat | 840  |
| tatgatgaat | ttacctgatg | taggcgaatt  | tggatctagt  | atgttgggga | aatatgaacc | 900  |
| tgacatgatt | aagattgctc | tttcgggtggc | tgggtaccag  | gcgcgccttt | cattttgttt | 960  |
| ttttctatgc | tataaatggg | acgtcctgta  | gaaaccccaa  | cccgtaaat  | caaaaaactc | 1020 |
| gacggcctgt | gggcattcag | tctggatcgc  | gaaaactgtg  | gaattgatca | gcgttggtgg | 1080 |
| gaaagcgcgt | tacaagaaag | ccgggcaatt  | gctgtgccag  | gcagttttta | cgatcagttc | 1140 |
| gccgatgcag | atattcgtaa | ttatgcgggc  | aacgtctggt  | atcagcgcga | agtctttata | 1200 |
| ccgaaagggt | gggcaggcca | gcgtatcgtg  | ctgcgtttcg  | atgcggtcac | tcattacggc | 1260 |
| aaagtgtggg | tcaataatca | ggaagtgatg  | gagcatcagg  | gcggctatac | gccatttgaa | 1320 |
| gcgatgtca  | cgccgtatgt | tattgccggg  | aaaagtgtac  | gtatcaccgt | ttgtgtgaac | 1380 |
| aacgaactga | actggcagac | tatcccgcgc  | ggaatggtga  | ttaccgacga | aaacggcaag | 1440 |
| aaaaagcagt | cttacttcca | tgatttcttt  | aactatgccg  | gaatccatcg | cagcgtaatg | 1500 |
| ctctacacca | cgccgaacac | ctgggtggac  | gatatacccg  | tggtgacgca | tgtcgcgcaa | 1560 |
| gactgtaacc | acgcgtctgt | tgactggcag  | gtggtggcca  | atggtgatgt | cagcgttgaa | 1620 |
| ctgcgtgatg | cggatcaaca | ggtggttgca  | actggacaag  | gcactagcgg | gactttgcaa | 1680 |

|             |             |             |             |             |             |      |
|-------------|-------------|-------------|-------------|-------------|-------------|------|
| gtggtgaatc  | cgcacctctg  | gcaaccgggt  | gaagggttatc | tctatgaact  | gtgcgtcaca  | 1740 |
| gccaaaagcc  | agacagagtg  | tgatatctac  | ccgcttcgeg  | tcggcatccg  | gtcagtggca  | 1800 |
| gtgaagggcg  | aacagttcct  | gattaaccac  | aaacggttct  | actttactgg  | ctttggtcgt  | 1860 |
| catgaagatg  | cggacttgcg  | tggcaaagga  | ttcgataacg  | tgctgatggg  | gcacgaccac  | 1920 |
| gcattaatgg  | actggattgg  | ggccaactcc  | taccgtacct  | cgcattaccc  | ttacgctgaa  | 1980 |
| gagatgctcg  | actgggcaga  | tgaacatggc  | atcgtgggtga | ttgatgaaac  | tgctgctgtc  | 2040 |
| ggctttaacc  | tctcttttagg | cattgggtttc | gaagcgggca  | acaagccgaa  | agaactgtac  | 2100 |
| agcgaagagg  | cagtcaacgg  | ggaaactcag  | caagcgcact  | tacaggcgat  | taaagagctg  | 2160 |
| atagcgcgtg  | acaaaaacca  | cccaagcgtg  | gtgatgtgga  | gtattgccaa  | cgaaccggat  | 2220 |
| acccgtccgc  | aaggtgcacg  | ggaatatattc | gcgccactgg  | cggagcaaac  | gcgtaaactc  | 2280 |
| gacccgacgc  | gtccgatcac  | ctgcgtcaat  | gtaatgttct  | gcgacgctca  | caccgatacc  | 2340 |
| atcagcgcgc  | tctttgatgt  | gctgtgcctg  | aaccgttatt  | acggatggta  | tgtccaaagc  | 2400 |
| ggcgattttg  | aaacggcaga  | gaaggtactg  | gaaaaagaac  | ttctggcctg  | gcaggagaaa  | 2460 |
| ctgcatcagc  | cgattatcat  | caccgaatac  | ggcgtggata  | cgtagccgg   | gctgcactca  | 2520 |
| atgtacaccg  | acatgtggag  | tgaagagtat  | cagtgtgcat  | ggctggatat  | gtatcaccgc  | 2580 |
| gtctttgatc  | gcgtcagcgc  | cgctcgtcgg  | gaacaggtat  | ggaatttcgc  | cgatttttgc  | 2640 |
| acctcgcaag  | gcatatttgc  | cgttggcggg  | aacaagaaag  | ggatcttcac  | tcgcgaccgc  | 2700 |
| aaaccgaagt  | cggcggtttt  | tctgctgcaa  | aaacgctgga  | ctggcatgaa  | cttcggtgaa  | 2760 |
| aaaccgcagc  | agggaggcaa  | acaatgagag  | ctcgggttgt  | gatggatctg  | tgatgcatgc  | 2820 |
| aatagctgat  | aatagaactt  | acgcaaatat  | tagcaaaaat  | atattagaca  | atactacaat  | 2880 |
| taacgatgag  | tgtagatgct  | gttattttga  | accacagatt  | aggattcttg  | atagagatga  | 2940 |
| gatgctcaat  | ggatcatcgt  | gtgatatgaa  | cagacattgt  | attatgatga  | atttacctga  | 3000 |
| tgtaggcgaa  | tttgatctta  | gtatgttggg  | gaaatatgaa  | cctgacatga  | ttaagattgc  | 3060 |
| tctttcgggtg | gctggcgggc  | cgctcgagta  | aaaaatgaaa  | aaatatctta  | atttatagga  | 3120 |
| cggttttgat  | tttctttttt  | tctatgctat  | aaataataaa  | tagcggccgc  | accatgaaag  | 3180 |
| tgaaggggat  | caggaagaat  | tatcagcact  | tgtggaaatg  | gggcatcatg  | ctccttggga  | 3240 |
| tgttgatgat  | ctgtagtgtc  | gtagaaaatt  | tgtgggtcac  | agtttattat  | ggggtacctg  | 3300 |
| tgtggaaaga  | agcaaccacc  | actctatttt  | gtgcatcaga  | tgctaaagca  | tatgatacag  | 3360 |
| aggtacataa  | tgtttggggc  | acacatgcct  | gtgtaccac   | agaccccaac  | ccacaagaag  | 3420 |
| tagtattgga  | aaatgtgaca  | gaaaatttta  | acatgtggaa  | aaataacatg  | gtagaacaga  | 3480 |
| tgcatgagga  | tataatcagt  | ttatgggatc  | aaagcctaaa  | gccatgtgta  | aaattaaccc  | 3540 |
| cactctgtgt  | tacttttaa   | tgcactgatt  | tgaggaatgt  | tactaatatc  | aataatagta  | 3600 |
| gtgaggggat  | gagaggagaa  | ataaaaaact  | gctctttcaa  | tatcaccaca  | agcataagag  | 3660 |
| ataaggtgaa  | gaaagactat  | gcacttttct  | atagacttga  | tgtagtacca  | atagataatg  | 3720 |
| ataatactag  | ctatagggtg  | ataaattgta  | atacctcaac  | cattacacag  | gcctgtccaa  | 3780 |
| aggtatcctt  | tgagccaatt  | cccatacatt  | attgtacccc  | ggctgggttt  | gcgattctaa  | 3840 |
| agtgtaaaga  | caagaagttc  | aatggaacag  | ggccatgtaa  | aaatgtcagc  | acagtacaat  | 3900 |
| gtacacatgg  | aattaggcca  | gtagtgtcaa  | ctcaactgct  | gttaaattggc | agtctagcag  | 3960 |
| aagaagaggt  | agtaattaga  | tctagtaatt  | tcacagacaa  | tgcaaaaaac  | ataatagtac  | 4020 |
| agttgaaaga  | atctgtagaa  | attaattgta  | caagacccaa  | caacaataca  | aggaaaagta  | 4080 |
| tacatatagg  | accaggaaga  | gcattttata  | caacaggaga  | aataatagga  | gatataagac  | 4140 |
| aagcacattg  | caacattagt  | agaacaaaat  | ggaataacac  | tttaaataca  | atagctacaa  | 4200 |
| aattaaaaga  | acaatttggg  | aataataaaa  | caatagtctt  | taatcaatcc  | tcaggagggg  | 4260 |
| accagaaat   | tgtaatgcac  | agtttttaatt | gtggagggga  | attcttctac  | tgtaattcaa  | 4320 |
| cacaactggt  | taatagtact  | tgggaatttta | atgggtacttg | gaatttaaca  | caatcgaatg  | 4380 |
| gtactgaagg  | aaatgacact  | atcacactcc  | catgtagaat  | aaaacaaatt  | ataaatatgt  | 4440 |
| ggcaggaagt  | aggaaaagca  | atgtatgccc  | ctcccatcag  | aggacaaatt  | agatgctcat  | 4500 |
| caaataattac | agggctaata  | ttaacaagag  | atgggtggaac | taacagtagt  | gggtccgaga  | 4560 |
| tcttcagacc  | tgggggagga  | gatatgaggg  | acaattggag  | aagtgaatta  | tataaatata  | 4620 |
| aagtagtaaa  | aattgaacca  | ttaggagtag  | caccaccaa   | ggcaaaaaga  | agagtgggtgc | 4680 |
| agagagaaaa  | aagagcagtg  | ggaacgatag  | gagctatgtt  | ccttgggttc  | ttgggagcag  | 4740 |
| caggaagcac  | tatgggcgca  | gcgtcaataa  | cgctgacggg  | acaggccaga  | ctattattgt  | 4800 |
| ctggatatagt | gcaacagcag  | aacaatttgc  | tgagggctat  | tgaggcgcaa  | cagcatctgt  | 4860 |
| tgcaactcac  | agtctggggc  | atcaagcagc  | tccaggcaag  | agtcctggct  | gtggaaagat  | 4920 |
| acctaaggga  | tcaacagctc  | ctagggattt  | ggggttgctc  | tggaaaactc  | atctgcacca  | 4980 |
| ctgctgtgcc  | ttggaatgct  | agttggagta  | ataaaactct  | ggatatgatt  | tgggataaca  | 5040 |
| tgacctggat  | ggagtgggaa  | agagaaatcg  | aaaattacac  | aggcttaata  | tacaccttaa  | 5100 |
| ttgaggaatc  | gcagaaccaa  | caagaaaaga  | atgaacaaga  | cttattagca  | ttagataagt  | 5160 |
| gggcaagttt  | gtggaattgg  | tttgacatat  | caaattggct  | gtggtatgta  | aaaatcttca  | 5220 |

|            |            |             |            |             |             |      |
|------------|------------|-------------|------------|-------------|-------------|------|
| taatgatagt | aggaggcttg | atagggttta  | gaatagtttt | tactgtactt  | tctatagtaa  | 5280 |
| atagagttag | gcagggatac | tcaccattgt  | catttcagac | ccacctcca   | gccccgaggg  | 5340 |
| gacccgacag | gcccgaagga | atcgaagaag  | aaggtggaga | cagagactaa  | tttttatgcg  | 5400 |
| gccgctggta | cccaacctaa | aaattgaaaa  | taaatacaaa | ggttcttgag  | ggttgtgtta  | 5460 |
| aattgaaagc | gagaaataat | cataaataag  | cccggggatc | ctctagagtc  | gacaccatgg  | 5520 |
| gtgcgagagc | gtcagtatta | agcggggggag | aattagatcg | atgggaaaaa  | attcgggttaa | 5580 |
| ggccaggggg | aaagaaaaaa | tataaattaa  | aacatatagt | atgggcaagc  | aggagagctag | 5640 |
| acgattcgc  | agttaatcct | ggcctgttag  | aaacatcaga | aggctgtaga  | caaatactgg  | 5700 |
| gacagctaca | accatccctt | cagacaggat  | cagaagaact | tagatcatta  | tataatacag  | 5760 |
| tagcaaccct | ctattgtgtg | catcaaagga  | tagagataaa | agacaccaag  | gaagcttttag | 5820 |
| acaagataga | ggaagagcaa | aacaaaagta  | agaaaaaagc | acagcaagca  | gcagctgaca  | 5880 |
| caggacacag | caatcaggtc | agccaaaatt  | accctatagt | gcagaacatc  | caggggcaaa  | 5940 |
| tggtacatca | ggccatatca | cctagaactt  | taaatgcatg | ggtaaaaagta | gtagaagaga  | 6000 |
| aggctttcag | cccagaagtg | atacccatgt  | tttcagcatt | atcagaagga  | gccacccac   | 6060 |
| aagattttaa | caccatgcta | aacacagtgg  | ggggacatca | agcagccatg  | caaatgttaa  | 6120 |
| aagagaccat | caatgaggaa | gctgcagaat  | gggatagagt | gcatccagtg  | catgcagggc  | 6180 |
| ctattgcacc | aggccagatg | agagaaccaa  | ggggaagtga | catagcagga  | actactagta  | 6240 |
| cccttcagga | acaaatagga | tggatgacaa  | ataatccacc | tatcccagta  | ggagaaattt  | 6300 |
| ataaaagatg | gataatcctg | ggattaaata  | aaatagtaag | aatgtatagc  | cctaccagca  | 6360 |
| ttctggacat | aagacaagga | ccaaaagaac  | cctttagaga | ctatgtagac  | cggttctata  | 6420 |
| aaactctaag | agccgagcaa | gcttcacagg  | aggtaaaaaa | ttggatgaca  | gaaaccttgt  | 6480 |
| tggtccaaaa | tgcgaacca  | gattgtaaga  | ctatttttaa | agcattggga  | ccagcggcta  | 6540 |
| cactagaaga | aatgatgaca | gcatgtcagg  | gagtaggagg | acccggccat  | aaggcaagag  | 6600 |
| ttttggctga | agcaatgagc | caagtaacaa  | attcagctac | cataatgatg  | cagagaggca  | 6660 |
| attttaggaa | ccaaagaaag | attgttaagt  | gtttcaattg | tggcaaagaa  | gggcacacag  | 6720 |
| ccagaaattg | cagggcccct | aggaaaaagg  | gctgttggaa | atgtggaaag  | gaaggacacc  | 6780 |
| aaatgaaaga | ttgtactgag | agacaggcta  | attttttagg | gaagatctgg  | ccttcctaca  | 6840 |
| agggaaggcc | agggaatttt | cttcagagca  | gaccagagcc | aacagcccca  | ccagaagaga  | 6900 |
| gcttcaggtc | tggggtagag | acaacaactc  | ccctcagaa  | gcaggagccg  | atagacaagg  | 6960 |
| aactgtatcc | tttaacttcc | ctcagatcac  | tctttggcaa | cgaccctcgc  | tcacaataaa  | 7020 |
| gatagggggg | caactaaagg | aagctctatt  | agatacagga | gcagatgata  | cagtattaga  | 7080 |
| agaaatgagt | ttgccaggaa | gatggaaacc  | aaaaatgata | gggggaattg  | gaggttttat  | 7140 |
| caaagtaaga | cagtatgatc | agatactcat  | agaaatctgt | ggacataaag  | ctataggtag  | 7200 |
| agtattagta | ggacctacac | ctgtcaacat  | aattggaaga | aatctgttga  | ctcagattgg  | 7260 |
| ttgcacttta | aattttccca | ttagccctat  | tgagactgta | ccagtaaaat  | taaagccagg  | 7320 |
| aatggatggc | ccaaaagtta | aacaatggcc  | attgacagaa | gaaaaaataa  | aagcattagt  | 7380 |
| agaaatttgt | acagaaatgg | aaaaggaagg  | gaaaatttca | aaaattgggc  | ctgagaatcc  | 7440 |
| atacaatact | ccagtatttg | ccataaagaa  | aaaagacagt | actaaatgga  | ggaaattagt  | 7500 |
| agatttcaga | gaacttaata | agagaactca  | agacttctgg | gaagttcaat  | taggaatacc  | 7560 |
| acatcccgcg | gggttaaaaa | agaaaaaatc  | agtaacagta | ctggatgtgg  | gtgatgcata  | 7620 |
| tttttcagtt | cccttagatg | aagacttcag  | gaagtatact | gcatttacca  | tacctagtat  | 7680 |
| aaacaatgag | acaccaggga | ttagatatca  | gtacaatgtg | cttccacagg  | gatggaaagg  | 7740 |
| atcaccagca | atattccaaa | gtagcatgac  | aaaaatctta | gagcctttta  | aaaaacaaaa  | 7800 |
| tccagacata | gttatctatc | aatacatgaa  | cgatttgtat | gtaggatctg  | acttagaaat  | 7860 |
| agggcagcat | agaacaaaaa | tagaggagct  | gagacaacat | ctgttgaggt  | ggggacttac  | 7920 |
| cacaccagac | aaaaaacatc | agaaagaacc  | tccattcctt | tggatgggtt  | atgaactcca  | 7980 |
| tcctgataaa | tggacagtac | agcctatagt  | gctgccagaa | aaagacagct  | ggactgtcaa  | 8040 |
| tgacatacag | aagtttagtg | ggaaattgaa  | taccgcaagt | cagatttacc  | cagggattaa  | 8100 |
| agtaaggcaa | ttatgtaaac | tccttagagg  | aaccaaaagc | ctaacagaag  | taataccact  | 8160 |
| aacagaagaa | gcagagctag | aactggcaga  | aaacagagag | attctaaaag  | aaccagtaca  | 8220 |
| tggagtgtat | tatgacccat | caaaagactt  | aatagcagaa | atacagaagc  | aggggcaagg  | 8280 |
| ccaatggaca | tatcaaattt | atcaagagcc  | atttaaaaaa | ctgaaaacag  | gaaaatatgc  | 8340 |
| aagaatgagg | ggtgcccaca | ctaattgatgt | aaaacaatta | acagaggcag  | tgcaaaaaat  | 8400 |
| aaccacagaa | agcatagtaa | tatggggaaa  | gactcctaaa | tttaaaactac | ccatacaaaa  | 8460 |
| ggaaacatgg | gaaacatggg | ggacagagta  | ttggcaagcc | acctggattc  | ctgagtggga  | 8520 |
| gtttgttaat | acccctcctt | tagtgaaatt  | atggtagcag | ttagagaaag  | aacccatagt  | 8580 |
| aggagcagaa | accttctatg | tagatggggc  | agctaacagg | gagactaaat  | taggaaaagc  | 8640 |
| aggatatgtt | actaacaag  | gaagacaaaa  | ggttgtcccc | ctaactaaca  | caacaaatca  | 8700 |
| gaaaactcag | ttacaagcaa | tttatctagc  | tttgcaggat | tcaggattag  | aagtaaacad  | 8760 |



|             |             |             |             |             |             |       |
|-------------|-------------|-------------|-------------|-------------|-------------|-------|
| agtaacagac  | tcacaatatg  | cattaggaat  | cattcaagca  | caaccagata  | aaagtgaatc  | 8820  |
| agagttagtc  | aatcaaataa  | tagagcagtt  | aataaaaaag  | gaaaagggtct | atctggcatg  | 8880  |
| ggtaccagca  | cacaaaggaa  | ttggaggaaa  | tgaacaagta  | gataaattag  | tcagtgtctgg | 8940  |
| aatcaggaaa  | atactatttt  | tagatggaat  | agataaggcc  | caagatgaac  | attagttttt  | 9000  |
| atgtcgacct  | gcagggaag   | ttttataggt  | agttgataga  | acaaaataca  | taatttttga  | 9060  |
| aaaataaatc  | actttttata  | ctaatatgac  | acgattacca  | atacttttgt  | tactaatatc  | 9120  |
| attagtatac  | gctacacctt  | ttcctcagac  | atctaaaaaa  | atagggtgatg | atgcaacttt  | 9180  |
| atcatgtaat  | cgaaataata  | caaatgacta  | cggtgttatg  | agtgtcttgg  | ataaggagcc  | 9240  |
| caattccatt  | attcttttag  | ctgctaaaag  | cgaggtcttg  | tattttgata  | attataccaa  | 9300  |
| ggataaaaata | tcttacgact  | ctccatacga  | tgatctagtt  | acaactatca  | caattaaatc  | 9360  |
| attgactgct  | agagatgccg  | gtacttatgt  | atgtgcattc  | tttatgacat  | cgcctacaaa  | 9420  |
| tgacactgat  | aaagtagatt  | atgaagaata  | ctccacagag  | ttgattgtaa  | atacagatag  | 9480  |
| tgaatcgact  | atagacataa  | tactatctgg  | atctacacat  | tcaccagaaa  | ctagttaagc  | 9540  |
| ttgtctccct  | atagttagtc  | gtatttagagc | ttggcgtaat  | catggtcata  | gctgtttcct  | 9600  |
| gtgtgaaatt  | gttatccgct  | cacaattcca  | cacaacatac  | gagccggaag  | cataaagtgt  | 9660  |
| aaagcctggg  | gtgcctaata  | agttagctaa  | ctcacattaa  | ttgcgttgcg  | ctcactgcc   | 9720  |
| gctttcgagt  | cgggaaacct  | gtcgtgccag  | ctgcattaat  | gaatcggcca  | acgcgcgggg  | 9780  |
| agaggcggtt  | tgogtattgg  | gcgctcttcc  | gcttcctcgc  | tcactgactc  | gctgcgctcg  | 9840  |
| gtcgttcggc  | tgccggcgagc | ggtatcagct  | cactcaaagg  | cggtaatacg  | gttatccaca  | 9900  |
| gaatcagggg  | ataacgcagg  | aaagaacatg  | tgagcaaaaag | gccagcaaaa  | ggccaggaac  | 9960  |
| cgtaaaaagg  | ccgcgttgct  | ggcgtttttc  | gataggctcc  | gccccctga   | cgagcatcac  | 10020 |
| aaaaatcgac  | gctcaagtca  | gaggtggcga  | aaccgcagag  | gactataaag  | ataccaggcg  | 10080 |
| tttccccctg  | gaagctccct  | cgtgcgctct  | cctgttccga  | ccctgcgct   | taccggatac  | 10140 |
| ctgtccgcct  | ttctcccttc  | gggaagcgtg  | gcgctttctc  | atagctcacg  | ctgtaggtat  | 10200 |
| ctcagttcgg  | tgtaggtcgt  | tcgctccaag  | ctgggctgtg  | tgacacgaacc | ccccgttcag  | 10260 |
| cccgaccgct  | gcgccttate  | cggtaactat  | cgtcttgagt  | ccaaccggt   | aagacacgac  | 10320 |
| ttatcgccac  | tggcagcagc  | cactggtaac  | aggattagca  | gagcgaggta  | tgtaggcggt  | 10380 |
| gctacagagt  | tcttgaagtg  | gtggcctaac  | tacggctaca  | ctagaaggac  | agtatttggt  | 10440 |
| atctgcgctc  | tgctgaagcc  | agttaccttc  | ggaaaaagag  | ttggtagctc  | ttgatccggc  | 10500 |
| aaacaaacca  | ccgctggtag  | cgggtggtttt | tttgtttgca  | agcagcagat  | tacgcgcaga  | 10560 |
| aaaaaaggat  | ctcaagaaga  | tccttttgatc | ttttctacgg  | ggtctgacgc  | tcagtggaac  | 10620 |
| gaaaactcac  | gttaagggat  | tttggtcattg | agattatcaa  | aaaggatctt  | cacctagatc  | 10680 |
| cttttaaat   | aaaaatgaag  | ttttaaatca  | atctaaagta  | tatatgagta  | aacttggtct  | 10740 |
| gacagttacc  | aatgcttaat  | cagttaggca  | cctatctcag  | cgatctgtct  | atttcgttca  | 10800 |
| tccatagttg  | cctgactccc  | cgtcgtgtag  | ataactacga  | tacgggaggg  | cttaccatct  | 10860 |
| ggccccagtg  | ctgcaatgat  | accgcgagac  | ccacgctcac  | cggctccaga  | tttatcagca  | 10920 |
| ataaaccagc  | cagccggaag  | ggccgagcgc  | agaagtggtc  | ctgcaacttt  | atccgcctcc  | 10980 |
| atccagtcta  | ttaattgttg  | ccgggaagct  | agagtaagta  | gttcgccagt  | taatagtttg  | 11040 |
| cgcaacgttg  | ttggcattgc  | tacaggcatc  | gtggtgtcac  | gctcgtcgtt  | tggtatggct  | 11100 |
| tcattcagct  | ccggttccca  | acgatcaagg  | cgagttacat  | gatcccccat  | gttgtgcaaa  | 11160 |
| aaagcggtta  | gctccttcgg  | tcctccgac   | gttgtcagaa  | gtaagtgggc  | cgcagtgtta  | 11220 |
| tcactcatgg  | ttatggcagc  | actgcataat  | tctcttactg  | tcatgccatc  | cgtaagatgc  | 11280 |
| ttttctgtga  | ctggtgagta  | ctcaaccaag  | tcattctgag  | aatagtgtat  | gcggcgaccg  | 11340 |
| agttgctctt  | gcccggcgct  | aatacgggat  | aataccgcgc  | cacatagcag  | aactttaaaa  | 11400 |
| gtgctcatca  | ttggaaaacg  | ttcttcgggg  | cgaaaactct  | caaggatctt  | accgctgttg  | 11460 |
| agatccagtt  | cgatgtaacc  | cactcgtgca  | cccaactgat  | cttcagcatc  | ttttactttc  | 11520 |
| accagcgttt  | ctgggtgagc  | aaaaacagga  | aggcaaaatg  | ccgcaaaaaa  | gggaataagg  | 11580 |
| gcgacacgga  | aatgttgaat  | actcatactc  | ttcctttttc  | aatattattg  | aagcatttat  | 11640 |
| cagggttatt  | gtctcatgag  | cggatacata  | tttgaatgta  | tttagaaaaa  | taaacaaata  | 11700 |
| ggggttccgc  | gcacatttcc  | ccgaaaagtg  | ccacctgacg  | tctaagaaac  | cattattatc  | 11760 |
| atgacattaa  | cctataaaaa  | taggcgtatc  | acgaggccct  | ttcgtctcgc  | gcgtttcggg  | 11820 |
| gatgacgggtg | aaaacctctg  | acacatgcag  | ctcccgagga  | cggtcacagc  | ttgtctgtaa  | 11880 |
| gcggatgccg  | ggagcagaca  | agcccgtcag  | ggcgcgtcag  | cgggtgttgg  | cgggtgtcgg  | 11940 |
| ggctggctta  | actatgcggc  | atcagagcag  | attgtactga  | gagtgcacca  | tatgcggtgt  | 12000 |
| gaaataaccgc | acagatgcgt  | aaggagaaaa  | taccgcatca  | ggcgccattc  | gccattcagg  | 12060 |
| ctgcgcaact  | gttgggaagg  | gcgatcggtg  | cgggcctctt  | cgctattacg  | ccagctggcg  | 12120 |
| aaagggggat  | gtgctgcaag  | gcgattaaagt | tgggtaacgc  | cagggttttc  | ccagtcacga  | 12180 |
| cgttgtaaaa  | cgacggccag  | tgaattggat  | ttaggtgaca  | ctata       |             | 12225 |

&lt;210&gt; 2

<211> 74  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Psyn II promoter

<400> 2  
taaaaaaatga aaaaatattc taatttatag gacgggttttg attttctttt tttctatgct 60  
ataaataata aata 74

<210> 3  
<211> 2214  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> HIV env gene

<400> 3  
atgaaagtga aggggatcag gaagaattat cagcacttgt ggaaatgggg catcatgctc 60  
cttgggatgt tgatgatctg tagtgctgta gaaaatttgt gggtcacagt ttattatggg 120  
gtacctgtgt ggaaagaagc aaccaccact ctattttgtg catcagatgc taaagcatat 180  
gatacagagg tacataatgt ttggggccaca catgcctgtg taccacacaga cccaaccca 240  
caagaagtag tattggaaaa tgtgacagaa aattttaaca tgtggaaaaa taacatggta 300  
gaacagatgc atgaggatat aatcagttta tgggatcaaa gcctaaagcc atgtgtaaaa 360  
ttaacccccc tctgtgttac tttaaattgc actgatttga ggaatgttac taatatcaat 420  
aatagtagtg agggaatgag aggagaaata aaaaactgct ctttcaatat caccacaagc 480  
ataagagata aggtgaagaa agactatgca cttttctata gacttgatgt agtaccaata 540  
gataatgata atactagcta taggttgata aattgtaata cctcaacccat tacacaggcc 600  
tgtccaaagg tatcctttga gccaatcccc atacattatt gtaccccggc tggttttgog 660  
attctaaagt gtaaagacaa gaagttcaat ggaacagggc catgtaaaaa tgtcagcaca 720  
gtacaatgta cacatggaat taggccagta gtgtcaactc aactgctgtt aaatggcagt 780  
ctagcagaag aagaggtagt aattagatct agtaatttca cagacaatgc aaaaaacata 840  
atagtacagt tgaaagaatc tgtagaaatt aattgtacaa gacccaacaa caatacaagg 900  
aaaagtatac atataggacc aggaagagca ttttatacaa caggagaaat aataggagat 960  
ataagacaag cacattgcaa cattagtaga acaaaatgga ataacacttt aaatcaaata 1020  
gctacaaaat taaaagaaca atttgggaat aataaaacaa tagtctttaa tcaatcctca 1080  
ggagggggacc cagaaattgt aatgcacagt ttttaattgtg gaggggaatt cttctactgt 1140  
aattcaacac aactgtttta tagtacttgg aatttttaatg gtacttgga tttaacacaa 1200  
tcgaatggta ctgaaggaaa tgacactatc acactcccat gtagaataaa acaaattata 1260  
aatatgtggc aggaagtagg aaaagcaatg tatgcccctc ccatcagagg acaaattaga 1320  
tgctcatcaa atattacagg gctaataatta acaagagatg gtggaactaa cagtagtggg 1380  
tccgagatct tcagacctgg gggaggagat atgagggaca attggagaag tgaattatat 1440  
aaatataaag tagtaaaaat tgaaccatta ggagtagcac ccaccaaggc aaaaagaaga 1500  
gtggtgcaga gagaaaaaag agcagtggga acgataggag ctatgttcct tgggttcttg 1560  
ggagcagcag gaagcactat gggcgcagcg tcaataacgc tgacggtaca ggccagacta 1620  
ttattgtctg gtatagtgca acagcagaac aatttgctga gggctattga ggcgcaacag 1680  
catctgttgc aactcacagt ctggggcatc aagcagctcc aggcaagagt cctggctgtg 1740  
gaaagatacc taagggatca acagctccta gggatttggg gttgctctgg aaaactcatc 1800  
tgcaccactg ctgtgccttg gaatgctagt tggagtaata aaactctgga tatgatttgg 1860  
gataacatga cctggatgga gtgggaaaga gaaatcgaaa attacacagg cttaataatac 1920  
accttaattg aggaatcgca gaaccaacaa gaaaagaatg aacaagactt attagcatta 1980  
gataagtggg caagtttgtg gaattggttt gacatatcaa attggctgtg gtatgtaaaa 2040  
atcttcataa tgatagtagg aggcttgata ggtttaagaa tagtttttac tgtactttct 2100  
atagtaaata gagttaggca gggatactca ccattgtcat ttcagaccca cctcccagcc 2160  
ccgagggggac ccgacaggcc cgaaggaatc gaagaagaag gtggagacag agac 2214

<210> 4

<211> 70  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> PmH5 promoter

<400> 4  
aaaaattgaa aataaataca aaggttcttg agggttg:gt taaattgaaa gcgagaaata 60  
atcataaata 70

<210> 5  
<211> 3479  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> HIV genes

<400> 5  
atgggtgcga gagcgtcagt attaagcggg ggagaattag atcgatggga aaaaattcgg 60  
ttaaggccag ggggaaagaa aaaatataaa ttaaaacata tagtatgggc aagcagggag 120  
ctagaacgat tcgcagttaa tcctggcctg ttagaaacat cagaaggctg tagacaaata 180  
ctgggacagc tacaaccatc ccttcagaca ggatcagaag aacttagatc attatataat 240  
acagtagcaa ccctctattg tgtgcatcaa aggatagaga taaaagacac caaggaagct 300  
ttagacaaga tagaggaaga gcaaaacaaa agtaagaaaa aagcacagca agcagcagct 360  
gacacaggac acagcaatca ggtcagccaa aattacccta tagtgcagaa catccagggg 420  
caaatggtac atcaggccat atcacctaga actttaaatg catgggtaaa agtagtagaa 480  
gagaaggctt tcagcccaga agtgataccc atgttttcag cattatcaga aggagccacc 540  
ccacaagatt taaacaccat gctaaacaca gtgggggggac atcaagcagc catgcaaattg 600  
ttaaaagaga ccatcaatga ggaagctgca gaatgggata gagtgcattc agtgcattgca 660  
gggcctattg caccaggcca gatgagagaa ccaaggggaa gtgacatagc aggaactact 720  
agtacccttc aggaacaaat aggatggatg acaataatc cacctatccc agtaggagaa 780  
atttataaaa gatggataat cctgggatta aataaaatag taagaatgta tagccctacc 840  
agcattctgg acataagaca aggacccaaa gaacccttta gagactatgt agaccgggtt 900  
tataaaactc taagagccga gcaagcttca caggaggtaa aaaattggat gacagaaacc 960  
ttgtttggtc aaaatgcgaa cccagattgt aagactattt taaaagcatt gggaccagcg 1020  
gctacactag aagaaatgat gacagcatgt caggagtagt gaggaccggg ccataaggca 1080  
agagtttttg ctgaagcaat gagccaagta acaaattcag ctaccataat gatgcagaga 1140  
ggcaatttta ggaaccaaag aaagattgtt aagtgtttca attgtggcaa agaagggcac 1200  
acagccagaa attgcagggc ccctaggaaa aagggtgtgt ggaaatgtgg aaaggaagga 1260  
caccaaataa aagattgtac tgagagacag gctaattttt tagggaagat ctggccttcc 1320  
tacaagggaa ggccagggaa ttttcttcag agcagaccag agccaacagc cccaccagaa 1380  
gagagcttca ggtctggggg agagacaaca actccccctc agaagcagga gccgatagac 1440  
aaggaactgt atcctttaac ttccctcaga tcaactcttg gcaacgaccc ctgcgtcaca 1500  
taaagatagg ggggcaacta aaggaagctc tattagatag aggagcagat gatacagtat 1560  
tagaagaaat gagtttgcca ggaagatgga aacccaaaat gataggggga attggaggtt 1620  
ttatcaaagt aagacagtat gatcagatac tcatagaaat ctgtggacat aaagctatag 1680  
gtacagtatt agtaggacct acacctgtca acataattgg aagaaatctg ttgactcaga 1740  
ttggttgcac tttaaatttt cccattagcc ctattgagac tgtaccagta aaattaaagc 1800  
caggaatgga tggcccaaaa gttaaacaat ggccattgac agaagaaaaa ataaaagcat 1860  
tagtagaaat ttgtacagaa atggaaaagg aagggaatat ttcaaaaatt gggcctgaga 1920  
atccatacaa tactccagta tttgccataa agaaaaaaga cagtactaaa tggaggaaat 1980  
tagtagatatt cagagaactt aataagagaa ctcaagactt ctgggaaggt caattaggaa 2040  
taccacatcc cgcagggtta aaaaagaaaa aatcagtaac agtactggat gtgggtgatg 2100  
catatttttc agttccctta gatgaagact tcaggaagta tactgcattt accataccta 2160  
gtataaacia tgagacacca gggattagat atcagtacaa tgtgcttcca cagggatgga 2220  
aaggatcacc agcaatatcc caaagtagca tgacaaaaat cttagagcct tttaaaaaac 2280  
aaaatccaga catagttatc tatcaataca tgaacgattt gtatgtagga tctgacttag 2340

```

aatagggca gcatagaaca aaaatagagg agctgagaca acatctgttg aggtggggac 2400
ttaccacacc agacaaaaaa catcagaaag aacctccatt cctttggatg ggttatgaac 2460
tccatcctga taaatggaca gtacagccta tagtgctgcc agaaaaagac agctggactg 2520
tcaatgacat acagaagtta gtgggggaaat tgaataccgc aagtcagatt tacccaggga 2580
ttaaagtaag gcaattatgt aaactcctta gaggaaccaa agcactaaca gaagtaatac 2640
cactaacaga agaagcagag ctagaactgg cagaaaacag agagattcta aaagaaccag 2700
tacatggagt gtattatgac ccatcaaaag acttaatagc agaaatacag aagcaggggc 2760
aaggccaatg gacatatcaa atttatcaag agccatttaa aaatctgaaa acaggaaaat 2820
atgcaagaat gaggggtgcc cacactaatg atgtaaaaca attaacagag gcagtgcaaa 2880
aaataaccac agaaagcata gtaatatggg gaaagactcc taaatttaaa ctaccatac 2940
aaaaggaaac atgggaaaca tgggtggacag agtattggca agccacctgg attcctgagt 3000
gggagtttgt taatacccct ccttttagtga aattatggta ccagttagag aaagaacca 3060
tagtaggagc agaaaccttc tatgtagatg gggcagctaa caggagact aaattaggaa 3120
aagcaggata tggtactaac aaaggaagac aaaaggttgt cccctaact aacacaacaa 3180
atcagaaaac tcagttacaa gcaatttatc tagctttgca ggattcagga ttagaagtaa 3240
acatagtaac agactcacia tatgcattag gaatcattca agcacaacca gataaaagt 3300
aatcagagtt agtcaatcaa ataatagagc agttaataaa aaaggaaaag gtctatctgg 3360
catgggtacc agcacacaaa ggaattggag gaaatgaaca agtagataaa ttagtcagt 3420
ctggaatcag gaaaatacta tttttagatg gaatagataa ggccaagat gaacattag 3479

```

<210> 6  
 <211> 9  
 <212> PRT  
 <213> Simian Immunodeficiency virus

<400> 6  
 Cys Thr Pro Tyr Asp Ile Asn Gln Met  
 1 5

<210> 7  
 <211> 8  
 <212> PRT  
 <213> Chicken

<400> 7  
 Ser Ile Ile Asn Phe Glu Lys Leu  
 1 5

<210> 8  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> probe

<400> 8  
 ctgtctgcgt catttggtgc 20

<210> 9  
 <211> 4  
 <212> PRT  
 <213> Human immunodeficiency Virus

<220>  
 <221> VARIANT  
 <222> (1) ... (4)

<223> Xaa = Any Amino Acid

<400> 9

Tyr Xaa Xaa Leu

1

<210> 10

<211> 93

<212> DNA

<213> Artificial Sequence

<220>

<223> m7.5 promoter

<400> 10

cgctttttat agtaagtttt tcaccataa ataataaata caataattaa tttctcgtaa 60  
aaattgaaaa actattctaa tttattgcac ggt 93

<210> 11

<211> 74

<212> DNA

<213> Artificial Sequence

<220>

<223> Psyn III promoter

<400> 11

taaaaattga aaaaatattc taatttatag gacggttttg attttctttt tttctatact 60  
ataaataata aata 74

<210> 12

<211> 74

<212> DNA

<213> Artificial Sequence

<220>

<223> Psyn IV promoter

<400> 12

taaaaattga aaaactattc taatttatag gacggttttg attttctttt tttctatact 60  
ataaataata aata 74

<210> 13

<211> 75

<212> DNA

<213> Artificial Sequence

<220>

<223> Psyn V promoter

<400> 13

aaaaaatgat aaagtaggtt cagttttatt gctggtttaa aatcacgctt tcgagtaaaa 60  
actacgaata taaat 75

AVAILABLE COPY



**THIS PAGE BLANK (USPTO)**

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
19 September 2002 (19.09.2002)

PCT

(10) International Publication Number  
**WO 02/072754 A3**

(51) International Patent Classification<sup>7</sup>: **A61K 39/12**,  
39/21, 39/275, 39/285

(21) International Application Number: PCT/US02/06713

(22) International Filing Date: 1 March 2002 (01.03.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/274,434 8 March 2001 (08.03.2001) US

(71) Applicant (*for all designated States except US*): **THE GOVERNMENT OF THE UNITED STATES OF AMERICA**, as represented by **THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES** [US/US]; National Institutes of Health, Office of Technology Transfer, Suite 325, 6011 Executive Boulevard, Rockville, MD 20852-3804 (US).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **MOSS, Bernard** [US/US]; 10301 Dickens Avenue, Bethesda, MD 20814 (US). **WYATT, Linda** [US/US]; 11201 Huntover Drive, Rockville, MD 20852 (US). **EARL, Patricia** [US/US]; 3520 Woodbine Street, Chevy Chase, MD 20815 (US).

(74) Agent: **ALTMAN, Daniel, E.**; Knobbe, Martens, Olson And Bear, LLP, 16th floor, 620 Newport Center Drive, Newport Beach, CA 92660 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT (utility model), AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA,

CH, CN, CO, CR, CU, CZ (utility model), CZ, DE (utility model), DE, DK (utility model), DK, DM, DZ, EC, EE (utility model), EE, ES, FI (utility model), FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK (utility model), SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Declaration under Rule 4.17:**

— *of inventorship (Rule 4.17(iv)) for US only*

**Published:**

— *with international search report*  
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

(88) Date of publication of the international search report:  
22 May 2003

**(15) Information about Correction:**

**Previous Correction:**

see PCT Gazette No. 01/2003 of 3 January 2003, Section II

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: MVA EXPRESSING MODIFIED HIV ENVELOPE, GAG, AND POL GENES

(57) Abstract: The invention provides modified virus Ankara (MVA), a replication-deficient strain of vaccinia virus, expressing human immunodeficiency virus (HIV) *env*, *gag*, and *pol* genes.

WO 02/072754 A3

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US02/06713

**A. CLASSIFICATION OF SUBJECT MATTER**IPC(7) : A61K 39/12, 39/21, 39/275, 39/285  
US CL : 424/199.1, 204.1, 207.1, 208.1, 232.1

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**Minimum documentation searched (classification system followed by classification symbols)  
U.S. : 424/199.1, 204.1, 207.1, 208.1, 232.1

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)  
Please See Continuation Sheet**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

| Category * | Citation of document, with indication, where appropriate, of the relevant passages  | Relevant to claim No. |
|------------|---|-----------------------|
| Y,P        | WO 01/47955 A2 (MEDICAL RESEARCH COUNCIL) 5 July 2001(05.07.2001), see entire document.   | 1-13                  |
| Y          | US 5,185,146 A (ALTENBURGER) 9 February 1993 (09.02.1999), see entire document.   | 1-13                  |
| Y          | OURMANOV et al. Comparative Efficacy of Recombinant Modified Vaccinia Virus Ankara Expressing Simian Immunodeficiency Virus (SIV) Gag-Pol and/or Env in Macaques Challenged with Pathogenic SIV. Journal of Virology, Vol. 74, No. 6, March 2000, pages 2740-2751, see entire document.               | 1-13                  |
| Y          | OURMANOV et al. Recombinant Modified Vaccinia Virus Ankara Expressing the Surface gp120 of Simian Immunodeficiency Virus (SIV) Primes for a Rapid Neutralizing Antibody Response to SIV Infection in Macaques. Journal of Virology, Vol. 74, No. 6, March 2000, pages 2960-2965, see entire document. | 1-13                  |
| Y          | GOMEZ et al. Recombinant proteins produced by vaccinia virus vectors can be incorporated within the virion (IMV form) into different compartments. Archives of Virology, Vol. 146, 2001, pages 875-892, see entire document.  | 1-13                  |



Further documents are listed in the continuation of Box C.



See patent family annex.

| Special categories of cited documents:  |  |
|---|--|
| "A" document defining the general state of the art which is not considered to be of particular relevance  | "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention  |
| "E" earlier application or patent published on or after the international filing date   | "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone   |
| "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) | "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art |
| "O" document referring to an oral disclosure, use, exhibition or other means  | "&" document member of the same patent family  |
| "P" document published prior to the international filing date but later than the priority date claimed  |  |

Date of the actual completion of the international search

20 March 2003 (20.03.2003)

Date of mailing of the international search report

31 MAR 2003

Name and mailing address of the ISA/US

Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Facsimile No. (703)305-3230

Authorized officer

Felicia D. Roberts for  
Robert A. Zeman

Telephone No. (703) 308-0196

Form PCT/ISA/210 (second sheet) (July 1998)

# INTERNATIONAL SEARCH REPORT

PCT/US02/06713

## C. (Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages   | Relevant to claim No. |
|------------|--|-----------------------|
| X          | MOSS et al. Protein and recombinant MVA immunization and challenge studies with SHIV 89.6. Retroviruses of Human AIDS and Related Animal Diseases, Colloque des Cent Gardes, 12th, Paris, France, Oct. 25-27, 1999 (2000), Meeting Date 1999, pages 105-107, see Abstract. | 1-13                  |

Form PCT/ISA/210 (second sheet) (July 1998)

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US02/06713

## Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claim Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claim Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☒ Claim Nos.: 23 and 24  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:  
Please See Continuation Sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.: 1-13

Remark on Protest

☐  
☐

- The additional search fees were accompanied by the applicant's protest.  
No protest accompanied the payment of additional search fees.

Form PCT/ISA/210 (continuation of first sheet(1)) (July 1998)



**BOX II. OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING**

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1. In order for all inventions to be searched, the appropriate additional search fees must be paid.

Claims 23 and 24 are improper multiple dependent claims and therefore are not grouped.

Group I, claim(s) 1-13, drawn to a pharmaceutical composition comprising a recombinant MVA virus expressing an HIV Env, Gag and Pol and wherein the *env* gene is modified to encode for an HIV Env protein comprised of gp120 and the membrane-spanning ectodomain of gp41.

Group II, claim(s) 1 and 14, drawn to pharmaceutical composition comprising a recombinant MVA virus expressing an HIV Env, Gag and Pol and wherein the *env* gene is modified to encode for an HIV Env protein comprised of gp120 and the membrane-spanning ectodomain of gp41. Said virus additionally expresses the HIV gene *vif*.

Group III, claim(s) 1 and 14, drawn to pharmaceutical composition comprising a recombinant MVA virus expressing an HIV Env, Gag and Pol and wherein the *env* gene is modified to encode for an HIV Env protein comprised of gp120 and the membrane-spanning ectodomain of gp41. Said virus additionally expresses the HIV gene *vpr*.

Group IV, claim(s) 1 and 14, drawn to pharmaceutical composition comprising a recombinant MVA virus expressing an HIV Env, Gag and Pol and wherein the *env* gene is modified to encode for an HIV Env protein comprised of gp120 and the membrane-spanning ectodomain of gp41. Said virus additionally expresses the HIV gene *tat*.

Group V, claim(s) 1 and 14, drawn to pharmaceutical composition comprising a recombinant MVA virus expressing an HIV Env, Gag and Pol and wherein the *env* gene is modified to encode for an HIV Env protein comprised of gp120 and the membrane-spanning ectodomain of gp41. Said virus additionally expresses the HIV gene *rev*.

Group VI, claim(s) 1 and 14, drawn to pharmaceutical composition comprising a recombinant MVA virus expressing an HIV Env, Gag and Pol and wherein the *env* gene is modified to encode for an HIV Env protein comprised of gp120 and the membrane-spanning ectodomain of gp41. Said virus additionally expresses the HIV gene *vpu*.

Group VII, claim(s) 1 and 14, drawn to pharmaceutical composition comprising a recombinant MVA virus expressing an HIV Env, Gag and Pol and wherein the *env* gene is modified to encode for an HIV Env protein comprised of gp120 and the membrane-spanning ectodomain of gp41. Said virus additionally expresses the HIV gene *nef*.

Group VIII, claim(s) 15, drawn to MVA/HIV-48 comprising SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4 and SEQ ID NO:5.

Group IX, claim(s) 16, drawn to pLW-48 having the sequence of SEQ ID NO:1.

Group X, claim(s) 17, drawn to a plasmid vector having the sequence of SEQ ID NO:1 excluding the HIV *env*, *gag* and *pol* genes.

Group XI, claim(s) 18, drawn to pLW-48 wherein the *env*, *gag* and *pol* genes have a sequence taken from another clade.

Group XII, claim(s) 19, drawn to a poxvirus comprising an m7.5 promoter having the sequence of SEQ ID NO:10.

Group XIII, claim(s) 19, drawn to a poxvirus comprising a Psyn II promoter having the sequence of SEQ ID NO:2.

Group XIV, claim(s) 19, drawn to a poxvirus comprising a Psyn III promoter having the sequence of SEQ ID NO:11.

Group XV, claim(s) 19, drawn to a poxvirus comprising a Psyn IV promoter having the sequence of SEQ ID NO:12.

Group XVI, claim(s) 19, drawn to a poxvirus comprising a Psyn V promoter having the sequence of SEQ ID NO:13.

# INTERNATIONAL SEARCH REPORT

PCT/US02/06713

Group XVII, claim(s) 20, drawn to a method of boosting CD8+ T cell immune response to an HIV Env, Gag or pol antigen in a primate, said method comprising administering to a primed primate a pharmaceutical composition comprising a recombinant MVA virus expressing an HIV Env, Gag and Pol and wherein the *env* gene is modified to encode for an HIV Env protein comprised of gp120 and the membrane-spanning ectodomain of gp41.

Group XVIII, claim(s) 20, drawn to a method of boosting CD8+ T cell immune response to an HIV Env, Gag or pol antigen in a primate, said method comprising administering to a primed primate a pharmaceutical composition comprising a recombinant MVA virus expressing an HIV Env, Gag and Pol and wherein the *env* gene is modified to encode for an HIV Env protein comprised of gp120 and the membrane-spanning ectodomain of gp41. Said virus additionally expresses the HIV gene *vif*.

Group XIX, claim(s) 20, drawn to a method of boosting CD8+ T cell immune response to an HIV Env, Gag or pol antigen in a primate, said method comprising administering to a primed primate a pharmaceutical composition comprising a recombinant MVA virus expressing an HIV Env, Gag and Pol and wherein the *env* gene is modified to encode for an HIV Env protein comprised of gp120 and the membrane-spanning ectodomain of gp41. Said virus additionally expresses the HIV gene *vpr*.

Group XX, claim(s) 20, drawn to a method of boosting CD8+ T cell immune response to an HIV Env, Gag or pol antigen in a primate, said method comprising administering to a primed primate a pharmaceutical composition comprising a recombinant MVA virus expressing an HIV Env, Gag and Pol and wherein the *env* gene is modified to encode for an HIV Env protein comprised of gp120 and the membrane-spanning ectodomain of gp41. Said virus additionally expresses the HIV gene *tat*.

Group XXI, claim(s) 20, drawn to a method of boosting CD8+ T cell immune response to an HIV Env, Gag or pol antigen in a primate, said method comprising administering to a primed primate a pharmaceutical composition comprising a recombinant MVA virus expressing an HIV Env, Gag and Pol and wherein the *env* gene is modified to encode for an HIV Env protein comprised of gp120 and the membrane-spanning ectodomain of gp41. Said virus additionally expresses the HIV gene *rev*.

Group XXII, claim(s) 20, drawn to a method of boosting CD8+ T cell immune response to an HIV Env, Gag or pol antigen in a primate, said method comprising administering to a primed primate a pharmaceutical composition comprising a recombinant MVA virus expressing an HIV Env, Gag and Pol and wherein the *env* gene is modified to encode for an HIV Env protein comprised of gp120 and the membrane-spanning ectodomain of gp41. Said virus additionally expresses the HIV gene *vpu*.

Group XXIII, claim(s) 20, drawn to a method of boosting CD8+ T cell immune response to an HIV Env, Gag or pol antigen in a primate, said method comprising administering to a primed primate a pharmaceutical composition comprising a recombinant MVA virus expressing an HIV Env, Gag and Pol and wherein the *env* gene is modified to encode for an HIV Env protein comprised of gp120 and the membrane-spanning ectodomain of gp41. Said virus additionally expresses the HIV gene *nef*.

Group XXIV, claim(s) 21, drawn to a method of inducing a CD8+ T cell immune response to an HIV Env, Gag or pol antigen in a primate, said method comprising administering to a primed primate a pharmaceutical composition comprising a recombinant MVA virus expressing an HIV Env, Gag and Pol and wherein the *env* gene is modified to encode for an HIV Env protein comprised of gp120 and the membrane-spanning ectodomain of gp41.

Group XXV, claim(s) 21, drawn to a method inducing a CD8+ T cell immune response to an HIV Env, Gag or pol antigen in a primate, said method comprising administering to a primate a pharmaceutical composition comprising a recombinant MVA virus expressing an HIV Env, Gag and Pol and wherein the *env* gene is modified to encode for an HIV Env protein comprised of gp120 and the membrane-spanning ectodomain of gp41. Said virus additionally expresses the HIV gene *vif*.

Group XXVI, claim(s) 21, drawn to a method of inducing a CD8+ T cell immune response to an HIV Env, Gag or pol antigen in a primate, said method comprising administering to a primate a pharmaceutical composition comprising a recombinant MVA virus expressing an HIV Env, Gag and Pol and wherein the *env* gene is modified to encode for an HIV Env protein comprised of gp120 and the membrane-spanning ectodomain of gp41. Said virus additionally expresses the HIV gene *vpr*.

Group XXVII, claim(s) 21, drawn to a method of inducing a CD8+ T cell immune response to an HIV Env, Gag or pol antigen in a primate, said method comprising administering to a primate a pharmaceutical composition comprising a recombinant MVA virus expressing an HIV Env, Gag and Pol and wherein the *env* gene is modified to encode for an HIV Env protein comprised of gp120 and the membrane-spanning ectodomain of gp41. Said virus additionally expresses the HIV gene *tat*.

Group XXVIII, claim(s) 21, drawn to a method of inducing a CD8+ T cell immune response to an HIV Env, Gag or pol antigen in a primate, said method comprising administering to a primate a pharmaceutical composition comprising a recombinant MVA virus expressing an HIV Env, Gag and Pol and wherein the *env* gene is modified to encode for an HIV Env protein comprised of gp120 and the membrane-spanning ectodomain of gp41. Said virus additionally expresses the HIV gene *rev*.

Form PCT/ISA/210 (second sheet) (July 1998)

# INTERNATIONAL SEARCH REPORT

PCT/US02/06713

Group XXIX, claim(s) 21, drawn to a method of inducing a CD8+ T cell immune response to an HIV Env, Gag or pol antigen in a primate, said method comprising administering to a primate a pharmaceutical composition comprising a recombinant MVA virus expressing an HIV Env, Gag and Pol and wherein the *env* gene is modified to encode for an HIV Env protein comprised of gp120 and the membrane-spanning ectodomain of gp41. Said virus additionally expresses the HIV gene *vpu*.

Group XXX, claim(s) 21, drawn to a method of inducing a boosting CD8+ T cell immune response to an HIV Env, Gag or pol antigen in a primate, said method comprising administering to a primate a pharmaceutical composition comprising a recombinant MVA virus expressing an HIV Env, Gag and Pol and wherein the *env* gene is modified to encode for an HIV Env protein comprised of gp120 and the membrane-spanning ectodomain of gp41. Said virus additionally expresses the HIV gene *nef*.

Group XXXI, claim(s) 22 and 25, drawn to a method inducing a CD8+ T cell immune response to an HIV Env, Gag or pol antigen in a primate, said method comprising administering to a primate a pharmaceutical composition comprising a recombinant MVA virus expressing an HIV Env, Gag and Pol and wherein the *env* gene is modified to encode for an HIV Env protein comprised of gp120 and the membrane-spanning ectodomain of gp41. Said primate being previously primed with a nucleic acid encoding said antigen.

Group XXXII, claim(s) 22 and 25, drawn to a method inducing a CD8+ T cell immune response to an HIV Env, Gag or pol antigen in a primate, said method comprising administering to a primate a pharmaceutical composition comprising a recombinant MVA virus expressing an HIV Env, Gag and Pol in addition to the HIV gene *vif* and wherein the *env* gene is modified to encode for an HIV Env protein comprised of gp120 and the membrane-spanning ectodomain of gp41. Said primate being previously primed with a nucleic acid encoding said antigen.

Group XXXIII, claim(s) 22 and 25, drawn to a method inducing a CD8+ T cell immune response to an HIV Env, Gag or pol antigen in a primate, said method comprising administering to a primate a pharmaceutical composition comprising a recombinant MVA virus expressing an HIV Env, Gag and Pol in addition to the HIV gene *vpr* and wherein the *env* gene is modified to encode for an HIV Env protein comprised of gp120 and the membrane-spanning ectodomain of gp41. Said primate being previously primed with a nucleic acid encoding said antigen.

Group XXXIV, claim(s) 22 and 25, drawn to a method inducing a CD8+ T cell immune response to an HIV Env, Gag or pol antigen in a primate, said method comprising administering to a primate a pharmaceutical composition comprising a recombinant MVA virus expressing an HIV Env, Gag and Pol in addition to the HIV gene *tat* and wherein the *env* gene is modified to encode for an HIV Env protein comprised of gp120 and the membrane-spanning ectodomain of gp41. Said primate being previously primed with a nucleic acid encoding said antigen.

Group XXXV, claim(s) 22 and 25, drawn to a method inducing a CD8+ T cell immune response to an HIV Env, Gag or pol antigen in a primate, said method comprising administering to a primate a pharmaceutical composition comprising a recombinant MVA virus expressing an HIV Env, Gag and Pol in addition to the HIV gene *vpu* and wherein the *env* gene is modified to encode for an HIV Env protein comprised of gp120 and the membrane-spanning ectodomain of gp41. Said primate being previously primed with a nucleic acid encoding said antigen.

Group XXXVI, claim(s) 22 and 25, drawn to a method inducing a CD8+ T cell immune response to an HIV Env, Gag or pol antigen in a primate, said method comprising administering to a primate a pharmaceutical composition comprising a recombinant MVA virus expressing an HIV Env, Gag and Pol in addition to the HIV gene *rev* and wherein the *env* gene is modified to encode for an HIV Env protein comprised of gp120 and the membrane-spanning ectodomain of gp41. Said primate being previously primed with a nucleic acid encoding said antigen.

Group XXXVII, claim(s) 22 and 25, drawn to a method inducing a CD8+ T cell immune response to an HIV Env, Gag or pol antigen in a primate, said method comprising administering to a primate a pharmaceutical composition comprising a recombinant MVA virus expressing an HIV Env, Gag and Pol in addition to the HIV gene *nef* and wherein the *env* gene is modified to encode for an HIV Env protein comprised of gp120 and the membrane-spanning ectodomain of gp41. Said primate being previously primed with a nucleic acid encoding said antigen.

Group XXXVIII, claim(s) 26, drawn to a method of making a pharmaceutical composition comprising a recombinant MVA virus expressing an HIV Env, Gag and Pol and wherein the *env* gene is modified to encode for an HIV Env protein comprised of gp120 and the membrane-spanning ectodomain of gp41.

Group XXXIX, claim(s) 26, drawn to a method of making a pharmaceutical composition comprising a recombinant MVA virus expressing an HIV Env, Gag and Pol and wherein the *env* gene is modified to encode for an HIV Env protein comprised of gp120 and the membrane-spanning ectodomain of gp41. Said virus additionally expresses the HIV gene *vif*.

Group XL, claim(s) 26, drawn to a method of making a pharmaceutical composition comprising a recombinant MVA virus expressing an HIV Env, Gag and Pol and wherein the *env* gene is modified to encode for an HIV Env protein comprised of gp120 and the membrane-spanning ectodomain of gp41. Said virus additionally expresses the HIV gene *vpr*.

Form PCT/ISA/210 (second sheet) (July 1998)

## INTERNATIONAL SEARCH REPORT

Group XLI, claim(s) 26, drawn to a method of making a pharmaceutical composition comprising a recombinant MVA virus expressing an HIV Env, Gag and Pol and wherein the *env* gene is modified to encode for an HIV Env protein comprised of gp120 and the membrane-spanning ectodomain of gp41. Said virus additionally expresses the HIV gene *tat*.

Group XLII claim(s) 26, drawn to a method of making a pharmaceutical composition comprising a recombinant MVA virus expressing an HIV Env, Gag and Pol and wherein the *env* gene is modified to encode for an HIV Env protein comprised of gp120 and the membrane-spanning ectodomain of gp41. Said virus additionally expresses the HIV gene *rev*.

Group XLIII, claim(s) 26, drawn to a method of making a pharmaceutical composition comprising a recombinant MVA virus expressing an HIV Env, Gag and Pol and wherein the *env* gene is modified to encode for an HIV Env protein comprised of gp120 and the membrane-spanning ectodomain of gp41. Said virus additionally expresses the HIV gene *vpu*.

Group XLIV, claim(s) 26, drawn to a method of making a pharmaceutical composition comprising a recombinant MVA virus expressing an HIV Env, Gag and Pol and wherein the *env* gene is modified to encode for an HIV Env protein comprised of gp120 and the membrane-spanning ectodomain of gp41. Said virus additionally expresses the HIV gene *nef*.

The inventions listed as Groups I-XLIV do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

Pursuant to 37 C.F.R. 1.475(d), the ISA/US considers that where multiple products and processes are claimed, the main invention shall consist of the first invention of the category first mentioned in the claims and the first recited invention of each of the other categories related thereto. Accordingly, the main invention (Group I) comprises the first recited product, a recombinant MVA virus expressing an HIV Env, Gag and Pol and wherein the *env* gene is modified to encode for an HIV Env protein comprised of gp120 and the membrane-spanning ectodomain of gp41. Further pursuant to 37 C.F.R. 1.475(d), the ISA/US considers that any feature which the subsequently recited products and methods share with the main invention does not constitute a special technical feature within the meaning of PCT rule 13.2 and that each of such products and methods accordingly defines a separate invention.

**Continuation of B. FIELDS SEARCHED Item 3:**  
STN, EAST, MEDLINE.

search terms: MVA, modified vaccinia Ankara, Env, Gag, Pol, HIV, gp120, gp41, cytoplasmic domain, deletion III, H5-like early/late promoter, vaccinia